BEYOND Pooled – part of the BEYOND study program (BEnefit of NOACs studY of nOn-valvular AF patieNts in NorDic countries)



Department of Clinical Epidemiology Aarhus University Hospital Olof Palmes Allé 43 -45 8200 Aarhus N DENMARK



UNIVERSITY OF BERGEN Department of Global Public Health and Primary Care University of Bergen Kalfarveien 31 5018 Bergen NORWAY



Centre for Pharmacoepidemiology Karolinska Institutet Karolinska University Hospital SE 171 76 Stockholm SWEDEN

FINAL REPORT

25 July 2019



Title	Beyond Pooled –Part of the BEYOND study program (BEnefit of NOACs studY of nOn-valvular AF patieNts in NorDic countries)		
Protocol number	B0661103		
Version identifier of the final study report	1.0		
Date	25 July 2019		
EU Post Authorisation Study (PAS) register number	EUPAS13470		
Active substance	ATC code B01ALL03 – warfarin ATC code B01AE07 – dabigatran ATC code B01AF01 – rivaroxaban ATC code B01AF02 – apixaban		
Medicinal product	Warfarin Pradaxa® - dabigatran Xarelto® - rivaroxaban Eliquis® - apixaban		
Product reference	EU/1/11/691/001 -015		
Procedure number	EMEA/H/C/002148		
Marketing Authorisation Holder (MAH)	Bristol -Myers Squibb/Pfizer European Economic Interest Group (EEIG)		
Joint PASS	No		
Research question and objectives	The overall aim of this study is to evaluate effectiveness and safety of each NOAC compared with warfarin in treatment-naïve initiators of anticoagulants with NVAF in routine clinical practice in Denmark, Norway and Sweden. The study used pooled data from nationwide registries in Denmark, Norway and Sweden.		
Author	Vera Ehrenstein, MPH, DSc Grethe S. Tell, MD, MPH, PhD Marie Linder, PhD		

his document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.

TABLE OF CONTENTS

1. ABSTRACT (STAND -ALONE DOCUMENT)
2. LIST OF ABBREVIATIONS
3. INVESTIGATORS
4. OTHER RESPONSIBLE PARTIES
5. MILESTONES
6. RATIONALE AND BACKGROUND
7. RESEARCH QUESTION AND OBJECTIVES
7.1. Primary objectives
7.2. Secondary objectives
7.3. Exploratory objective
8. AMENDMENTS AND UPDATES
9. RESEARCH METHODS
9.1. Study design
9.2. Setting
9.3. Subjects
9.3.1. Inclusion criteria 17
9.3.2. Exclusion criteria 17
9.4. Variables
9.4.1. Exposure
9.4.2. Endpoints
9.4.2.1. Primary endpoints
9.4.2.2. Secondary endpoints
9.4.2.3. Exploratory endpoints
9.4.3. Covariates
9.4.4. Subgroups
9.5. Data sources and measurement
9.6. Bias
9.7. Study size
9.8. Data transformation
9.9. Statistical methods
9.9.1. Main summary measures
9.9.2. Main statistical methods
9.9.3. Missing values
9.9.4. Sensitivity analyses

9.9.5. Exploratory analyses
9.9.6. Amendments to the statistical analysis plan
9.10. Quality control
9.11. Protection of human subjects
10. RESULTS
10.1. Participants
10.2. Descriptive data
10.3. Outcome data
10.4. Main results
10.4.1. Primary and secondary endpoints: crude analyses
10.4.2. Primary and secondary endpoints: analyses in PS-matched population 29
10.5. Other analyses
10.5.1. Post-hoc analyses
10.5.2. Sensitivity analyses
10.5.2.1. Conventional adjustment
10.5.2.2. ITT-like analyses
10.5.2.3. Alternative definition of warfarin discontinuation
10.5.2.4. Analyses in subgroups defined by initial NOAC dose with de-novo
PS matching
PS matching 34 10.5.3. Analyses of the exploratory endpoints 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35
PS matching 34 10.5.3. Analyses of the exploratory endpoints 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35
PS matching
PS matching 34 10.5.3. Analyses of the exploratory endpoints 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35
PS matching3410.5.3. Analyses of the exploratory endpoints3510.5.3.1. Denmark3510.5.3.2. Norway3510.5.3.3. Sweden3510.6. Adverse events/adverse reactions3511. DISCUSSION3511.1. Key results3511.2. Strengths and limitations37
PS matching 34 10.5.3. Analyses of the exploratory endpoints 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35 11.2. Strengths and limitations 37 11.3. Interpretation 38
PS matching 34 10.5.3. Analyses of the exploratory endpoints 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35 11.2. Strengths and limitations 37 11.3. Interpretation 38 11.4. Generalisability 38
PS matching 34 10.5.3. Analyses of the exploratory endpoints. 35 10.5.3.1. Denmark 35 10.5.3.2. Norway 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35 11.2. Strengths and limitations 37 11.3. Interpretation 38 11.4. Generalisability 38 12. OTHER INFORMATION 38
PS matching 34 10.5.3. Analyses of the exploratory endpoints. 35 10.5.3.1. Denmark. 35 10.5.3.2. Norway. 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions. 35 11. DISCUSSION 35 11.1. Key results. 35 11.2. Strengths and limitations 37 11.3. Interpretation 38 11.4. Generalisability 38 13. CONCLUSIONS 38
PS matching 34 10.5.3. Analyses of the exploratory endpoints. 35 10.5.3.1. Denmark. 35 10.5.3.2. Norway. 35 10.5.3.3. Sweden 35 10.6. Adverse events/adverse reactions 35 11. DISCUSSION 35 11.1. Key results 35 11.2. Strengths and limitations 37 11.3. Interpretation 38 12. OTHER INFORMATION 38 13. CONCLUSIONS 38 14. REFERENCES 38

LIST OF IN-TEXT TABLES AND FIGURES

Table 1. Amendments to the Protocol	
Table 2. National registries in Denmark, Norway and Sy available from each registry	• •
Table 3. Assumed costs for the selected health care reso	ource utilisation indicators 23
Table 4. Median follow-up time, months, for death and country and/or cohort	
Table 5. NOAC initiators included in the full populationpopulations, overall, by cohort, and by court	
Table 6. Hazard ratios for the primary endpoints obtained approaches	-
Table 7. Hazard ratios for the primary endpoints, overal dose after de-novo PS-matching within each dose.	h subgroup of initial NOAC

Annex 1. List of stand-alone documents

- Appendix 1. SIGNATURES
- Appendix 2. PROTOCOL
- Appendix 3. INVESTIGATORS AND CORRESPONDING INDEPENDENT ETHICS COMMITTEES (IECs) OR INSTITUTIONAL REVIEW BOARDS (IRBs)
 - Appendix 3.1. List of Investigators by Country. Refer to section 3 Investigators
 - Appendix 3.2. List of Independent Ethics Committee (IEC) or Institutional Review Board (IRB) and Corresponding Protocol Approval Dates
- Appendix 4. STATISTICAL ANALYSIS PLAN
- Appendix 5. SAMPLE CASE REPORT FORM (CRF) / DATA COLLECTION TOOL (DCT))

Not applicable.

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

Appendix 6.SAMPLE STANDARD SUBJECT INFORMATION SHEET ANDINFORMEDCONSENT DOCUMENT (ICD)

Not applicable.

Appendix 7. LIST OF SUBJECT DATA LISTINGS

Appendix 7.1 Withdrawn Subjects

Not applicable.

Appendix 7.2 Protocol Deviations

Appendix 7.3 Subjects Excluded from the Analysis

Not applicable.

Appendix 7.4 Demographic Data

Not applicable.

Appendix 7.5 Medication/Treatment Data

Not applicable.

Appendix 7.6 Endpoint Data

Not applicable.

Appendix 7.7 Adverse Events

Not applicable.

Appendix 7.8 Laboratory listings

Not applicable.

Appendix 8. ADDITIONAL DOCUMENTS

Not applicable.

1. ABSTRACT (STAND -ALONE DOCUMENT)

2. LIST OF ABBREVIATIONS

Abbreviation	Definition		
AF	Atrial fibrillation		
ACE	Angiotensin converting enzyme		
ATC	Anatomical Therapeutic Chemical		
BEYOND	BE nefit of NOACs stud Y of n On-valv ular AF patie N ts in Nor D ics		
CAD	Coronary artery disease		
CCI	Charlson Comorbidity Index		
CDM	Common data model		
CHADS ₂	Congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke [double weight]		
CHA ₂ DS ₂ VASc	Congestive heart failure/LV dysfunction, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65 -74 years, Sex category		
CI	Confidence interval		
CKD	Chronic kidney disease		
COPD	Chronic obstructive pulmonary disease		
DVT	Deep vein thrombosis		
EMA	European Medicines Agency		
GI	Gastrointestinal		
GPP	Good Pharmacoepidemiology Practices		
GVP	Good Pharmacovigilance Practice		
HAS-BLED	Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol		
HF	Heart failure		
HR	Hazard ratio		
ICMJE	International Committee of Medical Journal Editors		
ICD-10	International Classification of Diseases, Tenth Revision		
IEC	Independent Ethics Committee		
INR	International normalised ratio		
IQR	Interquartile range		
IRB	Institutional Review Board		
ISPE	International Society for Pharmacoepidemiology		
ITT	Intention-to-treat		
МАН	Marketing Authorisation Holder		

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

MI	Myocardial infarction			
NI	Non-interventional			
NOAC	Non-vitamin K oral anticoagulants			
NSAID	Non-steroidal anti-inflammatory drug			
NVAF	Non-valvular atrial fibrillation			
OAC	Oral anticoagulant			
PAD	Peripheral arterial disease			
PAS	Post -authorisation study			
PASS	Post -authorisation safety study			
PE	Pulmonary embolism			
PS	Propensity score			
RCT	Randomised controlled trial			
SAP	Statistical Analysis Plan			
SD	Standard deviation			
SMD	Standardised mean difference			
SE	Systemic embolism			
SSRI	Selective serotonin reuptake inhibitor			
TIA	Transient ischaemic attack			
US	United States			
VKA	Vitamin K antagonist			

3. INVESTIGATORS

Principal Investigator(s) of the Protocol

Name, degree(s)	Title	Affiliation
Henrik Toft Sørensen, MD, PhD, DMSc	Professor, legally responsible investigator	Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
Aaron Jenkins, PhD	Outcomes and Evidence Director, Pfizer NI study lead	Pfizer Inc.

Lead Country Investigator(s) of the Protocol

Name, degree(s)TitleAffiliation		Address	
Helle Kieler, MD, PhD	Professor, Principal Investigator, Sweden	Centre for Pharmacoepidemiol ogy Karolinska Institutet	Karolinska Universitetssjukhuset Solna, Centrum för läkemedelsepidemiologi T2 171 76 Stockholm, Sweden http://ki.se/en/meds/centre-for- pharmacoepidemiology
Grethe S. Tell, MD, MPH, PhD	Professor,Department of Global PublicPrincipalHealth and Primary CareNorwayUniversity of Bergen		Kalfarveien 31, NO-5018 Bergen, Norway http://www.uib.no/en/globpub
Vera Ehrenstein, MPH, DSc Professor, Lead Investigator, Denmark		Department of Clinical Epidemiology Aarhus University	Olof Palmes Allé 43-45 DK-8200 Aarhus N, Denmark, http://www.kea.au.dk/en/index.html

4. OTHER RESPONSIBLE PARTIES

Responsible Party name and affiliation	Role in the study		
Morten Madsen, MSc	Statistician, Denmark Department of Clinical Epidemiology Aarhus University Olof Palmes Allé 43-45 DK-8200 Aarhus N, Denmark		
Astrid Lunde, MSc, PhD	Statistician, Norway Department of Global Public Health and Primary Care University of Bergen Kalfarveien 31, NO-5018 Bergen, Norway		
Marie Linder, PhD	Statistician, Sweden Centre for Pharmacoepidemiology Karolinska Institutet Karolinska Universitetssjukhuset Solna Centrum för läkemedelsepidemiologi T2 171 76 Stockholm, Sweden		
Søren Paaske Johnsen, MD, PhD	Co-investigator, Denmark (through October 2018) Department of Clinical Epidemiology Aarhus University Hospital Olof Palmes Allé 43-45 DK-8200 Aarhus N, Denmark		
Morten Schmidt, MD, PhD	Clinical expert, Denmark (from November 2018) Registrar, Department of Clinical Epidemiology Aarhus University Hospital Olof Palmes Allé 43-45 DK-8200 Aarhus N, Denmark		
Gerhard Sulo, MD, PhD	Clinical expert, Norway Department of Global Public Health and Primary Care University of Bergen Kalfarveien 31, NO-5018 Bergen, Norway		
Zoltan Thinsz	Project manager, Sweden Centre for Pharmacoepidemiology Karolinska Institutet Karolinska Universitetssjukhuset Solna Centrum för läkemedelsepidemiologi T2 171 76 Stockholm, Sweden		
Anna Ingemarsdotter	Project administrator, Sweden Centre for Pharmacoepidemiology Karolinska Institutet Karolinska Universitetssjukhuset Solna Centrum för läkemedelsepidemiologi T2 171 76 Stockholm, Sweden		

Name, degree(s)	Title/Role	Affiliation	Address	
Denmark				
Søren Paaske Johnsen, MD, PhD	Professor Member of Steering Committee*	Center for Clinical Health Services Research, Aalborg University	Sdr. Skovvej 15, 9000 Aalborg, Denmark	
Gunnar Gislason, MD, PhD Professor Cardiologist Member of Steering Committee*		Department of Cardiology, Gentofte University Hospital	Herlev-Gentofte Hospital- Gentofte, Kildegårdsvej 28, 2900 Hellerup	
Norway				
Sigrun Halvorsen MD, Ph.D	Professor Cardiologist Member of Steering Committee*	Department of Cardiology, Oslo University Hospital, Ullevål, Oslo	Oslo University Hospital, Ullevål NO-0424 Oslo Norway	
Waleed Ghanima, MD, PhD	Professor, Haematologist Member of Steering Committee*	Østfold Hospital Trust Fredrikstad	Sigrid Undset v 12 1619 FREDRIKSTAD	
Sweden				
Faris Al-Khalili, MD	Senior Consultant Cardiologist Member of Steering Committee	Sophiahemmet Hospital,, Stockholm –Sweden	HLA-mottagningen Sophiahemmet Valhallavägen 91,E1 Stockholm Sweden	
Germany				
Stefan Hohnloser, MD	Professor Cardiologist Chair of Steering Committee*	Dep. of Cardiology J. W. Goethe University	J. W. Goethe University Dep. of Cardiology Div. of Clinical Electrophysiology Building 23 c Theodor Stern Kai 7 60590 Frankfurt Germany	
		gn, review of study results and		
authors in accordance with Ir	iternational Committe	e of Medical Journal Editors	(ICMJE) criteria.	

List of Steering Committee members

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

5. MILESTONES

Milestone	Planned date	Actual date 17 August 2018	
Start of data collection	17 August 2018		
End of data collection	22 September 2018	22 September 2018	
Registration in the EU PAS register	06 October 2017	5 October, 2017	
Final study report	15 March 2019	25 July 2019	

6. RATIONALE AND BACKGROUND

Atrial fibrillation (AF) is the most common cardiac rhythm disorder. AF is a disturbance of cardiac rhythm that results from dysfunction of the electrophysiological conduction system in the upper chambers of the heart. It is marked by disorganised, rapid, and irregular atrial activation. The ventricular response is also irregular. Symptoms of AF vary substantially. Many patients are asymptomatic and have no apparent haemodynamic consequences from AF. Other patients experience only minor palpitations or sense of irregularity of the pulse. However, haemodynamic effect in patients with AF can be dramatic, depending on the need of normal atrial contractivity and ventricular response. Hypotension, pulmonary congestion and angina symptoms may be severe in some patients (1-3).

In contrast to other cardiac diseases, such as acute myocardial infarction or stroke, the prevalence of AF is rising. In the last several decades, incidence of hospital-diagnosed AF has been increasing, on average, by 4% annually, owing, among other things, to diagnostic-advances driven improved detection and to population aging (1-3). Risk of AF increases with age, and affects 5% of persons 75 years or older. AF is more prevalent in men than in women. In addition to sex and age, risk factors for AF include hypothyroidism, hypertension, anaemia, ischaemic heart disease, and valvular heart disease (1). AF is associated with a five-fold increase in the risk of stroke and a two-fold increase in mortality (2).

AF treatment strategies include acute rate control, including termination; chronic rate control; and catheter and surgical ablation therapy for prevention of AF recurrence. AF is of particular importance in patients with risk factors for stroke. In patients not adequately anticoagulated and AF is lasting longer than 24-48 hours, a trans-oesophageal electrocardiogram can be performed to rule out the presence of left atrial thrombus that may dislodge, with attempted restoration of sinus rhythm with either non-pharmacologic or non-pharmacologic therapy.

Most AF patients require long-term pharmacologic treatment with oral anticoagulants (OACs), for which, until recently, vitamin K antagonists (VKAs), primarily warfarin, have been the standard care (4). When optimally dosed, VKAs are effective in stroke prevention. Challenges of treatment with VKAs include the need for close monitoring (via the international normalised ratio [INR] measures) to maintain the optimal anticoagulation level; dietary restrictions to allow for constant dosing; and concerns about drug interactions. Bleeding, especially intracranial bleeding, is the main safety concern associated with VKAs use (5).

Non-vitamin K oral anticoagulants (NOACs) are an alternative treatment option for patients with non-valvular AF (NVAF), since they allow for a more convenient anticoagulation regimen than VKAs, with comparable efficacy and safety (4). Current guidelines in the United States (US) (6) and in Europe (7) recommend NOACs as the first-line treatment strategy for stroke prevention in patients with AF. In Denmark, dabigatran was first introduced in August 2011, rivaroxaban in February 2012, and apixaban in December 2012 (8). The respective dates were July 2008, December 2008, and October 2011 in Norway (9-11); and March 2008, September 2008, and May 2011, in Sweden (12, 13). The NVAF indication was approved in Europe in August 2011 for dabigatran (14), in December 2011 for rivaroxaban (15), and in November 2012 for apixaban (16, 17).

In randomised controlled trials (RCTs) of individual NOACs vs. warfarin among patients with NVAF (the ARISTOTLE trial [apixaban] (18); the RE-LY trial [dabigatran] (19); and the ROCKET-AF trial [rivaroxaban] (20)), apixaban was the only NOAC with lower rate of discontinuation or major bleeding compared with warfarin (18-20). In two network metaanalyses of the trial data (adjusted indirect comparisons of each NOAC against warfarin), apixaban was safer and more efficacious than dabigatran or rivaroxaban as measured by

> PFIZER CONFIDENTIAL Page 12 of 253

bleeding or discontinuation and bleeding outcomes (21, 22). A subsequent meta-analysis, which also included RCTs evaluating edoxaban and ximelagatran in addition to apixaban, dabigatran and rivaroxaban, showed no evidence for superiority of any NOAC drug class of once vs. twice daily regimen (23).

Many previous observational studies that examined safety and effectiveness of NOACs in routine clinical practice generally found apixaban, dabigatran and rivaroxaban to have a positive benefit to risk balance when comparing each NOAC with warfarin (8, 24-29). Among the limitations affecting many of the previous studies are the relatively short followup, concerns about unmeasured confounding, and low precision of results, especially in subgroup analyses. The current study aims to use individually pooled routinely collected data from three Scandinavian countries to assess effectiveness and safety of apixaban, rivaroxaban, dabigatran, each compared with warfarin, among patients with NVAF, and to describe characteristics and health care utilisation level among the NOAC users. The specific projected contribution of this study will be to obtain precise estimates of association overall and in clinically important subgroups, while taking advantage of a longer follow-up, and applying previously used analytic strategy (26, 27) to facilitate comparison of results across studies. Other important advantages of the Scandinavian countries include universal access to health care, similar clinical practice, uniform recording practices, comparable patterns of hospitalisation and referral to specialist care, and high overall quality of care, including high quality of warfarin therapy (30-40).

This non-interventional study is designated as a Post-Authorisation Safety Study (PASS) and is conducted voluntarily by the MAH.

7. RESEARCH QUESTION AND OBJECTIVES

The overall aim of this study was to evaluate effectiveness and safety of each NOAC compared with warfarin in treatment-naïve adult initiators of anticoagulants with NVAF in routine clinical practice in Denmark, Norway and Sweden. The primary, secondary, and exploratory objectives are listed below.

7.1. Primary objectives

- To compare risks of the composite endpoint of ischaemic or haemorrhagic stroke (hereafter, any stroke) or systemic embolism (SE) at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of intracranial, gastrointestinal (GI) or other (hereafter any bleeding) at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin

7.2. Secondary objectives

- To compare risks of ischaemic stroke at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of haemorrhagic stroke at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of intracranial bleeding at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin

- To compare risks of GI bleeding at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of acute myocardial infarction (MI) at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of systemic embolism at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare all-cause mortality among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of the composite endpoint of ischaemic stroke at an acute hospitalisation with an overnight stay, SE at an acute hospitalisation with an overnight stay, acute MI at an acute hospitalisation with an overnight stay, or all-cause mortality among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of any bleeding at an acute or planned hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of any bleeding occurring at an acute hospital contact without an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin
- To compare risks of bleeding (intracranial, GI, other) recorded as the primary diagnosis at an acute hospitalisation with an overnight stay among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin (sensitivity analysis)
- To describe demographic, clinical, and socioeconomic (to the extent possible) characteristics for OAC treatment naïve patients with NVAF who initiate apixaban, dabigatran, rivaroxaban, or warfarin

7.3. Exploratory objective

To describe bleeding- and stroke-related acute hospital care resource utilisation among the OAC-treatment naïve NVAF patients who initiate apixaban, dabigatran, rivaroxaban, or warfarin, as measured by the number of hospitalisations and bed days, number of planned and acute outpatient hospital visits, and to assess, to the extent possible, associated costs.

8. AMENDMENTS AND UPDATES

Table 1. Amendments to the Protocol

Amendment number	Date	Substantial or administrative amendment	Protocol section(s) changed	Summary of amendment(s)	Reason
1.1	26 th June 2018	Administrative	2 (Responsible parties)	Update of names for responsible parties, and clarification of roles as principle investigators, steering committee and other responsible parties.	Change of personnel, and provision of additional clarification

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

Administra	ative 3 (Abstract)	Abstract updated to be consistent with changes in other section of the protocol and statistical analysis plan (SAP).	Review of SAP resulted in a number of further clarifications and amendments (see entries below).
Administra	ative 5 (Milestones)	End of data collection and date of final study report updated to reflect new timelines.	New timelines for availability of data from Norway has meant study timelines were required to be updated.
Administra	ative 7 (Research question and objectives)	Primary objectives to clarify definition of any stroke to include ischaemic or haemorrhagic stroke. Primary and secondary endpoints updated to require acute hospitalisation with an overnight stay	Provide clarity to study objectives, and select most robust endpoint definition for analysis.
		Additional secondary endpoint added to provide full breakdown of composite primary endpoint. Update of description of exploratory endpoints.	Secondary endpoints added to provide full breakdown of composite endpoints, capture safety events not requiring an overnight stay in hospital .Details on exploratory endpoints added to reflect outpatient hospital visits.
Administra	ative 8 (Research methods)	Updated to reflect availability of data from Sweden until 2016, so this is now in line with other countries in the study. Clarification of patient population as treatment naïve. Clarification of exclusion criteria look back periods (5 years for mitral stenosis or mechanical heart valves; 9 months for pregnancy).Definition of primary and secondary endpoints clarified to reflect updates in section 7.Additional subgroup analyses added and clarified. Additional section in 8 added for Record retention. Definition of cumulative incidence updated to incorporate data over full follow up period.	Changes made to be consistent with greater data availability in Sweden, provide clarification on definition of patients as treatment naïve and clarify exclusion criteria. Endpoints updated to reflect clarified definitions in other sections. Further subgroup analyses added after discussion with steering committee. Additional sub- sections in section 8 added as required by Pfizer Clinical and Medical Controlled Document (CMCD) communication on the Global Standard Operating Procedure (GSOP)

	1		
			informed consent
			document
			templates 25-JUN-
			2018, as required
			by the General
			Data Protection
			Regulation.

9. RESEARCH METHODS

Study Protocol version 1.1 (Appendix 2), amended 5 July 2018, describes the research methods in detail. Key elements of the research methods are presented below.

9.1. Study design

This was a cohort study based on routinely and prospectively collected data from populationbased health and administrative registries and databases in Denmark, Norway, and Sweden. The primary study endpoints were serious medical conditions requiring hospitalisation and are therefore expected to be well captured in the available data sources. Furthermore, this study used the active comparator new user design to maximise alignment of the start of follow-up with the start of treatment, thus reducing healthy adherer bias, which might potentially preclude identification of early adverse events (41). Propensity score (PS) matching was used to balance multiple measured covariates in each NOAC vs. warfarin contrasts.

9.2. Setting

This study was set in the three Scandinavian countries, each of which has tax-funded universal health care (42); routine recording of prescription dispensings, hospital diagnoses, migrations and deaths; and individual-level data linkage, thus enabling nearly complete follow-up of the entire populations and virtually no loss to follow-up (34, 36).

The source population of this study consisted of adults (persons ages 18 years or older) alive and residents of Denmark, Norway, or Sweden on 01 January 2013. During the relevant period, the adult population was 4.4 million in Denmark (www.statistikbanken.dk); 3.9 million Norway (https://www.ssb.no/en/befolkning); and 7.7 million in Sweden (http://www.scb.se).

9.3. Subjects

The study population were treatment-naïve adults in the source population diagnosed with AF, with a dispensing of apixaban, rivaroxaban or dabigatran ('the NOACs') or warfarin during the study population identification period. The study population identification period was from 01 January 2013 to 31 December 2016, with follow-up through 31 December 2016. The maximum baseline period was 5 years pre-index date, and was shorter for selected covariates, such as cancer (Appendix 4). For each patient included in the study, the date of dispensing of the first study OAC (apixaban, dabigatran, rivaroxaban, or warfarin) during the study population identification period was the index date. In the main analyses of the primary PFIZER CONFIDENTIAL

Page 16 of 253

and secondary endpoints (Section 9.4.2), patients were followed from the index date until a given endpoint, death, OAC treatment switch or discontinuation, emigration, or 31 December 2016, whichever came first. In the intention-to-treat (ITT)-like sensitivity analyses of the primary endpoints and the secondary composite endpoint, follow-up was not censored by treatment switch or discontinuation, i.e., patients were followed from the index date until a given endpoint, death, emigration, or 31 December 2016, whichever came first.

9.3.1. Inclusion criteria

Patients had to meet all of the following inclusion criteria on the index date:

- Be alive and of age 18 years or older;
- A dispensing of apixaban, dabigatran, rivaroxaban, or warfarin between 01 January 2013 and 31 December 2016;
- Diagnosis of AF recorded up to 5 years before or up to 60 days after the index date.

9.3.2. Exclusion criteria

Patients meeting any of the following criteria were ineligible and therefore excluded:

- A diagnosis of mitral stenosis or presence of mechanical heart valves recorded up to 5 years before and including the index date, to rule out non-NVAF indication of OAC use;
- A diagnosis of pulmonary embolism (PE) or deep vein thrombosis (DVT) recorded up to 6 months before and including the index date, to rule out non-NVAF indication of OAC use;
- A record of knee arthroplasty or hip arthroplasty 6 weeks before and including the index date, to rule out non-NVAF indication of OAC use;
- A dispensing, within the 12 months before the index date, of any VKAs, direct thrombin inhibitors, or direct factor Xa inhibitors;
- Dispensing of more than one different OACs on index date;
- Residence in a given country for less than 5 years before index date;
- A record of pregnancy within 9 months before index date.

9.4. Variables

9.4.1. Exposure

Initiation of an OAC was measured by a dispensing at a community pharmacy, as recorded in the nationwide prescription registries of the three Scandinavian countries (see Section 9.5).

9.4.2. Endpoints

Primary, secondary, and exploratory endpoints were defined.

9.4.2.1. Primary endpoints

- Composite endpoint of any stroke or SE at an acute hospitalisation with an overnight stay;
- Any bleeding at an acute hospitalisation with an overnight stay.

9.4.2.2. Secondary endpoints

• Ischaemic stroke at an acute hospitalisation with an overnight stay;

- Haemorrhagic stroke at an acute hospitalisation with an overnight stay;
- Intracranial bleeding at an acute hospitalisation with an overnight stay;
- GI bleeding at an acute hospitalisation with an overnight stay;
- Acute MI at an acute hospitalisation with an overnight stay;
- SE at an acute hospitalisation with an overnight stay;
- Death of any cause;
- The composite endpoint of ischaemic stroke at an acute hospitalisation with an overnight stay, SE at an acute hospitalisation with an overnight stay, acute MI at an acute hospitalisation with an overnight stay, or all-cause mortality;
- Any bleeding at an acute or planned hospitalisation with an overnight stay;
- Any bleeding occurring at an acute hospital contact without an overnight stay;
- Any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis).

9.4.2.3. Exploratory endpoints

In an exploratory analysis, bleeding- and stroke-related health care resource utilisation among the patients treated with the study OACs (number of hospitalisations and bed days) and the associated costs were assessed descriptively in the PS-matched population.

9.4.3. Covariates

Baseline characteristics of the study population were ascertained during up to 5-year baseline before and including the index date: age at index date (in groups and as a continuous variable), sex, overall comorbidity (using the Charlson Comorbidity Index [CCI]), the CHA₂DS₂VASc score, CHADS₂ score, the HAS-BLED score, major bleeding, ischaemic stroke, transient ischaemic attack (TIA), history of heart failure (HF), cancer, diabetes, chronic obstructive pulmonary disease (COPD), hypertension, chronic kidney disease (CKD), liver disease, MI, alcohol abuse, peripheral arterial disease (PAD), coronary artery disease (CAD), dementia, cancer, and cardioversion. Baseline concomitant medication use was assessed using dispensings records within 90 days of index date for angiotensin converting enzyme (ACE) inhibitors, amiodarone, dronedarone, beta-blockers, H2-receptor antagonists, proton pump inhibitors, antidiabetics, anti-platelets, statins, aspirin, selective serotonin reuptake inhibitors (SSRIs), and non-steroidal anti-inflammatory drugs (NSAIDs). Health care utilisation level at baseline was measured by inpatient and outpatient hospital encounters. Available socioeconomic characteristics varied by country. Denmark: household income in 3 years pre-index date, highest achieved education, and employment status. Sweden: personal income in 3 years pre-index date, and highest achieved education. Data on socioeconomic characteristics were not available in Norway for this analysis.

9.4.4. Subgroups

Consistency of the results for the primary endpoints and of the composite secondary endpoint were evaluated according to the following subgroups:

- In each country (Denmark, Norway, Sweden);
- By age on the index date (<65; 65-<75 years, ≥75-<85 years; and in patients ≥85 years old);
- By sex;

- According to CHA₂DS₂VASc score category in the baseline;
- According to CHADS₂ score category in the baseline;
- According to HAS-BLED score category in the baseline;
- According to initial dosage in the baseline (any licensed dose for AF vs reduced dose);
- In patients with/without CKD in the baseline;
- In patients with/without HF in the baseline;
- In patients with/without CAD in the baseline;
- In patients with/without PAD in the baseline;
- In patients with/without prior ischaemic stroke in the baseline;
- In patients with/without prior any stroke in the baseline;
- In patients with/without prior haemorrhagic stroke in the baseline;
- In patients with/without prior TIA in the baseline;
- In patients with/without prior SE at baseline;
- In patients with/without prior GI bleeding at baseline;
- In patients with/without prior intracranial bleeding at baseline;
- In patients with/without diabetes in the baseline.

9.5. Data sources and measurement

Data for this study originated from selected population-based health and administrative registries in Denmark, Norway and Sweden, summarised in Table 2. In each country, data from all registries are individually linkable via a unique personal identifier (34, 36). The Statistical Analysis Plan (SAP, Appendix 4) provides operational definitions for all variables.

Data in the Scandinavian national registries have been validated and the validity has in general been found to be high in all countries (27, 43-52). For example, the positive predictive value of the combined diagnosis of AF and/or atrial/flutter and other cardiovascular diagnoses typically exceeds 95% in Denmark (53-55), Norway (27) and Sweden (52). Other hospital diagnoses have also been validated (56), including the conditions included in the CCI (50, 57). For drugs used chronically, there is also high level of agreement between general practitioner reported use and dispensing records (58). Furthermore, the CHA₂DS₂VASc, CHADS₂ and the HAS-BLED scores can be constructed based on registry data (the HAS-BLED version does not require information regarding INR) (59, 60).

Table 2. National registries in Denmark, Norway and Sweden and type of data available from each registry

Variable	Role	Data source(s)
AF and inclusion/exclusion criteria based on hospital diagnoses and procedures	Definition of the study population	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)
Initiation of an OAC (apixaban, dabigatran, rivaroxaban, warfarin)	Exposure	Danish National Health Services Prescription Database (38, 62), Norwegian Prescription Database (38), Swedish Prescribed Drug Register (38)

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

Variable	Role	Data source(s)	
Any stroke/SE	Endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Ischaemic stroke	Endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Haemorrhagic stroke	Endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Any bleeding	Endpoint	Danish National Patient Registry(56), Norwegian Patient Registry(61), Swedish National Patient Register (37, 50)	
Intracranial bleeding	Endpoint	Danish National Patient Registry(56), Norwegian Patient Registry(61), Swedish National Patient Register (37, 50)	
GI bleeding	Endpoint	Danish National Patient Registry(56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Other bleeding	Endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Acute MI	Endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	
Death of all causes	Endpoint	Danish Civil Registration System (36), National Population Register of Norway, Swedish Total Population Register (34), National Registry (Norway) (63), Swedish Cause of Death Register (64)	
Emigration	Censoring variable	Danish Civil Registration System (36), National Population Register of Norway, Swedish Total Population Register (34), National Registry (Norway) (63), Swedish Population Register (34)	
Sex	Covariate	Danish Civil Registration System (36), National Population Register of Norway, Swedish Total Population Register (34), National Registry (Norway) (63), Swedish Population Register (34)	
Age, years	Covariate/subgroup variable	Danish Civil Registration System (36), National Population Register of Norway, Swedish Total Population Register (34), National Registry (Norway) (63), Swedish Population Register (34)	
CHA ₂ DS ₂ VASc score (65, 66)	Covariate/subgroup variable	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50), Danish National Health Services Prescription Database (38, 62), Norwegian Prescription Database (38), Swedish Prescribed Drug Register (38)	
CHADS ₂ score	Covariate/subgroup variable	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50), Danish National Health Services Prescription Database (38, 62), Norwegian Prescription Database (38), Swedish Prescribed Drug Register (38)	
HAS-BLED score (65, 66)	Covariate/subgroup variable	Danish National Patient Registry (56), Norwegian Patient Registry (41), Swedish National Patient Register (31, 42), Danish National Health Services Prescription Database (38, 62), Norwegian Prescription Database (38), Swedish Prescribed Drug Register (38)	
Concomitant medication	Covariate	Danish National Health Services Prescription Database (38, 62), Norwegian Prescription Database (38), Swedish Prescribed Drug Register (38)	
Comorbidities	Covariates	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)	

Variable	Role	Data source(s)
Health care utilisation	Descriptive characteristic, exploratory endpoint	Danish National Patient Registry (56), Norwegian Patient Registry (61), Swedish National Patient Register (37, 50)
Household income	Covariate	Statistics Denmark, Statistics Sweden
Education	Covariate	Statistics Denmark, Statistics Sweden
Employment	Covariate	Statistics Denmark, Statistics Sweden
Health care costs	Exploratory endpoint	Published data on mean health care costs for specific types of visit

9.6. Bias

An important source of bias is confounding by indication, *i.e.*, prognostically informative prescribing of NOACs vs. warfarin, which is expected to be absent when treatment is randomised (67). Confounding by indication will occur if physicians prescribe NOAC vs. warfarin based on patients' characteristics predictive of the study endpoints (e.g., sex, age, comorbidity, risk scores). In this study, covariates were balanced using 1-to-1 PS matching of members of each NOAC cohort to with members of warfarin cohort. Another important source of bias is Berkson's bias, whereby endpoints' detection rate varies by treatment (68). Because warfarin-treated patients require closer monitoring than NOAC-treated patients, the risks of endpoints may be inflated compared with NOAC-treated patients. In this study, treatment-specific sensitivity of ascertainment of the study endpoints is not known. Potential sources of information bias include misclassification of treatment status by dispensing records or interruptions during hospital stays, misclassification of treatment-naïve status by a 12-month washout period, and potentially differential according to treatment type ascertainment of absolute risks of the study endpoints by hospital encounters. At the same time, specificity of the events' recording is high and relative estimates are therefore expected to be unbiased due to outcome misclassification. Nor can severity of most comorbidities be established, potentially causing misclassification of treatment duration or covariates; the latter will result in residual confounding. Finally, routinely collected data contain no information on the quality of warfarin treatment control or dose for individual patients.

9.7. Study size

Detailed computations of study size and precision are presented in the Study Protocol (Appendix 2). Briefly, it was estimated that the number of patients across the three countries would be sufficient to detect a risk ratio (RR) of 0.8 with a power of 90% and an alpha of 0.05 in a population with a background annual bleeding risk of 2% if there are at least 17,307 apixaban users (assumed to be the smallest group). Similar computations apply to the other primary endpoint of stroke/SE.

9.8. Data transformation

The analyses were conducted on an individual-level dataset from the three countries, prepared according to a common data model (CDM) (69). Statisticians at the investigators' institutions in Denmark, Norway and Sweden completed all data management and quality control required to convert the raw data into the pre-specified CDM. Within each country, the CDM input data files were linked on individual level via a unique study identifier, which replaced the true personal identifier for the purposes of analysis. The completed input datasets from all countries were transferred for analysis to a secure server at Statistics Denmark, where all data were kept in accordance to the rules and regulations governing protection of personal data.

PFIZER CONFIDENTIAL Page 21 of 253

9.9. Statistical methods

9.9.1. Main summary measures

Continuous variables were summarised using either means and standard deviations (SDs) or medians and interquartile ranges (IQRs), or categorised as appropriate. Categorical variables were summarised using frequencies and proportions or percentages. Risk scores were computed using the definitions of the source covariates, as described in the SAP (Appendix 4).

For all primary and secondary endpoints, crude cumulative incidences over the available follow-up and 95% confidence intervals (CIs) within each OAC cohort were computed while treating death as a competing risk (70). Crude rate of each primary and secondary endpoint was computed as a ratio of a first-recorded endpoint-defining event during the follow-up divided by the total amount of person-time in a given cohort. The follow-up for computation of cumulative incidences and rates was censored by death, emigration, treatment switch or discontinuation, or 31 December 2016. Individual outcomes in non-composite endpoints did not censor one another's follow-up.

9.9.2. Main statistical methods

To compare risks of the primary and secondary endpoints among initiators of each NOAC vs warfarin, Cox's proportional-hazards regression was used. Crude and adjusted (via PSmatching) hazard ratios (HRs) and 95% CIs for all primary and secondary endpoints were estimated for initiators of each NOAC vs. propensity-score matched initiators of warfarin. For each patient, a PS was estimated, separately in each country, via logistic regression, as the probability of receiving the given NOAC vs. warfarin, given the covariates, entered into the model as first-order terms. The variables measuring health care utilisation were logtransformed. For each initiator of a given NOAC, initiators of warfarin were matched 1-to-1, without replacement, on the logit of the PS, using caliper of width equal to 0.2 of the standard deviation of the logit of the PS (71). Three NOAC-warfarin PS-matched populations were constructed, for apixaban, dabigatran, and rivaroxaban. Within each matched population, the balance of the measured covariates was assessed by examining standardised mean differences (SMDs) before and after the matching. A SMD <0.1 was considered to be indicative of balance of a given covariate. Members of NOAC cohorts without a match were excluded from the PS-matched analyses. To enable inclusion of all patients in the analysis, in a sensitivity analysis of the primary and composite secondary endpoints, confounding was controlled using conventional adjustment using Cox proportional-hazards regression.

Treatment duration was defined as described by Halvorsen et al (27): for each dispensing, the OAC days of supply was computed using information on date of dispensing, the number of packages, and the pack-size dispensed. For NOAC initiators, a patient was considered on-treatment from the index date and for the subsequent number of days corresponding to the number of tablets in all dispensed packages for rivaroxaban (used once daily) or half the number of tablets in all dispensed packages for dabigatran or apixaban (used twice daily).

For each patient, the on-treatment period was defined as index date + the estimated days supplied + 30-day grace period to account for incomplete adherence. To approximate the ontreatment period for warfarin in the absence of data on INR, first age-group-specific (age at index date <55 years, 55-<65 years, 65-<75 years, 75-<85 years, ≥85 years) mean daily dose was computed for all patients initiating warfarin in the study period by dividing the total amount dispensed during the follow-up by the follow-up length. For each patient in a given age group and country, median daily dose was used as the assumed warfarin daily dose in computing duration of warfarin use. A patient switched treatment if an OAC different from the index OAC was dispensed within 30 days after the estimated end of supply; the patient PFIZER CONFIDENTIAL

Page 22 of 253

discontinued the index OAC treatment if next OAC dispensing was more than 30 days after the estimated end of supply.

The subgroup analyses of the primary and the composite secondary endpoints were carried out within the subgroups of patients included in the overall pairwise PS-matched analysis sets. A Cox's proportional-hazards regression model was fit including, in addition to the treatment variable, a subgroup-by-treatment interaction term. Within each subgroup, covariate balance was evaluated as described above and covariates with a SMD \geq 0.1 were included in the regression model to estimate the subgroup-specific adjusted HRs and 95% CIs. Subgroup-specific adjusted HRs with fewer than 10 events per degree of freedom were not estimated, to avoid unstable estimates.

9.9.3. Missing values

There were 258 patients from Denmark and 37 patients from Sweden with missing data on income (a variable included in PS-estimation). To avoid automatic exclusion of these patients from the PS computation, median income value was imputed for these patients.

9.9.4. Sensitivity analyses

The following sensitivity analyses were performed overall, for the primary endpoints and the composite secondary endpoint:

- The ITT-like analyses: the overall PS-matched analyses to estimate HRs of the primary endpoints and the composite secondary endpoint were repeated without censoring by treatment switch or discontinuation;
- The overall comparative analyses of the primary endpoints and the composite secondary endpoint in the PS-matched population were repeated using an alternative definition of warfarin discontinuation, based on maximum likelihood estimation of a parametric two-component mixture model for the waiting time distribution, as recently described in a similar setting and using data on the percentiles of the waiting time distribution previously reported for Danish patients (72, 73);
- The overall comparative analyses of the primary endpoints and the composite secondary endpoint was repeated in the full analysis dataset using conventional adjustment instead of PS matching to avoid exclusion of non-matched patients from the analyses;
- For the analyses stratified on the initial dose, de-novo PS matching within the initial dose defined subgroups were performed.

To provide context to the findings, in a series of post-hoc analyses, computed crude cumulative incidences of treatment discontinuation and treatment switch were computed in each cohort.

9.9.5. Exploratory analyses

All analyses of the exploratory endpoints were conducted in the PS-matched population, separately in each country. Health care utilisation costs assumed for this analysis were based on published estimates are shown in Table 3. Costs are presented separately for patients with index dates at least one year and for patients with index dates at least two years of before the end of the study. The mean values were computed across all patients included in that year.

Table 3. Assumed costs for the selected health care resource utilisation indicators

DENMARK* (74) NORWAY (75) SWEDEN (76)

ELIQUIS® (apixaban) B0661103 NON-INTERVENTIONAL FINAL STUDY REPORT

Mean cost in 2016	Local currency (DKK)	2016 EURO exchange rate, mean*	EURO	Local currency (NOK)	2016 EURO exchange rate, mean*	EURO	Local currency (SEK)	2016 EURO exchange rate, mean*	EURO
Per hospital bed-day	4,000.00	7.4452	537.26	15,125.00	9.2906	1,627.99	9,562.00	9.4689	1,009.83
Planned outpatient visit	702.00	7.4452	94.29	502.00	9.2906	54.03	349.10	9.4689	36.87
Acute outpatient visit	702.00	7.4452	94.29	502.00	9.2906	54.03	349.10	9.4689	36.87

*https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-dkk.en.html (European Central Bank) Costs where local published data could not be obtained are based on the latest data from the World Health Organisation WHO unit costs (77)

Norway: https://statistikk.helsedirektoratet.no/bi/Dashboard/be512ba0-a6e6-4e8f-900a-bbee3f50cc29?e=false&vo=viewonly (75) Sweden: https://skl.se/tjanster/englishpages.411.html (76)

Data were analysed using SAS Software version 9.4 (SAS Inc., Cary, NC, USA). The detailed methodology is documented in the SAP, dated 05 June 2018 (Appendix 4).

9.9.6. Amendments to the statistical analysis plan

There were the following deviations from the SAP:

- Calendar year was not included in the computation of apixaban-warfarin propensity scores, as that would result in a substantial depletion of the PS-matched population; instead, calendar year was used as an adjustment variable in regression model.
- Stratification by unspecified stroke was not conducted as unspecified stroke could not be separated in the coded data from ischaemic stroke.
- In a post-hoc analysis, crude rates and HRs of treatment switch and treatment discontinuation were estimated, in addition to the planned analyses, to help inform interpretation of the results.

9.10. Quality control

Data management and analyses were carried out according to each investigator's institutional standard procedures. All study documents were reviewed by the entire research team and by clinicians with relevant expertise. A senior epidemiologist in each institution reviewed the report before submission to the MAH.

9.11. Protection of human subjects

Subject information and consent

Not applicable.

Independent Ethics Committee (IEC)/Institutional Review Board (IRB)

In Denmark, this study was approved by the Danish Data Protection Agency (journal number 2014-54-0922/KEA-2015-17). In Norway, the study was approved by the Regional Committee for Medical and Health Research Ethics, Region West (ref no. 2015/1503)) and the Norwegian Data Protection Agency (ref no. 17/01153). In Sweden, this study was approved by the regional ethical board in Stockholm, Sweden, on 20 November 2013 (record number 2013/1850-31/1), and two supplements that was approved on 17 July 2014 (record number 2014/1214-32) and 15 July 2016 (record number 2016/2218-32).

Ethical conduct of the study

The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor and follow generally accepted research practices described in in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), European Medicines Agency (EMA) Guideline for Good Pharmacovigilance Practice (GVP).

Regulations specific to Statistics Denmark

Data analysis for this study has been conducted in the servers of Statistics Denmark and therefore reporting must comply with Statistics Denmark's requirements in place to prevent inadvertent identification of individuals. These requirements include full anonymisation of the data; inability of the analysis to download individual data on own PC, and ban on reporting any cells with <5 individuals, including any complementary aggregate statistics that may potentially allow re-computation of such cells from the existing results. All results of this study are reported according to the regulations set by Statistics Denmark. To comply with data protection regulation of Statistics Denmark, 'clouding' was used in situations in which the number of events in a given cell was between 1 and 5 or could be computed from adjacent data. In such instances (e.g., computation of rates), numbers of events was rounded to the nearest 10. The rates and the CIs were based on the observed (i.e., unrounded) event counts.

10. RESULTS

10.1. Participants

Between 01 January 2013 and 31 December 2016, in Denmark, Norway and Sweden, there were 781,093 adults with a dispensing of apixaban, dabigatran, rivaroxaban, or warfarin. Among them, 450,969 (58%) patients had a diagnosis of AF. Among those, 197,515 (44%) patients had a dispensing of a VKA, a direct thrombin inhibitor or a direct factor Xa inhibitor in the 12 months before the index date did not fulfil eligibility criteria and were excluded. The second largest exclusion (21,591 patients, 5%) was due to history of mitral stenosis or a mechanical heart valve. After applying the inclusion and exclusion criteria, 219,545 patients were included in the total study population (Table 15.1, Figure 15.1): 71,585 patients entered the apixaban cohort; 31,209 patients entered the dabigatran cohort; 37,580 patients entered the rivaroxaban cohort and 79,171 patients entered the warfarin cohort (Figure 15.1). The country-specific inclusion and exclusion of patients are summarised in Figure 15.2 (Denmark), Figure 15.3 (Norway), and Figure 15.4 (Sweden). The apixaban cohort was the largest NOAC cohort in each country, and the largest OAC cohort in Norway (Figure 15.3).

10.2. Descriptive data

Table 15.1 shows distribution of the baseline characteristics of the study cohorts in the three countries combined. The OAC cohorts differed with respect to the year of OAC initiation, with most apixaban and rivaroxaban cohort members initiating the OAC in 2016 and most warfarin and dabigatran cohort members initiating the OAC in 2013. Patients in the apixaban cohort had a greater proportion of persons \geq 85 years old than patients in all other cohorts, and, related to age, patients in the apixaban cohort had a greater prevalence of overall comorbidity burden (CCI \geq 3) than the patients in the other NOACs cohorts). Patients in the apixaban cohort also had higher prevalence of prior intracranial bleeding, stroke, TIA,

PFIZER CONFIDENTIAL Page 25 of 253 diabetes, COPD, and dementia than patients in the other NOAC cohorts. Patients in the apixaban cohort had greater prevalence of high risk scores than patients in either the dabigatran or the rivaroxaban cohort. At the same time, patients in the apixaban cohort had lower prevalence of high risk scores than patients in the warfarin cohort. All cohorts had comparable prevalence of alcoholism, and 6-month baseline prevalence of cancer. Between one-quarter and one-third of the NOAC initiators started with a reduced dose. The country-specific distributions of the baseline characteristics by cohort are shown in Table 15.2 (Denmark), Table 15.3 (Norway), and Table 15.4 (Sweden).

10.3. Outcome data

The median (IQR) follow-up time for death in main/ITT-like sensitivity analyses and until the two primary endpoints (main analysis), in the full population, are shown, by country and/or cohort in Table 4.

Country	Cohort	Follow-up until a primary endpoint or death, median (interquartile range), months					
		Until death, main analysis	Until death, ITT-like analysis	Until primary endpoint stroke/SE, main analysis	Until primary endpoint any bleeding, main analysis		
Overall	All	9.88 (3.94-21.72)	21.42 (9.95 - 34.07)	9.72 (3.91 - 21.49)	9.59 (3.78 - 21.32)		
All	Apixaban	9.26 (3.75 - 17.84)	12.75 (5.88 - 21.19)	9.13 (3.75 - 17.64)	9.10 (3.75 - 17.61)		
All	Dabigatran	11.53 (3.94 - 29.67)	31.34 (19.42 - 39.16)	11.20 (3.94 - 29.34)	11.14 (3.94 - 29.21)		
All	Rivaroxaban	10.84 (4.21 - 21.95)	17.41 (8.34 - 29.54)	10.74 (4.21 - 21.75)	10.64 (4.21 - 21.52)		
All	Warfarin	9.58 (4.14 - 24.41)	30.72 (17.81 - 39.62)	9.47 (3.81 - 23.99)	9.47 (3.58 - 23.69)		
Denmark	All	8.77 (3.14 - 20.76)	20.40 (9.20 - 33.45)	8.54 (3.09 - 20.53)	8.42 (3.02 - 20.30)		
Norway	All	9.49 (3.94 - 21.13)	21.85 (10.25 - 34.53)	9.33 (3.88 - 20.86)	9.13 (3.75 - 20.60)		
Sweden	All	10.70 (4.34 - 22.37)	21.65 (10.22 - 34.14)	10.51 (4.27 - 22.16)	10.45 (4.21 - 22.08)		
Denmark	Apixaban	9.18 (3.52 - 18.40)	13.47 (6.01 - 22.41)	8.87 (3.38 - 18.04)	8.84 (3.35 - 18.04)		
	Dabigatran	12.91 (3.94 - 31.08)	32.10 (21.42 - 39.39)	12.48 (3.94 - 30.72)	12.29 (3.94 - 30.49)		
	Rivaroxaban	8.25 (3.09 - 18.04)	13.37 (5.65 - 25.40)	8.13 (3.02 - 17.74)	7.92 (2.92 - 17.51)		
	Warfarin	7.46 (2.97 - 18.87)	24.77 (12.65 - 36.90)	7.39 (2.97 - 18.66)	7.16 (2.97 - 18.27)		
Norway	Apixaban	8.74 (3.75 - 16.69)	12.55 (5.91 - 21.19)	8.61 (3.75 - 16.53)	8.51 (3.75 - 16.36)		
	Dabigatran	10.91 (3.94 - 30.37)	33.81 (23.75 - 41.07)	10.84 (3.94 - 30.14)	10.56 (3.83 - 29.86)		
	Rivaroxaban	12.02 (4.27 - 24.71)	21.39 (11.14 - 34.10)	11.83 (4.21 - 24.44)	11.56 (4.21 - 23.82)		
	Warfarin	8.21 (3.43 - 20.83)	31.80 (18.99 - 40.44)	8.06 (3.43 - 20.57)	7.82 (3.43 - 20.01)		
Sweden	Apixaban	9.56 (3.84 - 18.07)	12.58 (5.85 - 20.73)	9.46 (3.75 - 17.87)	9.46 (3.75 - 17.87)		
	Dabigatran	10.78 (3.94 - 27.17)	27.17 (12.68 - 36.86)	10.51 (3.94 - 26.84)	10.61 (3.94 - 26.84)		
	Rivaroxaban	12.58 (4.40 - 23.13)	18.50 (9.33 - 28.09)	12.45 (4.27 - 22.90)	12.29 (4.27 - 22.77)		
	Warfarin	11.40 (4.75 - 27.20)	32.53 (20.37 - 40.28)	11.16 (4.53 - 26.81)	11.03 (4.51 - 26.61)		

Table 4. Median follow-up time, months, for death and primary endpoints, by country and/or cohort

Table 15.5 – Table 15.17 show crude rates and crude pairwise NOAC-warfarin HRs with 95% CIs of the primary and secondary endpoints, overall and by country.

Crude rates (95% CI), per 100 person-years of any stroke or SE were 2.1 (2.0 - 2.2) in the apixaban cohort, 1.4 (1.3 - 1.5) in the dabigatran cohort, 1.9 (1.8 - 2.1) in the rivaroxaban cohort, and 1.9 (1.8 - 2.0) in the warfarin cohort (Table 15.5). Crude rates (95% CI) for any bleeding at an acute hospitalisation with an overnight stay were 3.0 (2.9 - 3.2) in the apixaban cohort, 2.5 (2.3 - 2.6) in the dabigatran cohort, 3.9 (3.7 - 4.1) in the rivaroxaban cohort, and

3.5 (3.4 - 3.6) in the warfarin cohort (Table 15.6). Crude rates (95% CI) for intracranial bleeding at an acute hospitalisation with an overnight stay were 0.6 (0.6 - 0.7) in the apixaban cohort, 0.3 (0.3 - 0.4) in the dabigatran cohort, 0.7 (0.6 - 0.8) in the rivaroxaban cohort, and 0.9 (0.8 - 0.9) in the warfarin cohort (Table 15.9). Crude rates (95% CI) for GI bleeding at an acute hospitalisation with an overnight stay were 1.2 (1.1 - 1.3) in the apixaban cohort, 1.3 (1.2 - 1.4) in the dabigatran cohort, 1.7 (1.6 - 1.8) in the rivaroxaban cohort, and 1.3 (1.2 - 1.4)1.4) in the warfarin cohort (Table 15.10). Crude rates (95% CI) for acute MI at an acute hospitalisation with an overnight stay were 1.4 (1.3 - 1.5) in the apixaban cohort, 0.9 (0.8 -1.0) in the dabigatran cohort, 1.1 (1.0 - 1.2) in the rivaroxaban cohort, and 1.4 (1.3 - 1.4) in the warfarin cohort (Table 15.11). Crude rates (95% CI) for SE at an acute hospitalisation with an overnight stay were 0.1 (0.1 - 0.1) in the apixaban cohort, 0.1 (0.0 - 0.1) in the dabigatran cohort, 0.1 (0.0 - 0.1) in the rivaroxaban cohort, and 0.1 (0.1 - 0.1) in the warfarin cohort (Table 15.12) Crude all-cause mortality (95% CI) was 7.6 (7.4 - 7.8) in the apixaban cohort, 3.6 (3.4 - 3.8) in the dabigatran cohort, 6.9 (6.6 - 7.1) in the rivaroxaban cohort, and 5.6 (5.4 - 5.7) in the warfarin cohort (Table 15.13). Crude rates (95% CI) for the secondary composite endpoint were 10.2 (9.9 - 10.4) in the apixaban cohort, 5.4 (5.2 - 5.6) in the dabigatran cohort, 8.9 (8.6 - 9.2) in the rivaroxaban cohort, and 7.9 (7.7 - 8.1) in the warfarin cohort (Table 15.14). Crude rates (95% CI) for any bleeding at an acute or planned hospitalisation with an overnight stay were 3.4 (3.2 - 3.5) in the apixaban cohort, 2.7 (2.5 -2.9) in the dabigatran cohort, 4.3 (4.1 - 4.5) in the rivaroxaban cohort, and 3.8 (3.7 - 3.9) in the warfarin cohort (Table 15.15). Crude rates (95% CI) for any bleeding at an acute hospital contact without an overnight stay were 1.9 (1.8 - 2.0) in the apixaban cohort, 1.0 (0.9 - 1.1) in the dabigatran cohort, 2.6 (2.5 - 2.8) in the rivaroxaban cohort, and 2.4 (2.3 - 2.5) in the warfarin cohort (Table 15.16). Crude rates (95% CI) for any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity endpoint) were 1.9 (1.8 - 2.0) in the apixaban cohort, 1.7 (1.6 - 1.8) in the dabigatran cohort, 2.7 (2.6 - 2.9) in the rivaroxaban cohort, and 2.5 (2.4 - 2.6) in the warfarin cohort (Table 15.17).

Figure 15.5 – Figure 15.17 display crude cumulative incidences of the primary and secondary endpoints, overall and by country, while treating death as a competing risk. Table 15.18 – Table 15.30 show corresponding numeric cumulative incidences (95% CIs) over 12, 24, 36 and 48 months of follow-up. Figure 15.5 and Table 15.18 show crude cumulative incidence for any stroke or SE at an acute hospitalisation with an overnight stay; Figure 15.6 and Table 15.19 show crude cumulative incidence for any bleeding at an acute hospitalisation with an overnight stay; Figure 15.7 and Table 15.20 show crude cumulative incidence of ischaemic stroke at an acute hospitalisation with an overnight stay; Figure 15.8 and Table 15.21 show crude cumulative incidence for haemorrhagic stroke at an acute hospitalisation with an overnight stay; Figure 15.9 and Table 15.22 shows crude cumulative incidence for intracranial bleeding at an acute hospitalisation with an overnight stay; Figure 15.10 and Table 15.23 show crude cumulative incidence for GI bleeding at an acute hospitalisation with an overnight stay; Figure 15.11 and Table 15.24 show crude cumulative incidence for acute MI at an acute hospitalisation with an overnight stay; Figure 15.12 and Table 15.25 show crude cumulative incidence for SE at an acute hospitalisation with an overnight stay; Figure 15.13 and Table 15.26 show crude cumulative mortality; Figure 15.14 and Table 15.27 show crude cumulative incidence for composite endpoint of ischaemic stroke at an acute hospitalisation with an overnight stay, SE at an acute hospitalisation with an overnight stay, acute MI at an acute hospitalisation with an overnight stay, or death of any cause; Figure 15.15 and Table 15.28 show crude cumulative incidence for any bleeding at an acute or planned hospitalisation with an overnight stay; Figure 15.16 and Table 15.29 show crude cumulative incidence for any bleeding occurring at an acute hospital contact without an overnight stay; and Figure 15.17 and Table 15.30 show crude cumulative incidence for any PFIZER CONFIDENTIAL

Page 27 of 253

bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis).

10.4. Main results

10.4.1. Primary and secondary endpoints: crude analyses

Table 15.5 – Table 15.17 show crude pairwise HRs (95% CIs) of the primary and secondary endpoints, overall and by country, comparing each NOAC vs. warfarin. Crude HR (95% CI) for any stroke or SE were 0.99 (0.92 - 1.06) for apixaban, 0.76 (0.69 - 0.83) for dabigatran, and 1.01 (0.93 - 1.09) for rivaroxaban. There were differences between countries: with higher crude rates for apixaban and rivaroxaban in Denmark vs. lower in Norway or Sweden (Table 15.5).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for any bleeding at an acute hospitalisation with an overnight stay were 0.79 (0.75 - 0.84) for apixaban, 0.72 (0.67 - 0.77) for dabigatran, and 1.10 (1.03 - 1.16) for rivaroxaban (Table 15.6).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for ischaemic stroke at an acute hospitalisation with an overnight stay 1.07 (0.99 - 1.15) for apixaban, 0.86 (0.78 - 0.95) for dabigatran, and 1.04 (0.95 - 1.14) for rivaroxaban (Table 15.7).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for haemorrhagic stroke at an acute hospitalisation with an overnight stay were 0.86 (0.74 - 1.01) for apixaban, 0.41 (0.32 - 0.53) for dabigatran, and 1.06 (0.89 - 1.26) for rivaroxaban (Table 15.8).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for intracranial bleeding at an acute hospitalisation with an overnight stay were 0.70 (0.63 - 0.79) for apixaban, 0.39 (0.33 - 0.47) for dabigatran, and 0.79 (0.70 - 0.90) for rivaroxaban (Table 15.9).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for GI bleeding at an acute hospitalisation with an overnight stay were 0.84 (0.77 - 0.91) for apixaban, 1.06 (0.96 - 1.17) for dabigatran, and 1.25 (1.14 - 1.37) for rivaroxaban (Table 15.10).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for acute MI at an acute hospitalisation with an overnight stay were 0.96 (0.88 - 1.04) for apixaban, 0.67 (0.60 - 0.75) for dabigatran, and 0.80 (0.72 - 0.89) for rivaroxaban (Table 15.11).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for SE at an acute hospitalisation with an overnight stay were 0.59 (0.43 - 0.83) for apixaban, 0.60 (0.40 - 0.92) for dabigatran, and 0.56 (0.37 - 0.85) for rivaroxaban (Table 15.12).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for death of all causes were 1.28 (1.23 - 1.33) for apixaban, 0.67 (0.63 - 0.70) for dabigatran, and 1.22 (1.17 - 1.28) for rivaroxaban (Table 15.13). Mortality rates differed among the three countries.

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for the secondary composite endpoint were 1.19 (1.16 - 1.23) for apixaban, 0.71 (0.68 - 0.75) for dabigatran, and 1.12 (1.08 - 1.16) for rivaroxaban (Table 15.14).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for any bleeding at an acute or planned hospitalisation with an overnight stay were 0.81 (0.77 - 0.85) for

apixaban, 0.73 (0.69 - 0.78) for dabigatran, and 1.10 (1.05 - 1.17) for rivaroxaban (Table 15.15).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for any bleeding at an acute hospital contact without an overnight stay were 0.78 (0.73 - 0.84) for apixaban, 0.42 (0.37 - 0.46) for dabigatran, and 1.11 (1.03 - 1.19) for rivaroxaban (Table 15.16).

In a pairwise comparison of each NOAC with warfarin, crude HR (95% CI) for any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis) were 0.70 (0.66 - 0.75) for apixaban, 0.70 (0.64 - 0.76) for dabigatran, and 1.07 (1.00 - 1.15) for rivaroxaban (Table 15.17).

10.4.2. Primary and secondary endpoints: analyses in PS-matched population

Table 5 summarises the initial size of each NOAC cohort available for matching, the sizes of the cohorts after exclusion of patients without a suitable match from the warfarin cohort, and SMDs before and after matching. Overall, proportions of the NOAC cohorts with a match were 78% for apixaban, 91% for dabigatran, and 81% for rivaroxaban. The proportion of NOAC patients with a successful warfarin match was the lowest in Norway.

	Apixaban vs.	Dabigatran vs.	Rivaroxaban vs.
All countries combined	warfarin	warfarin	warfarin
NOAC initiators in the full population	71,585	31,209	37,580
11	,		
NOAC initiators successfully matched	55,581 (78%)	28,428 (91%)	30,599 (81%)
Maximum SMD before/after matching	0.23/0.02	0.47/0.03	0.58/0.04
Source output	Table 15.31	Table 15.35	Table 15.39
Denmark			
NOAC initiators in the full population	14,980	12,446	12,682
NOAC initiators successfully matched	13,173 (89%)	11,465 (92%)	10,537 (83%)
Maximum SMD before/after matching	0.27/0.06	0.33/0.03	0.52/0.06
Source output	Table 15.32	Table 15.36	Table 15.40
Norway			
NOAC initiators in the full population	17,780	8,684	10,565
NOAC initiators successfully matche	10,598 (60%)	7,205 (83%)	7,268 (69%)
Maximum SMD before/after matching	0.37/0.05	0.43/0.05	0.49/0.06
Source output	Table 15.33	Table 15.37	Table 15.41
Sweden			
NOAC initiators in the full population	38,825	10,079	14,333
NOAC initiators successfully matched	31,810 (82%)	9,758 (97%)	12,794 (89%)
Maximum SMD before/after matching	0.42/0.03	0.43/0.03	0.80/0.04
Source output	Table 15.34	Table 15.38	Table 15.42

Table 5. NOAC initiators included in the full population and in the PS-matched
populations, overall, by cohort, and by country

Figure 15.18 – Figure 15.29 show adjusted HRs for each NOAC vs. warfarin pairwise comparison of the primary endpoints overall and in the prespecified subgroups (additionally adjusted within each subgroup for variables for which balance was not achieved, per SAP, Appendix 4).

Among patients initiating apixaban vs. warfarin in the three countries combined, the adjusted HR (95% CI) were 0.96 (0.87 - 1.06) for any stroke or SE at an acute hospitalisation with an overnight stay; 0.73 (0.67 - 0.78) for any bleeding at an acute hospitalisation with an overnight stay; and 1.12 (1.07 - 1.17) for the secondary composite endpoint. For the primary bleeding endpoint, there was no appreciable variability of HRs in any of the subgroups examined (Figure 15.18). The adjusted apixaban vs. warfarin HRs for the primary endpoints overall and subgroups for Denmark are in Figure 15.21, for Norway in Figure 15.24 and for Sweden in Figure 15.27.

Among patients initiating dabigatran vs. warfarin in the three countries combined, the adjusted HR (95% CI) were 0.89 (0.80 - 1.00) for any stroke or SE at an acute hospitalisation with an overnight stay; 0.89 (0.82 - 0.97) for any bleeding at an acute hospitalisation with an overnight stay; and 1.03 (0.97 - 1.10) for the secondary composite endpoint. Estimable HRs did not vary in a clinically important way in most subgroups, except by prior HF, age (for bleeding), and certain comorbidities (Figure 15.19). The adjusted dabigatran vs. warfarin HRs for the primary endpoints overall and subgroups for Denmark are in Figure 15.22 for Norway in Figure 15.25 and for Sweden in Figure 15.28.

Among patients initiating rivaroxaban vs. warfarin in the three countries combined, the adjusted HR (95% CI) were 1.03 (0.92 - 1.14) for any stroke or SE at an acute hospitalisation with an overnight stay; 1.15 (1.07 - 1.25) for any bleeding at an acute hospitalisation with an overnight stay; and 1.20 (1.14 - 1.26) for the secondary composite endpoint. Estimable HRs did not vary in clinically important way in any of the subgroups (Figure 15.20). The adjusted rivaroxaban vs. warfarin HRs for the primary endpoints overall and subgroups for Denmark are in Figure 15.23 for Norway in Figure 15.26, and for Sweden in Figure 15.29.

Death, as the most common event within the secondary composite endpoint, accounted for most of the observed results for this endpoint.

Figure 15.30 – Figure 15.33 show combined across all countries and country-specific adjusted HRs for the secondary endpoints using pairwise comparisons of apixaban vs. warfarin: ischaemic stroke and haemorrhagic stroke (Figure 15.30); intracranial bleeding and GI bleeding (Figure 15.31); the three definitions of any bleeding (Figure 15.32); and acute MI, SE and death of any cause (Figure 15.33). Apixaban compared with warfarin was associated with similar rates of ischaemic stroke, acute MI, and SE, higher rates of all-cause death, and lower rates of haemorrhagic stroke, and all bleeding endpoints.

Figure 15.34 – Figure 15.37 show combined across all countries and country-specific adjusted HRs for the secondary endpoints using pairwise comparisons of dabigatran vs. warfarin: ischaemic stroke and haemorrhagic stroke (Figure 15.34); intracranial bleeding and GI bleeding (Figure 15.35); the three definitions of any bleeding (Figure 15.36); and acute MI, SE and death of any cause (Figure 15.37). Dabigatran compared with warfarin was associated with similar rates of ischaemic stroke, acute MI, SE, and all-cause death, higher rates GI bleeding, and lower rates of haemorrhagic stroke, and the bleeding endpoints other than GI bleeding.

Figure 15.38 – Figure 15.41 show combined across all countries and country-specific adjusted (via PS-matching) HRs and 95% CIs for the secondary endpoints using pairwise comparisons of rivaroxaban vs. warfarin: ischaemic stroke and haemorrhagic stroke (Figure 15.38); intracranial bleeding and GI bleeding (Figure 15.39); the three definitions of any bleeding (Figure 15.40); and acute MI, SE and death of any cause (Figure 15.41). Rivaroxaban compared with warfarin was associated with similar rates of ischaemic stroke, haemorrhagic stroke and acute MI, higher rates of all bleeding endpoints except intracranial bleeding, and death of any cause, and lower rates of intracranial bleeding and SE.

10.5. Other analyses

10.5.1. Post-hoc analyses

Cumulative incidence of treatment switch was highest in the dabigatran cohort and lowest in the apixaban cohort. At the end of the follow-up, treatment switch occurred for approximately one-third of the dabigatran cohort and for slightly less than one-tenth of the apixaban cohort (Figure 1). Cumulative incidence of treatment discontinuation was the highest in the warfarin cohort and lowest in the apixaban cohort and in the rivaroxaban cohort. By the end of the follow-up, treatment discontinuation occurred in close to 60% of the warfarin cohort and in about one-quarter of the apixaban cohort or the rivaroxaban cohort (Figure 2).





Figure 1. Cumulative incidence of treatment switch, by country and cohort





10.5.2. Sensitivity analyses

10.5.2.1. Conventional adjustment

Figure 15.48 – Figure 15.50 show adjusted HRs for the primary endpoints and the composite secondary endpoints, whereby conventional adjustment is used in the Cox's proportional hazards regression using the entire study population available.

Among the 150,756 patients initiating apixaban vs. warfarin, conventionally adjusted HRs (95% CI) were 0.90 (0.83 - 0.99) for any stroke or SE at an acute hospitalisation with an overnight stay; and 0.73 (0.69 - 0.78) for any bleeding at an acute hospitalisation with an overnight stay (Figure 15.48 displays country-specific results).

Among the N=110,380 patients initiating dabigatran vs. warfarin, conventionally adjusted HRs (95% CI) were 0.88 (0.80 - 0.97) for any stroke or SE at an acute hospitalisation with an overnight stay; and 0.86 (0.80 - 0.93) for any bleeding at an acute hospitalisation with an overnight stay (Figure 15.49 displays country-specific results).

Among the 116,751 patients initiating rivaroxaban vs. warfarin, conventionally adjusted HR (95% CI) was 0.96 (0.88 - 1.05) for any stroke or SE at an acute hospitalisation with an overnight stay; and 1.10 (1.03 - 1.17) for any bleeding at an acute hospitalisation with an overnight stay (Figure 15.50 displays country-specific results).

10.5.2.2. ITT-like analyses

The ITT-like analyses of the primary and the composite secondary endpoints in the PS -score matched populations are presented, overall and stratified by country in Figure 15.42 for apixaban vs. warfarin contrast; in Figure 15.43 for the dabigatran vs. warfarin contrast and in

PFIZER CONFIDENTIAL Page 32 of 253 Figure 15.44 for the rivaroxaban vs. warfarin contrast. The HR estimates from the main analysis are presented for comparison.

10.5.2.3. Alternative definition of warfarin discontinuation

The analyses for the primary and composite secondary endpoints using the previously reported 80% percentile of the waiting time distribution to estimate the time of warfarin discontinuation are shown in Figure 15.45 for apixaban; in Figure 15.46 for dabigatran; and in Figure 15.47 for rivaroxaban.

Table 6 summarises HRs for the primary and the composite secondary endpoints obtained, using data combined from all three countries, using the different approaches: crude, conventionally adjusted (sensitivity analysis), PS-matched main analysis, and PS-matched ITT-like sensitivity analysis.

Table 6. Hazard ratios for the primary endpoints obtained from different analytic approaches

Primary endpoint	Hazard ratio (95% CI)						
	Crude*	Conventionally adjusted*	PS-matched* MAIN ANALYSIS	PS-matched** ITT-like	PS-matched* Alternative definition of warfarin discontinuation		
		A	Apixaban vs. warfari	n			
Any stroke or SE at an acute hospitalisation with an overnight stay	0.99 (0.92 - 1.06)	0.90 (0.83 - 0.99)	0.96 (0.87 - 1.06)	0.96 (0.88 - 1.04)	0.96 (0.86 - 1.06)		
Any bleeding at an acute hospitalisation with an overnight stay	0.79 (0.75 - 0.84)	0.73 (0.69 - 0.78)	0.73 (0.67 - 0.78)	0.75 (0.70 - 0.80)	0.74 (0.68 - 0.80)		
Source output	Table 15.5/Table 15.6	Figure 15.48	Figure 15.18	Figure 15.42	Figure 15.45		
	Dabigatran vs. warfarin						
Any stroke or SE at							
an acute hospitalisation with an overnight stay	0.76 (0.69 - 0.83)	0.88 (0.80 - 0.97)	0.89 (0.80 - 1.00)	0.90 (0.83 - 0.98)	0.89 (0.78 - 1.00)		
Any bleeding at an acute hospitalisation with an overnight stay	0.72 (0.67 - 0.77)	0.86 (0.80 - 0.93)	0.89 (0.82 - 0.97)	0.88 (0.82 - 0.94)	0.88 (0.80 - 0.97)		
Source output	Table 15.5/Table 15.6	Figure 15.49	Figure 15.19	Figure 15.43	Figure 15.46		
		Ri	varoxaban vs. warfa	rin			
Any stroke or SE at an acute hospitalisation with an overnight stay	1.01 (0.93 - 1.09)	0.96 (0.88 - 1.05)	1.03 (0.92 - 1.14)	1.03 (0.95 - 1.12)	1.04 (0.93 - 1.16)		
Any bleeding at an acute hospitalisation with an overnight stay	1.10 (1.03 - 1.16)	1.10 (1.03 - 1.17)	1.15 (1.07 - 1.25)	1.08 (1.01 - 1.15)	1.17 (1.07 - 1.27)		
Source output	Table 15.5/Table 15.6	Figure 15.50	Figure 15.20	Figure 15.44	Figure 15.47		

*Censored by death, emigration, discontinuation or switch.

**Censored by death or emigration.

10.5.2.4. Analyses in subgroups defined by initial NOAC dose with de-novo PS matching

The overall results of the PS-matching within the subgroups of initial dose (standard/reduced) for the apixaban cohort are presented in Table 15.43 and Table 15.44 (country specific results are in Table 15.45/Table 15.46 [Denmark]; Table 15.47/Table 15.48 [Norway]; Table 15.49/Table 15.50 [Sweden]).

The overall results of the PS-matching within the subgroups of initial dose (standard/reduced) for the dabigatran cohort are presented in Table 15.51 and Table 15.52 (country-specific results are in Table 15.53/Table 15.54 [Denmark]; Table 15.55/Table 15.56 [Norway]; Table 15.57/Table 15.58 [Sweden]).

The overall results of the PS-matching within the subgroups of initial dose (standard/reduced) for the rivaroxaban cohort are presented in Table 15.59 and Table 15.60 (country-specific results are in Table 15.61/Table 15.62 [Denmark]; Table 15.63/Table 15.64 [Norway]; Table 15.65/Table 15.66 [Sweden]).

The HRs for apixaban for the primary endpoint any stroke or SE at an acute hospitalisation with an overnight stay were associated with similar or slightly lower risk compared with warfarin in both initial dose subgroups, and the magnitude of the HR varied slightly by country. For the primary endpoint any bleeding at an acute hospitalisation with an overnight stay, apixaban was associated with a lower than warfarin risk in both standard and reduce initial dose subgroups. The estimates were consistent across the countries (Table 15.67).

The HRs for dabigatran for the primary endpoint any stroke or SE at an acute hospitalisation with an overnight stay were associated with no difference in risk compared with warfarin, in both initial dose subgroups and across the three countries. For the primary endpoint any bleeding at an acute hospitalisation with an overnight stay, dabigatran was associated with a lower than warfarin risk in the standard initial dose subgroup, but not in reduced initial dose subgroup, with this result being consistent across the countries (Table 15.68).

The HRs for rivaroxaban the primary endpoint any stroke or SE at an acute hospitalisation with an overnight stay were associated with no difference in risk compared with warfarin, in both initial dose subgroups and across the three countries, although the risks were numerically higher in Norway. For the primary endpoint any bleeding at an acute hospitalisation with an overnight stay, rivaroxaban was associated with a similar with warfarin risk for the standard dose and higher than warfarin in the reduced dose (Table 15.69).

Table 7 summarises initial -dose stratified analyses for each of the NOACs combined across the three countries for the primary endpoints.

Table 7. Hazard ratios for the primary endpoints, overall and stratified on initial dose after de-novo PS-matching within each subgroup of initial NOAC dose.

Group/subgroup		Hazard ratio (95% CI) after de-novo PS matching within			
			each subgroup of initial NOAC dose		
	Successfully matched Maximum		Any stroke or SE at an	Any bleeding at an acute	
	NOAC initiators/total	SMD	acute hospitalisation with	hospitalisation with an	
	NOAC initiators (%)	before	an overnight stay	overnight stay	
	matching/after				
		matching			
		Ар	ixaban vs. warfarin		
All*			0.92 (0.84 - 1.01)	0.73 (0.68 - 0.78)	
Standard dose	42,672/50,310 (85%)	0.29/0.02	0.88 (0.78 - 1.00)	0.75 (0.69 - 0.83)	
Reduced dose	18,794/21,275 (88%)	1.07/0.02	0.96 (0.83 - 1.10)	0.69 (0.61 - 0.76)	
	Dabigatran vs. warfarin				

Group/subgroup			Hazard ratio (95% CI) after de-novo PS matching within each subgroup of initial NOAC dose	
	Successfully matched	Maximum	Any stroke or SE at an	Any bleeding at an acute
	NOAC initiators/total	SMD	acute hospitalisation with	hospitalisation with an
	NOAC initiators (%)	before	an overnight stay	overnight stay
		matching/after		
		matching		
All**			0.93 (0.83 - 1.04)	0.87 (0.80 - 0.94)
Standard dose	18,701/20,478 (91%)	0.78/0.03	0.95 (0.80 - 1.12)	0.75 (0.66 - 0.85)
Reduced dose	10,669/10,731 (99%)	0.62/0.03	0.90 (0.76 - 1.05)	0.95 (0.85 - 1.07)
	Rivaroxaban vs. warfarin			
All***			0.97 (0.88 - 1.07)	1.11 (1.03 - 1.20)
Standard dose	23,703/28,366 (84%)	0.62/0.04	0.96 (0.85 - 1.09)	1.09 (0.99 - 1.20)
Reduced dose	9,088/9,214 (99%)	0.74/0.04	0.98 (0.83 - 1.16)	1.15 (1.02 - 1.29)

*Combined population of the successfully matched patients within each category of initial apixaban dose; country-specific results in Table 15.67

**Combined population of the successfully matched patients within each category of initial dabigatran dose; country-specific results in Table 15.68

***Combined population of the successfully matched patients within each category of initial rivaroxaban dose; country-specific results in Table 15.69

10.5.3. Analyses of the exploratory endpoints

10.5.3.1. Denmark

Results of the exploratory endpoints for Denmark are presented in Table 15.70 (apixaban and warfarin), Table 15.71 (dabigatran and warfarin), and Table 15.72 (rivaroxaban and warfarin).

10.5.3.2. Norway

Results of the exploratory endpoints for Norway are presented in Table 15.73 (dabigatran and warfarin), Table 15.74 (dabigatran and warfarin), and Table 15.75 (rivaroxaban and warfarin).

10.5.3.3. Sweden

Results of the exploratory endpoints for Sweden are presented in Table 15.76 (apixaban and warfarin) Table 15.77 (dabigatran and warfarin), and Table 15.78 (rivaroxaban and warfarin).

10.6. Adverse events/adverse reactions

Not applicable.

11. DISCUSSION

11.1. Key results

This population-based cohort study used combined individual-level data from Denmark, Norway, and Sweden and included 219,545 adult patients with NVAF initiating apixaban (N=71,585), dabigatran (N=31,209), rivaroxaban (N=37,580), or warfarin (N=79,171) in 2013 -2016. Patients initiating apixaban tended to be older and to have greater comorbidity indicators than patients initiating OACs. Between one-fourth and one-third of patients initiating the NOACs were started on a reduced initial dose.

In the PS-matched population, patients in the apixaban cohort (N=55,581, 78% of all apixaban initiators) had similar rates of any stroke or SE at an acute hospitalisation with an overnight stay compared with patients in the warfarin cohort (HR 0.96, 95% CI: 0.87 - 1.06), with similar results for standard (HR 0.88 95% CI: 0.78 - 1.00) and reduced (HR 0.96, 95% CI: 0.83 - 1.10) initial dose of apixaban. Patients in the apixaban cohort had a lower rate of any bleeding at an acute hospitalisation with an overnight stay than patients in the warfarin PFIZER CONFIDENTIAL

Page 35 of 253

cohort (adjusted HR 0.73, 95% CI: 0.67 - 0.78), with similar results for standard (HR 0.75, 95% CI 0.69 - 0.83) and reduced (HR 0.69, 95% CI: 0.61 - 0.76) initial apixaban dose. Patients in the apixaban cohort had similar with patients in the warfarin cohort rates of ischaemic stroke and acute MI, and had lower rates of haemorrhagic stroke, all bleeding endpoints, or SE. Treatment with apixaban was associated with a slightly higher all-cause mortality than treatment with warfarin. The rate of the secondary composite endpoint was higher in the low dose apixaban group than in the warfarin group.

In the PS-matched population, patients in the dabigatran cohort (N=28,428, 91% of all eligible) compared with patients in the warfarin cohort had a similar rate of any stroke or SE at an acute hospitalisation with an overnight stay (HR 0.89, 95% CI: 0.80 - 1.00), with similar results for standard (HR 0.95 (0.80 - 1.12)) and reduced (HR 0.90 (0.76 - 1.05)) initial dabigatran dose. Patients in the dabigatran cohort compared with warfarin had a lower rate of any bleeding at an acute hospitalisation with an overnight stay (HR 0.89 95% CI: 0.82 - 0.97). The association was more pronounced in patients with standard initial dabigatran dose (HR 0.75, 95% CI: 0.66 - 0.85) than in patients with reduced initial dabigatran dose (HR 0.95, 95% CI: 0.85 - 1.07). Patients in the dabigatran cohort had similar with patients in the warfarin cohort rates of ischaemic stroke, SE, acute MI, or death of any cause, had lower rates of haemorrhagic stroke, and of intracranial bleeding, but had a substantially higher rate of GI bleeding.

In the PS-matched population, patients in the rivaroxaban cohort (N=30,599, 81% of all initiators) had similar rates of any stroke or SE as compared with patients in the warfarin cohort (HR 1.03, 95% CI: 0.92 - 1.14), similar estimates in patients with standard initial rivaroxaban dose (HR 0.96, 95% CI: 0.85 - 1.09) and patients with reduced initial rivaroxaban dose (HR 0.98, 95% CI: 0.83 - 1.16). Patients in the rivaroxaban cohort had a higher rate of any bleeding at acute hospitalisation with an overnight stay compared with patients in the warfarin cohort (HR 1.15, 95% CI: 1.07 - 1.25), seen both in patients with standard (HR 1.09, 95% CI: 0.99 - 1.20) and reduced (HR 1.15, 95% CI: 1.02 - 1.29) initial rivaroxaban dose. Patients in the rivaroxaban cohort had similar with patients in the warfarin cohort rates of ischaemic stroke, or acute MI, but substantially higher rate of type of any bleeding except intracranial bleeding. Rates of GI bleeding were substantially higher in the rivaroxaban cohort than in the warfarin cohort.

The estimates for the primary and secondary endpoints were robust to changes in analytic approaches, and there was no evidence of strong measured confounding in the data.

Patients with NVAF in the apixaban cohort or in the rivaroxaban cohort were substantially less likely than their matched warfarin cohort to switch or discontinue treatment, resulting in shorter follow-up available in patients treated with warfarin, with potentially fewer endpoint events captured in the main (on-treatment) analysis. Initiators of dabigatran were more likely than their matched initiators of warfarin to switch to another OAC during the follow-up. High treatment/discontinuation rates in dabigatran and warfarin cohorts is consistent with findings from with another Danish study based on the BEYOND Protocol (26).

The uptake of NOACs in the Scandinavian countries has been high (78, 79). In this study, contrary to the expectation of apixaban initiators being the smallest group, apixaban cohort was the largest NOAC cohort and the largest cohort in Norway, which may partially explain smaller proportion of patients for whom a suitable warfarin match was available. The three countries have uniform health care system and high level of adherence to existing guidelines

(80). Sweden is the largest country among the three, and Swedish results likely drive most of the analyses.

Many previous observational studies in the US and Europe have examined the safety and effectiveness of NOACs in real world settings. In three recent Danish cohort studies, whose data overlap with the present dataset, NOACs and warfarin were associated with similar risks of ischaemic stroke, but apixaban and dabigatran conferred lower risks of death (24) and bleeding (24-26) compared with warfarin. In the current study, apixaban and rivaroxaban were associated with a greater risk of death compared with warfarin in all countries except Norway, while dabigatran was associated with a slightly lower risk of death. In a Norwegian study, apixaban and dabigatran each was associated with a lower than warfarin risk of major or clinically relevant non-major bleeding, with the exception of GI bleeding, which was higher with dabigatran or rivaroxaban (27) than with warfarin. This observation is likewise consistent with the present study. Similar findings have been reported from the US (28). A study among patients treated with reduced-dose OACs in Denmark found generally comparable rates of thromboembolic and bleeding events in all groups, noting a trend towards a higher rate of thromboembolic events associated with a reduced dose of apixaban (29). Another Danish study, which conducted a head-to-head inter-NOAC comparison, concluded that the three NOACs had comparable positive benefit-risk balance (8).

11.2. Strengths and limitations

Scandinavian countries have a nearly 100% completeness of out of hospital dispensings, person-level linkage to data from other high-quality registries with national coverage, and complete follow-up, making Scandinavian countries an optimal setting to address comparative effectiveness of anticoagulants in routine clinical practice. Other advantages of the Scandinavian countries for pharmacoepidemiologic research include universal access to health care, similar clinical practice, as well as uniform recording practices, comparable patterns of hospitalisation and referral to specialist care, and high overall quality of care, including high quality of warfarin therapy (30-34, 36-38, 42, 53, 56), an aspect that is unique among all published evidence.

Limitations of this study include small number of events in some subgroups, despite the large study size, and the associated loss in precision. Furthermore, SMD often exceeded the balance threshold of <0.1 in the subgroups, necessitating additional adjustment. Another limitation of this approach is potential loss of generalisability (by the necessary exclusion of patients for whom a match cannot be found and who may differ from the included patients). Furthermore, there was no data on OAC treatment during the hospital stay, and patients may change this medication upon discharge. ICD-10 code used for AF do not distinguish between AF and atrial flutter, so that up to 10% of patients with a diagnosis of AF may in fact have atrial flutter (81). Results of the primary endpoint component of 'any stroke' are difficult to interpret in terms of clinical implications, since prevention of ischaemic stroke is the intended treatment goal, when haemorrhagic stroke is a feared side effect. Furthermore, daily dose of warfarin is only crudely estimate because of the lack of data on INR.

Confounding by indication and detection bias are important potential limitations. Patients initiating apixaban were older and had higher comorbidity burdens than patients initiating dabigatran or rivaroxaban, but had lower prevalence of high risk scores than patients initiating warfarin. At the same time ascertainment of the endpoints is likely to be inflated in warfarin compared with NOAC-treated patients due to closer contact with the health care system. These two biases would drive relative estimates in the opposite directions. Potential sources of information bias include misclassification of treatment status by dispensing

PFIZER CONFIDENTIAL Page 37 of 253 records or interruptions during hospital stays, misclassification of treatment-naïve status by a 12-month washout period, and potentially differential according to treatment type ascertainment of absolute risks of the study endpoints by hospital encounters. At the same time, specificity of the events' recording is high and relative estimates are therefore expected to be unbiased due to outcome misclassification. Nor can severity of most comorbidities be established, potentially causing misclassification of treatment duration or covariates; the latter will result in residual confounding. Finally, routinely collected data contain no information on the quality of warfarin treatment control or dose for individual patients.

11.3. Interpretation

Relative to warfarin, apixaban and dabigatran were associated with lower rates of bleeding whereas rivaroxaban was associated with a higher rate. The three NOACs had comparable rates of stroke and systemic embolism relative to warfarin.

Treatment discontinuation and switch occurred more frequently in patients taking dabigatran or warfarin than in patients taking apixaban or rivaroxaban.

11.4. Generalisability

Generalisability of PS-matched analysis is limited because, by design, patients without a match are excluded from the analyses. Thus, results from the PS-matched population may not be fully generalisable to all patients treated with NOACs. Specifically, patients who are highly likely or highly unlikely to be treated with one or the other treatment based on unusual constellation of risk factors would be excluded from PS-score matched analysis. Finally, this study focussed on OACs initiators with a hospital diagnosis of AF and its results are not necessarily generalisable to patients who are not treatment-naïve or those treated exclusively in primary care. Any lack of generalisability is not a concern if the observed effects are biologically determined (82). Furthermore, HRs may still be generalisable to larger populations even if the underlying absolute risks of the endpoints in the study population are different from those in the source population. In this study, just under 60% of the NOAC - treated patients had a hospital diagnosis of AF within 5 years of treatment start during the study period, and, in this study of initiators, most patients' diagnosis was recent. In a recent study of apixaban utilisation in Denmark and Sweden close to 80% of apixaban initiators (both treatment naïve and switchers) had NVAF (83, 84).

12. OTHER INFORMATION

Not applicable.

13. CONCLUSIONS

Among patients with NVAF initiating OACs, compared with warfarin, apixaban and dabigatran were associated with lower rates of bleeding whereas rivaroxaban was associated with a higher rate. The three NOACs had comparable rates of stroke and systemic embolism relative to warfarin. The uptake of NOACs in the Scandinavian countries is high, and large studies with NOAC-NOAC comparisons are needed to help clinicians choose NOACs in comparable patient populations.

14. REFERENCES

1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-20.

2. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274(5):461-8.

3. Schmidt M, Ulrichsen SP, Pedersen L, Botker HE, Nielsen JC, Sorensen HT. 30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. Int J Cardiol. 2016;225:30-6.

4. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507.

5. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72.

6. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-75S.

7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47.

8. Andersson NW, Svanstrom H, Lund M, Pasternak B, Melbye M. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. Int J Cardiol. 2018;268:113-9.

9. https://legemiddelverket.no/nyheter/rivaroksaban-xarelto-ved-atrieflimmer-og-dvt [cited 2019 05 January].

10.

 $https://legemiddelverket.no/Documents/Offentlig\%20 finansiering\%20 og\%20 pris/Met odevurderinger/P/Pradaxa_atrieflimmer_2012.pdf.$

11. https://www.dagensmedisin.no/artikler/2011/08/28/pradaxa-i-salg-fra-15.-september/ [cited 2019 05 January].

12. http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel [cited 2019 05 January].

13. https://www.fass.se/LIF/atcregister [cited 2019 05 January].

14. Pradaxa approval in Europe [cited 2019 16 April]. Available from: http://www.drugdiscoverytoday.com/view/19918/pradaxa-gains-approval-for-strokeprevention-in-atrial-fibrillation-in-europe/. 15. Xarelto approval in Europe [cited 2019 16 April]. Available from: https://www.europeanpharmaceuticalreview.com/news/10555/bayers-xarelto-approved-in-the-eu-for-the-prevention-of-stroke-in-patients-with-af/.

16. Eliquis approval in Europe [cited 2019 16 April]. Available from: https://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europeprevention-stroke-and-systemic-embolism.

17. Vinter N, Linder M, Andersen M, Pedersen AB, Madsen M, Schachterle SE, et al. Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. Pharmacoepidemiol Drug Saf. 2019;28(6):867-78.

18. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.

19. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.

20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.

21. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(4):480-6.

22. Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. Clin Appl Thromb Hemost. 2013;19(6):619-31.

23. Providencia R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014;134(6):1253-64.

24. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.

25. Staerk L, Fosbol EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017;38(12):907-15.

26. Lamberts M, Staerk L, Olesen JB, Fosbol EL, Hansen ML, Harboe L, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc. 2017;6(2). 27. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):28-36.

28. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2016;5(6).

29. Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.

30. Health Care in Sweden [cited 2015 18 May]. Available from: https://sweden.se/society/health-care-in-sweden/.

31. National Population Register (Norway). https://helsedirektoratet.no/english/norwegian-patient-registry.

32. The Norwegian health care system and pharmaceutical system [cited 2015 18 May]. Available from: http://www.legemiddelverket.no/english/the-norwegian-health-care-system-and-pharmaceutical-system/sider/default.aspx.

33. Health Care in Denmark 2008 [cited 2015 18 May]. Available from: http://www.sum.dk/Aktuelt/Publikationer/~/media/Filer%20-%20Publikationer_i_pdf/2008/UK_Healthcare_in_dk/pdf.ashx.

34. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-67.

35. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl):30-6.

36. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-9.

37. Socialstyrelsenregister. The National Patient Register of Sweden 2016 [cited 2018 24 July]. Available from:

http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish.

38. Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review. Pharmacoepidemiol Drug Saf. 2013;22(7):691-9.

39. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282-9.

40. Lokkegaard T, Pedersen TH, Lind B, Siersma V, Waldorff FB. Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing. Dan Med J. 2015;62(2).

41. Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221-8.

42. Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, K L, Ehrenstein V, et al. The Danish healthcare system and epidemiological research: from healthcare contacts to database records Clin Epidemiol. 2019;11:563-91.

43. Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology. 1992;11(4-6):204-13.

44. Lindblad U, Rastam L, Ranstam J, Peterson M. Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project. Scand J Soc Med. 1993;21(1):3-9.

45. Johansson LA, Westerling R. Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000;29(3):495-502.

46. Linnersjo A, Hammar N, Gustavsson A, Reuterwall C. Recent time trends in acute myocardial infarction in Stockholm, Sweden. Int J Cardiol. 2000;76(1):17-21.

47. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol. 2001;30 Suppl 1:S30-4.

48. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787-91.

49. Appelros P, Terent A. Validation of the Swedish inpatient and cause-of-death registers in the context of stroke. Acta Neurol Scand. 2011;123(4):289-93.

50. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.

51. Andersson P, Londahl M, Abdon NJ, Terent A. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: implications for anticoagulation prophylaxis. J Intern Med. 2012;272(2):170-6.

52. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25(2):95-102.

53. Sundboll J, Adelborg K, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6(11):e012832.

54. Adelborg K, Sundboll J, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study. BMJ Open. 2016;6(12):e012817.

55. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J. 2012;46(3):149-53.

56. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-90.

57. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.

58. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012;4:303-13.

59. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

60. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9(8):1460-7.

61. Helsedirektoratet. Norwegian Patient Registry 2019 [cited 2019 11 April]. Available from: https://helsedirektoratet.no/english/norwegian-patient-registry.

62. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sorensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012;118(19):4768-76.

63. Carnahan RM. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:90-9.

64. Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765-73.

65. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287-92.

66. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.

67. Sorensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology. 2006;44(5):1075-82.

68. Pearce N, Richiardi L. Commentary: Three worlds collide: Berkson's bias, selection bias and collider bias. International Journal of Epidemiology. 2014;43(2):521-4.

69. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf. 2010;19(8):848-57.

70. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.

71. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceutical Statistics. 2011;10(2):150-61.

72. Stovring H, Pottegard A, Hallas J. Determining prescription durations based on the parametric waiting time distribution. Pharmacoepidemiol Drug Saf. 2016.

73. Stovring H, Pottegard A, Hallas J. Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution. Pharmacoepidemiol Drug Saf. 2017;26(8):900-8.

74. Kim K, Thomsen RW, Nicolaisen SK, Hasvold LP, Palaka E, Sørensen HT. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study. BMJ Open. 2019;9(4):e026465.

75. [cited 2019 30 March]. Available from: https://statistikk.helsedirektoratet.no/bi/Dashboard/be512ba0-a6e6-4e8f-900abbee3f50cc29?e=false&vo=viewonly.

76. SALAR [cited 2019 15 April]. Available from: https://skl.se/tjanster/englishpages.411.html.

77. WHO [cited 2019 30 March 2019]. Available from: www.who.int/choice/country/WHO-CHOICEunit_cost_estimates_2007_2008.xls.

78. Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2015;17(2):187-93.

79. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306-13 e1.

80. Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. 2017;83(3):642-52.

81. Mareedu RK, Abdalrahman IB, Dharmashankar KC, Granada JF, Chyou PH, Sharma PP, et al. Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onset. Clin Med Res. 2010;8(1):1-6.

82. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013;42(4):1012-4.

83. Post-approval safety study (PASS) of the utilization pattern of apixaban in Sweden 2016 [cited 2017 29 May]. Available from: http://www.encepp.eu/encepp/viewResource.htm?id=14474.

84. Post-Authorisation Safety Study (PASS) of the Utilisation Patterns of Apixaban in Denmark 2017. Available from:

http://www.encepp.eu/encepp/viewResource.htm;jsessionid=cxpy0Hewwgx_sCfkLET4UTEt ZqTSvtzg61kbSPdO_ZUrbnxRpL48!1888174422?id=18685.

15. LIST OF SOURCE TABLES AND FIGURES

15.1. List of tables

Table 15.1 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Denmark, Norway, Sweden, 2013 -2016)	58
Table 15.2 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Denmark, 2013 -2016)	50
Table 15.3 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Norway, 2013 -2016)	52
Table 15.4 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Sweden, 2013 -2016)	54
Table 15.5 Crude rates, and crude pairwise hazard ratios of any stroke or systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin in Denmark, Norway, and Sweden	56
Table 15.6 Crude rates, and crude pairwise hazard ratios of any bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin in Denmark, Norway, and Sweden	57
Table 15.7 Crude rates, and crude pairwise hazard ratios of ischaemic stroke at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	58
Table 15.8 Crude rates, and crude pairwise hazard ratios of haemorrhagic stroke at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	59
Table 15.9 Crude rates, and crude pairwise hazard ratios of intracranial bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	70
Table 15.10 Crude rates, and crude pairwise hazard ratios of gastrointestinal bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	71
Table 15.11 Crude rates, and crude pairwise hazard ratios of acute myocardial infarction at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	72
Table 15.12 Crude rates, and crude pairwise hazard ratios of systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	73

Table 15.13 Crude rates, and crude pairwise hazard ratios of death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	′4
Table 15.14 Crude rates, and crude pairwise hazard ratios of composite endpoint of ischaemic stroke at an acute hospitalisation with an overnight stay, systemic embolism at an acute hospitalisation with an overnight stay, acute myocardial infarction at an acute hospitalisation with an overnight stay or death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	75
Table 15.15 Crude rates, and crude pairwise hazard ratios of any bleeding at an acute or planned hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	′6
Table 15.16 Crude rates, and crude pairwise hazard ratios of any bleeding at an acute hospital contact without an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	7
Table 15.17 Crude rates, and crude pairwise hazard ratios of any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis) among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country	78
Table 15.18 Crude cumulative incidence of any stroke or systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	'9
Table 15.19 Crude cumulative incidence of any bleeding at an acute hospitalisationwith an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country8	30
Table 15.20 Cumulative incidence of ischaemic stroke at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	31
Table 15.21 Crude cumulative incidence of haemorrhagic stroke at an acutehospitalisation with an overnight stay among patients with NVAF initiatingapixaban, dabigatran, rivaroxaban, or warfarin, overall and by country8	32
Table 15.22 Crude cumulative incidence of intracranial bleeding at an acutehospitalisation with an overnight stay among patients with NVAF initiatingapixaban, dabigatran, rivaroxaban, or warfarin, overall and by country8	33
Table 15.23 Crude cumulative incidence of gastrointestinal bleeding at an acutehospitalisation with an overnight stay among patients with NVAF initiatingapixaban, dabigatran, rivaroxaban, or warfarin, overall and by country8	34
Table 15.24 Crude cumulative incidence of acute myocardial infarction at an acutehospitalisation with an overnight stay among patients with NVAF initiatingapixaban, dabigatran, rivaroxaban, or warfarin, overall and by country8	35

	Crude cumulative incidence of systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country
	Crude cumulative mortality among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country
	Crude cumulative incidence of composite outcome of ischaemic stroke at an acute hospitalisation with an overnight stay, systemic embolism at an acute hospitalisation with an overnight stay, acute myocardial infarction at an acute hospitalisation with an overnight stay, or death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country
	Crude cumulative incidence of any bleeding at an acute or planned hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country
	Crude cumulative incidence of any bleeding occurring at an acute hospital contact without an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country90
	Crude cumulative incidence of any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis) among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating apixaban or warfarin in Denmark, Norway, and Sweden and standardised mean differences before and after matching
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating apixaban or warfarin and standardised mean differences before and after matching, Denmark
:	Baseline characteristics of patients with non-valvular atrial fibrillation initiating apixaban or warfarin and standardised mean differences before and after matching, Norway
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating apixaban or warfarin and standardised mean differences before and after matching, Sweden
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching105
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin and standardised mean differences before and after matching, Denmark
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin and standardised mean differences before and after matching, Norway
	Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin and standardised mean differences before and after matching, Sweden
	I FIZER CONFIDENTIAL

init	seline characteristics of patients with non-valvular atrial fibrillation iating rivaroxaban or warfarin in Denmark, Norway, and Sweden and ndardised mean differences before and after matching11	17
init	seline characteristics of patients with non-valvular atrial fibrillation iating rivaroxaban or warfarin and standardised mean differences before l after matching, Denmark	20
init	seline characteristics of patients with non-valvular atrial fibrillation iating rivaroxaban or warfarin and standardised mean differences before l after matching, Norway	23
init	seline characteristics of patients with non-valvular atrial fibrillation iating rivaroxaban or warfarin and standardised mean differences before l after matching, Sweden	27
init star	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin in Denmark, Norway, or Sweden and ndardised mean differences before and after matching – STANDARD OSE	30
init star	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin in Denmark, Norway, or Sweden and ndardised mean differences before and after matching – REDUCED OSE	33
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Denmark – STANDARD DOSE13	36
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Denmark – REDUCED DOSE	39
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Norway – STANDARD DOSE14	43
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Norway – REDUCED DOSE14	17
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Sweden – STANDARD DOSE15	50
init	seline characteristics of patients with non-valvular atrial fibrillation iating apixaban or warfarin and standardised mean differences before l after matching, Sweden – REDUCED DOSE15	53
init star	seline characteristics of patients with non-valvular atrial fibrillation iating dabigatran or warfarin in Denmark, Norway, or Sweden and ndardised mean differences before and after matching – STANDARD OSE	56

Table 15.52 Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – REDUCED DOSE	8
Table 15.53 Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin and standardised mean differences before and after matching, Denmark – STANDARD DOSE 160)
Table 15.54 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating dabigatran or warfarin and standardised mean differences beforeand after matching, Denmark – REDUCED DOSE	3
Table 15.55 Baseline characteristics of patients with non-valvular atrial fibrillation initiating dabigatran or warfarin and standardised mean differences before and after matching, Norway – STANDARD DOSE	5
Table 15.56 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating dabigatran or warfarin and standardised mean differences beforeand after matching, Norway – REDUCED DOSE	3
Table 15.57 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating dabigatran or warfarin and standardised mean differences beforeand after matching, Sweden – STANDARD DOSE	0
Table 15.58 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating dabigatran or warfarin and standardised mean differences beforeand after matching, Sweden – REDUCED DOSE	3
Table 15.59 Baseline characteristics of patients with non-valvular atrial fibrillation initiating rivaroxaban or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – STANDARD DOSE	5
Table 15.60 Baseline characteristics of patients with non-valvular atrial fibrillation initiating rivaroxaban or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – REDUCED DOSE	8
Table 15.61 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating rivaroxaban or warfarin and standardised mean differences beforeand after matching, Denmark – STANDARD DOSE.180)
Table 15.62 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating rivaroxaban or warfarin and standardised mean differences beforeand after matching, Denmark – REDUCED DOSE.182	2
Table 15.63 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating rivaroxaban or warfarin and standardised mean differences beforeand after matching, Norway – STANDARD DOSE184	4
Table 15.64 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating rivaroxaban or warfarin and standardised mean differences beforeand after matching, Norway – REDUCED DOSE.186	5
Table 15.65 Baseline characteristics of patients with non-valvular atrial fibrillation initiating rivaroxaban or warfarin and standardised mean differences before and after matching, Sweden – STANDARD DOSE	8
PFIZER CONFIDENTIAL Page 50 of 253	

Table 15.66 Baseline characteristics of patients with non-valvular atrial fibrillation initiating rivaroxaban or warfarin and standardised mean differences before and after matching, Sweden – REDUCED DOSE	.91
Table 15.67 Sensitivity analysis (after re -matching within subgroups defined by initial dose): pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	.94
Table 15.68 Sensitivity subgroup analysis for initial dose: pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	.95
Table 15.69 Sensitivity subgroup analysis for initial dose: pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country1	.96
Table 15.70 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Denmark (propensity -score matched population)	.97
Table 15.71 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Denmark (propensity -score matched population)	.98
Table 15.72 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Denmark (propensity -score matched population)	.99
Table 15.73 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Norway (propensity -score matched population)	201
Table 15.74 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Norway (propensity -score matched population)	202
Table 15.75 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Norway (propensity -score matched population)	203
Table 15.76 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Sweden (propensity -score matched	205

Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Sweden (propensity -score matched population)	.207
Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Sweden (propensity -score matched population)	.209

15.2. List of figures

Figure	15.1	Flow diagram of identification of the study population (all countries combined)	211
Figure	15.2	Prove the study population (Denmark)	212
Figure	15.3	Flow diagram of identification of the study population (Norway)	213
Figure	15.4	Flow diagram of identification of the study population (Sweden)	214
Figure	15.5	Crude cumulative incidence of any stroke or systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	215
Figure	15.6	Crude cumulative incidence of any bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	216
Figure	15.7	Crude cumulative incidence of ischaemic stroke at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	217
Figure	15.8	Crude cumulative incidence of haemorrhagic stroke at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	218
Figure	15.9	Crude cumulative incidence of intracranial bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	219
Figure	15.1	0 Crude cumulative incidence of gastrointestinal bleeding at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	220
Figure	15.1	1 Crude cumulative incidence of acute myocardial infarction at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	221
Figure		2 Crude cumulative incidence of systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country*	222
Figure	15.1	3 Cumulative mortality among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	223
Figure	15.1	4 Crude cumulative incidence of ischaemic stroke at an acute hospitalisation with an overnight stay, systemic embolism at an acute hospitalisation with an overnight stay, acute myocardial infarction at an acute hospitalisation with an overnight stay, or death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	224
Figure	15.1	5 Crude cumulative incidence of any bleeding at an acute or planned hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country	225
Figure	15.1	6 Crude cumulative incidence of any bleeding at an acute hospital contact without an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country PFIZER CONFIDENTIAL Page 53 of 253	226

-	7 Crude cumulative incidence of any bleeding recorded as the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis) among patients with NVAF initiating apixaban, dabigatran, rivaroxaban	227
-	8 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – all countries combined	228
-	9 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin overall and in the subgroups – all countries combined	229
Figure 15.2	0 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – all countries combined	230
Figure 15.2	1 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – <i>Denmark</i>	231
Figure 15.2	2 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin overall and in the subgroups – <i>Denmark</i>	232
Figure 15.2	3 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – <i>Denmark</i>	233
Figure 15.24	4 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – <i>Norway</i>	234
Figure 15.2.	5 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin overall and in the subgroups – <i>Norway</i>	235
Figure 15.2	6 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – <i>Norway</i>	236
Figure 15.2	7 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – <i>Sweden</i>	237

Figure 15.28 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin overall and in the subgroups – <i>Sweden</i>	8
Figure 15.29 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – <i>Sweden</i>	9
Figure 15.30 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	0
Figure 15.31 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country24	0
Figure 15.32 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	1
Figure 15.33 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	1
Figure 15.34 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country, overall and by country	2
Figure 15.35 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country24	2
Figure 15.36 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	3
Figure 15.37 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	3
Figure 15.38 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country	4
Figure 15.39 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country24	4

Figure 15.40 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country	245
Figure 15.41 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country	245
Figure 15.42 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	246
Figure 15.43 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	247
Figure 15.44 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country	248
Figure 15.45 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	249
Figure 15.46 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	250
Figure 15.47 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of rivaroxaban vs. warfarin, overall and by country	250
Figure 15.48 Sensitivity analysis (conventional adjustment): Pairwise conventionally adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of apixaban vs. warfarin, overall and by country	251
Figure 15.49 Sensitivity analysis (conventional adjustment): Pairwise conventionally adjusted hazard ratios of the primary endpoints and the composite secondary endpoint among patients with NVAF comparing initiators of dabigatran vs. warfarin, overall and by country	251

Figure 15.50 Sensitivity analysis (conventional adjustment): Pairwise conventionally	
adjusted hazard ratios of the primary endpoints and the composite	
secondary endpoint among patients with NVAF comparing initiators of	
rivaroxaban vs. warfarin, overall and by country	252

Table 15.1 Baseline characteristics of patients with non-valvular atrial fibrillation
initiating apixaban, dabigatran, rivaroxaban or warfarin (Denmark, Norway, Sweden,
2013 - 2016)

Characteristic	Apixaban (N= 71,585)	Dabigatran (N= 31,209)	Rivaroxaban (N= 37,580)	Warfarin (N= 79,171)	Total (N=219,545)	
Country						
All countries	71,585 (100%)	31,209 (100%)	37,580 (100%)	79,171 (100%)	219,545 (100%)	
Year of OAC initiation						
2013	1,840 (2.57%)	12,566 (40.3%)	6,948 (18.5%)	34,996 (44.2%)	56,350 (25.7%)	
2014	13,102 (18.3%)	10,468 (33.5%)	8,284 (22.0%)	23,333 (29.5%)	55,187 (25.1%)	
2015	25,920 (36.2%)	4,218 (13.5%)	11,095 (29.5%)	13,387 (16.9%)	54,620 (24.9%)	
2016	30,723 (42.9%)	3,957 (12.7%)	11,253 (29.9%)	7,455 (9.42%)	53,388 (24.3%)	
Time form most recent relative to index date hospital AF	0.2 (0.0 - 3.1)	0.2 (0.0 - 10.0)	0.3 (0.0 - 12.1)	0.4 (0.1 - 15.5)	0.3 (0.0 - 9.3)	
diagnosis, median (IQR), months						
Time from AF diagnosis to index						
3 - 60 months	17,980 (25.1%)	9,275 (29.7%)	11,859 (31.6%)	26,198 (33.1%)	65,312 (29.7%)	
< 3 months	53,605 (74.9%)	21,934 (70.3%)	25,721 (68.4%)	52,973 (66.9%)	154,233 (70.3%)	
Sex						
Female	32,911 (46.0%)	12,261 (39.3%)	16,676 (44.4%)	32,984 (41.7%)	94,832 (43.2%)	
Male	38,674 (54.0%)	18,948 (60.7%)	20,904 (55.6%)	46,187 (58.3%)	124,713 (56.8%)	
Age, median (IQR), years	75.5 (68.2 - 83.5)	71.0 (64.6 - 78.7)	74.2 (67.3 - 82.0)	75.0 (67.5 - 82.2)	74.4 (67.2 - 82.2)	
Age group		0.404 (7.000)	1 000 (1 000)	4 401 /7 550	10.010 (7.170)	
< 55years	3,323 (4.64%)	2,434 (7.80%)	1,772 (4.72%)	4,481 (5.66%)	12,010 (5.47%)	
55-<65 years	8,416 (11.8%)	5,737 (18.4%)	4,961 (13.2%)	10,103 (12.8%)	29,217 (13.3%)	
65-<75 years	22,884 (32.0%)	11,793 (37.8%)	13,028 (34.7%)	25,057 (31.6%)	72,762 (33.1%)	
75-<85 years	22,328 (31.2%)	8,077 (25.9%)	11,463 (30.5%)	26,704 (33.7%)	68,572 (31.2%)	
\geq 85 years	14,634 (20.4%)	3,168 (10.2%)	6,356 (16.9%)	12,826 (16.2%)	36,984 (16.8%)	
Initial dose **	01.075 (00.5%)	10.701.01.100	0.014 (0.1.50)			
Reduced	21,275 (29.7%)	10,731 (34.4%)	9,214 (24.5%)			
Standard	50,310 (70.3%)	20,478 (65.6%)	28,366 (75.5%)			
Baseline comorbidity 5 years before and including index date						
Charlson Comorbidity Index score						
0	28,413 (39.7%)	15,333 (49.1%)	16,044 (42.7%)	29,605 (37.4%)	89,395 (40.7%)	
1-2	24,544 (34.3%)	10,286 (33.0%)	12,756 (33.9%)	25,602 (32.3%)	73,188 (33.3%)	
≥3	18,628 (26.0%)	5,590 (17.9%)	8,780 (23.4%)	23,964 (30.3%)	56,962 (25.9%)	
Baseline comorbidity 5 years						
before and including index date	0.016(11.000)	0.011 (0.010())		0.045 (11.00)	00 555 (10 50)	
Prior bleeding (any)	8,016 (11.2%)	2,811 (9.01%)	3,863 (10.3%)	8,865 (11.2%)	23,555 (10.7%)	
Prior gastrointestinal bleeding	670 (0.94%)	243 (0.78%)	327 (0.87%)	821 (1.04%)	2,061 (0.94%)	
Prior intracranial bleeding	899 (1.26%)	284 (0.91%)	417 (1.11%)	710 (0.90%)	2,310 (1.05%)	
Prior stroke (any)	10,044 (14.0%)	3,379 (10.8%)	4,857 (12.9%)	9,610 (12.1%)	27,890 (12.7%)	
Prior ischaemic stroke	9,741 (13.6%)	3,297 (10.6%)	4,720 (12.6%)	9,404 (11.9%)	27,162 (12.4%)	
Prior haemorrhagic stroke	695 (0.97%)	202 (0.65%)	296 (0.79%)	521 (0.66%)	1,714 (0.78%)	
Prior systemic embolism	395 (0.55%)	133 (0.43%)	223 (0.59%)	760 (0.96%)	1,511 (0.69%)	
Prior transient ischaemic attack	3,092 (4.32%)	1,157 (3.71%)	1,466 (3.90%)	3,117 (3.94%)	8,832 (4.02%)	
Chronic kidney disease	3,509 (4.90%)	555 (1.78%)	1,322 (3.52%)	6,529 (8.25%)	11,915 (5.43%)	
Heart failure	13,650 (19.1%)	4,332 (13.9%)	6,160 (16.4%)	18,006 (22.7%)	42,148 (19.2%)	
Coronary artery disease	15,580 (21.8%)	5,511 (17.7%)	7,533 (20.0%)	21,453 (27.1%)	50,077 (22.8%)	
Peripheral arterial disease	4,842 (6.76%)	1,630 (5.22%)	2,459 (6.54%)	6,031 (7.62%)	14,962 (6.82%)	
Cardioversion	4,396 (6.14%)	2,537 (8.13%)	2,112 (5.62%)	6,886 (8.70%)	15,931 (7.26%)	
Hypertension	47,785 (66.8%)	18,972 (60.8%)	24,334 (64.8%)	54,106 (68.3%)	145,197 (66.1%)	
Diabetes	11,785 (16.5%)	4,291 (13.7%)	5,988 (15.9%)	14,676 (18.5%)	36,740 (16.7%)	
Chronic obstructive pulmonary disease	9,151 (12.8%)	3,264 (10.5%)	4,622 (12.3%)	10,116 (12.8%)	27,153 (12.4%)	
Liver disease	608 (0.85%)	261 (0.84%)	325 (0.86%)	816 (1.03%)	2,010 (0.92%)	
Alcoholism	1,772 (2.48%)	857 (2.75%)	1,026 (2.73%)	1,785 (2.25%)	5,440 (2.48%)	
Dementia	1,821 (2.54%)	416 (1.33%)	897 (2.39%)	1,216 (1.54%)	4,350 (1.98%)	
Cancer 6 months before and	1,847 (2.58%)	878 (2.81%)	1,242 (3.30%)	2,135 (2.70%)	6,102 (2.78%)	
including index date						
Prescription medication dispensed in 90 days before and including						
index date		10.054 (05.000)	11110 (0	20.020.027.077	00.450 (07.5	
Platelet inhibitors (excluding	26,854 (37.5%)	10,354 (33.2%)	14,113 (37.6%)	30,838 (39.0%)	82,159 (37.4%)	
heparin)						
Low -dose aspirin	23,583 (32.9%)	9,175 (29.4%)	12,328 (32.8%)	27,177 (34.3%)	72,263 (32.9%)	
ADP receptor blockers	4,860 (6.79%)	1,645 (5.27%)	2,374 (6.32%)	7,098 (8.97%)	15,977 (7.28%)	
Renin -angiotensin system	33,264 (46.5%)	13,043 (41.8%)	16,481 (43.9%)	38,067 (48.1%)	100,855 (45.9%)	
inhibitors	1	1		1	1	

Angiotensin -converting	15,888 (22.2%)	5,969 (19.1%)	7,312 (19.5%)	20,500 (25.9%)	49,669 (22.6%)
enzyme inhibitors					
Angiotensin II antagonists, plain	11,222 (15.7%)	3,962 (12.7%)	5,318 (14.2%)	11,854 (15.0%)	32,356 (14.7%)
Angiotensin II antagonists,	5,821 (8.13%)	2,722 (8.72%)	3,424 (9.11%)	5,212 (6.58%)	17,179 (7.82%)
combinations	5,621 (6.15%)	2,722 (0.7270)	3,424 (9.1170)	5,212 (0.5870)	17,179 (7.8270)
Beta-blockers	51,522 (72.0%)	21,754 (69.7%)	25,190 (67.0%)	56,980 (72.0%)	155,446 (70.8%)
Proton pump inhibitors	15,636 (21.8%)	5,180 (16.6%)	7,502 (20.0%)	17,349 (21.9%)	45,667 (20.8%)
H2-receptor antagonists	379 (0.53%)	128 (0.41%)	214 (0.57%)	379 (0.48%)	1,100 (0.50%)
Non-steroidal anti-inflammatory	5,624 (7.86%)	2,995 (9.60%)	3,109 (8.27%)	5,861 (7.40%)	17,589 (8.01%)
drugs	3,024 (7.80%)	2,995 (9.00%)	5,109 (8.27%)	5,001 (7.40%)	17,389 (8.0170)
Statins	24,550 (34.3%)	9,851 (31.6%)	12,533 (33.4%)	28,743 (36.3%)	75,677 (34.5%)
Antidiabetic agents	8,226 (11.5%)	3,066 (9.82%)	4,283 (11.4%)	10,408 (13.1%)	25,983 (11.8%)
Loop diuretics	16,494 (23.0%)	5,372 (17.2%)	7,835 (20.8%)	22,174 (28.0%)	51,875 (23.6%)
Non-loop diuretics	901 (1.26%)	374 (1.20%)	448 (1.19%)	1,229 (1.55%)	2,952 (1.34%)
Alpha adrenergic blockers	12,537 (17.5%)	4,611 (14.8%)	6,158 (16.4%)	15,809 (20.0%)	39,115 (17.8%)
Amiodarone	1,691 (2.36%)	638 (2.04%)	727 (1.93%)	2,561 (3.23%)	5,617 (2.56%)
Dronedarone	678 (0.95%)	95 (0.30%)	158 (0.42%)	597 (0.75%)	1,528 (0.70%)
Antihypertensive, combination	7,933 (11.1%)	3,807 (12.2%)	4,683 (12.5%)	7,700 (9.73%)	24,123 (11.0%)
drugs					
Calcium channel blockers	16,995 (23.7%)	6,710 (21.5%)	8,599 (22.9%)	19,675 (24.9%)	51,979 (23.7%)
Selective serotonin reuptake	4,615 (6.45%)	1,546 (4.95%)	2,310 (6.15%)	4,793 (6.05%)	13,264 (6.04%)
inhibitors					
Drugs used in alcohol	112 (0.16%)	82 (0.26%)	73 (0.19%)	120 (0.15%)	387 (0.18%)
dependence					
Risk scores					
CHA2DS2-VASc score, mean	3.4 (1.7)	2.8 (1.7)	3.2 (1.7)	3.4 (1.8)	3.3 (1.7)
(SD)					
0 -1	10,417 (14.6%)	7,481 (24.0%)	6,152 (16.4%)	11,520 (14.6%)	35,570 (16.2%)
2 -3	28,435 (39.7%)	13,783 (44.2%)	16,023 (42.6%)	30,326 (38.3%)	88,567 (40.3%)
≥4	32,733 (45.7%)	9,945 (31.9%)	15,405 (41.0%)	37,325 (47.1%)	95,408 (43.5%)
CHADS2 score, mean (SD)	2.3 (1.5)	1.7 (1.4)	2.0 (1.5)	2.4 (1.5)	2.2 (1.5)
0	8,006 (11.2%)	6,303 (20.2%)	5,430 (14.4%)	8,298 (10.5%)	28,037 (12.8%)
1	15,830 (22.1%)	9,436 (30.2%)	9,770 (26.0%)	15,842 (20.0%)	50,878 (23.2%)
≥2	47,749 (66.7%)	15,470 (49.6%)	22,380 (59.6%)	55,031 (69.5%)	140,630 (64.1%)
HAS-BLED score, mean (SD)	2.0 (1.0)	1.8 (1.1)	2.0 (1.0)	2.0 (1.1)	2.0 (1.0)
<3	51,368 (71.8%)	23,531 (75.4%)	27,055 (72.0%)	56,153 (70.9%)	158,107 (72.0%)
≥3	20,217 (28.2%)	7,678 (24.6%)	10,525 (28.0%)	23,018 (29.1%)	61,438 (28.0%)
Health care utilisation in 12 months before the index date					
Hospitalisations, median (IQR)	1.0 (1.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 2.0)	1.0 (0.0 - 2.0)
Planned non-acute outpatient	2.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)	2.0 (1.0 - 4.0)	2.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)
visits, median (IQR)	2.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)	2.0 (1.0 - 7.0)	2.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)
Emergency/acute outpatient visits, median (IQR)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)

*Set to zero if AF diagnosed after index date (maximum 60 days) **Initial dose equals the strength of one tablet in the initial dispensing for rivaroxaban (used once daily) and to twice the strength of one in the initial dispensing for apixaban or dabigatran (used twice daily). Available socioeconomic characteristics vary by country and are reported in country-specific tables.

Table 15.2 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Denmark, 2013 -2016)

Characteristic	Apixaban (N= 14,980)	Dabigatran (N= 12,446)	Rivaroxaban (N= 12,682)	Warfarin (N= 20,070)	Total (N= 60,178)	
Country		· · · · · · · · · · · · · · · · · · ·				
Denmark	14,980 (100%)	12,446 (100%)	12,682 (100%)	20,070 (100%)	60,178 (100%)	
Year of OAC initiation						
2013	711 (4.75%)	5,381 (43.2%)	2,348 (18.5%)	6,808 (33.9%)	15,248 (25.3%)	
2014	3,136 (20.9%)	4,376 (35.2%)	1,881 (14.8%)	5,398 (26.9%)	14,791 (24.6%)	
2015	5,385 (35.9%)	1,625 (13.1%)	3,508 (27.7%)	4,582 (22.8%)	15,100 (25.1%)	
2016	5,748 (38.4%)	1,064 (8.55%)	4,945 (39.0%)	3,282 (16.4%)	15,039 (25.0%)	
Time form most recent relative to	0.2 (0.1 - 1.9)	0.2 (0.0 - 3.5)	0.2 (0.1 - 3.8)	0.3 (0.1 - 6.1)	0.3 (0.1 - 3.6)	
index date hospital AF diagnosis, median (IQR), months						
Time from AF diagnosis to index						
3 - 60 months	3,321 (22.2%)	3,202 (25.7%)	3,361 (26.5%)	5,787 (28.8%)	15,671 (26.0%)	
< 3 month	11,659 (77.8%)	9,244 (74.3%)	9,321 (73.5%)	14,283 (71.2%)	44,507 (74.0%)	
Sex	11,009 (11.070)	,211(11.570)	,521 (75.576)	11,203 (71.270)	11,507 (71.070)	
Female	7,111 (47.5%)	4,990 (40.1%)	5,710 (45.0%)	7,954 (39.6%)	25,765 (42.8%)	
Male	7,869 (52.5%)	7,456 (59.9%)	6,972 (55.0%)	12,116 (60.4%)	34,413 (57.2%)	
Age, median (IQR), years	75.8 (68.4 - 83.8)	71.2 (64.6 - 78.9)	74.1 (67.2 - 82.1)	73.3 (66.1 - 80.6)	73.6 (66.5 - 81.4)	
Age group	75.0 (00.4 05.0)	/1.2 (04.0 /0.7)	74.1 (07.2 02.1)	75.5 (00.1 00.0)	75.0 (00.5 01.4)	
< 55years	656 (4.38%)	945 (7.59%)	633 (4.99%)	1,524 (7.59%)	3,758 (6.24%)	
< 55years 55-<65 years	1,712 (11.4%)	2,298 (18.5%)	1,696 (13.4%)	2,869 (14.3%)	8,575 (14.2%)	
	/ / /		/ / /	/ / /		
65-<75 years 75-<85 years	4,748 (31.7%) 4,611 (30.8%)	4,600 (37.0%) 3,288 (26.4%)	4,365 (34.4%)	6,820 (34.0%)	20,533 (34.1%) 17,939 (29.8%)	
			3,765 (29.7%)	6,275 (31.3%)		
\geq 85 years	3,253 (21.7%)	1,315 (10.6%)	2,223 (17.5%)	2,582 (12.9%)	9,373 (15.6%)	
Initial dose **	5 071 (05 001)	4 502 (26 001)	2 102 (04 501)			
Reduced	5,271 (35.2%)	4,593 (36.9%)	3,123 (24.6%)			
Standard	9,709 (64.8%)	7,853 (63.1%)	9,559 (75.4%)			
Baseline comorbidity 5 years before						
and including index date						
Charlson Comorbidity Index score						
0	6,030 (40.3%)	6,446 (51.8%)	5,748 (45.3%)	8,598 (42.8%)	26,822 (44.6%)	
1 -2	5,337 (35.6%)	3,951 (31.7%)	4,281 (33.8%)	6,004 (29.9%)	19,573 (32.5%)	
≥3	3,613 (24.1%)	2,049 (16.5%)	2,653 (20.9%)	5,468 (27.2%)	13,783 (22.9%)	
Baseline comorbidity 5 years before						
and including index date						
Prior bleeding (any)	1,526 (10.2%)	998 (8.02%)	1,097 (8.65%)	1,941 (9.67%)	5,562 (9.24%)	
Prior gastrointestinal bleeding	198 (1.32%)	110 (0.88%)	129 (1.02%)	273 (1.36%)	710 (1.18%)	
Prior intracranial bleeding	200 (1.34%)	100 (0.80%)	125 (0.99%)	141 (0.70%)	566 (0.94%)	
Prior stroke (any)	2,542 (17.0%)	1,272 (10.2%)	1,741 (13.7%)	1,976 (9.85%)	7,531 (12.5%)	
Prior ischaemic stroke	2,493 (16.6%)	1,250 (10.0%)	1,707 (13.5%)	1,944 (9.69%)	7,394 (12.3%)	
Prior haemorrhagic stroke	132 (0.88%)	54 (0.43%)	77 (0.61%)	85 (0.42%)	348 (0.58%)	
Prior systemic embolism	64 (0.43%)	32 (0.26%)	45 (0.35%)	107 (0.53%)	248 (0.41%)	
Prior transient ischaemic attack	611 (4.08%)	426 (3.42%)	421 (3.32%)	604 (3.01%)	2,062 (3.43%)	
Chronic kidney disease	599 (4.00%)	171 (1.37%)	358 (2.82%)	1,690 (8.42%)	2,818 (4.68%)	
Heart failure	2,376 (15.9%)	1,596 (12.8%)	1,848 (14.6%)	3,567 (17.8%)	9,387 (15.6%)	
Coronary artery disease	2,712 (18.1%)	2,043 (16.4%)	2,135 (16.8%)	4,588 (22.9%)	11,478 (19.1%)	
Peripheral arterial disease	1,040 (6.94%)	622 (5.00%)	776 (6.12%)	1,628 (8.11%)	4,066 (6.76%)	
Cardioversion	553 (3.69%)	852 (6.85%)	608 (4.79%)	1,387 (6.91%)	3,400 (5.65%)	
Hypertension	9,507 (63.5%)	7,443 (59.8%)	7,822 (61.7%)	12,265 (61.1%)	37,037 (61.5%)	
Diabetes	2,516 (16.8%)	1,690 (13.6%)	1,965 (15.5%)	3,488 (17.4%)	9,659 (16.1%)	
Chronic obstructive pulmonary disease	1,976 (13.2%)	1,249 (10.0%)	1,540 (12.1%)	2,570 (12.8%)	7,335 (12.2%)	
Liver disease	157 (1.05%)	99 (0.80%)	110 (0.87%)	237 (1.18%)	603 (1.00%)	
Alcoholism	481 (3.21%)	406 (3.26%)	410 (3.23%)	590 (2.94%)	1,887 (3.14%)	
Dementia	443 (2.96%)	203 (1.63%)	312 (2.46%)	220 (1.10%)	1,178 (1.96%)	
Cancer 6 months before and	588 (3.93%)	388 (3.12%)	507 (4.00%)	926 (4.61%)	2,409 (4.00%)	
including index date	388 (3.93%)	388 (3.1270)	507 (4.00%)	920 (4.01%)	2,409 (4.00%)	
Prescription medication dispensed in 90 days before and including index date						
Platelet inhibitors (excluding heparin)	4,863 (32.5%)	3,611 (29.0%)	3,960 (31.2%)	6,764 (33.7%)	19,198 (31.9%)	
Low -dose aspirin	3,417 (22.8%)	2,810 (22.6%)	2,912 (23.0%)	5,109 (25.5%)	14,248 (23.7%)	
ADP receptor blockers	1,683 (11.2%)	985 (7.91%)	1,199 (9.45%)	2,256 (11.2%)	6,123 (10.2%)	
Renin -angiotensin system inhibitors	6,285 (42.0%)	5,023 (40.4%)	5,167 (40.7%)	8,422 (42.0%)	24,897 (41.4%)	
Angiotensin -converting enzyme inhibitors	3,095 (20.7%)	2,493 (20.0%)	2,550 (20.1%)	4,512 (22.5%)	12,650 (21.0%)	

Angiotensin II antagonists, plain	1,920 (12.8%)	1,330 (10.7%)	1,404 (11.1%)	2,217 (11.0%)	6,871 (11.4%)
Angiotensin II antagonists,	974 (6.50%)	881 (7.08%)	914 (7.21%)	1,214 (6.05%)	3,983 (6.62%)
combinations					
Beta-blockers	9,395 (62.7%)	8,150 (65.5%)	7,884 (62.2%)	12,424 (61.9%)	37,853 (62.9%)
Proton pump inhibitors	3,436 (22.9%)	2,116 (17.0%)	2,620 (20.7%)	4,508 (22.5%)	12,680 (21.1%)
Non-steroidal anti-inflammatory drugs	1,402 (9.36%)	1,340 (10.8%)	1,274 (10.0%)	1,980 (9.87%)	5,996 (9.96%)
Statins	5,044 (33.7%)	3,908 (31.4%)	4,168 (32.9%)	6,991 (34.8%)	20,111 (33.4%)
Antidiabetic agents	1,884 (12.6%)	1,305 (10.5%)	1,504 (11.9%)	2,651 (13.2%)	7,344 (12.2%)
Loop diuretics	3,975 (26.5%)	2,499 (20.1%)	3,019 (23.8%)	5,797 (28.9%)	15,290 (25.4%)
Non-loop diuretics	175 (1.17%)	163 (1.31%)	154 (1.21%)	345 (1.72%)	837 (1.39%)
Alpha adrenergic blockers	2,663 (17.8%)	2,135 (17.2%)	2,275 (17.9%)	3,668 (18.3%)	10,741 (17.8%)
Amiodarone	560 (3.74%)	392 (3.15%)	368 (2.90%)	974 (4.85%)	2,294 (3.81%)
Dronedarone	10 (0.07%)	9 (0.07%)	17 (0.13%)	25 (0.12%)	61 (0.10%)
Antihypertensive, combination drugs	1,603 (10.7%)	1,455 (11.7%)	1,474 (11.6%)	2,112 (10.5%)	6,644 (11.0%)
Calcium channel blockers	3,431 (22.9%)	2,812 (22.6%)	2,936 (23.2%)	4,789 (23.9%)	13,968 (23.2%)
Selective serotonin reuptake	1,065 (7.11%)	686 (5.51%)	825 (6.51%)	1,151 (5.73%)	3,727 (6.19%)
inhibitors	-, (,,)	(-, (0.,0,0)	-, (012770)
Drugs used in alcohol dependence	29 (0.19%)	43 (0.35%)	31 (0.24%)	49 (0.24%)	152 (0.25%)
Risk scores		(0.000,0)	0 0 (0.2 770)	., (0.2.1,0)	(0.10,00)
CHA2DS2-VASc score, mean (SD)	3.4 (1.7)	2.8 (1.6)	3.2 (1.7)	3.1 (1.7)	3.1 (1.7)
0 -1	1,982 (13.2%)	2,750 (22.1%)	2,001 (15.8%)	3,581 (17.8%)	10,314 (17.1%)
2 -3	5,861 (39.1%)	5,644 (45.3%)	5,477 (43.2%)	8,413 (41.9%)	25,395 (42.2%)
≥4	7,137 (47.6%)	4,052 (32.6%)	5,204 (41.0%)	8,076 (40.2%)	24,469 (40.7%)
CHADS2 score, mean (SD)	1.9 (1.3)	1.5 (1.2)	1.7 (1.2)	1.6 (1.2)	1.7 (1.2)
0	2,002 (13.4%)	2,510 (20.2%)	2,024 (16.0%)	3,468 (17.3%)	10,004 (16.6%)
1	4,278 (28.6%)	4,480 (36.0%)	4,040 (31.9%)	6,320 (31.5%)	19,118 (31.8%)
>2	8,700 (58.1%)	5,456 (43.8%)	6,618 (52.2%)	10,282 (51.2%)	31,056 (51.6%)
HAS-BLED score, mean (SD)	2.2 (1.1)	2.0 (1.1)	2.1 (1.1)	2.1 (1.2)	2.1 (1.1)
<3	9,065 (60.5%)	8,684 (69.8%)	8,237 (65.0%)	12,664 (63.1%)	38,650 (64.2%)
≥3	5,915 (39.5%)	3,762 (30.2%)	4,445 (35.0%)	7,406 (36.9%)	21,528 (35.8%)
Health care utilisation in 12 months before the index date					i
Hospitalisations, median (IQR)	1.0 (1.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)
Planned non-acute outpatient visits, median (IQR)	2.0 (0.0 - 5.0)	1.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)	2.0 (0.0 - 6.0)	2.0 (0.0 - 5.0)
Emergency/acute outpatient visits, median (IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)
Socioeconomic characteristics					
Standardised household income	40 (29 - 62)	46 (32 - 76)	41 (29 - 65)	41 (30 - 63)	42 (30 - 66)
during 3 full calendar years preceding the index date, median (IQR), thousand Euros	10 (2) (2)	10 (02 70)	11 (2) (3)	11 (30 03)	12 (30 00)
Highest education achieved					
Secondary compulsory	5,814 (38.8%)	4,398 (35.3%)	5,000 (39.4%)	8,430 (42.0%)	23,642 (39.3%)
Vocational / High school	5,913 (39.5%)	5,251 (42.2%)	4,982 (39.3%)	8,140 (40.6%)	24,286 (40.4%)
Higher education	2,626 (17.5%)	2,404 (19.3%)	2,256 (17.8%)	2,979 (14.8%)	10,265 (17.1%)
Unknown	627 (4.19%)	393 (3.16%)	444 (3.50%)	521 (2.60%)	1,985 (3.30%)
Employment status in calendar year before index date					
Employed or self -employed	2,331 (15.6%)	3,068 (24.7%)	2,242 (17.7%)	3,716 (18.5%)	11,357 (18.9%)
Unemployed	602 (4.02%)	708 (5.69%)	591 (4.66%)	1,194 (5.95%)	3,095 (5.14%)
Retired	11,935 (79.7%)	8,576 (68.9%)	9,765 (77.0%)	15,012 (74.8%)	45,288 (75.3%)
Unknown	112 (0.75%)	94 (0.76%)	84 (0.66%)	148 (0.74%)	438 (0.73%)

*Set to zero if AF diagnosed after index date (maximum 60 days) *Initial dose equals the strength of one tablet in the initial dispensing for rivaroxaban (used once daily) and to twice the strength of one in the initial dispensing for apixaban or dabigatran (used twice daily). IQR interquartile range; OAC oral anticoagulant; SD standard deviation

Table 15.3 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Norway, 2013 -2016)

Characteristic	Apixaban (N= 17,780)	Dabigatran (N= 8,684)	Rivaroxaban (N= 10,565)	Warfarin (N= 11,949)	Total (N= 48,978)	
Country						
Norway	17,780 (100%)	8,684 (100%)	10,565 (100%)	11,949 (100%)	48,978 (100%)	
Year of OAC initiation						
2013	336 (1.89%)	4,164 (48.0%)	2,705 (25.6%)	5,805 (48.6%)	13,010 (26.6%)	
2014	3,192 (18.0%)	2,852 (32.8%)	2,593 (24.5%)	3,447 (28.8%)	12,084 (24.7%)	
2015	6,307 (35.5%)	928 (10.7%)	2,848 (27.0%)	1,764 (14.8%)	11,847 (24.2%)	
2016	7,945 (44.7%)	740 (8.52%)	2,419 (22.9%)	933 (7.81%)	12,037 (24.6%)	
Time form most recent relative to	0.2 (0.0 - 1.7)	0.2 (0.0 - 16.3)	0.3 (0.0 - 16.1)	0.7 (0.1 - 23.2)	0.3 (0.0 - 11.3)	
index date hospital AF diagnosis, median (IQR), months						
Time from AF diagnosis to index						
3 - 60 months	3,998 (22.5%)	2,834 (32.6%)	3,487 (33.0%)	4,641 (38.8%)	14,960 (30.5%)	
< 3 month	13,782 (77.5%)	5,850 (67.4%)	7,078 (67.0%)	7,308 (61.2%)	34,018 (69.5%)	
Sex	, , ,	, , , ,	, , , ,	, , , ,	· · · · · · · · · · · · · · · · · · ·	
Female	7,901 (44.4%)	3,310 (38.1%)	4,513 (42.7%)	4,740 (39.7%)	20,464 (41.8%)	
Male	9,879 (55.6%)	5,374 (61.9%)	6,052 (57.3%)	7,209 (60.3%)	28,514 (58.2%)	
Age, median (IQR), years	74.7 (67.5 - 83.0)	70.7 (64.6 - 78.8)	73.4 (66.7 - 81.5)	75.3 (66.7 - 83.2)	73.8 (66.5 - 82.0)	
Age group	11.1 (01.5 05.0)	70.7 (01.0 70.0)	75.1(00.7 01.5)	15.5 (00.1 05.2)	75.0 (00.5 02.0)	
< 55years	935 (5.26%)	719 (8.28%)	553 (5.23%)	832 (6.96%)	3,039 (6.20%)	
55-<65 years	2,259 (12.7%)	1,598 (18.4%)	1,524 (14.4%)	1,692 (14.2%)	7,073 (14.4%)	
65-<75 years	5,835 (32.8%)	3,299 (38.0%)	3,756 (35.6%)	3,355 (28.1%)	16,245 (33.2%)	
75-<85 years	5,408 (30.4%)	2,171 (25.0%)	3,085 (29.2%)		14,520 (29.6%)	
				3,856 (32.3%)		
\geq 85 years Initial dose **	3,343 (18.8%)	897 (10.3%)	1,647 (15.6%)	2,214 (18.5%)	8,101 (16.5%)	
	4.017 (07.10)	2.054.(25.201)	2 640 (25 10)			
Reduced	4,817 (27.1%)	3,054 (35.2%)	2,649 (25.1%)			
Standard	12,963 (72.9%)	5,630 (64.8%)	7,916 (74.9%)			
Baseline comorbidity 5 years before						
and including index date						
Charlson Comorbidity Index score						
0	6,276 (35.3%)	3,872 (44.6%)	4,043 (38.3%)	3,336 (27.9%)	17,527 (35.8%)	
1 -2	6,089 (34.2%)	3,009 (34.6%)	3,747 (35.5%)	3,813 (31.9%)	16,658 (34.0%)	
≥3	5,415 (30.5%)	1,803 (20.8%)	2,775 (26.3%)	4,800 (40.2%)	14,793 (30.2%)	
Baseline comorbidity 5 years before						
and including index date						
Prior bleeding (any)	2,312 (13.0%)	904 (10.4%)	1,255 (11.9%)	1,779 (14.9%)	6,250 (12.8%)	
Prior gastrointestinal bleeding	196 (1.10%)	79 (0.91%)	122 (1.15%)	191 (1.60%)	588 (1.20%)	
Prior intracranial bleeding	222 (1.25%)	76 (0.88%)	110 (1.04%)	160 (1.34%)	568 (1.16%)	
Prior stroke (any)	2,133 (12.0%)	813 (9.36%)	1,261 (11.9%)	1,435 (12.0%)	5,642 (11.5%)	
Prior ischaemic stroke	2,080 (11.7%)	793 (9.13%)	1,225 (11.6%)	1,380 (11.5%)	5,478 (11.2%)	
Prior haemorrhagic stroke	136 (0.76%)	51 (0.59%)	67 (0.63%)	106 (0.89%)	360 (0.74%)	
Prior systemic embolism	87 (0.49%)	46 (0.53%)	56 (0.53%)	140 (1.17%)	329 (0.67%)	
Prior transient ischaemic attack	715 (4.02%)	301 (3.47%)	434 (4.11%)	463 (3.87%)	1,913 (3.91%)	
Chronic kidney disease	1,330 (7.48%)	252 (2.90%)	579 (5.48%)	1,560 (13.1%)	3,721 (7.60%)	
Heart failure	3,280 (18.4%)	1,221 (14.1%)	1 500 (15 00)	3,110 (26.0%)	9,214 (18.8%)	
Coronary artery disease	4,615 (26.0%)	1,847 (21.3%)	1,603 (15.2%) 2,512 (23.8%)	4,409 (36.9%)	13,383 (27.3%)	
Peripheral arterial disease			968 (9.16%)		4,636 (9.47%)	
•	1,733 (9.75%)	564 (6.49%)	· · · /	1,371 (11.5%)		
Cardioversion	1,021 (5.74%)	682 (7.85%)	550 (5.21%)	900 (7.53%)	3,153 (6.44%)	
Hypertension Disk store	10,534 (59.2%)	4,904 (56.5%)	6,258 (59.2%)	7,267 (60.8%)	28,963 (59.1%)	
Diabetes	2,627 (14.8%)	1,088 (12.5%)	1,485 (14.1%)	2,103 (17.6%)	7,303 (14.9%)	
Chronic obstructive pulmonary disease	2,626 (14.8%)	1,058 (12.2%)	1,425 (13.5%)	1,850 (15.5%)	6,959 (14.2%)	
Liver disease	153 (0.86%)	78 (0.90%)	107 (1.01%)	154 (1.29%)	492 (1.00%)	
Alcoholism	343 (1.93%)	162 (1.87%)	247 (2.34%)	170 (1.42%)	922 (1.88%)	
Dementia	356 (2.00%)	104 (1.20%)	183 (1.73%)	226 (1.89%)	869 (1.77%)	
Cancer 6 months before and including index date	1,037 (5.83%)	429 (4.94%)	639 (6.05%)	807 (6.75%)	2,912 (5.95%)	
Prescription medication dispensed in 90 days before and including index date						
Platelet inhibitors (excluding heparin)	7,472 (42.0%)	3,332 (38.4%)	4,450 (42.1%)	5,395 (45.2%)	20,649 (42.2%)	
Low -dose aspirin	7,080 (39.8%)	3,236 (37.3%)	4,273 (40.4%)	5,062 (42.4%)	19,651 (40.1%)	
ADP receptor blockers	896 (5.04%)	229 (2.64%)	331 (3.13%)	1,134 (9.49%)	2,590 (5.29%)	
Renin -angiotensin system	7,966 (44.8%)	3,545 (40.8%)	4,434 (42.0%)	5,502 (46.0%)	21,447 (43.8%)	
inhibitors Angiotensin -converting enzyme inhibitors	2,927 (16.5%)	1,221 (14.1%)	1,391 (13.2%)	2,497 (20.9%)	8,036 (16.4%)	

Angiotensin II antagonists, plain	2,609 (14.7%)	1,126 (13.0%)	1,458 (13.8%)	1,635 (13.7%)	6,828 (13.9%)
Angiotensin II antagonists,	2,542 (14.3%)	1,214 (14.0%)	1,600 (15.1%)	1,454 (12.2%)	6,810 (13.9%)
combinations					
Beta-blockers	12,344 (69.4%)	5,952 (68.5%)	6,727 (63.7%)	8,409 (70.4%)	33,432 (68.3%)
Proton pump inhibitors	3,807 (21.4%)	1,297 (14.9%)	1,987 (18.8%)	2,694 (22.5%)	9,785 (20.0%)
H2-receptor antagonists	228 (1.28%)	105 (1.21%)	152 (1.44%)	165 (1.38%)	650 (1.33%)
Non-steroidal anti-inflammatory	1,612 (9.07%)	885 (10.2%)	957 (9.06%)	907 (7.59%)	4,361 (8.90%)
drugs	,				
Statins	6,800 (38.2%)	2,932 (33.8%)	3,802 (36.0%)	5,018 (42.0%)	18,552 (37.9%)
Antidiabetic agents	1,754 (9.87%)	727 (8.37%)	1,001 (9.47%)	1,403 (11.7%)	4,885 (9.97%)
Loop diuretics	3,575 (20.1%)	1,229 (14.2%)	1,755 (16.6%)	3,392 (28.4%)	9,951 (20.3%)
Non-loop diuretics	284 (1.60%)	125 (1.44%)	151 (1.43%)	230 (1.92%)	790 (1.61%)
Alpha adrenergic blockers	1,152 (6.48%)	479 (5.52%)	610 (5.77%)	959 (8.03%)	3,200 (6.53%)
Amiodarone	688 (3.87%)	170 (1.96%)	226 (2.14%)	702 (5.87%)	1,786 (3.65%)
Dronedarone	262 (1.47%)	34 (0.39%)	71 (0.67%)	132 (1.10%)	499 (1.02%)
Antihypertensive, combination	2,954 (16.6%)	1,410 (16.2%)	1,850 (17.5%)	1,740 (14.6%)	7,954 (16.2%)
drugs					
Calcium channel blockers	3,835 (21.6%)	1,596 (18.4%)	2,194 (20.8%)	2,642 (22.1%)	10,267 (21.0%)
Selective serotonin reuptake	795 (4.47%)	329 (3.79%)	486 (4.60%)	533 (4.46%)	2,143 (4.38%)
inhibitors					
Drugs used in alcohol dependence	26 (0.15%)	20 (0.23%)	20 (0.19%)	15 (0.13%)	81 (0.17%)
Risk scores					
CHA2DS2-VASc score, mean (SD)	3.1 (1.7)	2.6 (1.7)	2.9 (1.7)	3.3 (1.9)	3.0 (1.8)
0 -1	3,289 (18.5%)	2,474 (28.5%)	2,215 (21.0%)	2,237 (18.7%)	10,215 (20.9%)
2 -3	7,757 (43.6%)	3,867 (44.5%)	4,690 (44.4%)	4,372 (36.6%)	20,686 (42.2%)
≥4	6,734 (37.9%)	2,343 (27.0%)	3,660 (34.6%)	5,340 (44.7%)	18,077 (36.9%)
CHADS2 score, mean (SD)	1.5 (1.3)	1.2 (1.2)	1.4 (1.3)	1.7 (1.4)	1.5 (1.3)
0	4,151 (23.3%)	2,811 (32.4%)	2,769 (26.2%)	2,526 (21.1%)	12,257 (25.0%)
1	5,860 (33.0%)	2,917 (33.6%)	3,466 (32.8%)	3,481 (29.1%)	15,724 (32.1%)
≥2	7,769 (43.7%)	2,956 (34.0%)	4,330 (41.0%)	5,942 (49.7%)	20,997 (42.9%)
HAS-BLED score, mean (SD)	2.0 (1.2)	1.8 (1.1)	2.0 (1.2)	2.1 (1.3)	2.0 (1.2)
<3	11,940 (67.2%)	6,470 (74.5%)	7,354 (69.6%)	7,412 (62.0%)	33,176 (67.7%)
≥3	5,840 (32.8%)	2,214 (25.5%)	3,211 (30.4%)	4,537 (38.0%)	15,802 (32.3%)
Health care utilisation in 12 months					
before the index date					
Hospitalisations, median (IQR)	1.0 (1.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 2.0)	1.0 (1.0 - 2.0)	1.0 (1.0 - 2.0)
Planned non-acute outpatient visits,	3.0 (1.0 - 5.0)	2.0 (1.0 - 5.0)	3.0 (1.0 - 5.0)	3.0 (1.0 - 5.0)	3.0 (1.0 - 5.0)
median (IQR)					
Emergency/acute outpatient visits, median (IQR)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)

 median (IQR)
 *Set to zero if AF diagnosed after index date (maximum 60 days)

 **Initial dose equals the strength of one tablet in the initial dispensing for rivaroxaban (used once daily) and to twice the strength of one in the initial dispensing for apixaban or dabigatran (used twice daily).

 IQR interquartile range; OAC oral anticoagulant; SD standard deviation Data on socioeconomic characteristics not available for Norway.

Table 15.4 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating apixaban, dabigatran, rivaroxaban or warfarin (Sweden, 2013 -2016)

Characteristic	Apixaban (N= 38,825)	Dabigatran (N= 10,079)	Rivaroxaban (N= 14,333)	Warfarin (N= 47,152)	Total (N=110,389)	
Country						
Sweden	38,825 (100%)	10,079 (100%)	14,333 (100%)	47,152 (100%)	110,389 (100%)	
Year of OAC initiation						
2013	793 (2.04%)	3,021 (30.0%)	1,895 (13.2%)	22,383 (47.5%)	28,092 (25.4%)	
2014	6,774 (17.4%)	3,240 (32.1%)	3,810 (26.6%)	14,488 (30.7%)	28,312 (25.6%)	
2015	14,228 (36.6%)	1,665 (16.5%)	4,739 (33.1%)	7,041 (14.9%)	27,673 (25.1%)	
2016	17,030 (43.9%)	2,153 (21.4%)	3,889 (27.1%)	3,240 (6.87%)	26,312 (23.8%)	
Time form most recent relative to index date hospital AF	0.2 (0.0 - 6.1)	0.2 (0.0 - 16.3)	0.4 (0.0 - 20.7)	0.4 (0.1 - 18.0)	0.3 (0.0 - 14.0)	
diagnosis, median (IQR), months						
Time from AF diagnosis to index						
3 - 60 months	10,661 (27.5%)	3,239 (32.1%)	5,011 (35.0%)	15,770 (33.4%)	34,681 (31.4%)	
< 3 month	28,164 (72.5%)	6,840 (67.9%)	9,322 (65.0%)	31,382 (66.6%)	75,708 (68.6%)	
Sex						
Female	17,899 (46.1%)	3,961 (39.3%)	6,453 (45.0%)	20,290 (43.0%)	48,603 (44.0%)	
Male	20,926 (53.9%)	6,118 (60.7%)	7,880 (55.0%)	26,862 (57.0%)	61,786 (56.0%)	
Age, median (IQR), years	75.7 (68.5 - 83.6)	71.1 (64.7 - 78.4)	74.9 (67.8 - 82.5)	75.6 (68.4 - 82.6)	75.1 (67.9 - 82.6)	
Age group						
< 55years	1,732 (4.46%)	770 (7.64%)	586 (4.09%)	2,125 (4.51%)	5,213 (4.72%)	
55-<65 years	4,445 (11.4%)	1,841 (18.3%)	1,741 (12.1%)	5,542 (11.8%)	13,569 (12.3%)	
65-<75 years	12,301 (31.7%)	3,894 (38.6%)	4,907 (34.2%)	14,882 (31.6%)	35,984 (32.6%)	
75-<85 years	12,309 (31.7%)	2,618 (26.0%)	4,613 (32.2%)	16,573 (35.1%)	36,113 (32.7%)	
≥ 85 years	8,038 (20.7%)	956 (9.49%)	2,486 (17.3%)	8,030 (17.0%)	19,510 (17.7%)	
Initial dose **	-,		_,	-, (1,10,0)	,>(1,1,70)	
Reduced	11,187 (28.8%)	3,084 (30.6%)	3,442 (24.0%)			
Standard	27,638 (71.2%)	6,995 (69.4%)	10,891 (76.0%)			
Baseline comorbidity 5 years	27,038 (71.270)	0,995 (09.470)	10,091 (70.070)			
before and including index date						
Charlson Comorbidity Index						
-						
score	16 107 (41 50/)	5.015 (40.90/)	()52 (42 (0/)	17 (71 (27 50))	45.046 (40.80()	
0	16,107 (41.5%)	5,015 (49.8%)	6,253 (43.6%)	17,671 (37.5%)	45,046 (40.8%)	
1-2	13,118 (33.8%)	3,326 (33.0%)	4,728 (33.0%)	15,785 (33.5%)	36,957 (33.5%)	
<u>≥3</u>	9,600 (24.7%)	1,738 (17.2%)	3,352 (23.4%)	13,696 (29.0%)	28,386 (25.7%)	
Baseline comorbidity 5 years						
before and including index date	4.170 (10.00()	000 (0.020()	1 511 (10 50()	5 1 45 (10 00()	11 742 (10 (0))	
Prior bleeding (any)	4,178 (10.8%)	909 (9.02%)	1,511 (10.5%)	5,145 (10.9%)	11,743 (10.6%)	
Prior gastrointestinal bleeding	276 (0.71%)	54 (0.54%)	76 (0.53%)	357 (0.76%)	763 (0.69%)	
Prior intracranial bleeding	477 (1.23%)	108 (1.07%)	182 (1.27%)	409 (0.87%)	1,176 (1.07%)	
Prior stroke (any)	5,369 (13.8%)	1,294 (12.8%)	1,855 (12.9%)	6,199 (13.1%)	14,717 (13.3%)	
Prior ischaemic stroke	5,168 (13.3%)	1,254 (12.4%)	1,788 (12.5%)	6,080 (12.9%)	14,290 (12.9%)	
Prior haemorrhagic stroke	427 (1.10%)	97 (0.96%)	152 (1.06%)	330 (0.70%)	1,006 (0.91%)	
Prior systemic embolism	244 (0.63%)	55 (0.55%)	122 (0.85%)	513 (1.09%)	934 (0.85%)	
Prior transient ischaemic attack	1,766 (4.55%)	430 (4.27%)	611 (4.26%)	2,050 (4.35%)	4,857 (4.40%)	
Chronic kidney disease	1,580 (4.07%)	132 (1.31%)	385 (2.69%)	3,279 (6.95%)	5,376 (4.87%)	
Heart failure	7,994 (20.6%)	1,515 (15.0%)	2,709 (18.9%)	11,329 (24.0%)	23,547 (21.3%)	
Coronary artery disease	8,253 (21.3%)	1,621 (16.1%)	2,886 (20.1%)	12,456 (26.4%)	25,216 (22.8%)	
Peripheral arterial disease	2,069 (5.33%)	444 (4.41%)	715 (4.99%)	3,032 (6.43%)	6,260 (5.67%)	
Cardioversion	2,822 (7.27%)	1,003 (9.95%)	954 (6.66%)	4,599 (9.75%)	9,378 (8.50%)	
Hypertension	27,744 (71.5%)	6,625 (65.7%)	10,254 (71.5%)	34,574 (73.3%)	79,197 (71.7%)	
Diabetes	6,642 (17.1%)	1,513 (15.0%)	2,538 (17.7%)	9,085 (19.3%)	19,778 (17.9%)	
Chronic obstructive pulmonary	4,549 (11.7%)	957 (9.49%)	1,657 (11.6%)	5,696 (12.1%)	12,859 (11.6%)	
disease	т,Jтэ (11./70)	JJI (J.+J70)	1,007 (11.070)	5,070 (12.170)	12,037 (11.0%)	
Liver disease	298 (0.77%)	84 (0.83%)	108 (0.75%)	425 (0.90%)	915 (0.83%)	
Alcoholism	948 (2.44%)	289 (2.87%)	369 (2.57%)	1,025 (2.17%)	2,631 (2.38%)	
		109 (1.08%)				
Dementia Cancer 6 months before and	1,022 (2.63%) 222 (0.57%)		402 (2.80%) 96 (0.67%)	770 (1.63%)	2,303 (2.09%) 781 (0.71%)	
	222 (0.57%)	61 (0.61%)	90 (0.07%)	402 (0.85%)	/81 (0./1%)	
including index date Prescription medication dispensed in 90 days before and including						
index date Platelet inhibitors (excluding	14,519 (37.4%)	3,411 (33.8%)	5,703 (39.8%)	18,679 (39.6%)	42,312 (38.3%)	
heparin)						
Low -dose aspirin	13,086 (33.7%)	3,129 (31.0%)	5,143 (35.9%)	17,006 (36.1%)	38,364 (34.8%)	
ADP receptor blockers	2,281 (5.88%)	431 (4.28%)	844 (5.89%)	3,708 (7.86%)	7,264 (6.58%)	
Renin -angiotensin system inhibitors	19,013 (49.0%)	4,475 (44.4%)	6,880 (48.0%)	24,143 (51.2%)	54,511 (49.4%)	

	0.055 (05.400)	0.055 (00.40)	2 271 (22 591)	10,401,(00,60())	20.002 (26.20)
Angiotensin -converting enzyme inhibitors	9,866 (25.4%)	2,255 (22.4%)	3,371 (23.5%)	13,491 (28.6%)	28,983 (26.3%)
Angiotensin II antagonists,	6,693 (17.2%)	1,506 (14.9%)	2,456 (17.1%)	8,002 (17.0%)	18,657 (16.9%)
plain	0,000 (171270)	1,000 (11,070)	2,100 (1111/0)	0,002 (171070)	10,007 (101370)
Angiotensin II antagonists,	2,305 (5.94%)	627 (6.22%)	910 (6.35%)	2,544 (5.40%)	6,386 (5.78%)
combinations	,	. ,	. ,		
Beta-blockers	29,783 (76.7%)	7,652 (75.9%)	10,579 (73.8%)	36,147 (76.7%)	84,161 (76.2%)
Proton pump inhibitors	8,393 (21.6%)	1,767 (17.5%)	2,895 (20.2%)	10,147 (21.5%)	23,202 (21.0%)
H2-receptor antagonists	151 (0.39%)	22 (0.22%)	61 (0.43%)	212 (0.45%)	446 (0.40%)
Non-steroidal anti-	2,610 (6.72%)	770 (7.64%)	878 (6.13%)	2,974 (6.31%)	7,232 (6.55%)
inflammatory drugs					
Statins	12,706 (32.7%)	3,011 (29.9%)	4,563 (31.8%)	16,734 (35.5%)	37,014 (33.5%)
Antidiabetic agents	4,588 (11.8%)	1,034 (10.3%)	1,778 (12.4%)	6,354 (13.5%)	13,754 (12.5%)
Loop diuretics	8,944 (23.0%)	1,644 (16.3%)	3,061 (21.4%)	12,985 (27.5%)	26,634 (24.1%)
Non-loop diuretics	442 (1.14%)	86 (0.85%)	143 (1.00%)	654 (1.39%)	1,325 (1.20%)
Alpha adrenergic blockers	8,722 (22.5%)	1,997 (19.8%)	3,273 (22.8%)	11,182 (23.7%)	25,174 (22.8%)
Amiodarone Dronedarone	443 (1.14%)	76 (0.75%)	133 (0.93%)	885 (1.88%)	1,537 (1.39%)
Antihypertensive, combination	406 (1.05%) 3,376 (8.70%)	52 (0.52%) 942 (9.35%)	70 (0.49%) 1,359 (9.48%)	440 (0.93%) 3,848 (8.16%)	968 (0.88%) 9,525 (8.63%)
drugs	5,570 (8.70%)	942 (9.55%)	1,559 (9.46%)	5,848 (8.10%)	9,525 (8.05%)
Calcium channel blockers	9,729 (25.1%)	2,302 (22.8%)	3,469 (24.2%)	12,244 (26.0%)	27,744 (25.1%)
Selective serotonin reuptake	2,755 (7.10%)	531 (5.27%)	999 (6.97%)	3,109 (6.59%)	7,394 (6.70%)
inhibitors	2,755 (7.1070)	551 (5.2770)	<i>(0.7170)</i>	5,109 (0.5970)	7,374 (0.7070)
Drugs used in alcohol	57 (0.15%)	19 (0.19%)	22 (0.15%)	56 (0.12%)	154 (0.14%)
dependence			(**** ***)		
Risk scores					
CHA2DS2-VASc score, mean	3.5 (1.7)	2.9 (1.8)	3.4 (1.7)	3.6 (1.8)	3.5 (1.8)
(SD)					
0 -1	5,146 (13.3%)	2,257 (22.4%)	1,936 (13.5%)	5,702 (12.1%)	15,041 (13.6%)
2 -3	14,817 (38.2%)	4,272 (42.4%)	5,856 (40.9%)	17,541 (37.2%)	42,486 (38.5%)
≥4	18,862 (48.6%)	3,550 (35.2%)	6,541 (45.6%)	23,909 (50.7%)	52,862 (47.9%)
CHADS2 score, mean (SD)	2.8 (1.5)	2.4 (1.5)	2.7 (1.5)	2.9 (1.5)	2.8 (1.5)
0	1,853 (4.77%)	982 (9.74%)	637 (4.44%)	2,304 (4.89%)	5,776 (5.23%)
1	5,692 (14.7%)	2,039 (20.2%)	2,264 (15.8%)	6,041 (12.8%)	16,036 (14.5%)
≥2	31,280 (80.6%)	7,058 (70.0%)	11,432 (79.8%)	38,807 (82.3%)	88,577 (80.2%)
HAS-BLED score, mean (SD)	1.9 (0.9)	1.7 (0.9)	1.9 (0.9)	1.9 (0.9)	1.9 (0.9)
<3	30,363 (78.2%)	8,377 (83.1%)	11,464 (80.0%)	36,077 (76.5%)	86,281 (78.2%)
<u>≥3</u>	8,462 (21.8%)	1,702 (16.9%)	2,869 (20.0%)	11,075 (23.5%)	24,108 (21.8%)
Health care utilisation in 12					
months before the index date Hospitalisations, median (IQR)	1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 2.0)	10(00 20)
Planned non-acute outpatient	1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 2.0)	1.0 (0.0 - 2.0) 1.0 (0.0 - 3.0)
visits, median (IQR)	1.0 (0.0 - 5.0)	1.0 (0.0 - 3.0)	1.0 (0.0 - 3.0)	1.0 (0.0 - 3.0)	1.0 (0.0 - 5.0)
Emergency/acute outpatient	1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)	0.0 (0.0 - 1.0)	1.0 (0.0 - 1.0)
visits, median (IQR)	1.0 (0.0 2.0)	1.0 (0.0 1.0)	1.0 (0.0 1.0)	0.0 (0.0 1.0)	1.0 (0.0 1.0)
Socioeconomic characteristics					
Standardised personal income	17 (14 - 26)	20 (15 - 32)	17 (14 - 26)	17 (13 - 24)	17 (14 - 26)
during 3 full calendar years		,			
preceding the index date, median					
(IQR), thousand Euros					
Highest education achieved					
Secondary compulsory	14,643 (37.7%)	2,962 (29.4%)	5,346 (37.3%)	18,846 (40.0%)	41,797 (37.9%)
Vocational / High school	14,787 (38.1%)	3,994 (39.6%)	5,472 (38.2%)	18,479 (39.2%)	42,732 (38.7%)
Higher education	8,970 (23.1%)	3,014 (29.9%)	3,338 (23.3%)	9,335 (19.8%)	24,657 (22.3%)
Unknown	408 (1.05%)	101 (1.00%)	167 (1.17%)	482 (1.02%)	1,158 (1.05%)

*Set to zero if AF diagnosed after index date (maximum 60 days)
 **Initial dose equals the strength of one tablet in the initial dispensing for rivaroxaban (used once daily) and to twice the strength of one in the initial dispensing for apixaban or dabigatran (used twice daily).
 IQR interquartile range; OAC oral anticoagulant; SD standard deviation Data on employment not available in Sweden.

Table 15.5 Crude rates, and crude pairwise hazard ratios of any stroke or systemic
embolism at an acute hospitalisation with an overnight stay among patients with NVAF
initiating apixaban, dabigatran, rivaroxaban vs. warfarin in Denmark, Norway, and
Sweden

Country	Cohort	n	Number of events (rounded)	Person-years	Crude rate per 100 person-years (95% CI)	Crude hazard ratio (95% CI)
All	Apixaban	71,585	1430	68,651.7		0.99 (0.92 - 1.06)
All	Dabigatran	31,209	610	43,462.8	1.4 (1.3 - 1.5)	0.76 (0.69 - 0.83)
All	Rivaroxaban	37,580	870	44,813.4	1.9 (1.8 - 2.1)	1.01 (0.93 - 1.09)
All	Warfarin	79,171	1890	98,817.3	1.9 (1.8 - 2.0)	Ref.
		11			I	
Denmark	Apixaban	14,980	390	14,541.7	2.6 (2.4 - 2.9)	1.34 (1.16 - 1.54)
Denmark	Dabigatran	12,446	280	18,021.7	1.6 (1.4 - 1.7)	0.90 (0.77 - 1.05)
Denmark	Rivaroxaban	12,682	280	13,011.1	2.2 (1.9 - 2.4)	1.14 (0.98 - 1.32)
Denmark	Warfarin	20,070	400	21,053.4	1.9 (1.7 - 2.1)	Ref.
Norway	Apixaban	17,780	330	16,312.5	2.0 (1.8 - 2.2)	0.93 (0.79 - 1.10)
Norway	Dabigatran	8,684	130	12,180.5	1.1 (0.9 - 1.3)	0.58 (0.47 - 0.71)
Norway	Rivaroxaban	10,565	270	13,870.0	2.0 (1.7 - 2.2)	1.01 (0.85 - 1.19)
Norway	Warfarin	11,949	270	13,466.2	2.0 (1.8 - 2.3)	Ref.
Sweden	Apixaban	38,825	710	37,797.5	1.9 (1.7 - 2.0)	0.88 (0.80 - 0.97)
Sweden	Dabigatran	10,079	190	13,260.7	1.5 (1.3 - 1.7)	0.77 (0.66 - 0.90)
Sweden	Rivaroxaban	14,333	320	17,932.3	1.8 (1.6 - 2.0)	0.91 (0.80 - 1.03)
Sweden	Warfarin	47,152	1210	64,316.1	1.9 (1.8 - 2.0)	Ref.

Table 15.6 Crude rates, and crude pairwise hazard ratios of any <u>bleeding</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin in Denmark, Norway, and Sweden

Country	Cabart		Number of events	D	Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	2080	68,479.0	3.0 (2.9 - 3.2)	0.79 (0.75 - 0.84)
All	Dabigatran	31,209	1070	43,270.0	2.5 (2.3 - 2.6)	0.72 (0.67 - 0.77)
All	Rivaroxaban	37,580	1740	44,309.3	3.9 (3.7 - 4.1)	1.10 (1.03 - 1.16)
All	Warfarin	79,171	3460	97,816.2	3.5 (3.4 - 3.6)	Ref.
Denmark	Apixaban	14,980	510	14,533.5	3.5 (3.2 - 3.8)	0.84 (0.75 - 0.94)
Denmark	Dabigatran	12,446	480	17,909.6	2.7 (2.4 - 2.9)	0.74 (0.66 - 0.83)
Denmark	Rivaroxaban	12,682	540	12,861.5	4.2 (3.8 - 4.5)	1.04 (0.94 - 1.16)
Denmark	Warfarin	20,070	820	20,778.2	4.0 (3.7 - 4.2)	Ref.
						1
Norway	Apixaban	17,780	610	16,175.6	3.8 (3.5 - 4.1)	0.71 (0.64 - 0.79)
Norway	Dabigatran	8,684	330	12,101.0	2.7 (2.4 - 3.0)	0.59 (0.51 - 0.67)
Norway	Rivaroxaban	10,565	610	13,638.9	4.5 (4.1 - 4.8)	0.94 (0.84 - 1.05)
Norway	Warfarin	11,949	650	13,210.9	4.9 (4.6 - 5.3)	Ref.
Sweden	Apixaban	38,825	960	37,770.0	2.6 (2.4 - 2.7)	0.76 (0.70 - 0.82)
Sweden	Dabigatran	10,079	260	13,259.4	2.0 (1.8 - 2.2)	0.64 (0.56 - 0.73)
Sweden	Rivaroxaban	14,333	590	17,808.9	3.3 (3.1 - 3.6)	1.05 (0.96 - 1.16)
Sweden	Warfarin	47,152	1980	63,868.0	3.1 (3.0 - 3.2)	Ref.

Table 15.7 Crude rates, and crude pairwise hazard ratios of <u>ischaemic stroke</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

			Number of events	_	Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	1160	68,713.5	1.7 (1.6 - 1.8)	1.07 (0.99 - 1.15)
All	Dabigatran	31,209	520	43,498.3	1.2 (1.1 - 1.3)	0.86 (0.78 - 0.95)
All	Rivaroxaban	37,580	680	44,859.1	1.5 (1.4 - 1.6)	1.04 (0.95 - 1.14)
All	Warfarin	79,171	1420	98,992.0	1.4 (1.4 - 1.5)	Ref.
Denmark	Apixaban	14,980	320	14,553.7	2.2 (2.0 - 2.4)	1.42 (1.21 - 1.66)
Denmark	Dabigatran	12,446	240	18,035.7	1.3 (1.2 - 1.5)	1.00 (0.85 - 1.19)
Denmark	Rivaroxaban	12,682	230	13,021.8	1.8 (1.5 - 2.0)	1.18 (1.00 - 1.40)
Denmark	Warfarin	20,070	310	21,076.5	1.5 (1.3 - 1.7)	Ref.
					1	
Norway	Apixaban	17,780	260	16,331.5	1.6 (1.4 - 1.8)	1.06 (0.88 - 1.27)
Norway	Dabigatran	8,684	110	12,193.7	0.9 (0.7 - 1.1)	0.66 (0.52 - 0.84)
Norway	Rivaroxaban	10,565	200	13,889.1	1.4 (1.2 - 1.6)	1.05 (0.86 - 1.28)
Norway	Warfarin	11,949	190	13,493.4	1.4 (1.2 - 1.6)	Ref.
					-	
Sweden	Apixaban	38,825	580	37,828.3	1.5 (1.4 - 1.7)	0.94 (0.85 - 1.05)
Sweden	Dabigatran	10,079	170	13,268.9	1.3 (1.1 - 1.5)	0.88 (0.75 - 1.04)
Sweden	Rivaroxaban	14,333	250	17,948.3	1.4 (1.2 - 1.6)	0.94 (0.81 - 1.08)
Sweden	Warfarin	47,152	920	64,442.9	1.4 (1.3 - 1.5)	Ref.

Table 15.8 Crude rates, and crude pairwise hazard ratios of <u>haemorrhagic stroke</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

Country	Cohort	n	Number of events (rounded)	Person-years	Crude rate per 100 person-years (95% CI)	Crude hazard ratio (95% CI)
All		71,585	(Tounded) 260	69,377.1	0.4 (0.3 - 0.4)	0.86 (0.74 - 1.01)
	Apixaban			,	. ,	
All	Dabigatran	31,209	70	43,889.8	0.2 (0.1 - 0.2)	0.41 (0.32 - 0.53)
All	Rivaroxaban	37,580	200	45,265.8	0.4 (0.4 - 0.5)	1.06 (0.89 - 1.26)
All	Warfarin	79,171	400	99,781.8	0.4 (0.4 - 0.4)	Ref.
Denmark	Apixaban	14,980	70	14,762.8	0.5 (0.4 - 0.6)	1.09 (0.79 - 1.50)
Denmark	Dabigatran	12,446	30	18,227.7	0.2 (0.1 - 0.3)	0.48 (0.32 - 0.71)
Denmark	Rivaroxaban	12,682	50	13,163.7	0.4 (0.3 - 0.5)	0.99 (0.70 - 1.39)
Denmark	Warfarin	20,070	90	21,205.9	0.4 (0.3 - 0.5)	Ref.
					[1
Norway	Apixaban	17,780	70	16,449.5	0.4 (0.3 - 0.5)	0.74 (0.53 - 1.03)
Norway	Dabigatran	8,684	20	12,276.3	0.2 (0.1 - 0.3)	0.33 (0.20 - 0.54)
Norway	Rivaroxaban	10,565	70	13,990.1	0.5 (0.4 - 0.6)	0.98 (0.71 - 1.36)
Norway	Warfarin	11,949	70	13,586.8	0.5 (0.4 - 0.7)	Ref.
Sweden	Apixaban	38,825	120	38,164.7	0.3 (0.3 - 0.4)	0.79 (0.63 - 0.99)
Sweden	Dabigatran	10,079	20	13,385.8	0.1 (0.1 - 0.2)	0.34 (0.21 - 0.55)
Sweden	Rivaroxaban	14,333	70	18,111.9	0.4 (0.3 - 0.5)	1.01 (0.77 - 1.32)
Sweden	Warfarin	47,152	240	65,010.8	0.4 (0.3 - 0.4)	Ref.

Table 15.9 Crude rates, and crude pairwise hazard ratios of <u>intracranial bleeding</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

<i>a</i> .			Number of events	-	Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	450	69,327.6	0.6 (0.6 - 0.7)	0.70 (0.63 - 0.79)
All	Dabigatran	31,209	150	43,856.7	0.3 (0.3 - 0.4)	0.39 (0.33 - 0.47)
All	Rivaroxaban	37,580	320	45,217.2	0.7 (0.6 - 0.8)	0.79 (0.70 - 0.90)
All	Warfarin	79,171	870	99,578.9	0.9 (0.8 - 0.9)	Ref.
	·		L			
Denmark	Apixaban	14,980	120	14,751.1	0.8 (0.6 - 0.9)	1.02 (0.80 - 1.30)
Denmark	Dabigatran	12,446	60	18,218.6	0.3 (0.3 - 0.4)	0.47 (0.35 - 0.63)
Denmark	Rivaroxaban	12,682	90	13,151.8	0.7 (0.6 - 0.8)	0.93 (0.72 - 1.20)
Denmark	Warfarin	20,070	160	21,179.0	0.7 (0.6 - 0.9)	Ref.
					-	
Norway	Apixaban	17,780	110	16,437.3	0.7 (0.5 - 0.8)	0.67 (0.52 - 0.87)
Norway	Dabigatran	8,684	40	12,264.6	0.3 (0.2 - 0.4)	0.38 (0.27 - 0.54)
Norway	Rivaroxaban	10,565	100	13,972.7	0.7 (0.6 - 0.9)	0.81 (0.63 - 1.06)
Norway	Warfarin	11,949	120	13,564.4	0.9 (0.8 - 1.1)	Ref.
Sweden	Apixaban	38,825	230	38,139.2	0.6 (0.5 - 0.7)	0.63 (0.54 - 0.73)
Sweden	Dabigatran	10,079	50	13,373.5	0.3 (0.3 - 0.5)	0.38 (0.28 - 0.52)
Sweden	Rivaroxaban	14,333	120	18,092.6	0.7 (0.6 - 0.8)	0.75 (0.62 - 0.91)
Sweden	Warfarin	47,152	580	64,858.7	0.9 (0.8 - 1.0)	Ref.

Table 15.10 Crude rates, and crude pairwise hazard ratios of gastrointestinal bleeding
at an acute hospitalisation with an overnight stay among patients with NVAF initiating
apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

			Number of events		Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	830	69,056.4	1.2 (1.1 - 1.3)	0.84 (0.77 - 0.91)
All	Dabigatran	31,209	580	43,577.0	1.3 (1.2 - 1.4)	1.06 (0.96 - 1.17)
All	Rivaroxaban	37,580	750	44,872.5	1.7 (1.6 - 1.8)	1.25 (1.14 - 1.37)
All	Warfarin	79,171	1300	99,117.7	1.3 (1.2 - 1.4)	Ref.
			L			
Denmark	Apixaban	14,980	220	14,677.2	1.5 (1.3 - 1.7)	0.83 (0.70 - 0.99)
Denmark	Dabigatran	12,446	270	18,057.5	1.5 (1.3 - 1.7)	0.99 (0.85 - 1.16)
Denmark	Rivaroxaban	12,682	250	13,029.6	1.9 (1.7 - 2.1)	1.11 (0.95 - 1.31)
Denmark	Warfarin	20,070	360	21,032.5	1.7 (1.5 - 1.9)	Ref.
Norway	Apixaban	17,780	210	16,366.5	1.3 (1.1 - 1.5)	0.72 (0.60 - 0.87)
Norway	Dabigatran	8,684	170	12,197.0	1.4 (1.2 - 1.6)	0.88 (0.72 - 1.08)
Norway	Rivaroxaban	10,565	260	13,850.4	1.8 (1.6 - 2.1)	1.16 (0.97 - 1.39)
Norway	Warfarin	11,949	220	13,468.4	1.6 (1.4 - 1.9)	Ref.
Sweden	Apixaban	38,825	410	38,012.7	1.1 (1.0 - 1.2)	0.87 (0.77 - 0.99)
Sweden	Dabigatran	10,079	140	13,322.5	1.1 (0.9 - 1.3)	0.97 (0.81 - 1.16)
Sweden	Rivaroxaban	14,333	250	17,992.5	1.4 (1.2 - 1.5)	1.20 (1.04 - 1.39)
Sweden	Warfarin	47,152	720	64,652.7	1.1 (1.0 - 1.2)	Ref.

Table 15.11 Crude rates, and crude pairwise hazard ratios of <u>acute myocardial</u><u>infarction</u> at an acute hospitalisation with an overnight stay among patients with NVAFinitiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

Country	Cohort	-	Number of events (rounded)	Dougon woong	Crude rate per 100 person-years (95% CI)	Crude hazard ratio (95% CI)
v		n	. ,	Person-years		
All	Apixaban	71,585	990	68,930.6	1.4 (1.3 - 1.5)	0.96 (0.88 - 1.04)
All	Dabigatran	31,209	380	43,669.3	0.9 (0.8 - 1.0)	0.67 (0.60 - 0.75)
All	Rivaroxaban	37,580	500	45,029.6	1.1 (1.0 - 1.2)	0.80 (0.72 - 0.89)
All	Warfarin	79,171	1340	98,840.2	1.4 (1.3 - 1.4)	Ref.
			·			
Denmark	Apixaban	14,980	150	14,707.2	1.0 (0.9 - 1.2)	0.94 (0.77 - 1.16)
Denmark	Dabigatran	12,446	140	18,119.0	0.8 (0.7 - 0.9)	0.85 (0.69 - 1.06)
Denmark	Rivaroxaban	12,682	100	13,128.4	0.8 (0.6 - 0.9)	0.75 (0.59 - 0.95)
Denmark	Warfarin	20,070	220	21,070.7	1.0 (0.9 - 1.2)	Ref.
					-	
Norway	Apixaban	17,780	310	16,329.0	1.9 (1.7 - 2.1)	0.81 (0.69 - 0.96)
Norway	Dabigatran	8,684	150	12,205.0	1.2 (1.0 - 1.4)	0.59 (0.49 - 0.72)
Norway	Rivaroxaban	10,565	200	13,879.3	1.5 (1.3 - 1.7)	0.71 (0.59 - 0.85)
Norway	Warfarin	11,949	290	13,399.0	2.1 (1.9 - 2.4)	Ref.
Sweden	Apixaban	38,825	530	37,894.3	1.4 (1.3 - 1.5)	0.96 (0.86 - 1.07)
Sweden	Dabigatran	10,079	100	13,345.3	0.7 (0.6 - 0.9)	0.54 (0.44 - 0.67)
Sweden	Rivaroxaban	14,333	200	18,021.9	1.1 (0.9 - 1.2)	0.81 (0.69 - 0.94)
Sweden	Warfarin	47,152	840	64,395.4	1.3 (1.2 - 1.4)	Ref.

Table 15.12 Crude rates, and crude pairwise hazard ratios of <u>systemic embolism</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

Country	Cohort	n	Number of events (rounded)	Person-years	Crude rate per 100 person-years (95% CI)	Crude hazard ratio (95% CI)
All	Apixaban	71,585	(rounded) 50	69,404.1	0.1 (0.1 - 0.1)	0.59 (0.43 - 0.83)
All	Dabigatran	31,209	30	43,894.7	0.1 (0.0 - 0.1)	0.60 (0.40 - 0.92)
All	Rivaroxaban	37,580	30	45,290.2	0.1 (0.0 - 0.1)	0.56 (0.37 - 0.85)
All	Warfarin	79,171	110	99,819.2	0.1 (0.1 - 0.1)	Ref.
		11			I	
Denmark	Apixaban	14,980	10	14,771.9	0.0 (0.0 - 0.1)	0.64 (0.26 - 1.57)
Denmark	Dabigatran	12,446	10	18,228.6	0.0 (0.0 - 0.1)	0.79 (0.34 - 1.81)
Denmark	Rivaroxaban	12,682	0	13,170.5	0.0 (0.0 - 0.1)	0.32 (0.09 - 1.10)
Denmark	Warfarin	20,070	20	21,223.8	0.1 (0.0 - 0.1)	Ref.
			·			
Norway	Apixaban	17,780	10	16,461.1	0.1 (0.0 - 0.1)	0.45 (0.20 - 0.99)
Norway	Dabigatran	8,684	10	12,277.1	0.1 (0.0 - 0.1)	0.55 (0.23 - 1.33)
Norway	Rivaroxaban	10,565	10	13,998.5	0.1 (0.0 - 0.1)	0.84 (0.40 - 1.74)
Norway	Warfarin	11,949	20	13,593.1	0.1 (0.1 - 0.2)	Ref.
Sweden	Apixaban	38,825	40	38,171.1	0.1 (0.1 - 0.1)	0.65 (0.43 - 0.97)
Sweden	Dabigatran	10,079	10	13,389.0	0.1 (0.0 - 0.1)	0.73 (0.40 - 1.35)
Sweden	Rivaroxaban	14,333	10	18,121.2	0.1 (0.0 - 0.1)	0.57 (0.32 - 1.02)
Sweden	Warfarin	47,152	80	65,022.5	0.1 (0.1 - 0.1)	Ref.

Table 15.13 Crude rates, and crude pairwise hazard ratios of <u>death of any cause among</u>
patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall
and by country

			Number of events		Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	5280	69,427.6	7.6 (7.4 - 7.8)	1.28 (1.23 - 1.33)
All	Dabigatran	31,209	1590	43,910.4	3.6 (3.4 - 3.8)	0.67 (0.63 - 0.70)
All	Rivaroxaban	37,580	3110	45,303.9	6.9 (6.6 - 7.1)	1.22 (1.17 - 1.28)
All	Warfarin	79,171	5570	99,891.9	5.6 (5.4 - 5.7)	Ref.
Denmark	Apixaban	14,980	1620	14,774.3	10.9 (10.4 - 11.5)	1.68 (1.56 - 1.81)
Denmark	Dabigatran	12,446	900	18,235.3	4.9 (4.6 - 5.2)	0.84 (0.77 - 0.91)
Denmark	Rivaroxaban	12,682	1350	13,172.8	10.2 (9.7 - 10.8)	1.61 (1.49 - 1.73)
Denmark	Warfarin	20,070	1350	21,227.2	6.4 (6.0 - 6.7)	Ref.
	· · ·					
Norway	Apixaban	17,780	920	16,467.0	5.6 (5.2 - 6.0)	0.91 (0.83 - 1.00)
Norway	Dabigatran	8,684	320	12,283.5	2.6 (2.3 - 2.9)	0.46 (0.40 - 0.52)
Norway	Rivaroxaban	10,565	660	14,005.5	4.7 (4.3 - 5.1)	0.82 (0.74 - 0.91)
Norway	Warfarin	11,949	800	13,604.8	5.9 (5.5 - 6.3)	Ref.
	·		·			
Sweden	Apixaban	38,825	2740	38,186.3	7.2 (6.9 - 7.4)	1.28 (1.22 - 1.35)
Sweden	Dabigatran	10,079	370	13,391.6	2.8 (2.5 - 3.1)	0.53 (0.48 - 0.59)
Sweden	Rivaroxaban	14,333	1110	18,125.6	6.1 (5.7 - 6.5)	1.15 (1.07 - 1.23)
Sweden	Warfarin	47,152	3400	65,082.2	5.2 (5.1 - 5.4)	Ref.

Table 15.14 Crude rates, and crude pairwise hazard ratios of composite endpoint of ischaemic stroke at an acute hospitalisation with an overnight stay, systemic embolism at an acute hospitalisation with an overnight stay, acute myocardial infarction at an acute hospitalisation with an overnight stay or death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country Cohort			Number of events	Daman	Crude rate per 100 person-years	Crude hazard ratio	
v		n	(rounded)	Person-years	(95% CI)	(95% CI)	
All	Apixaban	71,585	6930	68,209.9	10.2 (9.9 - 10.4)	1.19 (1.16 - 1.23)	
All	Dabigatran	31,209	2350	43,247.9	5.4 (5.2 - 5.6)	0.71 (0.68 - 0.75)	
All	Rivaroxaban	37,580	3970	44,588.7	8.9 (8.6 - 9.2)	1.12 (1.08 - 1.16)	
All	Warfarin	79,171	7720	97,901.3	7.9 (7.7 - 8.1)	Ref.	
Denmark	Apixaban	14,980	1970	14,486.4	13.6 (13.0 - 14.2)	1.57 (1.47 - 1.67)	
Denmark	Dabigatran	12,446	1200	17,918.0	6.7 (6.3 - 7.1)	0.87 (0.81 - 0.94)	
Denmark	Rivaroxaban	12,682	1580	12,977.6	12.1 (11.5 - 12.7)	1.44 (1.35 - 1.55)	
Denmark	Warfarin	20,070	1760	20,924.6	8.4 (8.0 - 8.8)	Ref.	
Norway	Apixaban	17,780	1380	16,193.1	8.5 (8.1 - 9.0)	0.90 (0.84 - 0.98)	
Norway	Dabigatran	8,684	550	12,108.9	4.5 (4.1 - 4.9)	0.54 (0.49 - 0.60)	
Norway	Rivaroxaban	10,565	970	13,765.0	7.0 (6.6 - 7.5)	0.82 (0.75 - 0.89)	
Norway	Warfarin	11,949	1180	13,279.9	8.9 (8.4 - 9.4)	Ref.	
	I						
Sweden	Apixaban	38,825	3590	37,530.4	9.6 (9.3 - 9.9)	1.17 (1.12 - 1.22)	
Sweden	Dabigatran	10,079	600	13,221.0	4.5 (4.2 - 4.9)	0.61 (0.56 - 0.66)	
Sweden	Rivaroxaban	14,333	1430	17,846.2	8.0 (7.6 - 8.4)	1.05 (0.99 - 1.11)	
Sweden	Warfarin	47,152	4770	63,718.0	7.5 (7.3 - 7.7)	Ref.	

Table 15.15 Crude rates, and crude pairwise hazard ratios of <u>any bleeding</u> at an acute or planned hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

C	Calvert		Number of events	D	Crude rate per 100 person-years	Crude hazard ratio
Country	Cohort	n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	2300	68,348.7	3.4 (3.2 - 3.5)	0.81 (0.77 - 0.85)
All	Dabigatran	31,209	1170	43,190.4	2.7 (2.5 - 2.9)	0.73 (0.69 - 0.78)
All	Rivaroxaban	37,580	1890	44,185.4	4.3 (4.1 - 4.5)	1.10 (1.05 - 1.17)
All	Warfarin	79,171	3730	97,592.7	3.8 (3.7 - 3.9)	Ref.
			·			
Denmark	Apixaban	14,980	550	14,504.8	3.8 (3.5 - 4.1)	0.86 (0.77 - 0.96)
Denmark	Dabigatran	12,446	510	17,884.0	2.8 (2.6 - 3.1)	0.73 (0.66 - 0.82)
Denmark	Rivaroxaban	12,682	580	12,823.5	4.5 (4.2 - 4.9)	1.06 (0.95 - 1.17)
Denmark	Warfarin	20,070	890	20,722.3	4.3 (4.0 - 4.6)	Ref.
		T. T. T.				
Norway	Apixaban	17,780	710	16,116.0	4.4 (4.1 - 4.7)	0.75 (0.67 - 0.83)
Norway	Dabigatran	8,684	380	12,060.7	3.1 (2.8 - 3.4)	0.61 (0.53 - 0.69)
Norway	Rivaroxaban	10,565	680	13,581.0	5.0 (4.6 - 5.4)	0.94 (0.85 - 1.05)
Norway	Warfarin	11,949	720	13,160.5	5.5 (5.1 - 5.9)	Ref.
					-	
Sweden	Apixaban	38,825	1040	37,727.8	2.7 (2.6 - 2.9)	0.76 (0.71 - 0.82)
Sweden	Dabigatran	10,079	280	13,245.7	2.1 (1.9 - 2.4)	0.65 (0.57 - 0.73)
Sweden	Rivaroxaban	14,333	630	17,781.0	3.5 (3.3 - 3.8)	1.05 (0.96 - 1.14)
Sweden	Warfarin	47,152	2110	63,754.2	3.3 (3.2 - 3.5)	Ref.

Table 15.16 Crude rates, and crude pairwise hazard ratios of any bleeding at an acutehospital contact without an overnight stayamong patients with NVAF initiatingapixaban, dabigatran, rivaroxaban vs. warfarin, overall and by country

			Number of		Crude rate per	
Country	Cohort	n	events (rounded)	Person-years	100 person-years (95% CI)	Crude hazard ratio (95% CI)
All	Apixaban	71,585	1320	68,601.6	1.9 (1.8 - 2.0)	0.78 (0.73 - 0.84)
All	Dabigatran	31,209	420	43,587.4	1.0 (0.9 - 1.1)	0.42 (0.37 - 0.46)
All	Rivaroxaban	37,580	1170	44,337.3	2.6 (2.5 - 2.8)	1.11 (1.03 - 1.19)
All	Warfarin	79,171	2320	97,841.1	2.4 (2.3 - 2.5)	Ref.
	I					
Denmark	Apixaban	14,980	160	14,662.3	1.1 (1.0 - 1.3)	0.79 (0.65 - 0.96)
Denmark	Dabigatran	12,446	80	18,162.1	0.5 (0.4 - 0.6)	0.36 (0.28 - 0.45)
Denmark	Rivaroxaban	12,682	220	12,983.9	1.7 (1.5 - 2.0)	1.26 (1.05 - 1.50)
Denmark	Warfarin	20,070	290	21,005.6	1.4 (1.2 - 1.5)	Ref.
			L			
Norway	Apixaban	17,780	130	16,379.5	0.8 (0.7 - 0.9)	0.56 (0.45 - 0.71)
Norway	Dabigatran	8,684	70	12,224.1	0.6 (0.4 - 0.7)	0.45 (0.34 - 0.60)
Norway	Rivaroxaban	10,565	190	13,829.2	1.3 (1.2 - 1.5)	1.04 (0.84 - 1.27)
Norway	Warfarin	11,949	180	13,435.0	1.3 (1.1 - 1.5)	Ref.
Sweden	Apixaban	38,825	1030	37,559.9	2.7 (2.6 - 2.9)	0.89 (0.83 - 0.97)
Sweden	Dabigatran	10,079	270	13,201.2	2.0 (1.8 - 2.3)	0.69 (0.61 - 0.79)
Sweden	Rivaroxaban	14,333	760	17,524.2	4.4 (4.1 - 4.7)	1.47 (1.35 - 1.60)
Sweden	Warfarin	47,152	1870	63,405.9	2.9 (2.8 - 3.1)	Ref.

Table 15.17 Crude rates, and crude pairwise hazard ratios of any bleeding recorded as
the primary diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis)
among patients with NVAF initiating apixaban, dabigatran, rivaroxaban vs. warfarin,
overall and by country

Country Cohort		-	Number of events	Dongon woong	Crude rate per 100 person-years	Crude hazard ratio
		n	(rounded)	Person-years	(95% CI)	(95% CI)
All	Apixaban	71,585	1320	68,835.5	1.9 (1.8 - 2.0)	0.70 (0.66 - 0.75)
All	Dabigatran	31,209	740	43,461.7	1.7 (1.6 - 1.8)	0.70 (0.64 - 0.76)
All	Rivaroxaban	37,580	1220	44,602.5	2.7 (2.6 - 2.9)	1.07 (1.00 - 1.15)
All	Warfarin	79,171	2470	98,420.0	2.5 (2.4 - 2.6)	Ref.
Denmark	Apixaban	14,980	400	14,579.5	2.7 (2.5 - 3.0)	0.80 (0.70 - 0.90)
Denmark	Dabigatran	12,446	390	17,979.6	2.2 (2.0 - 2.4)	0.73 (0.64 - 0.82)
Denmark	Rivaroxaban	12,682	460	12,902.1	3.6 (3.3 - 3.9)	1.07 (0.95 - 1.21)
Denmark	Warfarin	20,070	690	20,839.4	3.3 (3.1 - 3.6)	Ref.
Norway	Apixaban	17,780	290	16,332.2	1.8 (1.6 - 2.0)	0.64 (0.55 - 0.75)
Norway	Dabigatran	8,684	180	12,173.5	1.5 (1.3 - 1.7)	0.61 (0.51 - 0.74)
Norway	Rivaroxaban	10,565	340	13,808.7	2.4 (2.2 - 2.7)	0.97 (0.84 - 1.13)
Norway	Warfarin	11,949	340	13,405.8	2.6 (2.3 - 2.8)	Ref.
Sweden	Apixaban	38,825	630	37,923.8	1.7 (1.5 - 1.8)	0.69 (0.63 - 0.76)
Sweden	Dabigatran	10,079	170	13,308.5	1.3 (1.1 - 1.5)	0.57 (0.48 - 0.66)
Sweden	Rivaroxaban	14,333	430	17,891.7	2.4 (2.2 - 2.6)	1.04 (0.93 - 1.16)
Sweden	Warfarin	47,152	1430	64,209.8	2.2 (2.1 - 2.3)	Ref.

Table 15.18 Crude cumulative incidence of any stroke or systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	1430	0.021 (0.020 - 0.023)	0.032 (0.030 - 0.034)	0.043 (0.039 - 0.048)	0.065 (0.046 - 0.089)
All	Dabigatran	31,210	610	0.016 (0.015 - 0.018)	0.025 (0.023 - 0.027)	0.034 (0.031 - 0.037)	0.043 (0.035 - 0.053)
All	Rivaroxaban	37,580	870	0.020 (0.019 - 0.022)	0.034 (0.032 - 0.037)	0.044 (0.040 - 0.047)	0.051 (0.046 - 0.057)
All	Warfarin	79,170	1890	0.022 (0.020 - 0.023)	0.033 (0.031 - 0.034)	0.043 (0.040 - 0.045)	0.051 (0.048 - 0.055)
Denmark	Apixaban	14,980	390	0.026 (0.023 - 0.030)	0.039 (0.035 - 0.044)	0.054 (0.045 - 0.065)	0.073 (0.052 - 0.100)
Denmark	Dabigatran	12,450	280	0.018 (0.015 - 0.021)	0.028 (0.024 - 0.032)	0.037 (0.033 - 0.042)	0.055 (0.037 - 0.077)
Denmark	Rivaroxaban	12,680	280	0.021 (0.018 - 0.024)	0.036 (0.031 - 0.041)	0.048 (0.041 - 0.055)	0.054 (0.046 - 0.064)
Denmark	Warfarin	20,070	400	0.020 (0.018 - 0.023)	0.031 (0.028 - 0.035)	0.037 (0.033 - 0.042)	0.048 (0.039 - 0.058)
Norway	Apixaban	17,780	330	0.021 (0.018 - 0.024)	0.032 (0.028 - 0.037)	0.043 (0.032 - 0.057)	0.043 (0.032 - 0.057)
Norway	Dabigatran	8,680	130	0.013 (0.011 - 0.016)	0.020 (0.016 - 0.024)	0.026 (0.022 - 0.032)	0.030 (0.024 - 0.037)
Norway	Rivaroxaban	10,570	270	0.022 (0.019 - 0.025)	0.035 (0.030 - 0.040)	0.048 (0.041 - 0.055)	0.059 (0.049 - 0.071)
Norway	Warfarin	11,950	270	0.021 (0.018 - 0.024)	0.033 (0.029 - 0.038)	0.050 (0.043 - 0.057)	0.054 (0.046 - 0.063)
Sweden	Apixaban	38,830	710	0.020 (0.018 - 0.021)	0.029 (0.027 - 0.032)	0.038 (0.033 - 0.044)	0.061 (0.033 - 0.102)
Sweden	Dabigatran	10,080	190	0.017 (0.014 - 0.020)	0.025 (0.021 - 0.029)	0.036 (0.030 - 0.042)	0.039 (0.032 - 0.047)
Sweden	Rivaroxaban	14,330	320	0.019 (0.017 - 0.022)	0.032 (0.029 - 0.036)	0.037 (0.032 - 0.042)	0.042 (0.035 - 0.050)
Sweden	Warfarin	47,150	1210	0.022 (0.021 - 0.024)	0.033 (0.031 - 0.035)	0.043 (0.040 - 0.046)	0.051 (0.047 - 0.055)

Table 15.19 Crude cumulative incidence of any bleeding at an acute hospitalisation with
an overnight stay among patients with NVAF initiating apixaban, dabigatran,
rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	2080	0.030 (0.029 - 0.032)	0.050 (0.047 - 0.052)	0.064 (0.060 - 0.070)	0.071 (0.062 - 0.080)
All	Dabigatran	31,210	1070	0.028 (0.026 - 0.030)	0.045 (0.042 - 0.048)	0.060 (0.056 - 0.064)	0.077 (0.070 - 0.085)
All	Rivaroxaban	37,580	1740	0.042 (0.039 - 0.044)	0.068 (0.064 - 0.071)	0.087 (0.082 - 0.092)	0.108 (0.098 - 0.120)
All	Warfarin	79,170	3460	0.038 (0.037 - 0.040)	0.062 (0.059 - 0.064)	0.080 (0.077 - 0.083)	0.095 (0.091 - 0.100)
Denmark	Apixaban	14,980	510	0.034 (0.031 - 0.037)	0.055 (0.050 - 0.061)	0.074 (0.064 - 0.084)	0.079 (0.065 - 0.094)
Denmark	Dabigatran	12,450	480	0.030 (0.027 - 0.034)	0.049 (0.044 - 0.054)	0.063 (0.057 - 0.070)	0.080 (0.070 - 0.090)
Denmark	Rivaroxaban	12,680	540	0.041 (0.037 - 0.045)	0.067 (0.060 - 0.073)	0.087 (0.078 - 0.097)	0.101 (0.089 - 0.114)
Denmark	Warfarin	20,070	820	0.043 (0.040 - 0.047)	0.064 (0.059 - 0.069)	0.076 (0.070 - 0.083)	0.092 (0.082 - 0.102)
Norway	Apixaban	17,780	610	0.038 (0.035 - 0.042)	0.062 (0.056 - 0.068)	0.077 (0.066 - 0.089)	0.105 (0.069 - 0.149)
Norway	Dabigatran	8,680	330	0.030 (0.026 - 0.035)	0.049 (0.043 - 0.056)	0.068 (0.060 - 0.076)	0.083 (0.072 - 0.096)
Norway	Rivaroxaban	10,570	610	0.049 (0.045 - 0.054)	0.083 (0.076 - 0.090)	0.105 (0.096 - 0.115)	0.140 (0.106 - 0.180)
Norway	Warfarin	11,950	650	0.051 (0.047 - 0.056)	0.081 (0.074 - 0.088)	0.105 (0.095 - 0.114)	0.120 (0.108 - 0.132)
Sweden	Apixaban	38,830	960	0.026 (0.024 - 0.028)	0.043 (0.040 - 0.046)	0.055 (0.048 - 0.062)	0.055 (0.048 - 0.062)
Sweden	Dabigatran	10,080	260	0.022 (0.019 - 0.025)	0.035 (0.030 - 0.040)	0.049 (0.043 - 0.057)	0.071 (0.051 - 0.094)
Sweden	Rivaroxaban	14,330	590	-	0.057 (0.052 - 0.062)	0.072 (0.065 - 0.080)	0.095 (0.081 - 0.111)
Sweden	Warfarin	47,150	1980	0.033 (0.031 - 0.035)	0.055 (0.053 - 0.058)	0.075 (0.072 - 0.079)	0.091 (0.086 - 0.097)

Table 15.20 Cumulative incidence of <u>ischaemic stroke</u> at an acute hospitalisation with
an overnight stay among patients with NVAF initiating apixaban, dabigatran,
rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	1160	0.017 (0.016 - 0.018)	0.026 (0.024 - 0.027)	0.034 (0.030 - 0.038)	0.057 (0.038 - 0.081)
All	Dabigatran	31,210	520	0.014 (0.013 - 0.016)	0.021 (0.019 - 0.023)	0.028 (0.026 - 0.031)	0.036 (0.028 - 0.046)
All	Rivaroxaban	37,580	680	0.016 (0.015 - 0.018)	0.026 (0.024 - 0.029)	0.033 (0.030 - 0.036)	0.039 (0.035 - 0.044)
All	Warfarin	79,170	1420	0.016 (0.015 - 0.017)	0.024 (0.023 - 0.025)	0.031 (0.030 - 0.033)	0.037 (0.034 - 0.040)
Denmark	Apixaban	14,980	320	0.022 (0.019 - 0.024)	0.033 (0.029 - 0.037)	0.043 (0.035 - 0.052)	0.065 (0.043 - 0.092)
Denmark	Dabigatran	12,450	240	0.016 (0.014 - 0.018)	0.024 (0.021 - 0.027)	0.031 (0.027 - 0.036)	0.046 (0.029 - 0.069)
Denmark	Rivaroxaban	12,680	230	0.018 (0.015 - 0.021)	0.029 (0.025 - 0.033)	0.037 (0.031 - 0.043)	0.043 (0.035 - 0.053)
Denmark	Warfarin	20,070	310	0.016 (0.014 - 0.018)	0.024 (0.021 - 0.027)	0.028 (0.025 - 0.033)	0.036 (0.028 - 0.044)
Norway	Apixaban	17,780	260	0.017 (0.014 - 0.019)	0.025 (0.022 - 0.029)	0.036 (0.025 - 0.050)	0.036 (0.025 - 0.050)
Norway	Dabigatran	8,680	110	0.010 (0.008 - 0.013)	0.016 (0.013 - 0.020)	0.022 (0.018 - 0.027)	0.023 (0.019 - 0.029)
Norway	Rivaroxaban	10,570	200	0.016 (0.013 - 0.019)	0.025 (0.021 - 0.030)	0.034 (0.029 - 0.041)	0.042 (0.034 - 0.052)
Norway	Warfarin	11,950	190	0.015 (0.013 - 0.018)	0.023 (0.019 - 0.027)	0.036 (0.030 - 0.043)	0.039 (0.033 - 0.047)
Sweden	Apixaban	38,830	580	0.016 (0.015 - 0.018)	0.023 (0.021 - 0.025)	0.030 (0.026 - 0.034)	0.053 (0.026 - 0.095)
Sweden	Dabigatran	10,080	170	0.015 (0.012 - 0.018)	0.021 (0.018 - 0.025)	0.030 (0.025 - 0.036)	0.034 (0.028 - 0.041)
Sweden	Rivaroxaban	14,330	250		0.025 (0.022 - 0.029)	0.029 (0.025 - 0.033)	0.030 (0.025 - 0.036)
Sweden	Warfarin	47,150	920	0.017 (0.016 - 0.018)	0.024 (0.023 - 0.026)	0.032 (0.029 - 0.034)	0.037 (0.034 - 0.040)

Table 15.21 Crude cumulative incidence of <u>haemorrhagic stroke</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	260	0.004 (0.003 - 0.004)	0.007 (0.006 - 0.008)	0.009 (0.007 - 0.012)	0.009 (0.007 - 0.012)
All	Dabigatran	31,210	70	0.002 (0.001 - 0.002)	0.003 (0.002 - 0.004)	0.004 (0.003 - 0.006)	0.006 (0.004 - 0.008)
All	Rivaroxaban	37,580	200	0.004 (0.004 - 0.005)	0.008 (0.007 - 0.009)	0.011 (0.009 - 0.013)	0.013 (0.011 - 0.017)
All	Warfarin	79,170	400	0.004 (0.004 - 0.005)	0.008 (0.007 - 0.008)	0.010 (0.009 - 0.011)	0.013 (0.011 - 0.015)
Denmark	Apixaban	14,980	70	0.004 (0.003 - 0.006)	0.007 (0.006 - 0.010)	0.012 (0.007 - 0.019)	0.012 (0.007 - 0.019)
Denmark	Dabigatran	12,450	30	0.002 (0.001 - 0.003)	0.003 (0.002 - 0.005)	0.005 (0.004 - 0.008)	0.007 (0.004 - 0.011)
Denmark	Rivaroxaban	12,680	50	0.003 (0.002 - 0.005)	0.007 (0.005 - 0.010)	0.011 (0.008 - 0.015)	0.011 (0.008 - 0.015)
Denmark	Warfarin	20,070	90	0.004 (0.003 - 0.006)	0.007 (0.006 - 0.009)	0.009 (0.007 - 0.012)	0.012 (0.009 - 0.017)
Norway	Apixaban	17,780	70	0.005 (0.004 - 0.006)	0.008 (0.006 - 0.011)	0.008 (0.006 - 0.011)	0.008 (0.006 - 0.011)
Norway	Dabigatran	8,680	20	0.002 (0.001 - 0.003)	0.003 (0.002 - 0.005)	0.004 (0.003 - 0.007)	0.007 (0.004 - 0.012)
Norway	Rivaroxaban	10,570	70	0.006 (0.004 - 0.008)	0.010 (0.007 - 0.012)	0.014 (0.010 - 0.018)	0.017 (0.011 - 0.025)
Norway	Warfarin	11,950	70	0.005 (0.004 - 0.007)	0.010 (0.007 - 0.013)	0.014 (0.011 - 0.018)	0.014 (0.011 - 0.018)
Sweden	Apixaban	38,830	120	0.003 (0.002 - 0.004)	0.006 (0.005 - 0.007)	0.008 (0.005 - 0.013)	0.008 (0.005 - 0.013)
Sweden	Dabigatran	10,080	20	0.002 (0.001 - 0.003)	0.003 (0.002 - 0.004)	0.003 (0.002 - 0.004)	0.003 (0.002 - 0.004)
Sweden	Rivaroxaban	14,330	70	0.004 (0.003 - 0.005)	0.007 (0.005 - 0.009)	0.009 (0.006 - 0.012)	0.013 (0.008 - 0.020)
Sweden	Warfarin	47,150	240	0.004 (0.003 - 0.005)	0.007 (0.006 - 0.008)	0.010 (0.008 - 0.011)	0.013 (0.010 - 0.015)

Table 15.22 Crude cumulative incidence of <u>intracranial bleeding</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	450	0.007 (0.006 - 0.007)	0.011 (0.010 - 0.013)	0.015 (0.012 - 0.018)	0.015 (0.012 - 0.018)
All	Dabigatran	31,210	150	0.003 (0.003 - 0.004)	0.006 (0.005 - 0.008)	0.009 (0.007 - 0.011)	0.014 (0.011 - 0.018)
All	Rivaroxaban	37,580	320	0.007 (0.006 - 0.008)	0.013 (0.011 - 0.015)	0.017 (0.015 - 0.019)	0.025 (0.018 - 0.035)
All	Warfarin	79,170	870	0.009 (0.009 - 0.010)	0.016 (0.015 - 0.018)	0.022 (0.020 - 0.024)	0.027 (0.024 - 0.029)
Denmark	Apixaban	14,980	120	0.008 (0.006 - 0.009)	0.012 (0.010 - 0.015)	0.019 (0.013 - 0.026)	0.019 (0.013 - 0.026)
Denmark	Dabigatran	12,450	60	0.003 (0.002 - 0.004)	0.006 (0.004 - 0.008)	0.009 (0.006 - 0.012)	0.015 (0.010 - 0.021)
Denmark	Rivaroxaban	12,680	90	0.007 (0.005 - 0.008)	0.012 (0.010 - 0.016)	0.018 (0.014 - 0.023)	0.018 (0.014 - 0.023)
Denmark	Warfarin	20,070	160	0.008 (0.007 - 0.010)	0.013 (0.011 - 0.016)	0.016 (0.013 - 0.019)	0.019 (0.015 - 0.024)
Norway	Apixaban	17,780	110	0.007 (0.006 - 0.009)	0.012 (0.010 - 0.015)	0.014 (0.010 - 0.018)	0.014 (0.010 - 0.018)
Norway	Dabigatran	8,680	40	0.004 (0.002 - 0.006)	0.007 (0.005 - 0.009)	0.008 (0.006 - 0.012)	0.013 (0.008 - 0.020)
Norway	Rivaroxaban	10,570	100	0.008 (0.006 - 0.010)	0.014 (0.011 - 0.017)	0.019 (0.015 - 0.024)	0.042 (0.015 - 0.091)
Norway	Warfarin	11,950	120	0.009 (0.007 - 0.011)	0.017 (0.014 - 0.020)	0.022 (0.018 - 0.027)	0.026 (0.020 - 0.033)
Sweden	Apixaban	38,830	230	0.006 (0.005 - 0.007)	0.011 (0.009 - 0.012)	0.014 (0.010 - 0.018)	0.014 (0.010 - 0.018)
Sweden	Dabigatran	10,080	50		0.007 (0.005 - 0.009)	0.010 (0.007 - 0.014)	0.016 (0.010 - 0.025)
Sweden	Rivaroxaban	14,330	120		0.013 (0.010 - 0.015)	0.015 (0.012 - 0.018)	0.025 (0.017 - 0.034)
Sweden	Warfarin	47,150	580	0.010 (0.009 - 0.011)	0.017 (0.016 - 0.019)	0.023 (0.021 - 0.026)	0.029 (0.026 - 0.032)

Table 15.23 Crude cumulative incidence of <u>gastrointestinal bleeding</u> at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	830	0.012 (0.011 - 0.013)	0.020 (0.019 - 0.022)	0.027 (0.024 - 0.031)	0.032 (0.025 - 0.041)
All	Dabigatran	31,210	580	0.015 (0.014 - 0.017)	0.024 (0.022 - 0.026)	0.032 (0.030 - 0.035)	0.041 (0.035 - 0.047)
All	Rivaroxaban	37,580	750	0.018 (0.017 - 0.020)	0.029 (0.026 - 0.031)	0.037 (0.034 - 0.040)	0.045 (0.039 - 0.051)
All	Warfarin	79,170	1300	0.015 (0.014 - 0.016)	0.023 (0.021 - 0.024)	0.029 (0.027 - 0.031)	0.034 (0.032 - 0.037)
Denmark	Apixaban	14,980	220	0.014 (0.012 - 0.016)	0.023 (0.020 - 0.027)	0.034 (0.027 - 0.043)	0.040 (0.028 - 0.054)
Denmark	Dabigatran	12,450	270	0.018 (0.015 - 0.021)	0.028 (0.024 - 0.031)	0.036 (0.031 - 0.041)	0.043 (0.036 - 0.051)
Denmark	Rivaroxaban	12,680	250	0.019 (0.016 - 0.022)	0.030 (0.026 - 0.035)	0.039 (0.033 - 0.045)	0.047 (0.038 - 0.056)
Denmark	Warfarin	20,070	360	0.019 (0.017 - 0.021)	0.026 (0.023 - 0.029)	0.031 (0.027 - 0.035)	0.041 (0.033 - 0.049)
Norway	Apixaban	17,780	210	0.013 (0.011 - 0.015)	0.022 (0.019 - 0.026)	0.026 (0.020 - 0.033)	0.037 (0.019 - 0.066)
Norway	Dabigatran	8,680	170	0.015 (0.012 - 0.018)	0.025 (0.021 - 0.029)	0.034 (0.028 - 0.040)	0.040 (0.033 - 0.048)
Norway	Rivaroxaban	10,570	260	0.021 (0.018 - 0.024)	0.034 (0.030 - 0.039)	0.044 (0.038 - 0.050)	0.055 (0.042 - 0.070)
Norway	Warfarin	11,950	220	0.018 (0.015 - 0.021)	0.028 (0.024 - 0.032)	0.032 (0.028 - 0.038)	0.035 (0.030 - 0.041)
Sweden	Apixaban	38,830	410	0.011 (0.009 - 0.012)	0.018 (0.016 - 0.020)	0.024 (0.020 - 0.029)	0.024 (0.020 - 0.029)
Sweden	Dabigatran	10,080	140	0.013 (0.010 - 0.015)	0.018 (0.015 - 0.021)	0.027 (0.022 - 0.032)	0.041 (0.024 - 0.065)
Sweden	Rivaroxaban	14,330	250	0.016 (0.014 - 0.018)	0.023 (0.020 - 0.026)	0.030 (0.025 - 0.035)	0.036 (0.027 - 0.046)
Sweden	Warfarin	47,150	720	0.012 (0.011 - 0.014)	0.020 (0.018 - 0.022)	0.027 (0.025 - 0.030)	0.032 (0.029 - 0.035)

Table 15.24 Crude cumulative incidence of acute myocardial infarction at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	990	0.014 (0.013 - 0.015)	0.022 (0.021 - 0.024)	0.029 (0.026 - 0.032)	0.029 (0.026 - 0.032)
All	Dabigatran	31,210	380	0.010 (0.008 - 0.011)	0.017 (0.015 - 0.019)	0.021 (0.019 - 0.024)	0.026 (0.022 - 0.031)
All	Rivaroxaban	37,580	500	0.012 (0.010 - 0.013)	0.019 (0.017 - 0.021)	0.027 (0.024 - 0.030)	0.029 (0.026 - 0.033)
All	Warfarin	79,170	1340	0.015 (0.014 - 0.016)	0.023 (0.021 - 0.024)	0.030 (0.028 - 0.032)	0.037 (0.034 - 0.041)
Denmark	Apixaban	14,980	150	0.010 (0.008 - 0.012)	0.015 (0.013 - 0.018)	0.021 (0.016 - 0.026)	0.021 (0.016 - 0.026)
Denmark	Dabigatran	12,450	140	0.009 (0.007 - 0.011)	0.016 (0.013 - 0.019)	0.019 (0.016 - 0.022)	0.020 (0.016 - 0.024)
Denmark	Rivaroxaban	12,680	100	0.008 (0.006 - 0.010)	0.013 (0.010 - 0.016)	0.018 (0.014 - 0.023)	0.018 (0.014 - 0.023)
Denmark	Warfarin	20,070	220	0.011 (0.010 - 0.013)	0.016 (0.014 - 0.019)	0.020 (0.017 - 0.023)	0.022 (0.018 - 0.027)
Norway	Apixaban	17,780	310	0.019 (0.017 - 0.021)	0.030 (0.026 - 0.034)	0.036 (0.029 - 0.043)	0.036 (0.029 - 0.043)
Norway	Dabigatran	8,680	150	0.012 (0.010 - 0.015)	0.023 (0.019 - 0.027)	0.029 (0.024 - 0.035)	0.039 (0.029 - 0.052)
Norway	Rivaroxaban	10,570	200	0.015 (0.013 - 0.018)	0.026 (0.022 - 0.031)	0.039 (0.033 - 0.045)	0.043 (0.035 - 0.051)
Norway	Warfarin	11,950	290	0.023 (0.020 - 0.027)	0.035 (0.030 - 0.039)	0.045 (0.039 - 0.052)	0.054 (0.045 - 0.065)
Sweden	Apixaban	38,830	530	0.014 (0.013 - 0.015)	0.022 (0.020 - 0.024)	0.029 (0.025 - 0.034)	0.029 (0.025 - 0.034)
Sweden	Dabigatran	10,080	100	0.008 (0.006 - 0.010)	0.013 (0.010 - 0.016)	0.018 (0.014 - 0.022)	0.023 (0.016 - 0.031)
Sweden	Rivaroxaban	14,330	200		0.018 (0.016 - 0.022)	0.024 (0.020 - 0.029)	0.026 (0.022 - 0.032)
Sweden	Warfarin	47,150	840	0.015 (0.013 - 0.016)	0.022 (0.021 - 0.024)	0.030 (0.028 - 0.033)	0.039 (0.034 - 0.044)

Table 15.25 Crude cumulative incidence of systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	50	0.001 (0.001 - 0.001)	0.001 (0.001 - 0.001)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)
All	Dabigatran	31,210	30	0.001 (0.000 - 0.001)	0.001 (0.001 - 0.002)	0.002 (0.001 - 0.002)	0.002 (0.001 - 0.005)
All	Rivaroxaban	37,580	30	0.001 (0.000 - 0.001)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)
All	Warfarin	79,170	110	0.001 (0.001 - 0.002)	0.002 (0.002 - 0.002)	0.002 (0.002 - 0.003)	0.003 (0.002 - 0.004)
Denmark	Apixaban	14,980	10	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.003)	0.001 (0.000 - 0.003)
Denmark	Dabigatran	12,450	10	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)	0.003 (0.001 - 0.010)
Denmark	Rivaroxaban	12,680	0	0.000 (0.000 - 0.001)	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)
Denmark	Warfarin	20,070	20	0.001 (0.000 - 0.001)	0.001 (0.001 - 0.003)	0.001 (0.001 - 0.003)	0.001 (0.001 - 0.003)
Norway	Apixaban	17,780	10	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.001)	0.001 (0.000 - 0.001)
Norway	Dabigatran	8,680	10	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)	0.001 (0.000 - 0.002)
Norway	Rivaroxaban	10,570	10	0.001 (0.000 - 0.002)	0.002 (0.001 - 0.004)	0.002 (0.001 - 0.004)	0.002 (0.001 - 0.004)
Norway	Warfarin	11,950	20	0.001 (0.001 - 0.002)	0.002 (0.001 - 0.003)	0.002 (0.001 - 0.003)	0.003 (0.001 - 0.006)
Sweden	Apixaban	38,830	40	0.001 (0.001 - 0.001)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)
Sweden	Dabigatran	10,080	10	0.001 (0.000 - 0.001)	0.002 (0.001 - 0.003)	0.003 (0.002 - 0.006)	0.003 (0.002 - 0.006)
Sweden	Rivaroxaban	14,330	10		0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)	0.001 (0.001 - 0.002)
Sweden	Warfarin	47,150	80	0.002 (0.001 - 0.002)	0.002 (0.002 - 0.003)	0.003 (0.002 - 0.003)	0.003 (0.002 - 0.004)

Table 15.26 Crude cumulative mortality among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	5280	0.075 (0.073 - 0.077)	0.128 (0.124 - 0.132)	0.175 (0.167 - 0.184)	0.187 (0.174 - 0.200)
All	Dabigatran	31,210	1590	0.041 (0.038 - 0.043)	0.069 (0.065 - 0.073)	0.093 (0.088 - 0.098)	0.138 (0.108 - 0.171)
All	Rivaroxaban	37,580	3110	0.072 (0.069 - 0.075)	0.120 (0.115 - 0.124)	0.169 (0.162 - 0.176)	0.211 (0.195 - 0.228)
All	Warfarin	79,170	5570	0.061 (0.059 - 0.063)	0.098 (0.095 - 0.101)	0.133 (0.129 - 0.137)	0.171 (0.163 - 0.179)
Denmark	Apixaban	14,980	1620	0.110 (0.104 - 0.116)	0.173 (0.164 - 0.182)	0.242 (0.224 - 0.260)	0.252 (0.230 - 0.275)
Denmark	Dabigatran	12,450	900	0.056 (0.052 - 0.061)	0.091 (0.085 - 0.098)	0.121 (0.113 - 0.130)	0.205 (0.134 - 0.286)
Denmark	Rivaroxaban	12,680	1350	0.101 (0.095 - 0.108)	0.168 (0.158 - 0.178)	0.237 (0.222 - 0.252)	0.282 (0.258 - 0.307)
Denmark	Warfarin	20,070	1350	0.066 (0.062 - 0.070)	0.103 (0.097 - 0.110)	0.139 (0.130 - 0.148)	0.163 (0.150 - 0.176)
Norway	Apixaban	17,780	920	0.056 (0.052 - 0.060)	0.093 (0.087 - 0.101)	0.124 (0.110 - 0.138)	0.138 (0.115 - 0.164)
Norway	Dabigatran	8,680	320	0.031 (0.027 - 0.036)	0.050 (0.044 - 0.057)	0.068 (0.060 - 0.076)	0.085 (0.073 - 0.099)
Norway	Rivaroxaban	10,570	660	0.048 (0.043 - 0.053)	0.087 (0.080 - 0.095)	0.126 (0.115 - 0.137)	0.173 (0.132 - 0.219)
Norway	Warfarin	11,950	800	0.061 (0.056 - 0.067)	0.105 (0.097 - 0.113)	0.144 (0.133 - 0.156)	0.184 (0.163 - 0.206)
Sweden	Apixaban	38,830	2740	0.070 (0.067 - 0.073)	0.125 (0.120 - 0.131)	0.167 (0.156 - 0.178)	0.173 (0.159 - 0.187)
Sweden	Dabigatran	10,080	370	0.028 (0.025 - 0.033)	0.056 (0.050 - 0.062)	0.075 (0.067 - 0.084)	0.095 (0.082 - 0.110)
Sweden	Rivaroxaban	14,330	1110	0.065 (0.061 - 0.070)	0.107 (0.101 - 0.114)	0.150 (0.139 - 0.161)	0.184 (0.165 - 0.203)
Sweden	Warfarin	47,150	3400	0.058 (0.056 - 0.060)	0.095 (0.091 - 0.098)	0.127 (0.122 - 0.132)	0.170 (0.159 - 0.181)

Table 15.27 Crude cumulative incidence of <u>composite outcome of ischaemic stroke at an</u> <u>acute hospitalisation with an overnight stay, systemic embolism at an acute</u> <u>hospitalisation with an overnight stay, acute myocardial infarction at an acute</u> <u>hospitalisation with an overnight stay, or death of any cause</u> among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	6930	0.099 (0.097 -	0.163 (0.158 -	0.219 (0.210 -	0.244 (0.223 -
	1 ipinuoun	, 1,0 > 0	0,00	0.102)	0.167)	0.228)	0.266)
All	Dabigatran	31,210	2350	0.061 (0.058 - 0.064)	0.100 (0.096 - 0.105)	0.133 (0.127 - 0.139)	0.186 (0.155 - 0.220)
All	Rivaroxaban	37,580	3970	0.093 (0.089 - 0.096)	0.152 (0.147 - 0.158)	0.208 (0.200 - 0.216)	0.251 (0.235 - 0.267)
All	Warfarin	79,170	7720	0.086 (0.083 - 0.088)	0.134 (0.130 - 0.137)	0.177 (0.173 - 0.181)	0.220 (0.212 - 0.228)
Denmark	Apixaban	14,980	1970	0.133 (0.126 - 0.139)	0.207 (0.197 - 0.217)	0.284 (0.266 - 0.303)	0.310 (0.280 - 0.340)
Denmark	Dabigatran	12,450	1200	0.077 (0.072 - 0.083)	0.123 (0.116 - 0.130)	0.160 (0.151 - 0.170)	0.253 (0.180 - 0.333)
Denmark	Rivaroxaban	12,680	1580	0.119 (0.113 - 0.126)	0.198 (0.187 - 0.209)	0.268 (0.253 - 0.284)	0.313 (0.289 - 0.337)
Denmark	Warfarin	20,070	1760	0.087 (0.082 - 0.092)	0.132 (0.125 - 0.139)	0.174 (0.164 - 0.184)	0.203 (0.188 - 0.218)
Norway	Apixaban	17,780	1380	0.084 (0.079 - 0.089)	0.136 (0.128 - 0.145)	0.179 (0.161 - 0.198)	0.193 (0.167 - 0.222)
Norway	Dabigatran	8,680	550	0.052 (0.047 - 0.058)	0.085 (0.077 - 0.093)	0.112 (0.102 - 0.123)	0.137 (0.120 - 0.154)
Norway	Rivaroxaban	10,570	970	0.074 (0.068 - 0.080)	0.126 (0.117 - 0.135)	0.176 (0.164 - 0.189)	0.229 (0.188 - 0.272)
Norway	Warfarin	11,950	1180	0.093 (0.086 - 0.099)	0.148 (0.138 - 0.157)	0.201 (0.189 - 0.215)	0.249 (0.226 - 0.271)
Sweden	Apixaban	38,830	3590	0.093 (0.090 - 0.097)	0.157 (0.151 - 0.163)	0.207 (0.195 - 0.219)	0.219 (0.202 - 0.236)
Sweden	Dabigatran	10,080	600	0.049 (0.044 - 0.054)	0.084 (0.077 - 0.092)	0.115 (0.105 - 0.126)	0.138 (0.123 - 0.154)
Sweden	Rivaroxaban	14,330	1430	0.086 (0.081 - 0.091)	0.139 (0.131 - 0.146)	0.186 (0.175 - 0.198)	0.216 (0.198 - 0.234)
Sweden	Warfarin	47,150	4770		0.131 (0.127 - 0.135)	0.173 (0.167 - 0.178)	0.218 (0.208 - 0.228)

Table 15.28 Crude cumulative incidence of any bleeding at an acute or plannedhospitalisation with an overnight stayamong patients with NVAF initiating apixaban,dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	2300	0.034 (0.032 -	0.055 (0.052 -	0.071 (0.066 -	0.078 (0.069 -
				0.035)	0.058)	0.077)	0.088)
All	Dabigatran	31,210	1170	0.030 (0.028 -	0.049 (0.045 -	0.066 (0.062 -	0.084 (0.077 -
				0.032)	0.052)	0.071)	0.092)
All	Rivaroxaban	37,580	1890	0.045 (0.043 -	0.073 (0.070 -	0.095 (0.090 -	0.117 (0.106 -
				0.048)	0.077)	0.100)	0.129)
All	Warfarin	79,170	3730	0.042 (0.040 -	0.066 (0.064 -	0.086 (0.083 -	0.103 (0.099 -
				0.043)	0.068)	0.089)	0.108)
Denmark	Apixaban	14,980	550	0.037 (0.034 -	0.062 (0.056 -	0.080 (0.070 -	0.085 (0.071 -
				0.041)	0.068)	0.091)	0.100)
Denmark	Dabigatran	12,450	510	0.031 (0.028 -	0.052 (0.047 -	0.068 (0.062 -	0.085 (0.075 -
				0.035)	0.057)	0.075)	0.095)
Denmark	Rivaroxaban	12,680	580	0.044 (0.040 -	0.073 (0.066 -	0.096 (0.086 -	0.112 (0.099 -
				0.049)	0.080)	0.106)	0.125)
Denmark	Warfarin	20,070	890	0.047 (0.043 -	0.069 (0.064 -	0.082 (0.076 -	0.099 (0.089 -
				0.051)	0.074)	0.089)	0.111)
					1	1	1
Norway	Apixaban	17,780	710	0.044 (0.040 -	0.070 (0.064 -	0.090 (0.078 -	0.117 (0.081 -
				0.048)	0.076)	0.102)	0.160)
Norway	Dabigatran	8,680	380	0.034 (0.030 -	0.055 (0.049 -	0.077 (0.069 -	0.096 (0.084 -
				0.039)	0.062)	0.086)	0.109)
Norway	Rivaroxaban	10,570	680	· ·	0.091 (0.084 -	0.116 (0.107 -	0.151 (0.116 -
				0.061)	0.099)	0.126)	0.190)
Norway	Warfarin	11,950	720	· ·	0.088 (0.081 -	0.117 (0.107 -	0.135 (0.122 -
				0.062)	0.096)	0.127)	0.148)
					1		
Sweden	Apixaban	38,830	1040		0.046 (0.043 -	0.060 (0.053 -	0.060 (0.053 -
				0.030)	0.049)	0.068)	0.068)
Sweden	Dabigatran	10,080	280	(· · · ·	0.038 (0.034 -	0.053 (0.046 -	0.074 (0.055 -
				0.027)	0.044)	0.061)	0.098)
Sweden	Rivaroxaban	14,330	630		0.060 (0.055 -	0.078 (0.071 -	0.100 (0.085 -
				0.042)	0.066)	0.086)	0.116)
Sweden	Warfarin	47,150	2110	0.036 (0.034 -	0.059 (0.056 -	0.080 (0.076 -	0.097 (0.092 -
				0.038)	0.062)	0.083)	0.103)

Table 15.29 Crude cumulative incidence of any bleeding occurring at an acute hospitalcontact without an overnight stayamong patients with NVAF initiating apixaban,dabigatran, rivaroxaban, or warfarin, overall and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	1320	0.019 (0.018 - 0.020)	0.032 (0.030 - 0.034)	0.043 (0.039 - 0.047)	0.049 (0.041 - 0.059)
All	Dabigatran	31,210	420	0.010 (0.009 - 0.011)	0.018 (0.016 - 0.020)	0.025 (0.023 - 0.028)	0.031 (0.027 - 0.036)
All	Rivaroxaban	37,580	1170	0.028 (0.026 - 0.030)	0.046 (0.043 - 0.049)	0.060 (0.056 - 0.064)	0.073 (0.067 - 0.081)
All	Warfarin	79,170	2320	0.024 (0.023 - 0.025)	0.041 (0.039 - 0.043)	0.059 (0.056 - 0.062)	0.078 (0.073 - 0.083)
Denmark	Apixaban	14,980	160	0.010 (0.009 - 0.012)	0.018 (0.015 - 0.022)	0.022 (0.018 - 0.027)	0.031 (0.020 - 0.047)
Denmark	Dabigatran	12,450	80	0.005 (0.004 - 0.006)	0.009 (0.007 - 0.011)	0.011 (0.009 - 0.014)	0.015 (0.011 - 0.019)
Denmark	Rivaroxaban	12,680	220	0.017 (0.015 - 0.020)	0.030 (0.025 - 0.035)	0.038 (0.032 - 0.044)	0.047 (0.038 - 0.058)
Denmark	Warfarin	20,070	290	0.015 (0.013 - 0.017)	0.023 (0.020 - 0.027)	0.030 (0.026 - 0.035)	0.035 (0.029 - 0.041)
Norway	Apixaban	17,780	130	0.008 (0.007 - 0.010)	0.012 (0.010 - 0.015)	0.019 (0.014 - 0.026)	0.031 (0.013 - 0.062)
Norway	Dabigatran	8,680	70	0.006 (0.004 - 0.008)	0.011 (0.008 - 0.015)	0.015 (0.012 - 0.020)	0.018 (0.013 - 0.025)
Norway	Rivaroxaban	10,570	190	0.015 (0.012 - 0.018)	0.025 (0.021 - 0.029)	0.033 (0.027 - 0.039)	0.040 (0.031 - 0.051)
Norway	Warfarin	11,950	180	0.015 (0.012 - 0.018)	0.023 (0.019 - 0.027)	0.031 (0.026 - 0.037)	0.039 (0.030 - 0.048)
Sweden	Apixaban	38,830	1030	0.026 (0.025 - 0.028)	0.046 (0.043 - 0.050)	0.062 (0.055 - 0.069)	0.062 (0.055 - 0.069)
Sweden	Dabigatran	10,080	270	0.020 (0.017 - 0.023)	0.037 (0.032 - 0.042)	0.055 (0.047 - 0.063)	0.068 (0.056 - 0.082)
Sweden	Rivaroxaban	14,330	760		0.073 (0.067 - 0.079)	0.099 (0.090 - 0.108)	0.124 (0.108 - 0.140)
Sweden	Warfarin	47,150	1870		0.052 (0.049 - 0.054)	0.074 (0.070 - 0.078)	0.099 (0.092 - 0.106)

Table 15.30 Crude cumulative incidence of <u>any bleeding recorded as the primary</u>
diagnosis at an acute hospitalisation with an overnight stay (sensitivity analysis) among
patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall
and by country

Country	Cohort	Number of initiators - rounded	cases - rounded	Cumulative incidence after 12 m (95% CI)	Cumulative incidence after 24 m (95% CI)	Cumulative incidence after 36 m (95% CI)	Cumulative incidence after 48 m (95% CI)
All	Apixaban	71,590	1320	0.019 (0.018 - 0.020)	0.032 (0.030 - 0.035)	0.042 (0.038 - 0.047)	0.047 (0.039 - 0.056)
All	Dabigatran	31,210	740	0.019 (0.018 - 0.021)	0.031 (0.029 - 0.034)	0.042 (0.038 - 0.045)	0.053 (0.047 - 0.060)
All	Rivaroxaban	37,580	1220	0.029 (0.028 - 0.031)	0.047 (0.045 - 0.050)	0.060 (0.056 - 0.064)	0.078 (0.068 - 0.088)
All	Warfarin	79,170	2470	0.028 (0.026 - 0.029)	0.045 (0.043 - 0.047)	0.057 (0.055 - 0.060)	0.070 (0.066 - 0.074)
Denmark	Apixaban	14,980	400	0.027 (0.024 - 0.030)	0.043 (0.039 - 0.048)	0.057 (0.049 - 0.066)	0.062 (0.050 - 0.076)
Denmark	Dabigatran	12,450	390	0.025 (0.022 - 0.028)	0.041 (0.036 - 0.045)	0.052 (0.046 - 0.057)	0.064 (0.056 - 0.074)
Denmark	Rivaroxaban	12,680	460	0.035 (0.031 - 0.039)	0.058 (0.052 - 0.065)	0.074 (0.066 - 0.083)	0.088 (0.076 - 0.100)
Denmark	Warfarin	20,070	690	0.036 (0.033 - 0.040)	0.055 (0.050 - 0.059)	0.065 (0.059 - 0.071)	0.080 (0.070 - 0.090)
Norway	Apixaban	17,780	290	0.018 (0.016 - 0.021)	0.032 (0.028 - 0.036)	0.039 (0.031 - 0.049)	0.050 (0.030 - 0.078)
Norway	Dabigatran	8,680	180	0.017 (0.014 - 0.021)	0.027 (0.023 - 0.032)	0.036 (0.031 - 0.043)	0.044 (0.036 - 0.053)
Norway	Rivaroxaban	10,570	340	0.027 (0.024 - 0.031)	0.045 (0.040 - 0.051)	0.059 (0.052 - 0.067)	0.085 (0.053 - 0.127)
Norway	Warfarin	11,950	340	0.027 (0.023 - 0.030)	0.044 (0.039 - 0.050)	0.054 (0.048 - 0.061)	0.062 (0.054 - 0.072)
Sweden	Apixaban	38,830	630	0.017 (0.015 - 0.018)	0.029 (0.026 - 0.031)	0.038 (0.032 - 0.044)	0.038 (0.032 - 0.044)
Sweden	Dabigatran	10,080	170		0.022 (0.019 - 0.026)	0.033 (0.027 - 0.039)	0.049 (0.031 - 0.073)
Sweden	Rivaroxaban	14,330	430		0.041 (0.037 - 0.046)	0.049 (0.044 - 0.055)	0.068 (0.055 - 0.083)
Sweden	Warfarin	47,150	1430	0.024 (0.023 - 0.026)	0.041 (0.038 - 0.043)	0.054 (0.051 - 0.058)	0.067 (0.063 - 0.072)

Table 15.31 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin in Denmark, Norway, and Sweden and standardised mean differences before and after matching

Characteristic	Apixaban (round ed) before matching N=71585	Warfarin (round ed) before matching N=79171	Apixaban (round ed) after matching N=55581	Warfarin (round ed) after matching N=55581	Standardised m ean difference before matchin g (max= 0.23)	Standardised mea difference after matching (max= 0.02)
Time from AF diag:< 1 month	49,240 (68.8%)	47,550 (60.1%)	35,990 (64.8%)	36,040 (64.8%)	0.183	0.002
Time from AF diag:1 - 6 month	6,180 (8.6%)	7,970 (10.1%)	5,200 (9.4%)	5,140 (9.3%)	0.049	0.004
Time from AF diag:6 - 60 months	16,170 (22.6%)	23,650 (29.9%)	14,390 (25.9%)	14,400 (25.9%)	0.166	0.000
Sex:Female Sex:Male	32,910 (46.0%)	32,980 (41.7%) 46,190 (58.3%)	24,440 (44.0%) 31,140 (56.0%)	24,410 (43.9%)	0.087 0.087	0.001 0.001
Age,	38,670 (54.0%)	46,190 (38.3%) 75.0 (67.5 -		31,170 (56.1%) 75.1 (67.8 -		
median(IQR)	75.5 (68.2 - 83.5)	82.2)	75.1 (67.8 - 82.8)	82.8)	0.098	0.004
Age -group:< 55 years Age -	3,320 (4.6%)	4,480 (5.7%)	2,840 (5.1%)	2,740 (4.9%)	0.046	0.008
group:55-<65 years	8,420 (11.8%)	10,100 (12.8%)	6,850 (12.3%)	7,010 (12.6%)	0.031	0.009
Age - group:65-<75 years	22,880 (32.0%)	25,060 (31.6%)	17,840 (32.1%)	17,790 (32.0%)	0.007	0.002
Age - group:75-<85 years	22,330 (31.2%)	26,700 (33.7%)	17,980 (32.3%)	17,860 (32.1%)	0.054	0.004
Age -group:>= 85 years	14,630 (20.4%)	12,830 (16.2%)	10,080 (18.1%)	10,170 (18.3%)	0.110	0.004
CCI-group:0	28,410 (39.7%)	29,610 (37.4%)	22,000 (39.6%)	22,160 (39.9%)	0.047	0.006
CCI-group:1-2 CCI-	24,540 (34.3%)	25,600 (32.3%)	18,790 (33.8%)	18,290 (32.9%)	0.041	0.019
group:>=3	18,630 (26.0%)	23,960 (30.3%)	14,800 (26.6%)	15,130 (27.2%)	0.095	0.014
Prior bleeding (any)	8,020 (11.2%)	8,870 (11.2%)	6,110 (11.0%)	6,050 (10.9%)	0.000	0.003
Prior gastrointestinal bleeding	670 (0.9%)	820 (1.0%)	540 (1.0%)	550 (1.0%)	0.010	0.002
Prior intracranial bleeding	900 (1.3%)	710 (0.9%)	590 (1.1%)	570 (1.0%)	0.035	0.003
Prior stroke (any)	10,040 (14.0%)	9,610 (12.1%)	7,200 (13.0%)	7,190 (12.9%)	0.056	0.001
Prior ischaemic stroke	9,740 (13.6%)	9,400 (11.9%)	7,000 (12.6%)	7,000 (12.6%)	0.052	0.000
Prior haemorrhagic stroke	700 (1.0%)	520 (0.7%)	460 (0.8%)	430 (0.8%)	0.035	0.006
Prior systemic embolism	400 (0.6%)	760 (1.0%)	370 (0.7%)	360 (0.7%)	0.047	0.001
Prior transient ischaemic attack	3,090 (4.3%)	3,120 (3.9%)	2,310 (4.2%)	2,260 (4.1%)	0.019	0.005
Chronic kidney disease	3,510 (4.9%)	6,530 (8.2%)	3,170 (5.7%)	3,210 (5.8%)	0.135	0.003
Heart failure	13,650 (19.1%)	18,010 (22.7%)	11,220 (20.2%)	11,270 (20.3%)	0.090	0.003
Coronary artery disease	15,580 (21.8%)	21,450 (27.1%)	13,040 (23.5%)	13,110 (23.6%)	0.124	0.003
Peripheral arterial disease	4,840 (6.8%)	6,030 (7.6%)	3,840 (6.9%)	3,930 (7.1%)	0.033	0.006
Hypertension	47,790 (66.8%)	54,110 (68.3%)	37,340 (67.2%)	37,410 (67.3%)	0.034	0.003
Diabetes Chronic	11,790 (16.5%)	14,680 (18.5%)	9,520 (17.1%)	9,570 (17.2%)	0.055	0.002
obstructive	9,150 (12.8%)	10,120 (12.8%)	7,020 (12.6%)	6,970 (12.5%)	0.000	0.002

pulmonary						
disease	(10 (0.80/)	820 (1.00/)	510 (0.00/)	520 (0.0%)	0.010	0.004
Liver disease Alcoholism	610 (0.8%) 1,770 (2.5%)	820 (1.0%) 1,790 (2.3%)	510 (0.9%) 1,320 (2.4%)	530 (0.9%) 1,310 (2.4%)	0.019 0.015	0.004 0.001
Dementia	1,820 (2.5%)	1,790 (2.5%)	1,110 (2.0%)	1,050 (1.9%)	0.071	0.001
Cancer 6 months before and including index date	1,850 (2.6%)	2,140 (2.7%)	1,440 (2.6%)	1,480 (2.7%)	0.007	0.005
Platelet inhibitors (excluding heparin)	26,850 (37.5%)	30,840 (39.0%)	21,020 (37.8%)	21,110 (38.0%)	0.030	0.003
Low -dose aspirin	23,580 (32.9%)	27,180 (34.3%)	18,430 (33.2%)	18,550 (33.4%)	0.029	0.005
ADP receptor blockers	4,860 (6.8%)	7,100 (9.0%)	4,180 (7.5%)	4,150 (7.5%)	0.081	0.002
Renin - angiotensin system inhibitors	33,260 (46.5%)	38,070 (48.1%)	26,110 (47.0%)	26,120 (47.0%)	0.032	0.000
Angiotensin - converting enzyme inhibitors	15,890 (22.2%)	20,500 (25.9%)	13,190 (23.7%)	13,250 (23.8%)	0.087	0.002
Angiotensin II antagonists, plain	11,220 (15.7%)	11,850 (15.0%)	8,490 (15.3%)	8,450 (15.2%)	0.020	0.002
Angiotensin II antagonists, combinations	5,820 (8.1%)	5,210 (6.6%)	4,080 (7.3%)	4,070 (7.3%)	0.059	0.000
Beta-blockers	51,520 (72.0%)	56,980 (72.0%)	40,010 (72.0%)	39,970 (71.9%)	0.000	0.002
Proton pump inhibitors	15,640 (21.8%)	17,350 (21.9%)	12,040 (21.7%)	12,040 (21.7%)	0.002	0.000
Non-steroidal anti- inflammatory drugs	5,620 (7.9%)	5,860 (7.4%)	4,260 (7.7%)	4,250 (7.6%)	0.017	0.001
Statins	24,550 (34.3%)	28,740 (36.3%)	19,250 (34.6%)	19,370 (34.9%)	0.042	0.004
Antidiabetic agents	8,230 (11.5%)	10,410 (13.1%)	6,710 (12.1%)	6,740 (12.1%)	0.050	0.002
Loop diuretics	16,490 (23.0%)	22,170 (28.0%)	13,760 (24.8%)	13,650 (24.5%)	0.114	0.005
Non-loop diuretics	900 (1.3%)	1,230 (1.6%)	730 (1.3%)	720 (1.3%)	0.025	0.003
Alpha adrenergic blockers	12,540 (17.5%)	15,810 (20.0%)	10,390 (18.7%)	10,440 (18.8%)	0.063	0.002
Amiodarone Dronedarone	1,690 (2.4%) 680 (0.9%)	2,560 (3.2%) 600 (0.8%)	1,480 (2.7%) 450 (0.8%)	1,520 (2.7%) 450 (0.8%)	0.053 0.021	0.004 0.001
Antihypertensi ve, combination drugs	7,930 (11.1%)	7,700 (9.7%)	5,820 (10.5%)	5,800 (10.4%)	0.044	0.001
Calcium channel blockers	17,000 (23.7%)	19,680 (24.9%)	13,390 (24.1%)	13,410 (24.1%)	0.026	0.001
Selective serotonin reuptake inhibitors	4,620 (6.4%)	4,790 (6.1%)	3,460 (6.2%)	3,450 (6.2%)	0.016	0.001
Drugs used in alcohol dependence	110 (0.2%)	120 (0.2%)	90 (0.2%)	80 (0.1%)	0.001	0.005
CHA2DS2- VASc, mean(SD)	3.4 (1.74)	3.4 (1.76)	3.4 (1.74)	3.4 (1.74)	0.017	0.001
CHA2DS2- VASc:0 -1	10,420 (14.6%)	11,520 (14.6%)	8,210 (14.8%)	8,230 (14.8%)	0.000	0.001
CHA2DS2- VASc:2 -3	28,440 (39.7%)	30,330 (38.3%)	22,050 (39.7%)	21,800 (39.2%)	0.029	0.009
CHA2DS2- VASc:>=4	32,730 (45.7%)	37,330 (47.1%)	25,320 (45.6%)	25,550 (46.0%)	0.028	0.008
CHADS2, mean(SD)	2.3 (1.50)	2.4 (1.51)	2.3 (1.49)	2.3 (1.49)	0.056	0.002

CHADS2:0	8,010 (11.2%)	8,300 (10.5%)	5,810 (10.5%)	6,090 (11.0%)	0.023	0.016
CHADS2:1	15,830 (22.1%)	15,840 (20.0%)	12,090 (21.7%)	11,620 (20.9%)	0.052	0.021
CHADS2:>=2	47,750 (66.7%)	55,030 (69.5%)	37,680 (67.8%)	37,870 (68.1%)	0.060	0.007
HAS-BLED, mean(SD)	2.0 (1.03)	2.0 (1.05)	2.0 (1.04)	2.0 (1.04)	0.017	0.002
HAS- BLED:<3	51,370 (71.8%)	56,150 (70.9%)	40,000 (72.0%)	40,050 (72.1%)	0.018	0.002
HAS- BLED:>=3	20,220 (28.2%)	23,020 (29.1%)	15,580 (28.0%)	15,530 (27.9%)	0.018	0.002
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.025	0.008
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.7 (0.0 - 1.6)	0.038	0.004
log_n_outpatie nt, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.229	0.006

Table 15.32 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Denmark

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	ardised nean erence matching = 0.06) .005 .004 .003 .003 .003 .003 .001 .007 .006 .004
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	004 003 003 003 001 007 006
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$.003 .003 .003 .001 .007 .006
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$.003 .003 .001 .007 .006
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	003 001 007 006
Age, median(IQR) $75.8 (68.4 - 83.8)$ $73.3 (66.1 - 80.6)$ $74.5 (67.6 - 82.0)$ $74.6 (67.8 - 82.1)$ 0.270 0.70 Age -group: 55 $660 (4.4\%)$ $1,520 (7.6\%)$ $650 (5.0\%)$ $630 (4.8\%)$ 0.136 0.70 Age -group: $55 - 865$ $1,710 (11.4\%)$ $2,870 (14.3\%)$ $1,670 (12.6\%)$ $1,640 (12.4\%)$ 0.086 0.76 Age -group: $55 - <65$ $1,710 (11.4\%)$ $2,870 (14.3\%)$ $1,670 (12.6\%)$ $1,640 (12.4\%)$ 0.086 0.76 Age -group: $55 - <75$ $4.750 (31.7\%)$ $6.820 (34.0\%)$ $4.470 (33.9\%)$ $4.490 (34.1\%)$ 0.049 0.049	.001 .007 .006
Age, median(IQR) 83.8) 80.6) 82.0) 82.1) 0.270	.007 .006
Years 000 (4.4%) 1,320 (7.6%) 030 (3.0%) 030 (4.6%) 0.136 0. Age -group:55-<65 years 1,710 (11.4%) 2,870 (14.3%) 1,670 (12.6%) 1,640 (12.4%) 0.086 0. Age -group:65-<75	.006
years 1,710 (11.4%) 2,870 (14.5%) 1,670 (12.0%) 1,640 (12.4%) 0.086 0. Age -group:65-<75	
	.004
years ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
years years	.008
Age -group:>= 85 years $3,250 (21.7\%)$ $2,580 (12.9\%)$ $2,180 (16.5\%)$ $2,250 (17.1\%)$ 0.236 0.236	.014
	.025
	.062
	.040
	.003
bleeding	.001
bleeding	.006
	.001
stroke	.001
stroke	.003
embolism	.011
ischaemic attack	.000
disease	.000
	.006
disease	.007
Peripheral arterial disease 1,040 (6.9%) 1,630 (8.1%) 950 (7.2%) 980 (7.5%) 0.044 0.	.011
	.004
	.000
pulmonary disease	.000
	.001
	.005
	.003
Cancer 6 months 590 (3.9%) 930 (4.6%) 550 (4.1%) 580 (4.4%) 0.034 0. index date 0<	.012
Platelet inhibitors	.011
	.014
ADP recentor	.000
Renin - angiotensin	.004

Angiotensin - converting enzyme inhibitors	3,100 (20.7%)	4,510 (22.5%)	2,800 (21.3%)	2,760 (21.0%)	0.044	0.007
Angiotensin II antagonists, plain	1,920 (12.8%)	2,220 (11.0%)	1,610 (12.2%)	1,600 (12.1%)	0.055	0.002
Angiotensin II antagonists, combinations	970 (6.5%)	1,210 (6.0%)	860 (6.5%)	880 (6.7%)	0.019	0.006
Beta-blockers	9,400 (62.7%)	12,420 (61.9%)	8,320 (63.1%)	8,260 (62.7%)	0.017	0.009
Proton pump inhibitors	3,440 (22.9%)	4,510 (22.5%)	2,940 (22.3%)	2,970 (22.6%)	0.011	0.005
Non-steroidal anti- inflammatory drugs	1,400 (9.4%)	1,980 (9.9%)	1,280 (9.7%)	1,310 (9.9%)	0.017	0.007
Statins	5,040 (33.7%)	6,990 (34.8%)	4,470 (33.9%)	4,510 (34.2%)	0.024	0.007
Antidiabetic agents	1,880 (12.6%)	2,650 (13.2%)	1,680 (12.8%)	1,680 (12.8%)	0.019	0.000
Loop diuretics	3,980 (26.5%)	5,800 (28.9%)	3,480 (26.4%)	3,460 (26.2%)	0.052	0.004
Non-loop diuretics	180 (1.2%)	350 (1.7%)	170 (1.3%)	150 (1.2%)	0.046	0.008
Alpha adrenergic blockers	2,660 (17.8%)	3,670 (18.3%)	2,350 (17.8%)	2,340 (17.7%)	0.013	0.002
Amiodarone	560 (3.7%)	970 (4.9%)	520 (3.9%)	520 (4.0%)	0.055	0.002
Dronedarone	10 (0.1%)	30 (0.1%)	10 (0.1%)	10 (0.1%)	0.019	0.008
Antihypertensive, combination drugs	1,600 (10.7%)	2,110 (10.5%)	1,440 (10.9%)	1,460 (11.1%)	0.006	0.004
Calcium channel blockers	3,430 (22.9%)	4,790 (23.9%)	3,020 (22.9%)	3,060 (23.2%)	0.023	0.008
Selective serotonin reuptake inhibitors	1,070 (7.1%)	1,150 (5.7%)	840 (6.4%)	830 (6.3%)	0.056	0.004
Drugs used in alcohol dependence	30 (0.2%)	50 (0.2%)	30 (0.2%)	20 (0.2%)	0.011	0.005
CHA2DS2-VASc, mean(SD)	3.4 (1.69)	3.1 (1.67)	3.3 (1.65)	3.3 (1.66)	0.191	0.008
CHA2DS2-VASc:0 -1	1,980 (13.2%)	3,580 (17.8%)	1,970 (14.9%)	1,940 (14.7%)	0.128	0.005
CHA2DS2-VASc:2 -3	5,860 (39.1%)	8,410 (41.9%)	5,490 (41.7%)	5,470 (41.5%)	0.057	0.002
CHA2DS2- VASc:>=4	7,140 (47.6%)	8,080 (40.2%)	5,720 (43.4%)	5,760 (43.7%)	0.150	0.006
CHADS2, mean(SD)	1.9 (1.28)	1.6 (1.21)	1.7 (1.23)	1.8 (1.24)	0.186	0.003
CHADS2:0	2,000 (13.4%)	3,470 (17.3%)	1,970 (14.9%)	2,020 (15.3%)	0.109	0.010
CHADS2:1	4,280 (28.6%)	6,320 (31.5%)	4,050 (30.7%)	3,980 (30.2%)	0.064	0.011
CHADS2:>=2	8,700 (58.1%)	10,280 (51.2%)	7,160 (54.3%)	7,170 (54.5%)	0.138	0.002
HAS-BLED, mean(SD)	2.2 (1.13)	2.1 (1.17)	2.2 (1.12)	2.2 (1.12)	0.089	0.007
HAS-BLED:<3	9,070 (60.5%)	12,660 (63.1%)	8,290 (62.9%)	8,270 (62.7%)	0.053	0.003
HAS-BLED:>=3 log_n_hosp, median(IOB)	5,920 (39.5%) 0.7 (0.7 - 1.1)	7,410 (36.9%) 0.7 (0.0 - 1.1)	4,890 (37.1%) 0.7 (0.7 - 0.7)	4,910 (37.3%) 0.7 (0.0 - 1.1)	0.053	0.003
median(IQR) log_beddays, median(IQR)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.147	0.005
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.108	0.007
income, median(IQR), k€	120.8 (86.8 - 186.9)	122.8 (88.9 - 187.6)	122.7 (88.3 - 189.5)	122.5 (88.3 - 188.4)	0.003	0.009
education:Secondary compulsory	5,810 (38.8%)	8,430 (42.0%)	5,210 (39.6%)	5,260 (39.9%)	0.065	0.008
education:Vocationa 1 / High school	5,910 (39.5%)	8,140 (40.6%)	5,340 (40.5%)	5,310 (40.3%)	0.022	0.005
education:Higher education	2,630 (17.5%)	2,980 (14.8%)	2,240 (17.0%)	2,220 (16.9%)	0.073	0.004
education:Unknown	630 (4.2%)	520 (2.6%)	380 (2.9%)	390 (2.9%)	0.088	0.002
employment:Employ ed or self -employed	2,330 (15.6%)	3,720 (18.5%)	2,210 (16.8%)	2,200 (16.7%)	0.079	0.001
employment:Unemp loyed	600 (4.0%)	1,190 (5.9%)	580 (4.4%)	570 (4.3%)	0.089	0.004
employment:Retired	11,940 (79.7%)	15,010 (74.8%)	10,280 (78.1%)	10,290 (78.1%)	0.116	0.002
employment:Unkno wn	110 (0.7%)	150 (0.7%)	100 (0.8%)	110 (0.8%)	0.001	0.004




Table 15.33 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Norway

	Apixaban (round ed) before	Warfarin (rounde d) before	Apixaban (round ed) after matching	Warfarin (rounde d) after matching	Standardised mea n	Standardised mean difference
Characteristic	matching N=17780	matching N=11949	N=10598	N=10598	difference before matching (max= 0.37)	after matching (max= 0.05)
Time from AF diag:< 1 month	12,690 (71.3%)	6,410 (53.6%)	6,190 (58.4%)	6,190 (58.4%)	0.372	0.001
Time from AF diag:1 - 6 month	1,480 (8.3%)	1,340 (11.2%)	1,160 (10.9%)	1,140 (10.7%)	0.098	0.005
Time from AF diag:6 - 60 months	3,620 (20.3%)	4,200 (35.2%)	3,250 (30.7%)	3,270 (30.9%)	0.335	0.004
Sex:Female	7,900 (44.4%)	4,740 (39.7%)	4,340 (41.0%)	4,330 (40.8%)	0.097	0.002
Sex:Male	9,880 (55.6%)	7,210 (60.3%)	6,260 (59.0%)	6,270 (59.2%)	0.097	0.002
Age, median(IQR)	74.7 (67.5 - 83.0)	75.3 (66.7 - 83.2)	75.1 (66.8 - 83.2)	75.2 (66.8 - 83.1)	0.045	0.004
Age -group:< 55 years	940 (5.3%)	830 (7.0%)	690 (6.5%)	660 (6.2%)	0.071	0.012
Age -group:55- <65 years	2,260 (12.7%)	1,690 (14.2%)	1,440 (13.6%)	1,510 (14.3%)	0.043	0.019
Age -group:65- <75 years	5,840 (32.8%)	3,360 (28.1%)	3,130 (29.5%)	3,080 (29.1%)	0.103	0.010
Age -group:75- <85 years	5,410 (30.4%)	3,860 (32.3%)	3,350 (31.6%)	3,380 (31.9%)	0.040	0.006
Age -group:>= 85 years	3,340 (18.8%)	2,210 (18.5%)	1,990 (18.8%)	1,970 (18.6%)	0.007	0.006
CCI-group:0	6,280 (35.3%)	3,340 (27.9%)	3,260 (30.8%)	3,130 (29.5%)	0.159	0.027
CCI-group:1-2	6,090 (34.2%)	3,810 (31.9%)	3,470 (32.8%)	3,530 (33.3%)	0.050	0.013
CCI-group:>=3 Prior bleeding	5,420 (30.5%) 2,310 (13.0%)	4,800 (40.2%) 1,780 (14.9%)	3,870 (36.5%) 1,500 (14.2%)	3,940 (37.1%) 1,490 (14.1%)	0.204 0.054	0.013 0.003
(any)			,			
Prior gastrointestinal bleeding	200 (1.1%)	190 (1.6%)	150 (1.4%)	150 (1.4%)	0.043	0.005
Prior intracranial bleeding	220 (1.2%)	160 (1.3%)	140 (1.3%)	140 (1.3%)	0.008	0.002
Prior stroke (any)	2,130 (12.0%)	1,440 (12.0%)	1,280 (12.0%)	1,290 (12.1%)	0.000	0.003
Prior ischaemic stroke	2,080 (11.7%)	1,380 (11.5%)	1,230 (11.6%)	1,240 (11.7%)	0.005	0.001
Prior haemorrhagic stroke	140 (0.8%)	110 (0.9%)	90 (0.9%)	90 (0.9%)	0.014	0.003
Prior systemic embolism	90 (0.5%)	140 (1.2%)	80 (0.8%)	80 (0.8%)	0.075	0.003
Prior transient ischaemic attack	720 (4.0%)	460 (3.9%)	400 (3.8%)	420 (3.9%)	0.008	0.006
Chronic kidney disease	1,330 (7.5%)	1,560 (13.1%)	1,140 (10.8%)	1,160 (10.9%)	0.184	0.005
Heart failure	3,280 (18.4%)	3,110 (26.0%)	2,470 (23.3%)	2,510 (23.6%)	0.183	0.007
Coronary artery disease	4,620 (26.0%)	4,410 (36.9%)	3,510 (33.2%)	3,530 (33.3%)	0.237	0.003
Peripheral arterial disease	1,730 (9.7%)	1,370 (11.5%)	1,120 (10.6%)	1,130 (10.7%)	0.056	0.004
Hypertension	10,530 (59.2%)	7,270 (60.8%)	6,350 (59.9%)	6,360 (60.0%)	0.032	0.003
Diabetes Chronic obstructive pulmonary disease	2,630 (14.8%) 2,630 (14.8%)	2,100 (17.6%) 1,850 (15.5%)	1,730 (16.4%) 1,640 (15.5%)	1,760 (16.6%) 1,620 (15.3%)	0.077 0.020	0.006
Liver disease	150 (0.9%)	150 (1.3%)	110 (1.1%)	120 (1.2%)	0.042	0.011
Alcoholism	340 (1.9%)	170 (1.4%)	160 (1.5%)	160 (1.5%)	0.039	0.002
Dementia	360 (2.0%)	230 (1.9%)	200 (1.9%)	200 (1.9%)	0.008	0.001
Cancer 6 months before and including index date	1,040 (5.8%)	810 (6.8%)	690 (6.5%)	690 (6.5%)	0.038	0.001

Platelet inhibitors (excluding	7,470 (42.0%)	5,400 (45.2%)	4,720 (44.6%)	4,680 (44.2%)	0.063	0.007
heparin)						
Low -dose aspirin	7,080 (39.8%)	5,060 (42.4%)	4,440 (41.9%)	4,400 (41.5%)	0.052	0.007
ADP receptor blockers	900 (5.0%)	1,130 (9.5%)	800 (7.5%)	820 (7.7%)	0.172	0.008
Renin - angiotensin system inhibitors	7,970 (44.8%)	5,500 (46.0%)	4,810 (45.4%)	4,810 (45.4%)	0.025	0.001
Angiotensin - converting enzyme inhibitors	2,930 (16.5%)	2,500 (20.9%)	2,030 (19.2%)	2,060 (19.4%)	0.114	0.006
Angiotensin II antagonists, plain	2,610 (14.7%)	1,640 (13.7%)	1,460 (13.8%)	1,470 (13.9%)	0.028	0.002
Angiotensin II antagonists, combinations	2,540 (14.3%)	1,450 (12.2%)	1,380 (13.0%)	1,350 (12.8%)	0.063	0.009
Beta-blockers	12,340 (69.4%)	8,410 (70.4%)	7,430 (70.1%)	7,430 (70.1%)	0.021	0.001
Proton pump inhibitors	3,810 (21.4%)	2,690 (22.5%)	2,340 (22.0%)	2,320 (21.9%)	0.027	0.004
H2-receptor antagonists	230 (1.3%)	170 (1.4%)	140 (1.3%)	140 (1.3%)	0.009	0.002
Non-steroidal anti-inflammatory drugs	1,610 (9.1%)	910 (7.6%)	850 (8.0%)	850 (8.0%)	0.053	0.001
Statins	6,800 (38.2%)	5,020 (42.0%)	4,250 (40.1%)	4,290 (40.4%)	0.077	0.006
Antidiabetic agents	1,750 (9.9%)	1,400 (11.7%)	1,150 (10.9%)	1,170 (11.1%)	0.060	0.006
Loop diuretics	3,580 (20.1%)	3,390 (28.4%)	2,690 (25.4%)	2,680 (25.3%)	0.194	0.003
Non-loop diuretics	280 (1.6%)	230 (1.9%)	190 (1.8%)	190 (1.8%)	0.025	0.001
Alpha adrenergic blockers	1,150 (6.5%)	960 (8.0%)	790 (7.4%)	800 (7.5%)	0.060	0.003
Amiodarone	690 (3.9%)	700 (5.9%)	550 (5.2%)	560 (5.3%)	0.093	0.003
Dronedarone	260 (1.5%)	130 (1.1%)	120 (1.1%)	130 (1.2%)	0.033	0.005
Antihypertensive, combination drugs	2,950 (16.6%)	1,740 (14.6%)	1,640 (15.5%)	1,610 (15.2%)	0.057	0.009
Calcium channel blockers	3,840 (21.6%)	2,640 (22.1%)	2,340 (22.1%)	2,310 (21.8%)	0.013	0.008
Selective serotonin reuptake inhibitors	800 (4.5%)	530 (4.5%)	480 (4.5%)	460 (4.4%)	0.001	0.007
Drugs used in alcohol dependence	30 (0.1%)	20 (0.1%)	20 (0.1%)	10 (0.1%)	0.006	0.005
CHA2DS2- VASc, mean(SD)	3.1 (1.71)	3.3 (1.86)	3.2 (1.78)	3.2 (1.83)	0.102	0.006
CHA2DS2- VASc:0 -1	3,290 (18.5%)	2,240 (18.7%)	1,940 (18.3%)	2,020 (19.0%)	0.006	0.019
CHA2DS2- VASc:2 -3	7,760 (43.6%)	4,370 (36.6%)	4,320 (40.7%)	4,040 (38.1%)	0.144	0.053
CHA2DS2- VASc:>=4	6,730 (37.9%)	5,340 (44.7%)	4,340 (41.0%)	4,540 (42.8%)	0.139	0.037
CHADS2, mean(SD)	1.5 (1.29)	1.7 (1.35)	1.6 (1.32)	1.6 (1.33)	0.121	0.007
CHADS2:0	4,150 (23.3%)	2,530 (21.1%)	2,290 (21.6%)	2,320 (21.9%)	0.053	0.006
CHADS2:1	5,860 (33.0%)	3,480 (29.1%)	3,320 (31.3%)	3,200 (30.2%)	0.083 0.121	0.024 0.017
CHADS2:>=2 HAS-BLED, mean(SD)	7,770 (43.7%) 2.0 (1.19)	5,940 (49.7%) 2.1 (1.26)	5,000 (47.1%) 2.1 (1.24)	5,080 (48.0%) 2.1 (1.23)	0.121	0.002
HAS-BLED:<3	11,940 (67.2%)	7,410 (62.0%)	6,780 (64.0%)	6,770 (63.9%)	0.107	0.003
HAS-BLED:>=3	5,840 (32.8%)	4,540 (38.0%)	3,820 (36.0%)	3,830 (36.1%)	0.107	0.003
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.166	0.009
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.007	0.001
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.149	0.004




Table 15.34 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Sweden

					C(1 1' 1	G(1 1' 1
Characteristic	Apixaban (roun ded) before matching N=38825	Warfarin (round ed) before matching N=47152	Apixaban (roun ded) after matching N=31810	Warfarin (round ed) after matching N=31810	Standardised me an difference before matching (max= 0.42)	Standardised me an difference after matching (max= 0.03)
Time from AF diag:< 1 month	26,060 (67.1%)	28,530 (60.5%)	20,710 (65.1%)	20,730 (65.2%)	0.138	0.001
Time from AF diag:1 - 6 month	3,040 (7.8%)	4,220 (9.0%)	2,550 (8.0%)	2,520 (7.9%)	0.041	0.003
Time from AF diag:6 - 60 months	9,720 (25.0%)	14,400 (30.5%)	8,550 (26.9%)	8,550 (26.9%)	0.123	0.000
Sex:Female	17,900 (46.1%)	20,290 (43.0%)	14,200 (44.6%)	14,160 (44.5%)	0.062	0.002
Sex:Male	20,930 (53.9%)	26,860 (57.0%)	17,610 (55.4%)	17,650 (55.5%)	0.062	0.002
Age, median(IQR)	75.7 (68.5 - 83.6)	75.6 (68.4 - 82.6)	75.4 (68.2 - 83.0)	75.3 (68.2 - 82.9)	0.051	0.006
Age -group:< 55 years	1,730 (4.5%)	2,130 (4.5%)	1,500 (4.7%)	1,450 (4.6%)	0.002	0.007
Age -group:55- <65 years	4,450 (11.4%)	5,540 (11.8%)	3,740 (11.7%)	3,860 (12.1%)	0.010	0.012
Age -group:65- <75 years	12,300 (31.7%)	14,880 (31.6%)	10,240 (32.2%)	10,210 (32.1%)	0.003	0.002
Age -group:75- <85 years	12,310 (31.7%)	16,570 (35.1%)	10,420 (32.8%)	10,330 (32.5%)	0.073	0.006
Age -group:>= 85 years	8,040 (20.7%)	8,030 (17.0%)	5,910 (18.6%)	5,960 (18.7%)	0.094	0.004
CCI-group:0	16,110 (41.5%)	17,670 (37.5%)	13,130 (41.3%)	13,270 (41.7%)	0.082	0.009
CCI-group:1-2	13,120 (33.8%)	15,790 (33.5%)	10,750 (33.8%)	10,570 (33.2%)	0.007	0.012
CCI-group:>=3 Prior bleeding	9,600 (24.7%)	13,700 (29.0%)	7,930 (24.9%)	7,980 (25.1%)	0.098	0.003
(any)	4,180 (10.8%)	5,150 (10.9%)	3,360 (10.5%)	3,300 (10.4%)	0.005	0.006
Prior gastrointestinal bleeding	280 (0.7%)	360 (0.8%)	230 (0.7%)	230 (0.7%)	0.005	0.002
Prior intracranial bleeding	480 (1.2%)	410 (0.9%)	330 (1.0%)	310 (1.0%)	0.035	0.006
Prior stroke (any)	5,370 (13.8%)	6,200 (13.1%)	4,200 (13.2%)	4,180 (13.1%)	0.020	0.002
Prior ischaemic stroke	5,170 (13.3%)	6,080 (12.9%)	4,080 (12.8%)	4,070 (12.8%)	0.012	0.001
Prior haemorrhagic stroke	430 (1.1%)	330 (0.7%)	290 (0.9%)	270 (0.8%)	0.042	0.010
Prior systemic embolism	240 (0.6%)	510 (1.1%)	230 (0.7%)	220 (0.7%)	0.050	0.005
Prior transient ischaemic attack	1,770 (4.5%)	2,050 (4.3%)	1,430 (4.5%)	1,370 (4.3%)	0.010	0.010
Chronic kidney disease	1,580 (4.1%)	3,280 (7.0%)	1,440 (4.5%)	1,470 (4.6%)	0.127	0.003
Heart failure	7,990 (20.6%)	11,330 (24.0%)	6,650 (20.9%)	6,650 (20.9%)	0.083	0.000
Coronary artery disease	8,250 (21.3%)	12,460 (26.4%)	7,040 (22.1%)	7,060 (22.2%)	0.121	0.002
Peripheral arterial disease	2,070 (5.3%)	3,030 (6.4%)	1,770 (5.6%)	1,810 (5.7%)	0.047	0.005
Hypertension	27,740 (71.5%)	34,570 (73.3%)	22,790 (71.6%)	22,810 (71.7%)	0.042	0.002
Diabetes	6,640 (17.1%)	9,090 (19.3%)	5,580 (17.5%)	5,600 (17.6%)	0.056	0.002
Chronic obstructive pulmonary disease	4,550 (11.7%)	5,700 (12.1%)	3,670 (11.5%)	3,640 (11.4%)	0.011	0.003
Liver disease	300 (0.8%)	430 (0.9%)	250 (0.8%)	260 (0.8%)	0.015	0.004
Alcoholism	950 (2.4%)	1,030 (2.2%)	740 (2.3%)	750 (2.4%)	0.018	0.002
Dementia	1,020 (2.6%)	770 (1.6%)	700 (2.2%)	640 (2.0%)	0.069	0.012
Cancer 6 months before and including index date	220 (0.6%)	400 (0.9%)	200 (0.6%)	210 (0.7%)	0.033	0.004

inhibitors	14,520 (37.4%)	18,680 (39.6%)	12,050 (37.9%)	12,120 (38.1%)	0.046	0.004
(excluding heparin)	11,520 (57.170)	10,000 (39.070)	12,000 (07.070)	12,120 (30.170)	0.010	0.001
Low -dose	12 000 (22 70()	17.010 (26.1%)	10.020 (24.20()	11,000 (24,6%)	0.050	0.005
aspirin	13,090 (33.7%)	17,010 (36.1%)	10,920 (34.3%)	11,000 (34.6%)	0.050	0.005
ADP receptor blockers	2,280 (5.9%)	3,710 (7.9%)	1,970 (6.2%)	1,920 (6.0%)	0.079	0.007
Renin -						
angiotensin	19,010 (49.0%)	24,140 (51.2%)	15,750 (49.5%)	15,780 (49.6%)	0.045	0.002
system inhibitors Angiotensin -						
converting	9,870 (25.4%)	13,490 (28.6%)	8,360 (26.3%)	8,430 (26.5%)	0.072	0.005
enzyme inhibitors	9,870 (23.470)	13,490 (28.0%)	8,300 (20.3%)	8,450 (20.5%)	0.072	0.005
Angiotensin II						
antagonists,	6,690 (17.2%)	8,000 (17.0%)	5,420 (17.0%)	5,380 (16.9%)	0.007	0.003
plain Angiotensin II						
antagonists,	2,310 (5.9%)	2,540 (5.4%)	1,840 (5.8%)	1,850 (5.8%)	0.023	0.001
combinations						
Beta-blockers Proton pump	29,780 (76.7%)	36,150 (76.7%)	24,270 (76.3%)	24,290 (76.3%)	0.001	0.001
inhibitors	8,390 (21.6%)	10,150 (21.5%)	6,760 (21.2%)	6,750 (21.2%)	0.002	0.001
H2-receptor	150 (0.4%)	210 (0.4%)	130 (0.4%)	130 (0.4%)	0.009	0.001
antagonists Non-steroidal		- (******				
anti-	2,610 (6.7%)	2.070(6.20)	2120(670)	2,090 (6.6%)	0.017	0.005
inflammatory	2,010 (0.7%)	2,970 (6.3%)	2,130 (6.7%)	2,090 (0.0%)	0.017	0.003
drugs Statins	12,710 (32.7%)	16,730 (35.5%)	10,530 (33.1%)	10,580 (33.3%)	0.058	0.003
Antidiabetic	4,590 (11.8%)	6,350 (13.5%)	3,870 (12.2%)	3,880 (12.2%)	0.050	0.001
agents	,					
Loop diuretics Non-loop	8,940 (23.0%)	12,990 (27.5%)	7,590 (23.8%)	7,510 (23.6%)	0.104	0.006
diuretics	440 (1.1%)	650 (1.4%)	370 (1.2%)	370 (1.2%)	0.022	0.001
Alpha	8 730 (22 50()	11 190 (22 70/)	7 2(0 (22 80))	7 200 (22 00()	0.020	0.004
adrenergic blockers	8,720 (22.5%)	11,180 (23.7%)	7,260 (22.8%)	7,300 (23.0%)	0.030	0.004
Amiodarone	440 (1.1%)	890 (1.9%)	410 (1.3%)	440 (1.4%)	0.060	0.007
Dronedarone Antihypertensiv	410 (1.0%)	440 (0.9%)	320 (1.0%)	310 (1.0%)	0.011	0.002
e, combination	3,380 (8.7%)	3,850 (8.2%)	2,730 (8.6%)	2,740 (8.6%)	0.019	0.001
drugs	· 、 ,		· 、 、 /			
Calcium channel blockers	9,730 (25.1%)	12,240 (26.0%)	8,030 (25.2%)	8,040 (25.3%)	0.021	0.001
Selective						
serotonin	2,760 (7.1%)	3,110 (6.6%)	2,140 (6.7%)	2,160 (6.8%)	0.020	0.002
reuptake inhibitors		· 、 、 /				
Drugs used in						
alcohol dependence	60 (0.1%)	60 (0.1%)	50 (0.1%)	40 (0.1%)	0.008	0.005
CHA2DS2-						
CHA2DS2- VASc,	3.5 (1.75)	3.6 (1.75)	3.5 (1.75)	3.4 (1.74)	0.045	0.006
VASc, mean(SD)				, , , , , , , , , , , , , , , , , , ,		
VASc,	3.5 (1.75) 5,150 (13.3%)	3.6 (1.75) 5,700 (12.1%)	3.5 (1.75) 4,310 (13.5%)	3.4 (1.74) 4,270 (13.4%)	0.045	0.006
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2-				, , , , , , , , , , , , , , , , , , ,		
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3	5,150 (13.3%) 14,820 (38.2%)	5,700 (12.1%) 17,540 (37.2%)	4,310 (13.5%) 12,250 (38.5%)	4,270 (13.4%) 12,290 (38.6%)	0.035	0.003
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4	5,150 (13.3%)	5,700 (12.1%)	4,310 (13.5%)	4,270 (13.4%)	0.035	0.003
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2,	5,150 (13.3%) 14,820 (38.2%)	5,700 (12.1%) 17,540 (37.2%)	4,310 (13.5%) 12,250 (38.5%)	4,270 (13.4%) 12,290 (38.6%)	0.035	0.003
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2, mean(SD)	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47)	0.035 0.020 0.042 0.040	0.003 0.003 0.000 0.007
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2, mean(SD) CHADS2:0 CHADS2:1	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48) 1,850 (4.8%) 5,690 (14.7%)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47) 2,300 (4.9%) 6,040 (12.8%)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48) 1,560 (4.9%) 4,730 (14.9%)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47) 1,760 (5.5%) 4,440 (13.9%)	0.035 0.020 0.042 0.040 0.005 0.054	0.003 0.003 0.000 0.007 0.028 0.026
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2, mean(SD) CHADS2:0 CHADS2:1 CHADS2:>=2	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48) 1,850 (4.8%)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47) 2,300 (4.9%)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48) 1,560 (4.9%)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47) 1,760 (5.5%)	0.035 0.020 0.042 0.040 0.005	0.003 0.003 0.000 0.007 0.028
VASc, mean(SD) CHA2DS2- VASc:0-1 CHA2DS2- VASc:2-3 CHA2DS2- VASc:>=4 CHADS2, mean(SD) CHADS2:0 CHADS2:1 CHADS2:>=2 HAS-BLED,	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48) 1,850 (4.8%) 5,690 (14.7%)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47) 2,300 (4.9%) 6,040 (12.8%)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48) 1,560 (4.9%) 4,730 (14.9%)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47) 1,760 (5.5%) 4,440 (13.9%)	0.035 0.020 0.042 0.040 0.005 0.054	0.003 0.003 0.000 0.007 0.028 0.026
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2, mean(SD) CHADS2:0 CHADS2:1 CHADS2:>=2	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48) 1,850 (4.8%) 5,690 (14.7%) 31,280 (80.6%)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47) 2,300 (4.9%) 6,040 (12.8%) 38,810 (82.3%)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48) 1,560 (4.9%) 4,730 (14.9%) 25,530 (80.2%)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47) 1,760 (5.5%) 4,440 (13.9%) 25,620 (80.5%)	0.035 0.020 0.042 0.040 0.005 0.054 0.045	0.003 0.003 0.000 0.007 0.028 0.026 0.007
VASc, mean(SD) CHA2DS2- VASc:0 -1 CHA2DS2- VASc:2 -3 CHA2DS2- VASc:>=4 CHADS2- VASc:>=4 CHADS2, mean(SD) CHADS2:1 CHADS2:3 CHADS2	5,150 (13.3%) 14,820 (38.2%) 18,860 (48.6%) 2.8 (1.48) 1,850 (4.8%) 5,690 (14.7%) 31,280 (80.6%) 1.9 (0.90)	5,700 (12.1%) 17,540 (37.2%) 23,910 (50.7%) 2.9 (1.47) 2,300 (4.9%) 6,040 (12.8%) 38,810 (82.3%) 1.9 (0.92)	4,310 (13.5%) 12,250 (38.5%) 15,260 (48.0%) 2.8 (1.48) 1,560 (4.9%) 4,730 (14.9%) 25,530 (80.2%) 1.9 (0.90)	4,270 (13.4%) 12,290 (38.6%) 15,260 (48.0%) 2.8 (1.47) 1,760 (5.5%) 4,440 (13.9%) 25,620 (80.5%) 1.9 (0.91)	0.035 0.020 0.042 0.040 0.005 0.054 0.045 0.047	0.003 0.003 0.000 0.007 0.028 0.026 0.007 0.008

log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.088	0.006
log_n_outpatient , median(IQR)	0.7 (0.0 - 1.1)	0.0 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.419	0.007
income, median(IQR), k€	52.2 (42.3 - 78.7)	49.8 (40.5 - 72.3)	51.7 (41.7 - 77.1)	52.1 (42.0 - 77.5)	0.066	0.003
education:Secon dary compulsory	14,640 (37.7%)	18,850 (40.0%)	12,110 (38.1%)	12,070 (37.9%)	0.046	0.003
education:Vocati onal / High school	14,790 (38.1%)	18,480 (39.2%)	12,320 (38.7%)	12,310 (38.7%)	0.023	0.001
education:Highe r education	8,970 (23.1%)	9,340 (19.8%)	7,040 (22.1%)	7,100 (22.3%)	0.081	0.004
education:Unkn own	430 (1.1%)	490 (1.0%)	340 (1.1%)	340 (1.1%)	0.005	0.002




Table 15.35 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching

	Dabigatran (roun	Worforin (rounded	Dabigatran (roun	Worforin (rounded	Standardised mea	Standardised mea
Characteristic	ded) before	Warfarin (rounded) before matching	ded) after	Warfarin (rounded) after matching	n difference	n difference
Characteristic	matching	N=79171	matching	N=28428	before matching	after matching
	N=31209	N=/91/1	N=28428	IN=26426		
	10.550 (10.001)	25.000 (11.201)		11 510 (10 50()	(max = 0.47)	(max = 0.03)
index_year:2013	12,570 (40.3%)	35,000 (44.2%)	11,450 (40.3%)	11,510 (40.5%)	0.080	0.004
index_year:2014	10,470 (33.5%)	23,330 (29.5%)	9,360 (32.9%)	9,320 (32.8%)	0.088	0.003
index_year:2015	4,220 (13.5%)	13,390 (16.9%)	4,150 (14.6%)	4,130 (14.5%)	0.095	0.002
index_year:2016	3,960 (12.7%)	7,460 (9.4%)	3,470 (12.2%)	3,470 (12.2%)	0.104	0.001
Time from AF						0.007
diag:< 1 month Time from AF	20,160 (64.6%)	47,550 (60.1%)	17,980 (63.3%)	17,900 (63.0%)	0.094	0.006
diag:1 - 6 month Time from AF	2,640 (8.5%)	7,970 (10.1%)	2,530 (8.9%)	2,530 (8.9%)	0.055	0.000
diag:6 - 60 months	8,410 (26.9%)	23,650 (29.9%)	7,910 (27.8%)	8,000 (28.1%)	0.065	0.007
Sex:Female	12,260 (39.3%)	32,980 (41.7%)	11,300 (39.7%)	11,360 (40.0%)	0.048	0.004
Sex:Male	18,950 (60.7%)	46,190 (58.3%)	17,130 (60.3%)	17,070 (60.0%)	0.048	0.004
					0.277	0.004
Age, median(IQR)	71.0 (64.6 - 78.7)	75.0 (67.5 - 82.2)	71.7 (65.0 - 79.3)	71.7 (64.9 - 79.3)	0.277	0.002
Age -group:< 55 years	2,430 (7.8%)	4,480 (5.7%)	2,220 (7.8%)	2,230 (7.9%)	0.085	0.002
Age -group:55- <65 years	5,740 (18.4%)	10,100 (12.8%)	4,920 (17.3%)	4,970 (17.5%)	0.156	0.004
Age -group:65- <75 years	11,790 (37.8%)	25,060 (31.6%)	10,370 (36.5%)	10,290 (36.2%)	0.129	0.006
Age -group:75- <85 years	8,080 (25.9%)	26,700 (33.7%)	7,810 (27.5%)	7,800 (27.4%)	0.172	0.001
Age -group:>= 85 years	3,170 (10.2%)	12,830 (16.2%)	3,110 (10.9%)	3,140 (11.0%)	0.180	0.003
CCI-group:0	15,330 (49.1%)	29,610 (37.4%)	13,490 (47.4%)	13,290 (46.8%)	0.239	0.014
CCI-group:1-2	10,290 (33.0%)	25,600 (32.3%)	9,540 (33.6%)	9,390 (33.0%)	0.013	0.011
CCI-group:>=3	5,590 (17.9%)	23,960 (30.3%)	5,400 (19.0%)	5,750 (20.2%)	0.292	0.031
Prior bleeding						0.051
(any)	2,810 (9.0%)	8,870 (11.2%)	2,630 (9.2%)	2,660 (9.3%)	0.073	0.004
Prior gastrointestinal bleeding	240 (0.8%)	820 (1.0%)	240 (0.8%)	220 (0.8%)	0.027	0.008
Prior intracranial bleeding	280 (0.9%)	710 (0.9%)	250 (0.9%)	270 (1.0%)	0.001	0.007
Prior stroke (any)	3,380 (10.8%)	9,610 (12.1%)	3,110 (10.9%)	3,150 (11.1%)	0.041	0.004
Prior ischaemic stroke	3,300 (10.6%)	9,400 (11.9%)	3,040 (10.7%)	3,070 (10.8%)	0.042	0.004
Prior haemorrhagic stroke	200 (0.6%)	520 (0.7%)	190 (0.7%)	190 (0.7%)	0.001	0.003
Prior systemic embolism	130 (0.4%)	760 (1.0%)	130 (0.5%)	150 (0.5%)	0.064	0.008
Prior transient ischaemic attack	1,160 (3.7%)	3,120 (3.9%)	1,040 (3.7%)	1,060 (3.7%)	0.012	0.004
Chronic kidney disease	560 (1.8%)	6,530 (8.2%)	560 (2.0%)	610 (2.1%)	0.300	0.014
Heart failure	4,330 (13.9%)	18,010 (22.7%)	4,240 (14.9%)	4,280 (15.1%)	0.231	0.004
Coronary artery disease	5,510 (17.7%)	21,450 (27.1%)	5,360 (18.9%)	5,360 (18.9%)	0.228	0.000
Peripheral arterial disease	1,630 (5.2%)	6,030 (7.6%)	1,580 (5.6%)	1,620 (5.7%)	0.098	0.005
Hypertension	18,970 (60.8%)	54,110 (68.3%)	17,480 (61.5%)	17,390 (61.2%)	0.158	0.006
Diabetes	4,290 (13.7%)	14,680 (18.5%)	4,070 (14.3%)	4,070 (14.3%)	0.130	0.000
Chronic obstructive	3,260 (10.5%)	10,120 (12.8%)	3,080 (10.8%)	3,140 (11.0%)	0.072	0.006
pulmonary disease						
Liver disease	260 (0.8%)	820 (1.0%)	250 (0.9%)	260 (0.9%)	0.020	0.007
Alcoholism	860 (2.7%)	1,790 (2.3%)	760 (2.7%)	770 (2.7%)	0.031	0.002
Dementia	420 (1.3%)	1,220 (1.5%)	370 (1.3%)	370 (1.3%)	0.017	0.001
Cancer 6 months before and including index	880 (2.8%)	2,140 (2.7%)	840 (2.9%)	880 (3.1%)	0.007	0.009

Platelet inhibitors (excluding heparin)	10,350 (33.2%)	30,840 (39.0%)	9,620 (33.9%)	9,720 (34.2%)	0.120	0.007
Low -dose aspirin	9,180 (29.4%)	27,180 (34.3%)	8,480 (29.8%)	8,550 (30.1%)	0.106	0.005
ADP receptor blockers	1,650 (5.3%)	7,100 (9.0%)	1,610 (5.7%)	1,660 (5.8%)	0.144	0.007
Renin - angiotensin system inhibitors	13,040 (41.8%)	38,070 (48.1%)	12,070 (42.5%)	12,000 (42.2%)	0.127	0.005
Angiotensin - converting enzyme inhibitors	5,970 (19.1%)	20,500 (25.9%)	5,700 (20.0%)	5,700 (20.0%)	0.163	0.000
Angiotensin II antagonists, plain	3,960 (12.7%)	11,850 (15.0%)	3,640 (12.8%)	3,600 (12.7%)	0.066	0.004
Angiotensin II antagonists, combinations	2,720 (8.7%)	5,210 (6.6%)	2,360 (8.3%)	2,350 (8.2%)	0.081	0.002
Beta-blockers	21,750 (69.7%)	56,980 (72.0%)	19,730 (69.4%)	19,680 (69.2%)	0.050	0.004
Proton pump inhibitors	5,180 (16.6%)	17,350 (21.9%)	4,950 (17.4%)	5,010 (17.6%)	0.135	0.006
Non-steroidal anti-inflammatory drugs	3,000 (9.6%)	5,860 (7.4%)	2,660 (9.3%)	2,680 (9.4%)	0.079	0.003
Statins	9,850 (31.6%)	28,740 (36.3%)	9,140 (32.2%)	9,110 (32.0%)	0.100	0.002
Antidiabetic	3,070 (9.8%)	10,410 (13.1%)	2,920 (10.3%)	2,940 (10.3%)	0.104	0.002
agents Loop diuretics	5,370 (17.2%)	22,170 (28.0%)	5,310 (18.7%)	5,390 (19.0%)	0.260	0.008
Non-loop	,	, ,				
diuretics Alpha adrenergic	370 (1.2%)	1,230 (1.6%)	340 (1.2%)	310 (1.1%)	0.030	0.009
blockers	4,610 (14.8%)	15,810 (20.0%)	4,400 (15.5%)	4,430 (15.6%)	0.137	0.003
Amiodarone	640 (2.0%)	2,560 (3.2%)	640 (2.2%)	650 (2.3%)	0.074	0.003
Dronedarone Antihypertensive,	100 (0.3%)	600 (0.8%)	100 (0.3%)	110 (0.4%)	0.062	0.006
combination drugs Calcium channel	3,810 (12.2%)	7,700 (9.7%)	3,370 (11.9%)	3,360 (11.8%)	0.079	0.001
blockers Selective	6,710 (21.5%)	19,680 (24.9%)	6,260 (22.0%)	6,320 (22.2%)	0.079	0.005
serotonin reuptake inhibitors	1,550 (5.0%)	4,790 (6.1%)	1,440 (5.1%)	1,470 (5.2%)	0.048	0.006
Drugs used in alcohol dependence	80 (0.3%)	120 (0.2%)	70 (0.2%)	60 (0.2%)	0.024	0.002
CHA2DS2-VASc, mean(SD)	2.8 (1.70)	3.4 (1.76)	2.9 (1.70)	2.9 (1.71)	0.352	0.002
CHA2DS2- VASc:0 -1	7,480 (24.0%)	11,520 (14.6%)	6,330 (22.3%)	6,380 (22.4%)	0.241	0.004
CHA2DS2- VASc:2 -3	13,780 (44.2%)	30,330 (38.3%)	12,510 (44.0%)	12,260 (43.1%)	0.119	0.018
CHA2DS2- VASc:>=4	9,950 (31.9%)	37,330 (47.1%)	9,590 (33.7%)	9,800 (34.5%)	0.316	0.015
CHADS2, mean(SD)	1.7 (1.38)	2.4 (1.51)	1.8 (1.38)	1.8 (1.39)	0.467	0.003
CHADS2:0 CHADS2:1	6,300 (20.2%) 9,440 (30.2%)	8,300 (10.5%) 15,840 (20.0%)	5,140 (18.1%) 8,470 (29.8%)	5,430 (19.1%) 8,150 (28.7%)	0.272 0.237	0.027 0.025
CHADS2:1 CHADS2:>=2	<u>9,440 (30.2%)</u> 15,470 (49.6%)	15,840 (20.0%) 55,030 (69.5%)	8,470 (29.8%) 14,830 (52.2%)	8,150 (28.7%) 14,850 (52.2%)	0.237	0.025
HAS-BLED, mean(SD)	1.8 (1.07)	2.0 (1.05)	1.8 (1.07)	1.8 (1.08)	0.187	0.001
HAS-BLED:<3	23,530 (75.4%)	56,150 (70.9%)	21,260 (74.8%)	21,110 (74.3%)	0.101	0.012
HAS-BLED:>=3	7,680 (24.6%)	23,020 (29.1%)	7,170 (25.2%)	7,320 (25.7%)	0.101	0.012
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.193	0.003
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.016	0.008
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.114	0.001

Table 15.36 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Denmark

Characteristic	Dabigatran (rou nded) before	Warfarin (round ed) before	Dabigatran (rou nded) after	Warfarin (round ed) after	Standardised me an	Standardised me an
	matching	matching	matching	matching	difference	difference
	N=12446	N=20070	N=11465	N=11465	before matching	after matching
	11 12110	11 20070	11 11 100	11 11 100	(max = 0.33)	(max = 0.03)
index_year:2013	5,380 (43.2%)	6,810 (33.9%)	4,860 (42.4%)	4,860 (42.4%)	0.192	0.000
index year:2014	4,380 (35.2%)	5,400 (26.9%)	3,920 (34.2%)	3,900 (34.0%)	0.179	0.003
index_year:2015	1,630 (13.1%)	4,580 (22.8%)	1,620 (14.2%)	1,640 (14.3%)	0.257	0.004
index_year:2016	1,060 (8.5%)	3,280 (16.4%)	1,060 (9.3%)	1,060 (9.3%)	0.238	0.000
Time from AF	8,470 (68.1%)	12,620 (62.9%)	7,620 (66.5%)	7,610 (66.4%)	0.110	0.002
diag:< 1 month	0,470 (00.170)	12,020 (02.970)	7,020 (00.570)	7,010 (00.470)	0.110	0.002
Time from AF	1,130 (9.1%)	2,410 (12.0%)	1,120 (9.7%)	1,120 (9.7%)	0.095	0.000
diag:1 - 6 month	1,100 ()11/0)	2,110 (1210/0)	1,120 ()11 /0)	1,120 ().1.70)	0.070	0.000
Time from AF	2,840 (22.8%)	5,040 (25.1%)	2,730 (23.8%)	2,740 (23,9%)	0.054	0.002
diag:6 - 60	_,()	=,=:=(==:=;=)	_,,	_, (,)		
months						
Sex:Female	4,990 (40.1%)	7,950 (39.6%)	4,630 (40.4%)	4,660 (40.6%)	0.009	0.004
Sex:Male	7,460 (59.9%)	12,120 (60.4%)	6,830 (59.6%)	6,810 (59.4%)	0.009	0.004
Age,	71.2 (64.6 -	73.3 (66.1 -	71.8 (65.0 -	71.8 (65.0 -	0.117	0.003
median(IQR)	78.9)	80.6)	79.3)	79.4)	0.117	0.005
Age -group:< 55	950 (7.6%)	1,520 (7.6%)	870 (7.6%)	850 (7.4%)	0.000	0.007
	950 (7.0%)	1,520 (7.0%)	870 (7.0%)	830 (7.4%)	0.000	0.007
years	2,300 (18.5%)	2,970,(14,20)	1.000 (17.20/)	2,000 (17,40/)	0.113	0.006
Age -group:55-	2,500 (18.5%)	2,870 (14.3%)	1,980 (17.2%)	2,000 (17.4%)	0.115	0.000
<65 years	4 (00 (27 00/)	6 920 (24 00/)	4 170 (26 40()	4 100 (26 50()	0.070	0.002
Age -group:65-	4,600 (37.0%)	6,820 (34.0%)	4,170 (36.4%)	4,180 (36.5%)	0.062	0.002
<75 years						
Age -group:75-	3,290 (26.4%)	6,280 (31.3%)	3,180 (27.7%)	3,130 (27.3%)	0.107	0.011
<85 years						
Age -group:>=	1,320 (10.6%)	2,580 (12.9%)	1,270 (11.0%)	1,310 (11.4%)	0.072	0.011
85 years						
CCI-group:0	6,450 (51.8%)	8,600 (42.8%)	5,780 (50.4%)	5,700 (49.8%)	0.180	0.013
CCI-group:1-2	3,950 (31.7%)	6,000 (29.9%)	3,710 (32.4%)	3,640 (31.7%)	0.040	0.013
CCI-group:>=3	2,050 (16.5%)	5,470 (27.2%)	1,970 (17.2%)	2,120 (18.5%)	0.263	0.033
Prior bleeding	1,000 (8.0%)	1,940 (9.7%)	930 (8.1%)	940 (8.2%)	0.058	0.003
(any)						
Prior	110 (0.9%)	270 (1.4%)	110 (1.0%)	100 (0.9%)	0.045	0.005
gastrointestinal						
bleeding						
Prior intracranial	100 (0.8%)	140 (0.7%)	80 (0.7%)	90 (0.8%)	0.012	0.005
bleeding						
Prior stroke	1,270 (10.2%)	1,980 (9.8%)	1,140 (9.9%)	1,180 (10.3%)	0.012	0.013
(any)						
Prior ischaemic	1,250 (10.0%)	1,940 (9.7%)	1,120 (9.8%)	1,160 (10.2%)	0.012	0.013
stroke						
Prior	50 (0.4%)	90 (0.4%)	50 (0.4%)	50 (0.5%)	0.002	0.005
haemorrhagic						
stroke						
Prior systemic	30 (0.3%)	110 (0.5%)	30 (0.3%)	30 (0.3%)	0.044	0.003
embolism	20 (0.270)	110 (010 /0)	20 (01270)	20 (01270)	0.011	01000
Prior transient	430 (3.4%)	600 (3.0%)	370 (3.2%)	390 (3.4%)	0.023	0.008
ischaemic attack	100 (011/0)	000 (010/0)	070 (01270)	0,00 (011/0)	01020	0.000
Chronic kidney	170 (1.4%)	1,690 (8.4%)	170 (1.5%)	160 (1.4%)	0.331	0.006
disease	170 (1.470)	1,000 (0.470)	170 (1.570)	100 (1.470)	0.551	0.000
Heart failure	1,600 (12.8%)	3,570 (17.8%)	1,570 (13.7%)	1,560 (13.6%)	0.138	0.003
Coronary artery	2,040 (16.4%)	4,590 (22.9%)	2,010 (17.5%)	2,050 (17.9%)	0.163	0.003
disease	2,040 (10.470)	+,550 (22.970)	2,010 (17.3%)	2,050 (17.970)	0.105	0.010
Peripheral	620 (5.0%)	1,630 (8.1%)	620 (5.4%)	610 (5.3%)	0.126	0.001
arterial disease	020 (3.0%)	1,030 (8.1%)	020 (3.4%)	010 (3.3%)	0.120	0.001
Hypertension	7 440 (50 80/)	12,270 (61.1%)	6 800 (60 10/)	6,840 (59.7%)	0.027	0.009
Diabetes	7,440 (59.8%) 1,690 (13.6%)	3,490 (17.4%)	6,890 (60.1%) 1,620 (14.1%)	1,610 (14.0%)	0.105	0.009
Chronic	1,250 (10.0%)	2,570 (12.8%)	1,200 (10.4%)	1,250 (10.9%)	0.087	0.013
obstructive						
pulmonary						
disease	100 (0.99/)	240 (1.20()	100 (0.89()	110 (1.00/)	0.020	0.012
Liver disease	100 (0.8%)	240 (1.2%)	100 (0.8%)	110 (1.0%)	0.039	0.013
Alcoholism	410 (3.3%)	590 (2.9%)	360 (3.1%)	360 (3.1%)	0.019	0.002
Dementia	200 (1.6%)	220 (1.1%)	160 (1.4%)	160 (1.4%)	0.046	0.001

Cancer 6 months before and including index	390 (3.1%)	930 (4.6%)	380 (3.3%)	420 (3.6%)	0.078	0.018
date Platelet inhibitors (excluding	3,610 (29.0%)	6,760 (33.7%)	3,450 (30.1%)	3,510 (30.6%)	0.101	0.010
heparin) Low -dose	2,810 (22.6%)	5,110 (25.5%)	2,680 (23.4%)	2,710 (23.6%)	0.067	0.006
aspirin ADP receptor blockers	990 (7.9%)	2,260 (11.2%)	960 (8.3%)	1,010 (8.8%)	0.113	0.017
Renin - angiotensin system inhibitors	5,020 (40.4%)	8,420 (42.0%)	4,670 (40.8%)	4,660 (40.7%)	0.033	0.002
Angiotensin - converting enzyme inhibitors	2,490 (20.0%)	4,510 (22.5%)	2,360 (20.5%)	2,350 (20.5%)	0.060	0.000
Angiotensin II antagonists, plain	1,330 (10.7%)	2,220 (11.0%)	1,240 (10.8%)	1,230 (10.7%)	0.012	0.003
Angiotensin II antagonists, combinations	880 (7.1%)	1,210 (6.0%)	780 (6.8%)	780 (6.8%)	0.042	0.001
Beta-blockers	8,150 (65.5%)	12,420 (61.9%)	7,400 (64.5%)	7,360 (64.2%)	0.074	0.006
Proton pump inhibitors	2,120 (17.0%)	4,510 (22.5%)	2,040 (17.8%)	2,080 (18.2%)	0.138	0.010
Non-steroidal anti- inflammatory	1,340 (10.8%)	1,980 (9.9%)	1,230 (10.7%)	1,240 (10.8%)	0.030	0.003
drugs	2.010 (21.40/)	(000 (24 00()	2 (70 (22 00))	2 (00 (22 10))	0.072	0.002
Statins Antidiabetic	3,910 (31.4%) 1,310 (10.5%)	6,990 (34.8%) 2,650 (13.2%)	3,670 (32.0%)	3,680 (32.1%)	0.073 0.084	0.003 0.001
agents	2,500 (20.1%)	5,800 (28.9%)	1,250 (10.9%)	1,260 (11.0%) 2,500 (21.8%)	0.084	0.001
Loop diuretics Non-loop	<u>2,500 (20.1%)</u> 160 (1.3%)	350 (1.7%)	2,460 (21.5%) 160 (1.4%)	2,500 (21.8%) 140 (1.2%)	0.034	0.008
diuretics			· · ·	. ,		
Alpha adrenergic blockers	2,140 (17.2%)	3,670 (18.3%)	2,010 (17.5%)	2,000 (17.5%)	0.029	0.002
Amiodarone	390 (3.1%)	970 (4.9%)	390 (3.4%)	400 (3.5%)	0.087	0.004
Dronedarone	10 (0.1%)	30 (0.1%)	10 (0.1%)	10 (0.1%)	0.017	0.010
Antihypertensiv e, combination drugs	1,460 (11.7%)	2,110 (10.5%)	1,310 (11.4%)	1,320 (11.5%)	0.037	0.004
Calcium channel blockers	2,810 (22.6%)	4,790 (23.9%)	2,620 (22.8%)	2,630 (22.9%)	0.030	0.002
Selective serotonin reuptake inhibitors	690 (5.5%)	1,150 (5.7%)	630 (5.5%)	640 (5.6%)	0.010	0.005
Drugs used in alcohol dependence	40 (0.3%)	50 (0.2%)	30 (0.3%)	30 (0.3%)	0.019	0.002
CHA2DS2- VASc, mean(SD)	2.8 (1.64)	3.1 (1.67)	2.9 (1.63)	2.9 (1.64)	0.169	0.005
CHA2DS2- VASc:0 -1	2,750 (22.1%)	3,580 (17.8%)	2,400 (20.9%)	2,420 (21.1%)	0.107	0.005
CHA2DS2- VASc:2 -3	5,640 (45.3%)	8,410 (41.9%)	5,190 (45.2%)	5,090 (44.4%)	0.069	0.017
CHA2DS2- VASc:>=4	4,050 (32.6%)	8,080 (40.2%)	3,880 (33.9%)	3,950 (34.5%)	0.160	0.013
CHADS2, mean(SD)	1.5 (1.16)	1.6 (1.21)	1.5 (1.16)	1.5 (1.18)	0.138	0.002
CHADS2:0	2,510 (20.2%)	3,470 (17.3%)	2,200 (19.2%)	2,320 (20.2%)	0.074	0.026
CHADS2:1	4,480 (36.0%)	6,320 (31.5%)	4,090 (35.7%)	3,930 (34.3%)	0.095	0.028
CHADS2:>=2 HAS-BLED,	5,460 (43.8%) 2.0 (1.10)	10,280 (51.2%) 2.1 (1.17)	5,180 (45.1%) 2.0 (1.09)	5,210 (45.5%) 2.0 (1.11)	0.148 0.155	0.006 0.005
mean(SD)			· · ·			
HAS-BLED:<3	8,680 (69.8%)	12,660 (63.1%)	7,920 (69.1%)	7,810 (68.1%)	0.142	0.020

HAS- BLED:>=3	3,760 (30.2%)	7,410 (36.9%)	3,550 (30.9%)	3,650 (31.9%)	0.142	0.020
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.123	0.006
log_beddays, median(IQR)	0.7 (0.0 - 1.6)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.263	0.006
log_n_outpatient , median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.007	0.006
income, median(IQR), k€	136.8 (94.7 - 226.6)	122.8 (88.9 - 187.6)	131.7 (93.0 - 211.8)	131.2 (92.5 - 212.8)	0.114	0.006
education:Secon dary compulsory	4,400 (35.3%)	8,430 (42.0%)	4,250 (37.1%)	4,310 (37.6%)	0.137	0.011
education:Vocati onal / High school	5,250 (42.2%)	8,140 (40.6%)	4,820 (42.1%)	4,750 (41.4%)	0.033	0.013
education:Highe r education	2,400 (19.3%)	2,980 (14.8%)	2,050 (17.9%)	2,050 (17.9%)	0.119	0.000
education:Unkn own	390 (3.2%)	520 (2.6%)	340 (3.0%)	360 (3.1%)	0.034	0.010
employment:Em ployed or self - employed	3,070 (24.7%)	3,720 (18.5%)	2,570 (22.4%)	2,590 (22.5%)	0.150	0.003
employment:Un employed	710 (5.7%)	1,190 (5.9%)	660 (5.8%)	670 (5.9%)	0.011	0.003
employment:Ret ired	8,580 (68.9%)	15,010 (74.8%)	8,140 (71.0%)	8,120 (70.9%)	0.131	0.003
employment:Un known	90 (0.8%)	150 (0.7%)	90 (0.8%)	90 (0.7%)	0.002	0.006




Table 15.37 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Norway

	Dabigatran (rou nded) before	Warfarin (rounde d) before	Dabigatran (rou nded) after	Warfarin (rounde d) after matching	Standardised me an	Standardised me an
Characteristic	matching N= 8684	matching N=11949	matching N= 7205	N= 7205	difference before matching (max= 0.43)	difference after matching (max= 0.05)
index_year:2013	4,160 (48.0%)	5,810 (48.6%)	3,570 (49.5%)	3,590 (49.8%)	0.013	0.005
index_year:2014	2,850 (32.8%)	3,450 (28.8%)	2,200 (30.6%)	2,230 (31.0%)	0.087	0.008
index_year:2015	930 (10.7%)	1,760 (14.8%)	860 (12.0%)	850 (11.7%)	0.123	0.006
index_year:2016	740 (8.5%)	930 (7.8%)	570 (7.9%)	540 (7.5%)	0.026	0.015
Time from AF diag:< 1 month	5,370 (61.9%)	6,410 (53.6%)	4,240 (58.8%)	4,220 (58.5%)	0.167	0.006
Time from AF diag:1 - 6 month	720 (8.2%)	1,340 (11.2%)	650 (9.1%)	660 (9.2%)	0.100	0.003
Time from AF diag:6 - 60 months	2,600 (29.9%)	4,200 (35.2%)	2,320 (32.1%)	2,330 (32.3%)	0.113	0.004
Sex:Female	3,310 (38.1%)	4,740 (39.7%)	2,790 (38.8%)	2,820 (39.1%)	0.032	0.007
Sex:Male	5,370 (61.9%)	7,210 (60.3%)	4,410 (61.2%)	4,390 (60.9%)	0.032	0.007
Age,	70.7 (64.6 -	75.3 (66.7 -	72.2 (64.8 -	72.2 (64.9 -	0.266	0.004
median(IQR)	78.8)	83.2)	80.3)	80.2)		
Age -group:< 55 years	720 (8.3%)	830 (7.0%)	630 (8.7%)	590 (8.2%)	0.050	0.021
Age -group:55- <65 years	1,600 (18.4%)	1,690 (14.2%)	1,210 (16.8%)	1,230 (17.1%)	0.115	0.009
Age -group:65- <75 years	3,300 (38.0%)	3,360 (28.1%)	2,440 (33.9%)	2,450 (33.9%)	0.212	0.001
Age -group:75- <85 years	2,170 (25.0%)	3,860 (32.3%)	2,040 (28.3%)	2,050 (28.5%)	0.161	0.004
Age -group:>= 85 years	900 (10.3%)	2,210 (18.5%)	890 (12.4%)	890 (12.4%)	0.235	0.000
CCI-group:0	3,870 (44.6%)	3,340 (27.9%)	2,880 (40.0%)	2,810 (39.0%)	0.352	0.021
CCI-group:1-2	3,010 (34.6%)	3,810 (31.9%)	2,610 (36.2%)	2,540 (35.2%)	0.058	0.021
CCI-group:>=3 Prior bleeding	1,800 (20.8%) 900 (10.4%)	4,800 (40.2%) 1,780 (14.9%)	1,710 (23.8%) 820 (11.4%)	1,860 (25.8%) 860 (11.9%)	0.431 0.135	0.047 0.016
(any) Prior gastrointestinal bleeding	80 (0.9%)	190 (1.6%)	70 (1.0%)	70 (1.0%)	0.062	0.007
Prior intracranial bleeding	80 (0.9%)	160 (1.3%)	70 (1.0%)	70 (1.0%)	0.044	0.003
Prior stroke (any)	810 (9.4%)	1,440 (12.0%)	740 (10.3%)	750 (10.4%)	0.086	0.003
Prior ischaemic stroke	790 (9.1%)	1,380 (11.5%)	720 (10.0%)	730 (10.1%)	0.079	0.002
Prior haemorrhagic stroke	50 (0.6%)	110 (0.9%)	50 (0.6%)	50 (0.6%)	0.035	0.002
Prior systemic embolism	50 (0.5%)	140 (1.2%)	50 (0.6%)	50 (0.7%)	0.070	0.002
Prior transient ischaemic attack	300 (3.5%)	460 (3.9%)	260 (3.6%)	270 (3.7%)	0.022	0.002
Chronic kidney disease	250 (2.9%)	1,560 (13.1%)	250 (3.5%)	290 (4.0%)	0.381	0.028
Heart failure	1,220 (14.1%)	3,110 (26.0%)	1,180 (16.3%)	1,220 (16.9%)	0.302	0.015
Coronary artery disease	1,850 (21.3%)	4,410 (36.9%)	1,750 (24.3%)	1,720 (23.9%)	0.349	0.010
Peripheral arterial disease	560 (6.5%)	1,370 (11.5%)	530 (7.4%)	530 (7.4%)	0.175	0.001
Hypertension	4,900 (56.5%)	7,270 (60.8%)	4,120 (57.1%)	4,110 (57.1%)	0.088	0.001
Diabetes Chronic obstructive pulmonary disease	1,090 (12.5%) 1,060 (12.2%)	2,100 (17.6%) 1,850 (15.5%)	980 (13.5%) 940 (13.0%)	960 (13.3%) 960 (13.4%)	0.142 0.096	0.007
Liver disease	80 (0.9%)	150 (1.3%)	70 (0.9%)	70 (1.0%)	0.038	0.006
Alcoholism	160 (1.9%)	170 (1.4%)	120 (1.7%)	120 (1.7%)	0.035	0.003
Dementia	100 (1.2%)	230 (1.9%)	100 (1.4%)	110 (1.5%)	0.056	0.010

Cancer 6 months before and including index date	430 (4.9%)	810 (6.8%)	400 (5.5%)	400 (5.6%)	0.077	0.004
Platelet inhibitors (excluding heparin)	3,330 (38.4%)	5,400 (45.2%)	2,820 (39.2%)	2,860 (39.7%)	0.138	0.010
Low -dose aspirin	3,240 (37.3%)	5,060 (42.4%)	2,730 (37.9%)	2,750 (38.2%)	0.104	0.007
ADP receptor blockers	230 (2.6%)	1,130 (9.5%)	230 (3.2%)	240 (3.3%)	0.290	0.006
Renin - angiotensin system inhibitors	3,550 (40.8%)	5,500 (46.0%)	3,020 (41.9%)	2,970 (41.2%)	0.106	0.013
Angiotensin - converting enzyme inhibitors	1,220 (14.1%)	2,500 (20.9%)	1,110 (15.5%)	1,110 (15.4%)	0.181	0.003
Angiotensin II antagonists, plain	1,130 (13.0%)	1,640 (13.7%)	940 (13.0%)	920 (12.7%)	0.021	0.007
Angiotensin II antagonists, combinations	1,210 (14.0%)	1,450 (12.2%)	980 (13.6%)	950 (13.2%)	0.054	0.009
Beta-blockers	5,950 (68.5%)	8,410 (70.4%)	4,920 (68.3%)	4,920 (68.3%)	0.040	0.001
Proton pump inhibitors	1,300 (14.9%)	2,690 (22.5%)	1,170 (16.2%)	1,180 (16.4%)	0.196	0.006
H2-receptor antagonists	110 (1.2%)	170 (1.4%)	90 (1.3%)	100 (1.3%)	0.015	0.006
Non-steroidal anti- inflammatory drugs	890 (10.2%)	910 (7.6%)	670 (9.4%)	670 (9.3%)	0.091	0.003
Statins	2,930 (33.8%)	5,020 (42.0%)	2,550 (35.4%)	2,540 (35.3%)	0.170	0.001
Antidiabetic agents	730 (8.4%)	1,400 (11.7%)	660 (9.1%)	660 (9.1%)	0.112	0.001
Loop diuretics	1,230 (14.2%)	3,390 (28.4%)	1,210 (16.7%)	1,220 (16.9%)	0.353	0.004
Non-loop diuretics	130 (1.4%)	230 (1.9%)	100 (1.4%)	110 (1.5%)	0.038	0.003
Alpha adrenergic blockers	480 (5.5%)	960 (8.0%)	430 (6.0%)	430 (6.0%)	0.100	0.002
Amiodarone	170 (2.0%)	700 (5.9%)	170 (2.4%)	180 (2.5%)	0.203	0.008
Dronedarone	30 (0.4%)	130 (1.1%)	30 (0.5%)	30 (0.5%)	0.083	0.000
Antihypertensive , combination drugs	1,410 (16.2%)	1,740 (14.6%)	1,150 (16.0%)	1,120 (15.5%)	0.046	0.012
Calcium channel blockers	1,600 (18.4%)	2,640 (22.1%)	1,390 (19.3%)	1,400 (19.4%)	0.093	0.002
Selective serotonin reuptake inhibitors	330 (3.8%)	530 (4.5%)	290 (4.0%)	290 (4.1%)	0.034	0.004
Drugs used in alcohol dependence	20 (0.2%)	20 (0.1%)	20 (0.2%)	10 (0.2%)	0.025	0.006
CHA2DS2- VASc, mean(SD)	2.6 (1.68)	3.3 (1.86)	2.7 (1.72)	2.7 (1.75)	0.387	0.001
CHA2DS2- VASc:0 -1	2,470 (28.5%)	2,240 (18.7%)	1,800 (25.0%)	1,870 (25.9%)	0.232	0.022
CHA2DS2- VASc:2 -3	3,870 (44.5%)	4,370 (36.6%)	3,180 (44.2%)	3,010 (41.7%)	0.162	0.050
CHA2DS2- VASc:>=4	2,340 (27.0%)	5,340 (44.7%)	2,220 (30.9%)	2,330 (32.4%)	0.376	0.033
CHADS2, mean(SD)	1.2 (1.21)	1.7 (1.35)	1.4 (1.23)	1.4 (1.25)	0.351	0.005
CHADS2:0	2,810 (32.4%)	2,530 (21.1%)	2,020 (28.0%)	2,130 (29.5%)	0.256	0.033
CHADS2:1	2,920 (33.6%)	3,480 (29.1%)	2,430 (33.8%)	2,330 (32.4%)	0.096	0.030
CHADS2:>=2 HAS-BLED,	2,960 (34.0%) 1.8 (1.15)	5,940 (49.7%) 2.1 (1.26)	2,750 (38.2%) 1.8 (1.16)	2,750 (38.1%) 1.8 (1.18)	0.322 0.302	0.002 0.006
mean(SD)						
HAS-BLED:<3	6,470 (74.5%)	7,410 (62.0%)	5,240 (72.7%)	5,160 (71.6%)	0.270	0.024

HAS-BLED:>=3	2,210 (25.5%)	4,540 (38.0%)	1,970 (27.3%)	2,050 (28.4%)	0.270	0.024
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.394	0.004
log_beddays, median(IQR)	1.1 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.121	0.001
log_n_outpatient , median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.062	0.011




Table 15.38 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Sweden

U/						
Characteristic	Dabigatran (roun ded) before matching	Warfarin (rounde d) before matching	Dabigatran (roun ded) after matching	Warfarin (rounde d) after matching	Standardised mea n difference	Standardised mea n difference
	N=10079	N=47152	N= 9758	N= 9758	before matching $(max=0.43)$	after matching (max= 0.03)
index_year:2013	3,020 (30.0%)	22,380 (47.5%)	3,020 (31.0%)	3,060 (31.4%)	0.365	0.009
index_year:2014	3,240 (32.1%)	14,490 (30.7%)	3,240 (33.2%)	3,180 (32.6%)	0.031	0.012
index_year:2015	1,670 (16.5%)	7,040 (14.9%)	1,670 (17.1%)	1,640 (16.8%)	0.044	0.006
index_year:2016	2,150 (21.4%)	3,240 (6.9%)	1,830 (18.8%)	1,870 (19.1%)	0.425	0.009
Time from AF	2,130 (21.4%)	5,240 (0.9%)	1,830 (18.8%)	1,870 (19.1%)	0.423	0.009
diag:< 1 month	6,310 (62.6%)	28,530 (60.5%)	6,130 (62.8%)	6,070 (62.2%)	0.044	0.012
Time from AF diag:1 - 6 month	800 (7.9%)	4,220 (9.0%)	760 (7.8%)	750 (7.7%)	0.038	0.003
Time from AF diag:6 - 60 months	2,970 (29.5%)	14,400 (30.5%)	2,870 (29.4%)	2,930 (30.1%)	0.023	0.014
Sex:Female	3,960 (39.3%)	20,290 (43.0%)	3,870 (39.7%)	3,890 (39.8%)	0.076	0.003
Sex:Male	6,120 (60.7%)	26,860 (57.0%)	5,890 (60.3%)	5,870 (60.2%)	0.076	0.003
Age, median(IQR)	71.1 (64.7 - 78.4)	75.6 (68.4 - 82.6)	71.4 (65.0 - 78.6)	71.3 (64.7 - 78.5)	0.359	0.014
Age -group:< 55 years	770 (7.6%)	2,130 (4.5%)	720 (7.3%)	800 (8.2%)	0.131	0.031
Age -group:55- <65 years	1,840 (18.3%)	5,540 (11.8%)	1,740 (17.8%)	1,740 (17.8%)	0.183	0.001
Age -group:65- <75 years	3,890 (38.6%)	14,880 (31.6%)	3,750 (38.5%)	3,660 (37.5%)	0.149	0.020
Age -group:75- <85 years	2,620 (26.0%)	16,570 (35.1%)	2,590 (26.6%)	2,620 (26.9%)	0.200	0.007
Age -group:>= 85 years	960 (9.5%)	8,030 (17.0%)	960 (9.8%)	940 (9.7%)	0.224	0.005
CCI-group:0	5,020 (49.8%)	17,670 (37.5%)	4,830 (49.5%)	4,780 (49.0%)	0.250	0.010
CCI-group:1-2	3,330 (33.0%)	15,790 (33.5%)	3,220 (33.0%)	3,210 (32.9%)	0.010	0.002
CCI-group:>=3	1,740 (17.2%)	13,700 (29.0%)	1,710 (17.6%)	1,770 (18.1%)	0.283	0.015
Prior bleeding (any)	910 (9.0%)	5,150 (10.9%)	880 (9.0%)	860 (8.8%)	0.063	0.005
Prior gastrointestinal bleeding	50 (0.5%)	360 (0.8%)	50 (0.5%)	50 (0.5%)	0.028	0.012
Prior intracranial bleeding	110 (1.1%)	410 (0.9%)	100 (1.0%)	110 (1.2%)	0.021	0.013
Prior stroke (any)	1,290 (12.8%)	6,200 (13.1%)	1,230 (12.6%)	1,210 (12.4%)	0.009	0.005
Prior ischaemic stroke	1,250 (12.4%)	6,080 (12.9%)	1,190 (12.2%)	1,180 (12.1%)	0.014	0.005
Prior haemorrhagic stroke	100 (1.0%)	330 (0.7%)	90 (0.9%)	100 (1.0%)	0.029	0.004
Prior systemic embolism	60 (0.5%)	510 (1.1%)	50 (0.6%)	70 (0.7%)	0.060	0.016
Prior transient ischaemic attack	430 (4.3%)	2,050 (4.3%)	410 (4.2%)	410 (4.2%)	0.004	0.001
Chronic kidney disease	130 (1.3%)	3,280 (7.0%)	130 (1.4%)	160 (1.6%)	0.286	0.022
Heart failure	1,520 (15.0%)	11,330 (24.0%)	1,500 (15.4%)	1,510 (15.5%)	0.228	0.003
Coronary artery disease	1,620 (16.1%)	12,460 (26.4%)	1,610 (16.5%)	1,590 (16.3%)	0.255	0.003
Peripheral arterial disease	440 (4.4%)	3,030 (6.4%)	430 (4.4%)	470 (4.8%)	0.090	0.018
Hypertension	6,630 (65.7%)	34,570 (73.3%)	6,470 (66.3%)	6,440 (66.0%)	0.166	0.007
Diabetes	1,510 (15.0%)	9,090 (19.3%)	1,480 (15.2%)	1,510 (15.5%)	0.113	0.008
	-,	,	-,	-,	0.110	0.000
Chronic obstructive pulmonary	960 (9.5%)	5,700 (12.1%)	950 (9.7%)	930 (9.5%)	0.083	0.005
Chronic obstructive pulmonary disease	. ,					
Chronic obstructive pulmonary	960 (9.5%) 80 (0.8%) 290 (2.9%)	5,700 (12.1%) 430 (0.9%) 1,030 (2.2%)	950 (9.7%) 80 (0.9%) 280 (2.8%)	930 (9.5%) 80 (0.9%) 290 (2.9%)	0.083 0.007 0.044	0.005 0.001 0.007

	~				1		
(exclaring beparin) 3.10 (3.3%) 18.80 (39.6%) 3.20 (3.4%) 3.200 (3.4%) 0.120 0.002 Low-dece septin 3.10 (3.0%) 1.701 (36.1%) 3.707 (3.1%) 3.200 (3.1%) 0.016 0.004 MDP reception 4.30 (4.3%) 3.710 (7.9%) 4.30 (4.4%) 4.10 (4.2%) 0.151 0.003 magineorini 4.480 (4.4%) 24.14 (51.2%) 4.380 (4.9%) 4.370 (4.7%) 0.117 0.003 converting 2.200 (22.4%) 13.490 (28.6%) 2.230 (22.9%) 0.114 0.002 converting 2.200 (22.4%) 13.490 (28.6%) 2.230 (22.9%) 0.014 0.005 Angiotaxin analegoniss, Bill 1.510 (14.9%) 8.000 (17.0%) 1.470 (15.9%) 1.470 (15.9%) 0.017 0.006 Prostoping 1.770 (7.5%) 7.420 (76.0%) 7.390 (75.8%) 0.017 0.006 Bet-blockcert 7.650 (75.9%) 36.150 (76.7%) 7.420 (76.0%) 7.80 (7.9%) 0.010 0.002 Markanization 3.010 (2.9%) 1.0150 (1.4%) 1.020 (1.05%) 0.0	including index	60 (0.6%)	400 (0.9%)	60 (0.6%)	60 (0.6%)	0.029	0.001
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	(excluding	3,410 (33.8%)	18,680 (39.6%)	3,350 (34.3%)	3,360 (34.4%)	0.120	0.002
Blackers 4.40 (4.3%) 7.10 (7.9%) 4.40 (4.4%) 4.10 (4.2%) 0.131 0.008 Rein- angiotensin 4.40 (04.4%) 24,140 (51.2%) 4.380 (44.9%) 4.370 (44.7%) 0.137 0.003 Angiotensin - converting 2.260 (22.4%) 13,490 (28.6%) 2.230 (22.8%) 2.240 (22.9%) 0.144 0.002 angoensin I angoensin I angoensin I angoensin I combinations 500 (6.2%) 2.540 (5.4%) 600 (6.2%) 1.450 (14.9%) 0.035 0.001 Pets-blockers 7.650 (75.9%) 36.150 (75.7%) 7.420 (76.9%) 7.300 (75.8%) 0.011 0.006 Potor pump inhibitors 1.770 (17.5%) 10,150 (21.5%) 1.740 (17.8%) 1.740 (17.8%) 0.040 0.007 Neasceptor angoensit 3.010 (29.9%) 16,730 (35.5%) 2.930 (30.9%) 2.880 (29.6%) 0.120 0.010 Antidaberic 1.360 (16.3%) 1.290 (27.5%) 1.640 (16.8%) 1.020 (10.5%) 0.0010 0.002 Antidaberic 1.990 (27.9%) 6.90 (1.9%) 2.930 (30.9%) 7.00 (7%) 0.0051 0.0101	Low -dose aspirin	3,130 (31.0%)	17,010 (36.1%)	3,070 (31.5%)	3,090 (31.7%)	0.106	0.004
angiotesin Angiotesin Angiotesin enzyme inhibitors 4,480 (44.4%) 24,140 (51.2%) 4,380 (44.9%) 4,370 (44.7%) 0.137 0.003 Angiotesin enzyme inhibitors 2,260 (22.4%) 13,490 (28.6%) 2,230 (22.8%) 2,240 (22.9%) 0.144 0.002 Angiotesin angoonesin angoonesin enzyme inhibitors 1,510 (14.9%) 8,000 (17.9%) 1,470 (15.0%) 1,450 (14.9%) 0.035 0.001 Deta-blockers 7,650 (75.9%) 36,150 (76.7%) 7,420 (76.0%) 7,390 (75.8%) 0.010 0.006 Deta-blockers 7,00 (75.%) 10,150 (21.5%) 1,740 (17.8%) 10,101 0.000 IB2-receptor 20 (0.2%) 20 (0.2%) 20 (0.2%) 0.032 0.003 Non-steroidal anti-infimmatory 770 (7.6%) 2.970 (6.3%) 780 (7.7%) 780 (7.9%) 0.052 0.000 Segmentiblicities 1.640 (16.3%) 12.990 (27.5%) 1.640 (16.8%) 1.680 (17.2%) 0.010 0.010 Non-steroidal anti-infimmatory 900 (0.9%) 650 (1.4%) 80 (0.9%) 70 (0.7%) 0.010 0.010 Non-steroid	1	430 (4.3%)	3,710 (7.9%)	430 (4.4%)	410 (4.2%)	0.151	0.008
$ \begin{array}{c} converting con$	angiotensin system inhibitors	4,480 (44.4%)	24,140 (51.2%)	4,380 (44.9%)	4,370 (44.7%)	0.137	0.003
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	converting enzyme inhibitors	2,260 (22.4%)	13,490 (28.6%)	2,230 (22.8%)	2,240 (22.9%)	0.144	0.002
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	antagonists, plain	1,510 (14.9%)	8,000 (17.0%)	1,470 (15.0%)	1,450 (14.9%)	0.055	0.004
Proton pump inhibitors 1.770 (17.5%) 10,150 (21.5%) 1.740 (17.8%) 1.740 (17.8%) 0.101 0.000 H2-receptor antagonists 20 (0.2%) 210 (0.4%) 20 (0.2%) 20 (0.2%) 0.040 0.007 Non-steroidal anti-inflammatory 770 (7.6%) 2.970 (6.3%) 750 (7.7%) 780 (7.9%) 0.052 0.009 Matti-abelic agents 3.010 (29.9%) 16.730 (35.5%) 2.930 (30.0%) 2.880 (29.6%) 0.100 0.002 Loop diructics 1.640 (16.3%) 12.990 (27.5%) 1.1010 (10.4%) 1.620 (10.5%) 0.010 0.002 Non-loop gents 2.000 (19.8%) 11.180 (23.7%) 1.960 (20.1%) 2.000 (20.5%) 0.099 0.007 Alpha adrenergic blockers 2.000 (19.8%) 11.180 (23.7%) 1.960 (20.1%) 2.000 (20.5%) 0.009 0.007 Antidpertensive, combination 940 (9.3%) 3.850 (8.2%) 910 (9.3%) 70 (0.7%) 0.042 0.002 Calcium channel vertotini reuptake 2.300 (22.8%) 12.240 (26.0%) 2.250 (23.5%) 0.073 0.010	antagonists, combinations	630 (6.2%)	2,540 (5.4%)	600 (6.2%)	610 (6.2%)		0.001
inhibitor: 1,70 (17.5%) 10,150 (21.5%) 1,740 (17.5%) 0.101 0.000 attragenists 20 (0.2%) 210 (0.4%) 20 (0.2%) 20 (0.2%) 0.040 0.007 auti-inflammatory 770 (7.6%) 2.970 (6.3%) 750 (7.7%) 780 (7.9%) 0.052 0.009 drugs 3.010 (29.9%) 16,730 (35.5%) 2.930 (30.0%) 2.880 (29.6%) 0.120 0.010 Antidiabetic 1.030 (10.3%) 6,350 (13.5%) 1.010 (10.4%) 1.020 (10.5%) 0.100 0.002 agents 1.030 (10.3%) 6,550 (14.4%) 80 (0.9%) 70 (0.7%) 0.051 0.012 Apha adrenergic 2.000 (19.8%) 11,180 (23.7%) 1.960 (20.1%) 2.000 (20.5%) 0.099 0.007 Dronedarone 80 (0.8%) 890 (1.9%) 50 (0.5%) 70 (0.7%) 0.049 0.017 Amiodarone 80 (0.8%) 980 (1.9%) 50 (0.5%) 70 (0.7%) 0.049 0.007 Chancersite 2.000 (12.8%) 11,240 (26.0%) 2.250 (23.0%) 2.290 (9.4%) 0		7,650 (75.9%)	36,150 (76.7%)	7,420 (76.0%)	7,390 (75.8%)	0.017	0.006
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	inhibitors	1,770 (17.5%)	10,150 (21.5%)	1,740 (17.8%)	1,740 (17.8%)	0.101	0.000
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	antagonists	20 (0.2%)	210 (0.4%)	20 (0.2%)	20 (0.2%)	0.040	0.007
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	anti-inflammatory	770 (7.6%)	2,970 (6.3%)	750 (7.7%)	780 (7.9%)	0.052	0.009
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Statins	3,010 (29.9%)	16,730 (35.5%)	2,930 (30.0%)	2,880 (29.6%)	0.120	0.010
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	agents				,		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		1,640 (16.3%)	12,990 (27.5%)	1,640 (16.8%)	1,680 (17.2%)	0.274	0.010
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	diuretics	90 (0.9%)	650 (1.4%)	80 (0.9%)	70 (0.7%)	0.051	0.012
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	blockers	,		,	,		
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		· /		<u>)</u> /			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		50 (0.5%)	440 (0.9%)	50 (0.5%)	/0 (0./%)	0.049	0.017
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	combination drugs	940 (9.3%)	3,850 (8.2%)	910 (9.3%)	920 (9.4%)	0.042	0.002
seriotinin reuptake inhibitors 530 (5.3%) 3,110 (6.6%) 520 (5.3%) 540 (5.6%) 0.056 0.009 Drugs used in alcohol 20 (0.2%) 60 (0.1%) 20 (0.2%) 20 (0.2%) 0.018 0.005 CH2DS2- VASc, mean(SD) 2.9 (1.76) 3.6 (1.75) 3.0 (1.76) 3.0 (1.75) 0.356 0.001 CHA2DS2- VASc: 0-1 2.260 (22.4%) 5,700 (12.1%) 2,130 (21.8%) 2.0990 (21.4%) 0.275 0.011 CHA2DS2- VASc: 2-3 4,270 (42.4%) 17,540 (37.2%) 4,140 (42.4%) 4,160 (42.6%) 0.106 0.004 CHA2DS2- VASc:>=4 3,550 (35.2%) 23,910 (50.7%) 3,490 (35.7%) 3,510 (36.0%) 0.317 0.005 CHADS2, mean(SD) 2.4 (1.50) 2.9 (1.47) 2.4 (1.49) 2.4 (1.50) 0.328 0.008 CHADS2: 2.7060 (70.0%) 38.810 (82.3%) 6.900 (70.7%) 6.890 (70.6%) 0.291 0.0025 CHADS2: 7,060 (70.0%) 38.810 (82.3%) 6.900 (70.7%) 6.890 (70.6%) 0.291 0.002 HAS-BLED, mean(SD) 1.7 (0.93)<	blockers	2,300 (22.8%)	12,240 (26.0%)	2,250 (23.0%)	2,290 (23.5%)	0.073	0.010
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	serotonin reuptake inhibitors	530 (5.3%)	3,110 (6.6%)	520 (5.3%)	540 (5.6%)	0.056	0.009
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	alcohol	20 (0.2%)	60 (0.1%)	20 (0.2%)	20 (0.2%)	0.018	0.005
VASc: 0 - 12,260 (22.4%)5,700 (12.1%)2,130 (21.8%)2,090 (21.4%)0.2750.011CHA2DS2- VASc: 2 - 34,270 (42.4%)17,540 (37.2%)4,140 (42.4%)4,160 (42.6%)0.1060.004CHA2DS2- VASc:>=43,550 (35.2%)23,910 (50.7%)3,490 (35.7%)3,510 (36.0%)0.3170.005CHADS2, mean(SD)2.4 (1.50)2.9 (1.47)2.4 (1.49)2.4 (1.50)0.3280.008CHADS2:0980 (9.7%)2,300 (4.9%)920 (9.4%)990 (10.1%)0.1870.025CHADS2:12,040 (20.2%)6,040 (12.8%)1,940 (19.9%)1,880 (19.3%)0.2010.016CHADS2:>=27,060 (70.0%)38,810 (82.3%)6,900 (70.7%)6,890 (70.6%)0.2910.002HAS-BLED, mean(SD)1.7 (0.93)1.9 (0.92)1.7 (0.93)1.7 (0.94)0.2750.016HAS-BLED:<3	VASc, mean(SD)	2.9 (1.76)	3.6 (1.75)	3.0 (1.76)	3.0 (1.75)	0.356	0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	VASc:0 -1	2,260 (22.4%)	5,700 (12.1%)	2,130 (21.8%)	2,090 (21.4%)	0.275	0.011
VASc:>=43,550 (35.2%)23,910 (50.7%)3,490 (35.7%)3,510 (36.0%) 0.317 0.005 CHADS2, mean(SD)2.4 (1.50)2.9 (1.47)2.4 (1.49)2.4 (1.50) 0.328 0.008 CHADS2:0980 (9.7%)2,300 (4.9%)920 (9.4%)990 (10.1%) 0.187 0.025 CHADS2:12,040 (20.2%)6,040 (12.8%)1,940 (19.9%)1,880 (19.3%) 0.201 0.016 CHADS2:>=27,060 (70.0%)38,810 (82.3%)6,900 (70.7%)6,890 (70.6%) 0.291 0.002 HAS-BLED, mean(SD)1.7 (0.93)1.9 (0.92)1.7 (0.93)1.7 (0.94) 0.275 0.016 HAS-BLED:<3	VASc:2 -3	4,270 (42.4%)	17,540 (37.2%)	4,140 (42.4%)	4,160 (42.6%)	0.106	0.004
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	VASc:>=4	3,550 (35.2%)	23,910 (50.7%)	3,490 (35.7%)	3,510 (36.0%)	0.317	0.005
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	mean(SD)		× ,		× ,		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $,			
HAS-BLED, mean(SD) $1.7 (0.93)$ $1.9 (0.92)$ $1.7 (0.93)$ $1.7 (0.94)$ 0.275 0.016 HAS-BLED:<3					/ / /		
HAS-BLED:<3 $8,380 (83.1\%)$ $36,080 (76.5\%)$ $8,100 (83.0\%)$ $8,140 (83.4\%)$ 0.165 0.011 HAS-BLED:>=3 $1,700 (16.9\%)$ $11,080 (23.5\%)$ $1,660 (17.0\%)$ $1,620 (16.6\%)$ 0.165 0.011 log_n_hosp, median(IQR) $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 1.1)$ $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 0.7)$ 0.232 0.000 log_beddays, $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ 0.053 0.016	HAS-BLED,						
HAS-BLED:>=3 1,700 (16.9%) 11,080 (23.5%) 1,660 (17.0%) 1,620 (16.6%) 0.165 0.011 $log_n_hosp,$ $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 1.1)$ $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 0.7)$ 0.232 0.000 $log_beddays,$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ 0.053 0.016		8,380 (83,1%)	36,080 (76,5%)	8,100 (83.0%)	8,140 (83.4%)	0.165	0.011
$log_n_hosp,$ $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 1.1)$ $0.7 (0.0 - 0.7)$ $0.7 (0.0 - 0.7)$ 0.232 0.000 $log_beddays,$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ $0.7 (0.0 - 1.4)$ 0.000							
log_beddays, $0.7(0.0-1.4)$ $0.7(0.0-1.4)$ $0.7(0.0-1.4)$ $0.7(0.0-1.4)$ 0.053 0.016	log_n_hosp,						
	log_beddays,	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.053	0.016

log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.091	0.008
income, median(IQR), k€	60.6 (44.0 - 95.1)	49.8 (40.5 - 72.3)	59.3 (43.8 - 92.7)	58.9 (43.6 - 90.7)	0.188	0.006
education:Second ary compulsory	2,960 (29.4%)	18,850 (40.0%)	2,930 (30.0%)	2,900 (29.7%)	0.224	0.007
education:Vocatio nal / High school	3,990 (39.6%)	18,480 (39.2%)	3,880 (39.8%)	3,920 (40.2%)	0.009	0.008
education:Higher education	3,010 (29.9%)	9,340 (19.8%)	2,840 (29.1%)	2,840 (29.1%)	0.235	0.001
education:Unkno wn	110 (1.1%)	490 (1.0%)	110 (1.1%)	100 (1.0%)	0.004	0.011




Table 15.39 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin in Denmark, Norway, and Sweden and standardised mean differences before and after matching

			0		Standardized me	Standardized m
	Rivaroxaban (ro	Warfarin (rounde	Rivaroxaban (ro	Warfarin (rounde	Standardised me an	Standardised me an
Characteristic	unded) before	d) before	unded) after	d) after matching	difference	difference
Characteristic	matching	matching	matching	N=30599	before matching	after matching
	N=37580	N=79171	N=30599	11-50577	(max=0.58)	(max=0.04)
index year:2013	6,950 (18.5%)	35,000 (44.2%)	6,910 (22.6%)	6,870 (22.5%)	0.577	0.003
index year:2014	8,280 (22.0%)	23,330 (29.5%)	8,000 (26.1%)	7,790 (25.5%)	0.170	0.016
index_year:2015	11,100 (29.5%)	13,390 (16.9%)	9,140 (29.9%)	9,390 (30.7%)	0.302	0.017
index_year:2016	11,250 (29.9%)	7,460 (9.4%)	6,550 (21.4%)	6,550 (21.4%)	0.534	0.000
Time from AF						
diag:< 1 month	23,240 (61.8%)	47,550 (60.1%)	18,600 (60.8%)	18,480 (60.4%)	0.036	0.008
Time from AF diag:1 - 6 month	3,730 (9.9%)	7,970 (10.1%)	3,150 (10.3%)	3,220 (10.5%)	0.005	0.007
Time from AF diag:6 - 60 months	10,610 (28.2%)	23,650 (29.9%)	8,850 (28.9%)	8,910 (29.1%)	0.036	0.004
Sex:Female	16,680 (44.4%)	32,980 (41.7%)	13,420 (43.9%)	13,420 (43.8%)	0.055	0.000
Sex:Male	20,900 (55.6%)	46,190 (58.3%)	17,180 (56.1%)	17,180 (56.2%)	0.055	0.000
Age, median(IQR)	74.2 (67.3 - 82.0)	75.0 (67.5 - 82.2)	74.6 (67.4 - 82.3)	74.7 (67.4 - 82.4)	0.003	0.004
Age -group:< 55 years	1,770 (4.7%)	4,480 (5.7%)	1,550 (5.1%)	1,520 (5.0%)	0.043	0.004
Age -group:55- <65 years	4,960 (13.2%)	10,100 (12.8%)	4,010 (13.1%)	4,060 (13.3%)	0.013	0.005
Age -group:65- <75 years	13,030 (34.7%)	25,060 (31.6%)	10,140 (33.1%)	10,030 (32.8%)	0.064	0.007
Age -group:75- <85 years	11,460 (30.5%)	26,700 (33.7%)	9,620 (31.4%)	9,650 (31.5%)	0.069	0.002
Age -group:>= 85 years	6,360 (16.9%)	12,830 (16.2%)	5,290 (17.3%)	5,340 (17.4%)	0.019	0.004
CCI-group:0	16,040 (42.7%)	29,610 (37.4%)	12,670 (41.4%)	12,530 (40.9%)	0.108	0.009
CCI-group:1-2	12,760 (33.9%)	25,600 (32.3%)	10,360 (33.8%)	10,020 (32.7%)	0.034	0.023
CCI-group:>=3	8,780 (23.4%)	23,960 (30.3%)	7,570 (24.7%)	8,050 (26.3%)	0.156	0.036
Prior bleeding	· · · · · · · · · · · · · · · · · · ·			· , , , ,		
(any)	3,860 (10.3%)	8,870 (11.2%)	3,250 (10.6%)	3,320 (10.9%)	0.030	0.008
Prior gastrointestinal bleeding	330 (0.9%)	820 (1.0%)	280 (0.9%)	290 (1.0%)	0.017	0.005
Prior intracranial bleeding	420 (1.1%)	710 (0.9%)	330 (1.1%)	330 (1.1%)	0.021	0.001
Prior stroke (any)	4,860 (12.9%)	9,610 (12.1%)	3,910 (12.8%)	3,980 (13.0%)	0.024	0.007
Prior ischaemic stroke	4,720 (12.6%)	9,400 (11.9%)	3,800 (12.4%)	3,870 (12.7%)	0.021	0.007
Prior haemorrhagic stroke	300 (0.8%)	520 (0.7%)	230 (0.8%)	230 (0.7%)	0.015	0.001
Prior systemic embolism	220 (0.6%)	760 (1.0%)	200 (0.7%)	230 (0.7%)	0.042	0.010
Prior transient ischaemic attack	1,470 (3.9%)	3,120 (3.9%)	1,210 (4.0%)	1,200 (3.9%)	0.002	0.003
Chronic kidney disease	1,320 (3.5%)	6,530 (8.2%)	1,280 (4.2%)	1,420 (4.6%)	0.202	0.022
Heart failure	6,160 (16.4%)	18,010 (22.7%)	5,480 (17.9%)	5,540 (18.1%)	0.161	0.006
Coronary artery disease	7,530 (20.0%)	21,450 (27.1%)	6,670 (21.8%)	6,820 (22.3%)	0.167	0.012
Peripheral arterial disease	2,460 (6.5%)	6,030 (7.6%)	2,080 (6.8%)	2,160 (7.1%)	0.042	0.011
Hypertension	24,330 (64.8%)	54,110 (68.3%)	20,050 (65.5%)	20,130 (65.8%)	0.076	0.005
Diabetes	5,990 (15.9%)	14,680 (18.5%)	5,050 (16.5%)	5,150 (16.8%)	0.069	0.009
Chronic obstructive	4,620 (12.3%)	10,120 (12.8%)	3,820 (12.5%)	3,890 (12.7%)	0.014	0.007
pulmonary disease						
disease	330 (0.9%)	820 (1.0%)	280 (0.9%)	310 (1.0%)	0.017	0.010
	330 (0.9%) 1,030 (2.7%)	820 (1.0%) 1,790 (2.3%)	280 (0.9%) 790 (2.6%)	310 (1.0%) 810 (2.7%)	0.017	0.010

before and including index dist 1.240 (3.3%) 2.140 (2.7%) 1.010 (3.3%) 1.030 (3.4%) 0.036 0.002 Blacket inspario 14,110 (3.6%) 30,840 (39.0%) 11,610 (37.9%) 11,720 (38.3%) 0.029 0.008 Low -dow aprin 12.330 (32.8%) 27,180 (34.3%) 10.090 (33.0%) 10,180 (33.3%) 0.032 0.008 ADP receptor 2.370 (6.3%) 7.100 (0.0%) 2.120 (6.9%) 2.200 (7.2%) 0.100 0.010 Renin- magnotestim- converting enzyme 16,480 (43.9%) 35.070 (48.1%) 13,560 (44.6%) 13,700 (48.8%) 0.085 0.003 Angiotestin I mangonits II amagonits II amagonits II amagonits II 3,200 (14.3%) 52,50 (6.5%) 6,460 (21.1%) 6,440 (1.0%) 0.0154 0.002 Pertor pump inhibritors 3,200 (14.2%) 11,850 (15.0%) 4,340 (14.2%) 4,370 (14.3%) 0.023 0.002 Pertor pump inhibritors 3,200 (0.1%) 5,210 (6.6%) 2,470 (8.1%) 2,550 (6.3%) 0.017 0.0052 Post pump inhibritors 11,850 (15.0%) 4,400 (14.5%) 0.0416 0.002 <	Cancer 6 months						
Placks inhibitors (excluding legurin) 14,110 (37.6%) 30,840 (39.0%) 11,610 (37.9%) 11,720 (38.3%) 0.029 0.008 Low dose aspira 12,330 (32.8%) 27,180 (34.3%) 10.090 (33.0%) 10,180 (33.3%) 0.032 0.006 ADP receptor blocks 2,370 (6.3%) 7,100 (9.0%) 2,120 (6.9%) 2,200 (7.2%) 0.100 0.010 system inhibitors angenersin recovering enzyme inhibitors 16,480 (43.9%) 38,070 (48.1%) 13,640 (44.6%) 13,700 (44.8%) 0.085 0.002 Angiorensin I anagoniss, plin 7,310 (19.5%) 20,500 (25.9%) 6,440 (21.0%) 0.154 0.002 Pattering enzyme 5,520 (14.2%) 11,850 (15.0%) 4,340 (14.2%) 4,370 (14.3%) 0.023 0.002 Pattering enzyme 5,120 (0.70%) 5,200 (7.0%) 20,207 (80.9%) 0.0740 (67.8%) 0.004 0.008 Nus-steroidal anfi 3,110 (8.3%) 5,860 (7.4%) 2,470 (8.1%) 2,470 (8.1%) 0.032 0.000 Nus-steroidal anfi 3,110 (8.3%) 28,670 (3.5%) 10,410 (4.0%) 10,450 (4.2%) 0.0033 0	including index	1,240 (3.3%)	2,140 (2.7%)	1,010 (3.3%)	1,030 (3.4%)	0.036	0.002
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Platelet inhibitors (excluding	14,110 (37.6%)	30,840 (39.0%)	11,610 (37.9%)	11,720 (38.3%)	0.029	0.008
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		12,330 (32.8%)	27,180 (34.3%)	10,090 (33.0%)	10,180 (33.3%)	0.032	0.006
angioransin System inbibitors 16,480 (43.9%) 38,070 (48.1%) 13,640 (44.6%) 13,700 (44.8%) 0.085 0.003 Angiotensin I antagonists, plain 7,310 (19.5%) 20,500 (25.9%) 6,460 (21.1%) 6,440 (21.0%) 0.154 0.002 Angiotensin II antagonists, plain 5,320 (14.2%) 11.850 (15.0%) 4,340 (14.2%) 4,370 (14.3%) 0.023 0.002 Ben-blockers 25,190 (67.0%) 56,980 (72.0%) 2,680 (81.%) 2,550 (8.3%) 0.004 0.005 Porton pamp inhibriors 7,500 (20.0%) 17,350 (21.9%) 2,470 (8.1%) 2,470 (8.1%) 0.032 0.000 Non-steroidal nati- inflammatory 3,110 (8.3%) 5,860 (7.4%) 2,470 (8.1%) 2,470 (8.1%) 0.033 0.010 Statins 12,550 (33.4%) 28,740 (36.3%) 10,410 (34.0%) 10,450 (34.2%) 0.062 0.003 Matiofiabetic agents 12,550 (33.4%) 22,170 (28.0%) 6,960 (23.8%) 7070 (23.1%) 0.031 0.006 Loog durietics 7,840 (28.4%) 1,580 (20.0%) 5,800 (17.5%) 5,410 (17.3%) 0.031	ADP receptor blockers	2,370 (6.3%)	7,100 (9.0%)	2,120 (6.9%)	2,200 (7.2%)	0.100	0.010
converting enzyme inhibitors 7,310 (19.5%) 20,500 (25.9%) 6.460 (21.1%) 6,440 (21.0%) 0.154 0.002 Angiotensin II antagoniss, plain 5,320 (14.2%) 11,850 (15.0%) 4,340 (14.2%) 4,370 (14.3%) 0.023 0.002 Angiotensin II antagoniss, combinations 3,420 (0.1%) 5,210 (6.6%) 2,480 (8.1%) 2,550 (8.3%) 0.004 0.008 Beta-blockers 25,190 (67.0%) 56,980 (72.0%) 20,820 (68.0%) 20,740 (67.8%) 0.017 0.008 Proton pump inhibitors 7,500 (20.0%) 17,350 (21.9%) 6,520 (20.7%) 6,350 (20.7%) 0.002 0.0002 Non-sterridul anti- inlammatory 3,110 (8.3%) 28,740 (36.3%) 10,410 (34.0%) 10,450 (34.2%) 0.053 0.010 Statins 12,250 (33.4%) 28,740 (28.%) 6,960 (22.%) 700 (21.8%) 0.031 0.009 Statins 12,250 (33.4%) 28,170 (28.%) 6,960 (22.%) 700 (23.%) 0.0167 0.003 Loop ditercitics 7,840 (12.8%) 1,5810 (20.0%) 5,410 (17.5%) 0.0167 0.000	angiotensin system inhibitors	16,480 (43.9%)	38,070 (48.1%)	13,640 (44.6%)	13,700 (44.8%)	0.085	0.003
antagonists, plain 5.320 (14.2%) 11,850 (15.0%) 4.340 (14.2%) 4.370 (14.3%) 0.023 0.002 Angiorensin II antagonists, combinations 3.420 (9.1%) 5.210 (6.6%) 2.480 (8.1%) 2.550 (8.3%) 0.004 0.008 Beta-blockers 25.190 (67.0%) 56.980 (72.0%) 20.820 (68.0%) 20.740 (67.3%) 0.107 0.005 Non-steroidal anti- inflammatory drugs 7.500 (20.0%) 17.350 (21.9%) 6.320 (20.7%) 6.350 (20.7%) 0.048 0.002 Non-steroidal anti- inflammatory drugs 3.110 (8.3%) 5.860 (74.%) 2.470 (8.1%) 2.470 (8.1%) 0.062 0.003 Antidiabetic agents 12.530 (33.4%) 28.740 (36.3%) 10.410 (34.0%) 10.450 (34.2%) 0.062 0.003 Non-loop 450 (1.2%) 10.210 (28.0%) 6.960 (22.8%) 7.070 (23.1%) 0.167 0.008 Non-loop 450 (1.4%) 15.810 (20.0%) 5.640 (17.7%) 5.410 (17.7%) 0.093 0.007 Antipatrone 160 (0.4%) 15.810 (20.0%) 5.460 (17.7%) 5.410 (17.7%) 0.044 0.001	converting enzyme	7,310 (19.5%)	20,500 (25.9%)	6,460 (21.1%)	6,440 (21.0%)	0.154	0.002
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	antagonists, plain	5,320 (14.2%)	11,850 (15.0%)	4,340 (14.2%)	4,370 (14.3%)	0.023	0.002
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	antagonists,	3,420 (9.1%)	5,210 (6.6%)	2,480 (8.1%)	2,550 (8.3%)	0.094	0.008
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Beta-blockers	25,190 (67.0%)	56,980 (72.0%)	20,820 (68.0%)	20,740 (67.8%)	0.107	0.005
Non-steroidal inflammatory drugs 3,110 (8.3%) 5,860 (7.4%) 2,470 (8.1%) 2,470 (8.1%) 0.032 0.000 drugs 12,530 (33.4%) 28,740 (36.3%) 10,410 (34.0%) 10,450 (34.2%) 0.062 0.003 Antidiabetic agents 4,280 (11.4%) 10,410 (13.1%) 3,600 (11.8%) 3,700 (12.1%) 0.061 0.003 Non-loop diurcics 7,840 (20.8%) 22,170 (28.0%) 6,960 (22.8%) 7,070 (23.1%) 0.0167 0.008 Mon-loop diurcics 6,160 (16.4%) 15,810 (20.0%) 5,360 (17.5%) 5,410 (17.7%) 0.093 0.0051 Aniba actenergic blockers 6,160 (16.4%) 15,810 (20.0%) 140 (0.5%) 150 (0.5%) 0.082 0.0031 Anibypertensive combination 4,680 (12.5%) 7,700 (7.7%) 3,540 (11.6%) 3,600 (11.8%) 0.046 0.0052 Selective serotonin reuptake inhibitors 2,310 (6.1%) 4,790 (6.1%) 1,890 (6.2%) 1,870 (6.1%) 0.016 0.001 0.002 CHA2DS2- VASc: -1 70 (0.2%) 120 (0.2%) 60 (0.2%) 60 (0.2%) 0.011 <td< td=""><td></td><td>7,500 (20.0%)</td><td>17,350 (21.9%)</td><td>6,320 (20.7%)</td><td>6,350 (20.7%)</td><td>0.048</td><td>0.002</td></td<>		7,500 (20.0%)	17,350 (21.9%)	6,320 (20.7%)	6,350 (20.7%)	0.048	0.002
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Non-steroidal anti- inflammatory	3,110 (8.3%)	5,860 (7.4%)	2,470 (8.1%)	2,470 (8.1%)	0.032	0.000
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Statins	12,530 (33.4%)	28,740 (36.3%)	10,410 (34.0%)	10,450 (34.2%)	0.062	0.003
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		4,280 (11.4%)	10,410 (13.1%)	3,600 (11.8%)	3,700 (12.1%)	0.053	0.010
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		7,840 (20.8%)	22,170 (28.0%)	6,960 (22.8%)	7,070 (23.1%)	0.167	0.008
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	diuretics	450 (1.2%)	1,230 (1.6%)	380 (1.3%)	410 (1.3%)	0.031	0.009
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		6,160 (16.4%)	15,810 (20.0%)	5,360 (17.5%)	5,410 (17.7%)	0.093	0.005
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		160 (0.4%)	600 (0.8%)	140 (0.5%)	150 (0.5%)	0.044	0.001
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$, combination drugs	4,680 (12.5%)	7,700 (9.7%)	3,540 (11.6%)	3,600 (11.8%)	0.087	0.007
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		8,600 (22.9%)	19,680 (24.9%)	7,150 (23.4%)	7,220 (23.6%)	0.046	0.005
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	serotonin reuptake	2,310 (6.1%)	4,790 (6.1%)	1,890 (6.2%)	1,870 (6.1%)	0.004	0.002
VASc, mean(SD)3.2 (1.71)3.4 (1.76)3.3 (1.72)3.3 (1.75)0.1180.011CHA2DS2- VASc:0-16,150 (16.4%)11,520 (14.6%)4,750 (15.5%)4,920 (16.1%)0.0500.015CHA2DS2- VASc:2-316,020 (42.6%)30,330 (38.3%)12,800 (41.8%)12,200 (39.9%)0.0880.040CHA2DS2- VASc:>=415,410 (41.0%)37,330 (47.1%)13,050 (42.7%)13,480 (44.1%)0.1240.028CHADS2, WASc:>=42.0 (1.45)2.4 (1.51)2.1 (1.45)2.1 (1.48)0.2370.006CHADS2:05,430 (14.4%)8,300 (10.5%)3,860 (12.6%)4,280 (14.0%)0.1200.041CHADS2:19,770 (26.0%)15,840 (20.0%)7,700 (25.2%)7,130 (23.3%)0.1430.043CHADS2:>=222,380 (59.6%)55,030 (69.5%)19,050 (62.3%)19,180 (62.7%)0.2090.009HAS-BLED, mean(SD)2.0 (1.04)2.0 (1.05)2.0 (1.04)2.0 (1.07)0.0300.007	alcohol dependence	70 (0.2%)	120 (0.2%)	60 (0.2%)	60 (0.2%)	0.010	0.000
VASc:0-1 6,150 (16.4%) 11,520 (14.6%) 4,750 (15.5%) 4,920 (16.1%) 0.050 0.015 CHA2DS2- VASc:2-3 16,020 (42.6%) 30,330 (38.3%) 12,800 (41.8%) 12,200 (39.9%) 0.088 0.040 CHA2DS2- VASc:>=4 15,410 (41.0%) 37,330 (47.1%) 13,050 (42.7%) 13,480 (44.1%) 0.124 0.028 CHADS2, mean(SD) 2.0 (1.45) 2.4 (1.51) 2.1 (1.45) 2.1 (1.48) 0.237 0.006 CHADS2:0 5,430 (14.4%) 8,300 (10.5%) 3,860 (12.6%) 4,280 (14.0%) 0.120 0.041 CHADS2:1 9,770 (26.0%) 15,840 (20.0%) 7,700 (25.2%) 7,130 (23.3%) 0.143 0.043 CHADS2:>=2 22,380 (59.6%) 55,030 (69.5%) 19,050 (62.3%) 19,180 (62.7%) 0.209 0.009 HAS-BLED, mean(SD) 2.0 (1.04) 2.0 (1.05) 2.0 (1.04) 2.0 (1.07) 0.030 0.007 HAS-BLED:<3	VASc,	3.2 (1.71)	3.4 (1.76)	3.3 (1.72)	3.3 (1.75)	0.118	0.011
VASc:2 -3 16,020 (42.6%) 30,330 (38.3%) 12,800 (41.8%) 12,200 (39.9%) 0.088 0.040 CHA2DS2- VASc:>=4 15,410 (41.0%) 37,330 (47.1%) 13,050 (42.7%) 13,480 (44.1%) 0.124 0.028 CHADS2, mean(SD) 2.0 (1.45) 2.4 (1.51) 2.1 (1.45) 2.1 (1.48) 0.237 0.006 CHADS2:0 5,430 (14.4%) 8,300 (10.5%) 3,860 (12.6%) 4,280 (14.0%) 0.120 0.041 CHADS2:1 9,770 (26.0%) 15,840 (20.0%) 7,700 (25.2%) 7,130 (23.3%) 0.143 0.043 CHADS2:>=2 22,380 (59.6%) 55,030 (69.5%) 19,050 (62.3%) 19,180 (62.7%) 0.209 0.009 HAS-BLED, mean(SD) 2.0 (1.04) 2.0 (1.05) 2.0 (1.04) 2.0 (1.07) 0.030 0.007 HAS-BLED:<3		6,150 (16.4%)	11,520 (14.6%)	4,750 (15.5%)	4,920 (16.1%)	0.050	0.015
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CHA2DS2-	16,020 (42.6%)	30,330 (38.3%)	12,800 (41.8%)	12,200 (39.9%)	0.088	0.040
CHADS2, mean(SD) 2.0 (1.45) 2.4 (1.51) 2.1 (1.45) 2.1 (1.48) 0.237 0.006 CHADS2:0 5,430 (14.4%) 8,300 (10.5%) 3,860 (12.6%) 4,280 (14.0%) 0.120 0.041 CHADS2:1 9,770 (26.0%) 15,840 (20.0%) 7,700 (25.2%) 7,130 (23.3%) 0.143 0.043 CHADS2:>=2 22,380 (59.6%) 55,030 (69.5%) 19,050 (62.3%) 19,180 (62.7%) 0.209 0.009 HAS-BLED, mean(SD) 2.0 (1.04) 2.0 (1.04) 2.0 (1.07) 0.030 0.007 HAS-BLED:<3	CHA2DS2-	15,410 (41.0%)	37,330 (47.1%)	13,050 (42.7%)	13,480 (44.1%)	0.124	0.028
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	CHADS2,	2.0 (1.45)	2.4 (1.51)	2.1 (1.45)	2.1 (1.48)	0.237	0.006
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CHADS2:0			/ /			
HAS-BLED, mean(SD) 2.0 (1.04) 2.0 (1.05) 2.0 (1.04) 2.0 (1.07) 0.030 0.007 HAS-BLED:<3			, , ,				
mean(SD) Fill			· · · · · · · · · · · · · · · · · · ·				
	mean(SD)	. ,			. ,		
$- HAN_{BLEUN=3} + HIN3H(7X10%) + 73H(117910%) + X7H(7XN0%) + 0.0807(7070%) + 0.097 + 0.097$	HAS-BLED:<3 HAS-BLED:>=3	27,060 (72.0%) 10,530 (28.0%)	56,150 (70.9%) 23,020 (29.1%)	21,890 (71.5%) 8,710 (28.5%)	21,520 (70.3%) 9,080 (29.7%)	0.024	0.027

log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.140	0.012
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.012	0.012
log_n_outpatient , median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.014	0.006

Table 15.40 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Denmark

					Standard' 1	
Characteristic	Rivaroxaban (r ounded) before matching N=12682	Warfarin (roun ded) before matching N=20070	Rivaroxaban (r ounded) after matching N=10537	Warfarin (roun ded) after matching N=10537	Standardised m ean difference before matchin g (max= 0.52)	Standardised m ean difference after matching (max= 0.06)
index_year:201 3	2,350 (18.5%)	6,810 (33.9%)	2,320 (22.1%)	2,270 (21.5%)	0.356	0.013
index_year:201 4	1,880 (14.8%)	5,400 (26.9%)	1,860 (17.7%)	1,840 (17.5%)	0.300	0.005
index_year:201 5	3,510 (27.7%)	4,580 (22.8%)	3,200 (30.4%)	3,380 (32.1%)	0.111	0.037
index_year:201 6	4,950 (39.0%)	3,280 (16.4%)	3,150 (29.9%)	3,040 (28.9%)	0.523	0.022
Time from AF diag:< 1 month	8,370 (66.0%)	12,620 (62.9%)	6,830 (64.8%)	6,720 (63.8%)	0.065	0.020
Time from AF diag:1 - 6 month	1,470 (11.6%)	2,410 (12.0%)	1,260 (12.0%)	1,270 (12.0%)	0.013	0.001
Time from AF diag:6 - 60 months	2,850 (22.4%)	5,040 (25.1%)	2,450 (23.3%)	2,550 (24.2%)	0.063	0.022
Sex:Female	5,710 (45.0%)	7,950 (39.6%)	4,570 (43.3%)	4,580 (43.5%)	0.109	0.003
Sex:Male	6,970 (55.0%)	12,120 (60.4%)	5,970 (56.7%)	5,960 (56.5%)	0.109	0.003
Age, median(IQR)	74.1 (67.2 - 82.1)	73.3 (66.1 - 80.6)	73.9 (66.9 - 81.6)	74.0 (67.0 - 81.8)	0.143	0.008
Age -group:< 55 years	630 (5.0%)	1,520 (7.6%)	590 (5.6%)	590 (5.6%)	0.107	0.002
Age -group:55- <65 years	1,700 (13.4%)	2,870 (14.3%)	1,460 (13.9%)	1,420 (13.4%)	0.027	0.013
Age -group:65- <75 years	4,370 (34.4%)	6,820 (34.0%)	3,620 (34.3%)	3,590 (34.1%)	0.009	0.006
Age -group:75- <85 years	3,770 (29.7%)	6,280 (31.3%)	3,180 (30.2%)	3,210 (30.4%)	0.034	0.006
Age -group:>= 85 years	2,220 (17.5%)	2,580 (12.9%)	1,690 (16.0%)	1,730 (16.4%)	0.130	0.011
CCI-group:0	5,750 (45.3%)	8,600 (42.8%)	4,770 (45.3%)	4,810 (45.7%)	0.050	0.008
CCI-group:1-2	4,280 (33.8%)	6,000 (29.9%)	3,530 (33.5%)	3,260 (30.9%)	0.083	0.055
CCI-group:>=3	2,650 (20.9%)	5,470 (27.2%)	2,240 (21.3%)	2,470 (23.4%)	0.148	0.052
Prior bleeding (any)	1,100 (8.7%)	1,940 (9.7%)	930 (8.9%)	940 (8.9%)	0.035	0.001
Prior gastrointestinal bleeding	130 (1.0%)	270 (1.4%)	110 (1.1%)	120 (1.1%)	0.032	0.003
Prior intracranial bleeding	130 (1.0%)	140 (0.7%)	90 (0.8%)	90 (0.8%)	0.031	0.002
Prior stroke (any)	1,740 (13.7%)	1,980 (9.8%)	1,310 (12.4%)	1,330 (12.6%)	0.121	0.005
Prior ischaemic stroke	1,710 (13.5%)	1,940 (9.7%)	1,290 (12.2%)	1,310 (12.4%)	0.118	0.006
Prior haemorrhagic stroke	80 (0.6%)	90 (0.4%)	50 (0.5%)	50 (0.5%)	0.026	0.003
Prior systemic embolism	50 (0.4%)	110 (0.5%)	40 (0.4%)	50 (0.5%)	0.027	0.013
Prior transient ischaemic attack	420 (3.3%)	600 (3.0%)	350 (3.3%)	360 (3.4%)	0.018	0.008
Chronic kidney disease	360 (2.8%)	1,690 (8.4%)	350 (3.4%)	380 (3.6%)	0.245	0.016
Heart failure	1,850 (14.6%)	3,570 (17.8%)	1,590 (15.1%)	1,610 (15.2%)	0.087	0.005
Coronary artery disease	2,140 (16.8%)	4,590 (22.9%)	1,910 (18.1%)	1,940 (18.4%)	0.151	0.007
Peripheral arterial disease	780 (6.1%)	1,630 (8.1%)	690 (6.6%)	730 (7.0%)	0.078	0.015
Hypertension	7,820 (61.7%)	12,270 (61.1%)	6,470 (61.4%)	6,470 (61.4%)	0.012	0.000
Diabetes	1,970 (15.5%)	3,490 (17.4%)	1,660 (15.7%)	1,690 (16.0%)	0.051	0.009

<u> </u>	L					1
Chronic obstructive pulmonary disease	1,540 (12.1%)	2,570 (12.8%)	1,290 (12.3%)	1,340 (12.7%)	0.020	0.013
Liver disease	110 (0.9%)	240 (1.2%)	100 (1.0%)	110 (1.1%)	0.031	0.010
Alcoholism	410 (3.2%)	590 (2.9%)	330 (3.1%)	340 (3.2%)	0.017	0.006
Dementia	310 (2.5%)	220 (1.1%)	190 (1.8%)	190 (1.8%)	0.103	0.002
Cancer 6 months before and including index date	510 (4.0%)	930 (4.6%)	440 (4.2%)	450 (4.3%)	0.030	0.005
Platelet inhibitors (excluding heparin)	3,960 (31.2%)	6,760 (33.7%)	3,350 (31.8%)	3,410 (32.3%)	0.053	0.013
Low -dose aspirin	2,910 (23.0%)	5,110 (25.5%)	2,480 (23.5%)	2,540 (24.1%)	0.058	0.013
ADP receptor blockers	1,200 (9.5%)	2,260 (11.2%)	1,020 (9.7%)	1,030 (9.7%)	0.059	0.003
Renin - angiotensin system inhibitors	5,170 (40.7%)	8,420 (42.0%)	4,330 (41.1%)	4,320 (41.0%)	0.025	0.003
Angiotensin - converting enzyme inhibitors	2,550 (20.1%)	4,510 (22.5%)	2,200 (20.8%)	2,210 (20.9%)	0.058	0.002
Angiotensin II antagonists, plain	1,400 (11.1%)	2,220 (11.0%)	1,160 (11.0%)	1,130 (10.8%)	0.001	0.007
Angiotensin II antagonists, combinations	910 (7.2%)	1,210 (6.0%)	710 (6.7%)	740 (7.0%)	0.047	0.009
Beta-blockers	7,880 (62.2%)	12,420 (61.9%)	6,510 (61.7%)	6,470 (61.4%)	0.005	0.007
Proton pump inhibitors	2,620 (20.7%)	4,510 (22.5%)	2,240 (21.2%)	2,220 (21.1%)	0.044	0.003
Non-steroidal anti- inflammatory drugs	1,270 (10.0%)	1,980 (9.9%)	1,070 (10.2%)	1,090 (10.4%)	0.006	0.007
Statins	4,170 (32.9%)	6,990 (34.8%)	3,520 (33.4%)	3,500 (33.2%)	0.042	0.003
Antidiabetic agents	1,500 (11.9%)	2,650 (13.2%)	1,270 (12.0%)	1,300 (12.3%)	0.041	0.009
Loop diuretics	3,020 (23.8%)	5,800 (28.9%)	2,620 (24.8%)	2,620 (24.8%)	0.115	0.000
Non-loop diuretics	150 (1.2%)	350 (1.7%)	140 (1.3%)	160 (1.5%)	0.042	0.015
Alpha adrenergic blockers	2,280 (17.9%)	3,670 (18.3%)	1,940 (18.4%)	1,930 (18.3%)	0.009	0.002
Amiodarone	370 (2.9%)	970 (4.9%)	340 (3.3%)	350 (3.3%)	0.101	0.005
Dronedarone	20 (0.1%)	30 (0.1%)	20 (0.1%)	10 (0.1%)	0.003	0.005
Antihypertensiv e, combination drugs	1,470 (11.6%)	2,110 (10.5%)	1,190 (11.3%)	1,190 (11.3%)	0.035	0.000
Calcium channel blockers	2,940 (23.2%)	4,790 (23.9%)	2,470 (23.5%)	2,480 (23.5%)	0.017	0.001
Selective serotonin reuptake inhibitors	830 (6.5%)	1,150 (5.7%)	660 (6.3%)	670 (6.3%)	0.032	0.002
Drugs used in alcohol dependence	30 (0.2%)	50 (0.2%)	30 (0.2%)	30 (0.3%)	0.000	0.004
CHA2DS2- VASc, mean(SD)	3.2 (1.65)	3.1 (1.67)	3.1 (1.66)	3.2 (1.69)	0.051	0.015
CHA2DS2- VASc:0 -1	2,000 (15.8%)	3,580 (17.8%)	1,740 (16.5%)	1,770 (16.8%)	0.055	0.008
CHA2DS2- VASc:2 -3	5,480 (43.2%)	8,410 (41.9%)	4,590 (43.5%)	4,380 (41.5%)	0.026	0.040
CHA2DS2- VASc:>=4	5,200 (41.0%)	8,080 (40.2%)	4,220 (40.0%)	4,390 (41.7%)	0.016	0.034

GUADGA						
CHADS2, mean(SD)	1.7 (1.24)	1.6 (1.21)	1.7 (1.23)	1.7 (1.25)	0.051	0.010
CHADS2:0	2,020 (16.0%)	3,470 (17.3%)	1,710 (16.3%)	1,840 (17.5%)	0.035	0.032
CHADS2:1	4,040 (31.9%)	6,320 (31.5%)	3,430 (32.5%)	3,150 (29.9%)	0.008	0.056
CHADS2:>=2	6,620 (52.2%)	10,280 (51.2%)	5,400 (51.2%)	5,550 (52.6%)	0.019	0.028
HAS-BLED, mean(SD)	2.1 (1.09)	2.1 (1.17)	2.1 (1.10)	2.1 (1.13)	0.009	0.012
HAS-BLED:<3	8,240 (65.0%)	12,660 (63.1%)	6,850 (65.0%)	6,730 (63.9%)	0.039	0.024
HAS- BLED:>=3	4,450 (35.0%)	7,410 (36.9%)	3,690 (35.0%)	3,810 (36.1%)	0.039	0.024
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.037	0.003
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.190	0.016
log_n_outpatien t, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.064	0.008
income, median(IQR), k€	124.6 (88.5 - 195.1)	122.8 (88.9 - 187.6)	123.5 (88.5 - 193.1)	123.7 (88.5 - 192.5)	0.039	0.009
education:Seco ndary compulsory	5,000 (39.4%)	8,430 (42.0%)	4,230 (40.2%)	4,240 (40.2%)	0.052	0.002
education:Voca tional / High school	4,980 (39.3%)	8,140 (40.6%)	4,220 (40.1%)	4,210 (40.0%)	0.026	0.002
education:High er education	2,260 (17.8%)	2,980 (14.8%)	1,740 (16.5%)	1,750 (16.6%)	0.080	0.003
education:Unkn own	440 (3.5%)	520 (2.6%)	340 (3.2%)	330 (3.1%)	0.053	0.004
employment:E mployed or self -employed	2,240 (17.7%)	3,720 (18.5%)	1,900 (18.0%)	1,870 (17.8%)	0.022	0.006
employment:Un employed	590 (4.7%)	1,190 (5.9%)	530 (5.0%)	520 (5.0%)	0.058	0.001
employment:Re tired	9,770 (77.0%)	15,010 (74.8%)	8,040 (76.3%)	8,070 (76.6%)	0.051	0.006
employment:Un known	80 (0.7%)	150 (0.7%)	70 (0.7%)	70 (0.7%)	0.009	0.002




Table 15.41 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Norway

Russenstan (market) bergen underlap bergen (hinderlap bergen N=1055) Warrain (round matching N=1055) Warrain (round matching N=1055) Standardised me and matching N=1055) Standardised me difference hor matching N=1055) Standardised me and difference hor matching N=1055) Standardised me and difference hor matching N=1055) Standardised me difference hor matching N=10550 Standardised me difference hor matching N=1050 Standardised me difference hor N=1000 Standardised me difference hor N=1000 Standardised me difference hor N=10000 Standardised me difference hor N=100000 Standardised me difference hor N=1000000 Standardised me difference hor N=100000000 Standardised me difference hor N=1000000000000000000000000000000000000							
index_year:2014 2.590 (24.5%) 3.490 (28.8%) 2.330 (22.1%) 2.250 (31.0%) 0.001 index_year:2016 2.450 (22.0%) 1.760 (44.8%) 1.470 (22.2%) 1.500 (20.7%) 0.034 0.0013 index_year:2016 2.420 (22.9%) 9.90 (7.8%) 780 (10.8%) 850 (11.7%) 0.428 0.027 finite from Af 6.440 (60.9%) 1.340 (11.2%) 750 (10.3%) 760 (10.5%) 0.072 0.005 finite from Af 960 (9.0%) 1.340 (11.2%) 750 (10.3%) 7.80 (10.3%) 0.072 0.0015 Sex:Male 6.059 (57.3%) 7.21 (0.633) 1.30 (55.9%) 4.190 (57.6%) 0.062 0.015 Age: 73.3 (66.7 - 73.3 (65.7 + 74.8 (65.9%) 74.9 (56.9%) 0.007 0.004 years 1.500 (14.4%) 1.690 (14.2%) 1.020 (14.4%) 1.090 (14.4%) 0.0067 0.0011 defs years 5.50 (52.2%) 3.800 (22.9%) 2.240 (30.8%) 2.270 (3.3 %) 0.016 0.011 e.55 years 1.650 (15.6%) 3.300 (22.9%) 2.240 (30.8%		unded) before matching N=10565	d) before matching N=11949	unded) after matching N= 7268	d) after matching N= 7268	an difference before matching	an difference after matching (max= 0.06)
$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	index_year:2013	2,710 (25.6%)	5,810 (48.6%)	2,690 (37.0%)	2,670 (36.7%)	0.490	0.006
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	index_year:2014	2,590 (24.5%)	3,450 (28.8%)	2,330 (32.1%)	2,250 (31.0%)	0.097	0.023
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	index year:2015	2,850 (27.0%)	1,760 (14.8%)	1,470 (20.2%)	1,500 (20.7%)	0.304	0.013
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			<u>, , , , , , , , , , , , , , , , , , , </u>	, , ,	, , , , ,		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	diag:< 1 month	6,440 (60.9%)	6,410 (53.6%)	4,110 (56.5%)	4,130 (56.8%)	0.148	0.005
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	diag:1 - 6 month	960 (9.0%)	1,340 (11.2%)	750 (10.3%)	760 (10.5%)	0.072	0.005
	diag:6 - 60	3,170 (30.0%)	4,200 (35.2%)	2,410 (33.1%)	2,380 (32.7%)	0.110	0.008
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Sex:Female	4,510 (42.7%)	4,740 (39.7%)	3,130 (43.1%)	3,080 (42.4%)	0.062	0.015
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Sex:Male	6.050 (57.3%)	7.210 (60.3%)			0.062	0.015
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		73 4 (66 7 -					
years 3.00 (3.2%) 6.80 (1.3%) 4.20 (1.7%) 4.20 (1.7%) 4.20 (1.7%) 4.20 (1.8%) 0.0072 0.0074 Age -group:55 1.520 (14.4%) 1.690 (14.2%) 1.020 (14.1%) 1.050 (14.4%) 0.008 0.011 Age group:55 3.760 (35.6%) 3.360 (28.1%) 2.240 (30.8%) 2.270 (31.3%) 0.161 0.011 Age group:55 (3.090 (29.2%) 3.860 (32.3%) 2.250 (30.9%) 2.240 (30.8%) 0.067 0.001 Age group:54 (3.090 (29.2%) 3.860 (32.3%) 2.250 (33.4%) 2.410 (33.4%) 0.075 0.024 CCI-group:1 4.040 (38.3%) 3.340 (27.9%) 2.430 (33.4%) 2.410 (33.4%) 0.075 0.027 CCI-group:2 3.750 (35.5%) 3.810 (31.9%) 2.240 (30.9%) 2.360 (32.5%) 0.028 0.035 Prior bleeding 1.260 (11.9%) 1.780 (14.9%) 950 (13.1%) 1.000 (13.7%) 0.088 0.018 Prior tructarialia 110 (1.9%) 1.60 (1.3%) 90 (1.2%) 90 (1.3%) 0.002 0.005 Prior truscr	median(IQR)			``		0.047	0.016
$\begin{array}{c} \frac{1}{1650} (14.4\%) & 10.99 (14.2\%) & 10.29 (14.1\%) & 10.99 (14.4\%) & 10.99 (14.5\%) & 12.99 (13.4\%) & 12.99 (13.4\%) & 12.99 (13.4\%) & 12.99 (13.4\%) & 12.99 (13.4\%) & 0.97 & 0.024 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.027 & 0.028 & 0.035 & 0.028 & 0.038 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.018 & 0.004 & 0.005 & 0.027 & 0.005 & 0.029 & 0.011 & 0.013 & 0.002 & 0.006 & 0.009 & 0.011 & 0.005 & 0.029 & 0.011 & 0.003 & 0.009 & 0.009 & 0.000 & 0.005 & 0.029 & 0.011 & 0.001 & 0.005 & 0.029 & 0.011 & 0.001 & 0.005 & 0.029 & 0.011 & 0.001 & 0.005 & 0.029 & 0.011 & 0.013 & 0.006 & 0.059 & 0.020 & 0.001 & 0.005 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.020 & 0.006 & 0.002 & 0.006 & 0.002 & 0.0$	years	550 (5.2%)	830 (7.0%)	420 (5.7%)	420 (5.8%)	0.072	0.004
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<65 years	1,520 (14.4%)	1,690 (14.2%)	1,020 (14.1%)	1,050 (14.4%)	0.008	0.011
	<75 years	3,760 (35.6%)	3,360 (28.1%)	2,240 (30.8%)	2,270 (31.3%)	0.161	0.011
85 years 1,050 (13.0%) 2,210 (13.5%) 1,050 (13.5%) 2,240 (33.4%) 2,240 (33.1%) 0,075 0,0024 CCL group:1-2 3,750 (35.5%) 3,340 (27.9%) 2,240 (33.4%) 2,410 (33.1%) 0.221 0,008 CCL-group:>=3 2,780 (26.3%) 4,800 (40.2%) 2,240 (33.9%) 2,360 (32.5%) 0.298 0.035 Prior bleeding (ary) 1,260 (11.9%) 1,780 (14.9%) 950 (13.1%) 1,000 (13.7%) 0.088 0.018 Prior gastrointestinal bleeding (ary) 120 (1.2%) 190 (1.6%) 90 (1.3%) 100 (1.3%) 0.038 0.004 Prior stroke (ary) 1,260 (11.9%) 1440 (12.0%) 940 (12.9%) 950 (13.1%) 0.002 0.005 Prior stroke (ary) 1,230 (11.6%) 1,380 (11.5%) 910 (12.5%) 920 (12.7%) 0.001 0.005 Prior stroke stroke 1,230 (11.6%) 110 (0.9%) 50 (0.7%) 60 (0.8%) 0.012 0.011 Prior transient stroke 1,260 (13.1%) 550 (7.5%) 630 (8.7%) 0.263 0.043 Chronic kidney <td< td=""><td><85 years</td><td>3,090 (29.2%)</td><td>3,860 (32.3%)</td><td>2,250 (30.9%)</td><td>2,240 (30.8%)</td><td>0.067</td><td>0.001</td></td<>	<85 years	3,090 (29.2%)	3,860 (32.3%)	2,250 (30.9%)	2,240 (30.8%)	0.067	0.001
$\begin{array}{c} \mbox{CCL-group:1-2} & 3,750 (35.5\%) & 3,810 (31.9\%) & 2,590 (35.7\%) & 2,500 (34.4\%) & 0.075 & 0.027 \\ \mbox{CCL-group:>=3} & 2,780 (26.3\%) & 4,800 (40.2\%) & 2,240 (30.9\%) & 2,360 (32.5\%) & 0.298 & 0.035 \\ \mbox{Piror bleeding} & 1,260 (11.9\%) & 1,780 (14.9\%) & 950 (13.1\%) & 1,000 (13.7\%) & 0.088 & 0.018 \\ \mbox{Deleding} & 120 (1.2\%) & 190 (1.6\%) & 90 (1.3\%) & 100 (1.3\%) & 0.038 & 0.004 \\ \mbox{bleeding} & 110 (1.0\%) & 160 (1.3\%) & 90 (1.2\%) & 90 (1.3\%) & 0.027 & 0.005 \\ \mbox{Piror inscharmic} & 1,260 (11.9\%) & 1,440 (12.0\%) & 940 (12.9\%) & 950 (13.1\%) & 0.002 & 0.006 \\ \mbox{(any)} & 1,260 (11.9\%) & 1,440 (12.0\%) & 940 (12.9\%) & 950 (13.1\%) & 0.002 & 0.006 \\ \mbox{(any)} & 1,260 (11.9\%) & 1,380 (11.5\%) & 910 (12.5\%) & 920 (12.7\%) & 0.001 & 0.005 \\ \mbox{Piror inscharmic} & 1,230 (11.6\%) & 1,380 (11.5\%) & 910 (12.5\%) & 920 (12.7\%) & 0.001 & 0.005 \\ \mbox{Piror inscharmic} & 60 (0.5\%) & 110 (0.9\%) & 50 (0.7\%) & 60 (0.8\%) & 0.070 & 0.008 \\ \mbox{Prior transient} & 60 (0.5\%) & 140 (1.2\%) & 50 (0.7\%) & 60 (0.8\%) & 0.070 & 0.008 \\ \mbox{Prior transient} & 60 (0.5\%) & 1,560 (13.1\%) & 550 (7.5\%) & 630 (8.7\%) & 0.263 & 0.043 \\ \mbox{Chronic kidney} & 580 (5.5\%) & 1,560 (13.1\%) & 550 (7.5\%) & 630 (8.7\%) & 0.263 & 0.043 \\ \mbox{Heat failare} & 1.600 (15.2\%) & 3,110 (26.0\%) & 1,300 (18.7\%) & 1,380 (19.0\%) & 0.271 & 0.006 \\ \mbox{Coronary artery} & 2,510 (23.8\%) & 4,410 (36.9\%) & 2,040 (28.1\%) & 2,080 (28.6\%) & 0.288 & 0.012 \\ \mbox{Prior transient} & 1,490 (14.1\%) & 2,100 (17.6\%) & 1,100 (15.2\%) & 1,120 (15.4\%) & 0.032 & 0.006 \\ \mbox{Diabetes} & 1,490 (14.1\%) & 2,100 (17.6\%) & 1,100 (15.2\%) & 1,040 (14.3\%) & 0.057 & 0.002 \\ \mbox{Coronary artery} & 2,510 (23.8\%) & 1,850 (15.5\%) & 1,030 (14.2\%) & 1,040 (14.3\%) & 0.057 & 0.002 \\ \mbox{Chronic} & 0.260 (59.2\%) & 1,270 (0.8\%) & 4,380 (60.2\%) & 4,400 (60.5\%) & 0.032 & 0.006 \\ \mbox{Diabetes} & 1,490 (14.1\%) & 2,100 (17.6\%) & 1,101 (15.2\%) & 1,120 (15.4\%) & 0.057 & 0.002 \\ \mbox{Chronic} & 0.250 (2.3\%) & 1,850 (15.5\%) & 1,030 (14.2\%) & 1,040 (14.3\%) & 0.057 & 0.002 \\ $	85 years	,		,	1,280 (17.6%)	0.078	0.024
$\begin{array}{c cccccc} CCLgroup: >=3 & 2,780 (26.3\%) & 4,800 (40.2\%) & 2,240 (30.9\%) & 2,360 (32.5\%) & 0.298 & 0.035 \\ \hline Prior bleeding (ary) & 1,260 (11.9\%) & 1,780 (14.9\%) & 950 (13.1\%) & 1,000 (13.7\%) & 0.088 & 0.018 \\ \hline Prior gastrointestinal & 120 (1.2\%) & 190 (1.6\%) & 90 (1.3\%) & 100 (1.3\%) & 0.038 & 0.004 \\ \hline Beeding & 100 (1.0\%) & 160 (1.3\%) & 90 (1.2\%) & 90 (1.3\%) & 0.027 & 0.005 \\ \hline Prior stroke (ary) & 1,260 (11.9\%) & 1,440 (12.0\%) & 940 (12.9\%) & 950 (13.1\%) & 0.002 & 0.006 \\ \hline Prior stroke & 1,230 (11.6\%) & 1,380 (11.5\%) & 910 (12.5\%) & 920 (12.7\%) & 0.001 & 0.005 \\ \hline Prior stroke & 1,230 (11.6\%) & 110 (0.9\%) & 50 (0.7\%) & 60 (0.8\%) & 0.029 & 0.011 \\ \hline Prior ransient & 70 (0.6\%) & 110 (0.9\%) & 50 (0.7\%) & 60 (0.8\%) & 0.012 & 0.008 \\ \hline Prior transient & 430 (4.1\%) & 460 (3.9\%) & 330 (4.5\%) & 310 (4.3\%) & 0.012 & 0.013 \\ \hline Chronic kidney disease & 580 (5.5\%) & 1,560 (13.1\%) & 550 (7.5\%) & 630 (8.7\%) & 0.263 & 0.043 \\ \hline Coronaty artery disease & 970 (9.2\%) & 1,370 (11.5\%) & 720 (9.9\%) & 730 (10.1\%) & 0.076 & 0.004 \\ \hline Pertoric ransient & 1,600 (15.2\%) & 3,110 (26.0\%) & 1,360 (18.7\%) & 1,380 (19.0\%) & 0.271 & 0.006 \\ \hline Coronaty artery disease & 970 (9.2\%) & 1,370 (11.5\%) & 720 (9.9\%) & 730 (10.1\%) & 0.076 & 0.004 \\ \hline Heart failure & 1,600 (15.2\%) & 1,370 (11.5\%) & 720 (9.9\%) & 730 (10.1\%) & 0.076 & 0.004 \\ \hline Hypertension & 6,260 (59.2\%) & 7,270 (60.8\%) & 4,480 (60.2\%) & 1,120 (15.4\%) & 0.097 & 0.005 \\ \hline Chronic disease & 110 (1.0\%) & 1,850 (15.5\%) & 1,030 (14.2\%) & 1,040 (14.3\%) & 0.057 & 0.002 \\ \hline Chronic disease & 110 (1.0\%) & 150 (1.3\%) & 80 (1.0\%) & 90 (1.2\%) & 0.026 & 0.012 \\ \hline Diabetes & 1,490 (14.1\%) & 1,850 (15.5\%) & 1,030 (14.2\%) & 1,040 (14.3\%) & 0.057 & 0.002 \\ \hline Chronic disease & 110 (1.0\%) & 150 (1.3\%) & 80 (1.0\%) & 90 (1.2\%) & 0.026 & 0.012 \\ \hline Chronic disease & 110 (1.0\%) & 150 (1.3\%) & 80 (1.0\%) & 140 (1.9\%) & 0.067 & 0.002 \\ \hline Chronic disease & 110 (1.0\%) & 150 (1.3\%) & 140 (1.9\%) & 140 (1.9\%) & 0.067 & 0.002 \\ \hline Chronic disease & 110 (1.0\%) & 150 (1.3\%) & 140 (1.9\%) & 140 (1.9\%) & 0.067 & 0.00$	CCI-group:0	4,040 (38.3%)	3,340 (27.9%)	2,430 (33.4%)	2,410 (33.1%)	0.221	0.008
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CCI-group:1-2	3,750 (35.5%)	3,810 (31.9%)	2,590 (35.7%)	2,500 (34.4%)	0.075	0.027
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CCI-group:>=3	2,780 (26.3%)	4,800 (40.2%)	2,240 (30.9%)	2,360 (32.5%)	0.298	0.035
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Prior bleeding				· , , , , ,		
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Prior gastrointestinal	120 (1.2%)	190 (1.6%)	90 (1.3%)	100 (1.3%)	0.038	0.004
(any) 1,260 (11.9%) 1,440 (12.0%) 940 (12.9%) 950 (13.1%) 0.002 0.006 Prior ischaemic stroke 1,230 (11.6%) 1,380 (11.5%) 910 (12.5%) 920 (12.7%) 0.001 0.005 Prior haemorrhagic embolism 70 (0.6%) 110 (0.9%) 50 (0.7%) 60 (0.8%) 0.029 0.011 Prior systemic embolism 60 (0.5%) 140 (1.2%) 50 (0.7%) 60 (0.8%) 0.012 0.008 Prior transient ischaemic attack 430 (4.1%) 460 (3.9%) 330 (4.5%) 310 (4.3%) 0.012 0.013 Chronic kidney disease 580 (5.5%) 1,560 (13.1%) 550 (7.5%) 630 (8.7%) 0.263 0.043 Heart failure 1,600 (15.2%) 3,110 (26.0%) 1,360 (18.7%) 1,380 (19.0%) 0.271 0.006 Coronary artery disease 2,510 (23.8%) 4,410 (36.9%) 2,040 (28.1%) 2,080 (28.6%) 0.032 0.004 Hypertension 6,260 (59.2%) 7.270 (60.8%) 4,380 (60.2%) 4,400 (60.5%) 0.032 0.006 Diabetes 1,490 (14.1%)<		110 (1.0%)	160 (1.3%)	90 (1.2%)	90 (1.3%)	0.027	0.005
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	(any)	1,260 (11.9%)	1,440 (12.0%)	940 (12.9%)	950 (13.1%)	0.002	0.006
haemorrhagic stroke 70 (0.6%) 110 (0.9%) 50 (0.7%) 60 (0.8%) 0.029 0.011 Prior systemic embolism 60 (0.5%) 140 (1.2%) 50 (0.7%) 60 (0.8%) 0.070 0.008 Prior systemic embolism 430 (4.1%) 460 (3.9%) 330 (4.5%) 310 (4.3%) 0.012 0.013 Chronic kidney disease 580 (5.5%) 1,560 (13.1%) 550 (7.5%) 630 (8.7%) 0.263 0.043 Heart failure 1,600 (15.2%) 3,110 (26.0%) 1,360 (18.7%) 1,380 (19.0%) 0.271 0.006 Coronary artery disease 2,510 (23.8%) 4,410 (36.9%) 2,040 (28.1%) 2,080 (28.6%) 0.288 0.012 Peripheral arterial disease 970 (9.2%) 1,370 (11.5%) 720 (9.9%) 730 (10.1%) 0.076 0.004 Hypertension 6,260 (59.2%) 7,270 (60.8%) 4,380 (60.2%) 4,400 (60.5%) 0.032 0.006 Diabetes 1,490 (14.1%) 2,100 (17.6%) 1,110 (15.2%) 1,120 (15.4%) 0.097 0.002 Obstructive pulmonary disease 14	stroke	1,230 (11.6%)	1,380 (11.5%)	910 (12.5%)	920 (12.7%)	0.001	0.005
embolism 60 (0.5%) 140 (1.2%) 50 (0.7%) 60 (0.8%) 0.070 0.008 Prior transient ischaemic attack 430 (4.1%) 460 (3.9%) 330 (4.5%) 310 (4.3%) 0.012 0.013 Chronic kidney disease 580 (5.5%) 1,560 (13.1%) 550 (7.5%) 630 (8.7%) 0.263 0.043 Heart failure 1,600 (15.2%) 3,110 (26.0%) 1,360 (18.7%) 1,380 (19.0%) 0.271 0.006 Coronary artery disease 2,510 (23.8%) 4,410 (36.9%) 2,040 (28.1%) 2,080 (28.6%) 0.288 0.012 Peripheral arterial disease 970 (9.2%) 1,370 (11.5%) 720 (9.9%) 730 (10.1%) 0.076 0.004 Hypertension 6,260 (59.2%) 7,270 (60.8%) 4,380 (60.2%) 4,400 (60.5%) 0.032 0.006 Diabetes 1,490 (14.1%) 2,100 (17.6%) 1,110 (15.2%) 1,120 (15.4%) 0.097 0.002 Obstructive pulmonary disease 1,430 (13.5%) 1,850 (15.5%) 1,030 (14.2%) 1,040 (14.3%) 0.057 0.002 Liver disease <td< td=""><td>haemorrhagic stroke</td><td>70 (0.6%)</td><td>110 (0.9%)</td><td>50 (0.7%)</td><td>60 (0.8%)</td><td>0.029</td><td>0.011</td></td<>	haemorrhagic stroke	70 (0.6%)	110 (0.9%)	50 (0.7%)	60 (0.8%)	0.029	0.011
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	embolism	60 (0.5%)	140 (1.2%)	50 (0.7%)	60 (0.8%)	0.070	0.008
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ischaemic attack	430 (4.1%)	460 (3.9%)	330 (4.5%)	310 (4.3%)	0.012	0.013
Coronary artery disease2,510 (23.8%)4,410 (36.9%)2,040 (28.1%)2,080 (28.6%)0.2880.012Peripheral arterial disease970 (9.2%)1,370 (11.5%)720 (9.9%)730 (10.1%)0.0760.004Hypertension6,260 (59.2%)7,270 (60.8%)4,380 (60.2%)4,400 (60.5%)0.0320.006Diabetes1,490 (14.1%)2,100 (17.6%)1,110 (15.2%)1,120 (15.4%)0.0970.005Chronic obstructive pulmonary disease1,430 (13.5%)1,850 (15.5%)1,030 (14.2%)1,040 (14.3%)0.0570.002Liver disease110 (1.0%)150 (1.3%)80 (1.0%)90 (1.2%)0.0260.012Alcoholism250 (2.3%)170 (1.4%)140 (1.9%)140 (1.9%)0.0670.002	disease	. ,	,		. ,		
disease 2,310 (23.8%) 4,410 (36.9%) 2,040 (28.1%) 2,080 (28.6%) 0.0288 0.012 Peripheral arterial disease 970 (9.2%) 1,370 (11.5%) 720 (9.9%) 730 (10.1%) 0.076 0.004 Hypertension 6,260 (59.2%) 7,270 (60.8%) 4,380 (60.2%) 4,400 (60.5%) 0.032 0.006 Diabetes 1,490 (14.1%) 2,100 (17.6%) 1,110 (15.2%) 1,120 (15.4%) 0.097 0.005 Chronic obstructive pulmonary disease 1,430 (13.5%) 1,850 (15.5%) 1,030 (14.2%) 1,040 (14.3%) 0.057 0.002 Liver disease 110 (1.0%) 150 (1.3%) 80 (1.0%) 90 (1.2%) 0.026 0.012 Alcoholism 250 (2.3%) 170 (1.4%) 140 (1.9%) 140 (1.9%) 0.067 0.002		1,600 (15.2%)	3,110 (26.0%)	1,360 (18.7%)	1,380 (19.0%)	0.271	0.006
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		2,510 (23.8%)	4,410 (36.9%)	2,040 (28.1%)	2,080 (28.6%)	0.288	0.012
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		970 (9.2%)	1,370 (11.5%)	720 (9.9%)	730 (10.1%)	0.076	0.004
Diabetes 1,490 (14.1%) 2,100 (17.6%) 1,110 (15.2%) 1,120 (15.4%) 0.097 0.005 Chronic obstructive pulmonary disease 1,430 (13.5%) 1,850 (15.5%) 1,030 (14.2%) 1,040 (14.3%) 0.057 0.002 Liver disease 110 (1.0%) 150 (1.3%) 80 (1.0%) 90 (1.2%) 0.026 0.012 Alcoholism 250 (2.3%) 170 (1.4%) 140 (1.9%) 140 (1.9%) 0.067 0.002	Hypertension	6,260 (59.2%)	7,270 (60.8%)	4,380 (60.2%)	4,400 (60.5%)	0.032	0.006
Chronic obstructive pulmonary disease 1,430 (13.5%) 1,850 (15.5%) 1,030 (14.2%) 1,040 (14.3%) 0.057 0.002 Liver disease 110 (1.0%) 150 (1.3%) 80 (1.0%) 90 (1.2%) 0.026 0.012 Alcoholism 250 (2.3%) 170 (1.4%) 140 (1.9%) 140 (1.9%) 0.067 0.002	Diabetes						0.005
Liver disease 110 (1.0%) 150 (1.3%) 80 (1.0%) 90 (1.2%) 0.026 0.012 Alcoholism 250 (2.3%) 170 (1.4%) 140 (1.9%) 140 (1.9%) 0.067 0.002	Chronic obstructive pulmonary						
Alcoholism 250 (2.3%) 170 (1.4%) 140 (1.9%) 140 (1.9%) 0.067 0.002		110 (1.0%)	150 (1.3%)	80 (1.0%)	90 (1.2%)	0.026	0.012
			· /		· · · · · ·		
	Dementia	180 (1.7%)	230 (1.9%)	140 (1.9%)	140 (1.9%)	0.007	0.002

		r	r			
Cancer 6 months before and including index date	640 (6.0%)	810 (6.8%)	480 (6.6%)	480 (6.5%)	0.029	0.002
Platelet inhibitors (excluding heparin)	4,450 (42.1%)	5,400 (45.2%)	3,160 (43.5%)	3,120 (42.9%)	0.061	0.012
Low -dose aspirin	4,270 (40.4%)	5,060 (42.4%)	3,000 (41.3%)	2,950 (40.6%)	0.039	0.016
ADP receptor blockers	330 (3.1%)	1,130 (9.5%)	320 (4.4%)	360 (4.9%)	0.264	0.025
Renin - angiotensin system inhibitors	4,430 (42.0%)	5,500 (46.0%)	3,090 (42.6%)	3,130 (43.0%)	0.082	0.009
Angiotensin - converting enzyme inhibitors	1,390 (13.2%)	2,500 (20.9%)	1,130 (15.6%)	1,130 (15.6%)	0.207	0.000
Angiotensin II antagonists, plain	1,460 (13.8%)	1,640 (13.7%)	990 (13.6%)	1,010 (13.8%)	0.003	0.008
Angiotensin II antagonists, combinations	1,600 (15.1%)	1,450 (12.2%)	990 (13.6%)	990 (13.7%)	0.087	0.002
Beta-blockers	6,730 (63.7%)	8,410 (70.4%)	4,780 (65.8%)	4,810 (66.1%)	0.143	0.007
Proton pump inhibitors	1,990 (18.8%)	2,690 (22.5%)	1,450 (20.0%)	1,480 (20.3%)	0.092	0.009
H2-receptor antagonists	150 (1.4%)	170 (1.4%)	100 (1.4%)	100 (1.3%)	0.005	0.005
Non-steroidal anti- inflammatory	960 (9.1%)	910 (7.6%)	630 (8.6%)	590 (8.1%)	0.053	0.018
drugs	2 800 (26 00/)	5 020 (42 0%)	2 720 (27 (0))	2760 (28.0%)	0.122	0.009
Statins Antidiabetic	3,800 (36.0%)	5,020 (42.0%)	2,730 (37.6%)	2,760 (38.0%)	0.123	0.008
agents	1,000 (9.5%)	1,400 (11.7%)	740 (10.2%)	750 (10.3%)	0.074	0.005
Loop diuretics Non-loop	1,760 (16.6%)	3,390 (28.4%)	1,490 (20.5%)	1,510 (20.8%)	0.285	0.007
diuretics	150 (1.4%)	230 (1.9%)	110 (1.6%)	110 (1.5%)	0.039	0.004
Alpha adrenergic blockers	610 (5.8%)	960 (8.0%)	470 (6.4%)	480 (6.6%)	0.089	0.009
Amiodarone	230 (2.1%)	700 (5.9%)	210 (2.9%)	220 (3.1%)	0.191	0.008
Dronedarone Antihypertensive	70 (0.7%)	130 (1.1%)	60 (0.9%)	60 (0.8%)	0.046	0.003
, combination drugs	1,850 (17.5%)	1,740 (14.6%)	1,170 (16.1%)	1,190 (16.3%)	0.080	0.006
Calcium channel blockers	2,190 (20.8%)	2,640 (22.1%)	1,560 (21.5%)	1,540 (21.2%)	0.033	0.007
Selective serotonin reuptake inhibitors	490 (4.6%)	530 (4.5%)	350 (4.8%)	330 (4.6%)	0.007	0.011
Drugs used in alcohol dependence	20 (0.2%)	20 (0.1%)	10 (0.2%)	10 (0.2%)	0.016	0.007
CHA2DS2- VASc, mean(SD)	2.9 (1.70)	3.3 (1.86)	3.1 (1.74)	3.1 (1.82)	0.185	0.009
CHA2DS2- VASc:0 -1	2,220 (21.0%)	2,240 (18.7%)	1,340 (18.5%)	1,500 (20.6%)	0.056	0.053
CHA2DS2- VASc:2 -3	4,690 (44.4%)	4,370 (36.6%)	3,040 (41.8%)	2,840 (39.0%)	0.159	0.058
CHA2DS2- VASc:>=4	3,660 (34.6%)	5,340 (44.7%)	2,890 (39.7%)	2,940 (40.4%)	0.206	0.015
CHADS2, mean(SD)	1.4 (1.26)	1.7 (1.35)	1.6 (1.29)	1.6 (1.33)	0.192	0.012
CHADS2:0	2,770 (26.2%)	2,530 (21.1%)	1,590 (21.9%)	1,770 (24.4%)	0.119	0.058
CHADS2:1	3,470 (32.8%)	3,480 (29.1%)	2,320 (31.9%)	2,210 (30.4%)	0.080	0.031
CHADS2:>=2 HAS-BLED,	4,330 (41.0%)	5,940 (49.7%)	3,360 (46.3%)	3,290 (45.2%)	0.176	0.021
mean(SD)	2.0 (1.15)	2.1 (1.26)	2.1 (1.18)	2.1 (1.23)	0.132	0.004
HAS-BLED:<3	7,350 (69.6%)	7,410 (62.0%)	4,850 (66.8%)	4,690 (64.6%)	0.160	0.046

HAS-BLED:>=3	3,210 (30.4%)	4,540 (38.0%)	2,420 (33.2%)	2,580 (35.4%)	0.160	0.046
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.341	0.015
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.057	0.008
log_n_outpatient , median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.066	0.015




Table 15.42 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Sweden

			1			
	Rivaroxaban (ro	Warfarin (round	Rivaroxaban (ro	Warfarin (round	Standardised me	Standardised me
CI () ()	unded) before	ed) before	unded) after	ed) after	an	an
Characteristic	matching	matching	matching	matching	difference	difference
	N=14333	N=47152	N=12794	N=12794	before matching $(max = 0.80)$	after matching (max= 0.04)
index	1 000 (12 20/)	22,380 (47.5%)	1 200 (14 20/)	1.040 (15.20()	(max = 0.80) 0.803	$(\max = 0.04)$ 0.010
index_year:2013 index_year:2014	1,900 (13.2%)		1,890 (14.8%)	1,940 (15.2%)	0.803	0.010
	3,810 (26.6%)	14,490 (30.7%)	3,810 (29.8%)	3,700 (28.9%)		
index_year:2015	4,740 (33.1%)	7,040 (14.9%)	4,480 (35.0%)	4,500 (35.2%)	0.434	0.004
index_year:2016	3,890 (27.1%)	3,240 (6.9%)	2,620 (20.5%)	2,660 (20.8%)	0.560	0.008
Time from AF diag:< 1 month	8,440 (58.9%)	28,530 (60.5%)	7,660 (59.9%)	7,630 (59.6%)	0.033	0.005
Time from AF diag:1 - 6 month	1,310 (9.1%)	4,220 (9.0%)	1,140 (8.9%)	1,190 (9.3%)	0.005	0.013
Time from AF diag:6 - 60	4,590 (32.0%)	14,400 (30.5%)	3,990 (31.2%)	3,980 (31.1%)	0.032	0.002
months	5 450 (45 00))		5 500 (11 50)		0.040	0.007
Sex:Female	6,450 (45.0%)	20,290 (43.0%)	5,720 (44.7%)	5,760 (45.0%)	0.040	0.005
Sex:Male	7,880 (55.0%)	26,860 (57.0%)	7,070 (55.3%)	7,040 (55.0%)	0.040	0.005
Age, median(IQR)	74.9 (67.8 - 82.5)	75.6 (68.4 - 82.6)	75.1 (68.0 - 82.6)	75.3 (68.2 - 82.7)	0.015	0.012
Age -group:< 55 years	590 (4.1%)	2,130 (4.5%)	540 (4.3%)	510 (3.9%)	0.021	0.015
Age -group:55- <65 years	1,740 (12.1%)	5,540 (11.8%)	1,520 (11.9%)	1,590 (12.5%)	0.012	0.018
Age -group:65- <75 years	4,910 (34.2%)	14,880 (31.6%)	4,280 (33.5%)	4,170 (32.6%)	0.057	0.019
Age -group:75- <85 years	4,610 (32.2%)	16,570 (35.1%)	4,190 (32.8%)	4,200 (32.8%)	0.063	0.001
Age -group:>= 85 years	2,490 (17.3%)	8,030 (17.0%)	2,260 (17.6%)	2,320 (18.2%)	0.008	0.014
CCI-group:0	6,250 (43.6%)	17,670 (37.5%)	5,470 (42.8%)	5,310 (41.5%)	0.126	0.025
CCI-group:1-2	4,730 (33.0%)	15,790 (33.5%)	4,240 (33.1%)	4,260 (33.3%)	0.010	0.004
CCI-group:>=3	3,350 (23.4%)	13,700 (29.0%)	3,090 (24.1%)	3,220 (25.2%)	0.129	0.024
Prior bleeding (any)	1,510 (10.5%)	5,150 (10.9%)	1,360 (10.6%)	1,390 (10.8%)	0.012	0.007
Prior gastrointestinal bleeding	80 (0.5%)	360 (0.8%)	70 (0.5%)	80 (0.6%)	0.028	0.009
Prior intracranial bleeding	180 (1.3%)	410 (0.9%)	160 (1.2%)	150 (1.2%)	0.039	0.004
Prior stroke (any)	1,860 (12.9%)	6,200 (13.1%)	1,660 (13.0%)	1,700 (13.3%)	0.006	0.009
Prior ischaemic stroke	1,790 (12.5%)	6,080 (12.9%)	1,610 (12.6%)	1,650 (12.9%)	0.013	0.009
Prior haemorrhagic stroke	150 (1.1%)	330 (0.7%)	130 (1.0%)	120 (0.9%)	0.039	0.006
Prior systemic embolism	120 (0.9%)	510 (1.1%)	120 (0.9%)	130 (1.0%)	0.024	0.009
Prior transient ischaemic attack	610 (4.3%)	2,050 (4.3%)	540 (4.2%)	530 (4.1%)	0.004	0.005
Chronic kidney disease	390 (2.7%)	3,280 (7.0%)	380 (3.0%)	410 (3.2%)	0.200	0.010
Heart failure	2,710 (18.9%)	11,330 (24.0%)	2,530 (19.8%)	2,560 (20.0%)	0.125	0.006
Coronary artery disease	2,890 (20.1%)	12,460 (26.4%)	2,720 (21.2%)	2,810 (21.9%)	0.149	0.017
Peripheral arterial disease	720 (5.0%)	3,030 (6.4%)	660 (5.2%)	700 (5.5%)	0.062	0.013
Hypertension	10,250 (71.5%)	34,570 (73.3%)	9,200 (71.9%)	9,260 (72.4%)	0.040	0.010
Diabetes	2,540 (17.7%)	9,090 (19.3%)	2,290 (17.9%)	2,340 (18.3%)	0.040	0.012
Chronic obstructive pulmonary disease	1,660 (11.6%)	5,700 (12.1%)	1,500 (11.7%)	1,520 (11.9%)	0.016	0.005
	110 (0.8%)	430 (0.9%)	100 (0.8%)	110 (0.9%)	0.016	0.008
Liver disease						
Liver disease Alcoholism	370 (2.6%)	1,030 (2.2%)	320 (2.5%)	330 (2.6%)	0.026	0.005

0 1						
Cancer 6 months before and including index date	100 (0.7%)	400 (0.9%)	90 (0.7%)	100 (0.8%)	0.021	0.005
Platelet inhibitors (excluding heparin)	5,700 (39.8%)	18,680 (39.6%)	5,110 (39.9%)	5,200 (40.6%)	0.004	0.015
Low -dose aspirin	5,140 (35.9%)	17,010 (36.1%)	4,610 (36.0%)	4,690 (36.7%)	0.004	0.014
ADP receptor blockers	840 (5.9%)	3,710 (7.9%)	790 (6.1%)	820 (6.4%)	0.078	0.010
Renin - angiotensin system inhibitors	6,880 (48.0%)	24,140 (51.2%)	6,220 (48.6%)	6,250 (48.9%)	0.064	0.005
Angiotensin - converting enzyme inhibitors	3,370 (23.5%)	13,490 (28.6%)	3,130 (24.5%)	3,100 (24.2%)	0.116	0.006
Angiotensin II antagonists, plain	2,460 (17.1%)	8,000 (17.0%)	2,200 (17.2%)	2,230 (17.4%)	0.004	0.006
Angiotensin II antagonists, combinations	910 (6.3%)	2,540 (5.4%)	780 (6.1%)	820 (6.4%)	0.041	0.012
Beta-blockers	10,580 (73.8%)	36,150 (76.7%)	9,530 (74.5%)	9,470 (74.0%)	0.066	0.011
Proton pump inhibitors	2,900 (20.2%)	10,150 (21.5%)	2,640 (20.6%)	2,650 (20.7%)	0.033	0.002
H2-receptor antagonists	60 (0.4%)	210 (0.4%)	50 (0.4%)	60 (0.5%)	0.004	0.005
Non-steroidal anti- inflammatory drugs	880 (6.1%)	2,970 (6.3%)	770 (6.0%)	790 (6.1%)	0.008	0.005
Statins	4,560 (31.8%)	16,730 (35.5%)	4,170 (32.6%)	4,190 (32.7%)	0.077	0.004
Antidiabetic agents	1,780 (12.4%)	6,350 (13.5%)	1,590 (12.4%)	1,650 (12.9%)	0.032	0.015
Loop diuretics	3,060 (21.4%)	12,990 (27.5%)	2,860 (22.3%)	2,940 (23.0%)	0.144	0.015
Non-loop diuretics	140 (1.0%)	650 (1.4%)	130 (1.0%)	150 (1.1%)	0.036	0.012
Alpha adrenergic blockers	3,270 (22.8%)	11,180 (23.7%)	2,950 (23.1%)	3,000 (23.4%)	0.021	0.008
Amiodarone	130 (0.9%)	890 (1.9%)	130 (1.0%)	120 (1.0%)	0.081	0.005
Dronedarone	70 (0.5%)	440 (0.9%)	70 (0.5%)	70 (0.6%)	0.053	0.006
Antihypertensiv e, combination drugs	1,360 (9.5%)	3,850 (8.2%)	1,180 (9.2%)	1,230 (9.6%)	0.047	0.014
Calcium channel blockers	3,470 (24.2%)	12,240 (26.0%)	3,120 (24.4%)	3,200 (25.0%)	0.041	0.015
Selective serotonin reuptake inhibitors	1,000 (7.0%)	3,110 (6.6%)	880 (6.9%)	870 (6.8%)	0.015	0.002
Drugs used in alcohol dependence	20 (0.2%)	60 (0.1%)	20 (0.2%)	20 (0.2%)	0.009	0.000
CHA2DS2- VASc, mean(SD)	3.4 (1.73)	3.6 (1.75)	3.4 (1.73)	3.5 (1.74)	0.095	0.020
CHA2DS2- VASc:0 -1	1,940 (13.5%)	5,700 (12.1%)	1,670 (13.1%)	1,650 (12.9%)	0.042	0.005
CHA2DS2- VASc:2 -3	5,860 (40.9%)	17,540 (37.2%)	5,170 (40.4%)	4,990 (39.0%)	0.075	0.029
CHA2DS2- VASc:>=4	6,540 (45.6%)	23,910 (50.7%)	5,950 (46.5%)	6,150 (48.1%)	0.102	0.032
CHADS2, mean(SD)	2.7 (1.46)	2.9 (1.47)	2.8 (1.46)	2.8 (1.47)	0.082	0.014
CHADS2:0	640 (4.4%)	2,300 (4.9%)	550 (4.3%)	670 (5.3%)	0.021	0.044
CHADS2:1	2,260 (15.8%)	6,040 (12.8%)	1,960 (15.3%)	1,770 (13.9%)	0.085	0.041
CHADS2:>=2	11,430 (79.8%)	38,810 (82.3%)	10,290 (80.4%)	10,350 (80.9%)	0.065	0.012
HAS-BLED, mean(SD)	1.9 (0.87)	1.9 (0.92)	1.9 (0.87)	1.9 (0.89)	0.079	0.009

HAS-BLED:<3	11,460 (80.0%)	36,080 (76.5%)	10,190 (79.6%)	10,100 (78.9%)	0.084	0.018
HAS- BLED:>=3	2,870 (20.0%)	11,080 (23.5%)	2,600 (20.4%)	2,700 (21.1%)	0.084	0.018
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.186	0.017
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.062	0.011
log_n_outpatient , median(IQR)	0.7 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.252	0.008
income, median(IQR), k€	52.1 (41.9 - 78.9)	49.8 (40.5 - 72.3)	51.6 (41.8 - 77.0)	51.4 (41.5 - 77.2)	0.056	0.001
education:Secon dary compulsory	5,350 (37.3%)	18,850 (40.0%)	4,840 (37.8%)	4,850 (37.9%)	0.055	0.002
education:Vocat ional / High school	5,470 (38.2%)	18,480 (39.2%)	4,950 (38.7%)	4,950 (38.7%)	0.021	0.000
education:Highe r education	3,340 (23.3%)	9,340 (19.8%)	2,850 (22.3%)	2,840 (22.2%)	0.085	0.002
education:Unkn own	180 (1.2%)	490 (1.0%)	160 (1.2%)	160 (1.3%)	0.018	0.003




Table 15.43 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – STANDARD DOSE

Characteristic	Apixaban (roun ded) before matching N=50310	Warfarin (round ed) before matching N=79171	Apixaban (roun ded) after matching N=42672	Warfarin (round ed) after matching N=42672	Standardised m ean difference before matching (max= 0.29)	Standardised m ean difference after matching (max= 0.03)
Time from AF diag:< 1 month	35,640 (70.8%)	47,550 (60.1%)	28,930 (67.8%)	28,860 (67.6%)	0.228	0.003
Time from AF diag:1 - 6 month	3,980 (7.9%)	7,970 (10.1%)	3,660 (8.6%)	3,670 (8.6%)	0.075	0.001
Time from AF diag:6 - 60 months	10,690 (21.2%)	23,650 (29.9%)	10,090 (23.6%)	10,140 (23.8%)	0.199	0.003
Sex:Female	20,060 (39.9%)	32,980 (41.7%)	16,980 (39.8%)	16,790 (39.3%)	0.036	0.009
Sex:Male	30,250 (60.1%)	46,190 (58.3%)	25,700 (60.2%)	25,880 (60.7%)	0.036	0.009
Age, median(IQR)	71.8 (65.8 - 77.8)	75.0 (67.5 - 82.2)	72.2 (65.9 - 78.5)	72.1 (66.0 - 78.4)	0.266	0.006
Age -group:< 55 years	3,220 (6.4%)	4,480 (5.7%)	2,740 (6.4%)	2,640 (6.2%)	0.031	0.010
Age -group:55- <65 years	7,990 (15.9%)	10,100 (12.8%)	6,620 (15.5%)	6,730 (15.8%)	0.089	0.007
Age -group:65- <75 years	20,970 (41.7%)	25,060 (31.6%)	16,810 (39.4%)	16,980 (39.8%)	0.209	0.008
Age -group:75- <85 years	14,600 (29.0%)	26,700 (33.7%)	13,010 (30.5%)	12,920 (30.3%)	0.102	0.004
Age -group:>= 85 years	3,550 (7.0%)	12,830 (16.2%)	3,490 (8.2%)	3,390 (7.9%)	0.289	0.009
CCI-group:0	22,970 (45.7%)	29,610 (37.4%)	18,970 (44.5%)	19,220 (45.0%)	0.168	0.012
CCI-group:1-2	17,280 (34.4%)	25,600 (32.3%)	14,710 (34.5%)	14,180 (33.2%)	0.043	0.026
CCI-group:>=3	10,060 (20.0%)	23,960 (30.3%)	9,000 (21.1%)	9,280 (21.7%)	0.239	0.016
Prior bleeding (any)	4,670 (9.3%)	8,870 (11.2%)	4,080 (9.6%)	4,070 (9.5%)	0.063	0.000
Prior gastrointestinal bleeding	340 (0.7%)	820 (1.0%)	320 (0.7%)	330 (0.8%)	0.040	0.004
Prior intracranial bleeding	450 (0.9%)	710 (0.9%)	380 (0.9%)	370 (0.9%)	0.000	0.002
Prior stroke (any)	5,800 (11.5%)	9,610 (12.1%)	4,930 (11.6%)	4,910 (11.5%)	0.019	0.002
Prior ischaemic stroke	5,630 (11.2%)	9,400 (11.9%)	4,790 (11.2%)	4,770 (11.2%)	0.021	0.002
Prior haemorrhagic stroke	340 (0.7%)	520 (0.7%)	300 (0.7%)	300 (0.7%)	0.002	0.001
Prior systemic embolism	220 (0.4%)	760 (1.0%)	210 (0.5%)	200 (0.5%)	0.063	0.003
Prior transient ischaemic attack	1,840 (3.7%)	3,120 (3.9%)	1,580 (3.7%)	1,540 (3.6%)	0.015	0.006
Chronic kidney disease	1,170 (2.3%)	6,530 (8.2%)	1,150 (2.7%)	1,150 (2.7%)	0.267	0.000
Heart failure	7,480 (14.9%)	18,010 (22.7%)	6,870 (16.1%)	6,870 (16.1%)	0.203	0.000
Coronary artery disease	9,310 (18.5%)	21,450 (27.1%)	8,480 (19.9%)	8,490 (19.9%)	0.206	0.000
Peripheral arterial disease	2,990 (5.9%)	6,030 (7.6%)	2,540 (6.0%)	2,580 (6.0%)	0.067	0.004
Hypertension	32,380 (64.4%)	54,110 (68.3%)	27,810 (65.2%)	27,900 (65.4%)	0.084	0.004
Diabetes	8,010 (15.9%)	14,680 (18.5%)	7,020 (16.4%)	7,050 (16.5%)	0.069	0.002
Chronic obstructive pulmonary disease	5,730 (11.4%)	10,120 (12.8%)	4,950 (11.6%)	4,880 (11.4%)	0.043	0.005
Liver disease	410 (0.8%)	820 (1.0%)	370 (0.9%)	380 (0.9%)	0.022	0.002
Alcoholism	1,380 (2.7%)	1,790 (2.3%)	1,130 (2.6%)	1,110 (2.6%)	0.031	0.002
Dementia	630 (1.3%)	1,220 (1.5%)	550 (1.3%)	560 (1.3%)	0.024	0.002

Cancer 6 months before and including index date	1,200 (2.4%)	2,140 (2.7%)	1,010 (2.4%)	970 (2.3%)	0.020	0.005
Platelet inhibitors (excluding heparin)	16,790 (33.4%)	30,840 (39.0%)	14,630 (34.3%)	14,850 (34.8%)	0.117	0.011
Low -dose aspirin	14,950 (29.7%)	27,180 (34.3%)	12,960 (30.4%)	13,160 (30.8%)	0.099	0.010
ADP receptor	2,630 (5.2%)	7,100 (9.0%)	2,510 (5.9%)	2,540 (6.0%)	0.146	0.003
blockers Renin - angiotensin system inhibitors	23,250 (46.2%)	38,070 (48.1%)	19,790 (46.4%)	19,790 (46.4%)	0.037	0.000
Angiotensin - converting enzyme inhibitors	10,680 (21.2%)	20,500 (25.9%)	9,640 (22.6%)	9,680 (22.7%)	0.110	0.002
Angiotensin II antagonists, plain	7,790 (15.5%)	11,850 (15.0%)	6,440 (15.1%)	6,410 (15.0%)	0.014	0.002
Angiotensin II antagonists, combinations	4,410 (8.8%)	5,210 (6.6%)	3,360 (7.9%)	3,330 (7.8%)	0.082	0.002
Beta-blockers	36,420 (72.4%)	56,980 (72.0%)	30,860 (72.3%)	30,860 (72.3%)	0.009	0.000
Proton pump inhibitors	9,670 (19.2%)	17,350 (21.9%)	8,300 (19.4%)	8,250 (19.3%)	0.066	0.003
Non-steroidal anti- inflammatory	4,370 (8.7%)	5,860 (7.4%)	3,560 (8.3%)	3,580 (8.4%)	0.047	0.001
drugs Statins	17,400 (34.6%)	28,740 (36.3%)	14,770 (34.6%)	14,820 (34.7%)	0.036	0.002
Antidiabetic	5,840 (11.6%)	10,410 (13.1%)	5,090 (11.9%)	5,120 (12.0%)	0.047	0.002
agents Loop diuretics	8,470 (16.8%)	22,170 (28.0%)	7,970 (18.7%)	7,910 (18.5%)	0.270	0.004
Non-loop diuretics	630 (1.3%)	1,230 (1.6%)	550 (1.3%)	530 (1.2%)	0.026	0.005
Alpha adrenergic blockers	8,390 (16.7%)	15,810 (20.0%)	7,620 (17.9%)	7,610 (17.8%)	0.085	0.001
Amiodarone	1,120 (2.2%)	2,560 (3.2%)	1,050 (2.5%)	1,030 (2.4%)	0.062	0.004
Dronedarone	620 (1.2%)	600 (0.8%)	430 (1.0%)	440 (1.0%)	0.048	0.002
Antihypertensiv e, combination drugs	5,990 (11.9%)	7,700 (9.7%)	4,730 (11.1%)	4,730 (11.1%)	0.070	0.000
Calcium channel blockers	11,570 (23.0%)	19,680 (24.9%)	9,950 (23.3%)	10,050 (23.5%)	0.044	0.005
Selective serotonin reuptake inhibitors	2,690 (5.3%)	4,790 (6.1%)	2,360 (5.5%)	2,290 (5.4%)	0.031	0.007
Drugs used in alcohol dependence	100 (0.2%)	120 (0.2%)	70 (0.2%)	80 (0.2%)	0.010	0.003
CHA2DS2- VASc, mean(SD)	2.9 (1.64)	3.4 (1.76)	3.0 (1.65)	3.0 (1.68)	0.276	0.006
CHA2DS2- VASc:0 -1	10,050 (20.0%)	11,520 (14.6%)	7,990 (18.7%)	8,170 (19.1%)	0.144	0.011
CHA2DS2- VASc:2 -3	23,000 (45.7%)	30,330 (38.3%)	19,140 (44.9%)	18,890 (44.3%)	0.151	0.012
VASC:2-3 CHA2DS2- VASc:>=4	17,260 (34.3%)	37,330 (47.1%)	15,540 (36.4%)	15,610 (36.6%)	0.263	0.004
CHADS2, mean(SD)	2.0 (1.42)	2.4 (1.51)	2.1 (1.42)	2.1 (1.43)	0.272	0.007
CHADS2:0	7,580 (15.1%)	8,300 (10.5%)	5,510 (12.9%)	5,880 (13.8%)	0.138	0.025
CHADS2:1	13,200 (26.2%)	15,840 (20.0%)	10,820 (25.3%)	10,380 (24.3%)	0.148	0.024
CHADS2:>=2 HAS-BLED,	29,530 (58.7%) 1.8 (1.00)	55,030 (69.5%) 2.0 (1.05)	26,350 (61.7%) 1.8 (1.00)	26,420 (61.9%) 1.8 (1.01)	0.227	0.003
mean(SD)		. ,	. ,	· · · ·		
HAS-BLED:<3	39,110 (77.7%)	56,150 (70.9%)	32,920 (77.2%)	32,770 (76.8%)	0.156	0.009

HAS- BLED:>=3	11,200 (22.3%)	23,020 (29.1%)	9,750 (22.8%)	9,900 (23.2%)	0.156	0.009
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.157	0.011
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.7 (0.0 - 1.6)	0.034	0.002
log_n_outpatien t, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.196	0.013

Table 15.44 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – REDUCED DOSE

			-			
Characteristic	Apixaban (roun ded) before matching N=21275	Warfarin (round ed) before matching N=79171	Apixaban (roun ded) after matching N=18794	Warfarin (round ed) after matching N=18794	Standardised me an difference before matching (max= 1.07)	Standardised me an difference after matching (max= 0.03)
Time from AF diag:< 1 month	13,600 (63.9%)	47,550 (60.1%)	11,900 (63.3%)	11,830 (62.9%)	0.079	0.008
Time from AF diag:1 - 6 month	2,200 (10.3%)	7,970 (10.1%)	1,980 (10.6%)	2,020 (10.8%)	0.009	0.007
Time from AF diag:6 - 60 months	5,480 (25.8%)	23,650 (29.9%)	4,910 (26.1%)	4,940 (26.3%)	0.092	0.004
Sex:Female	12,850 (60.4%)	32,980 (41.7%)	10,900 (58.0%)	10,790 (57.4%)	0.382	0.012
Sex:Male	8,420 (39.6%)	46,190 (58.3%)	7,900 (42.0%)	8,010 (42.6%)	0.382	0.012
Age, median(IQR)	85.4 (80.5 - 89.7)	75.0 (67.5 - 82.2)	84.5 (79.9 - 88.7)	84.5 (80.0 - 88.5)	1.066	0.001
Age -group:< 55 years	110 (0.5%)	4,480 (5.7%)	110 (0.6%)	100 (0.5%)	0.302	0.006
Age -group:55- <65 years	430 (2.0%)	10,100 (12.8%)	430 (2.3%)	410 (2.2%)	0.419	0.006
Age -group:65- <75 years	1,920 (9.0%)	25,060 (31.6%)	1,920 (10.2%)	1,880 (10.0%)	0.586	0.007
Age -group:75- <85 years	7,730 (36.3%)	26,700 (33.7%)	7,530 (40.1%)	7,640 (40.7%)	0.055	0.012
Age -group:>= 85 years	11,090 (52.1%)	12,830 (16.2%)	8,810 (46.9%)	8,770 (46.6%)	0.818	0.005
CCI-group:0	5,440 (25.6%)	29,610 (37.4%)	5,000 (26.6%)	5,120 (27.2%)	0.256	0.014
CCI-group:1-2	7,260 (34.1%)	25,600 (32.3%)	6,440 (34.3%)	6,180 (32.9%)	0.038	0.030
CCI-group:>=3	8,570 (40.3%)	23,960 (30.3%)	7,350 (39.1%)	7,500 (39.9%)	0.211	0.016
Prior bleeding (any)	3,350 (15.7%)	8,870 (11.2%)	2,850 (15.2%)	2,860 (15.2%)	0.133	0.001
Prior gastrointestinal bleeding	330 (1.6%)	820 (1.0%)	280 (1.5%)	300 (1.6%)	0.047	0.009
Prior intracranial bleeding	450 (2.1%)	710 (0.9%)	340 (1.8%)	330 (1.7%)	0.100	0.005
Prior stroke (any)	4,250 (20.0%)	9,610 (12.1%)	3,480 (18.5%)	3,450 (18.3%)	0.214	0.005
Prior ischaemic stroke	4,110 (19.3%)	9,400 (11.9%)	3,380 (18.0%)	3,350 (17.8%)	0.206	0.004
Prior haemorrhagic stroke	350 (1.7%)	520 (0.7%)	260 (1.4%)	260 (1.4%)	0.094	0.000
Prior systemic embolism	180 (0.8%)	760 (1.0%)	170 (0.9%)	180 (1.0%)	0.014	0.007
Prior transient ischaemic attack	1,250 (5.9%)	3,120 (3.9%)	1,050 (5.6%)	1,020 (5.4%)	0.090	0.007
Chronic kidney disease	2,340 (11.0%)	6,530 (8.2%)	2,070 (11.0%)	2,200 (11.7%)	0.093	0.022
Heart failure	6,170 (29.0%)	18,010 (22.7%)	5,350 (28.5%)	5,350 (28.5%)	0.144	0.000
Coronary artery disease	6,270 (29.5%)	21,450 (27.1%)	5,640 (30.0%)	5,750 (30.6%)	0.053	0.013
Peripheral arterial disease	1,860 (8.7%)	6,030 (7.6%)	1,670 (8.9%)	1,690 (9.0%)	0.040	0.004
Hypertension	15,400 (72.4%)	54,110 (68.3%)	13,590 (72.3%)	13,670 (72.7%)	0.089	0.010
Diabetes	3,780 (17.7%)	14,680 (18.5%)	3,390 (18.0%)	3,470 (18.5%)	0.021	0.011
Chronic obstructive pulmonary disease	3,430 (16.1%)	10,120 (12.8%)	3,010 (16.0%)	3,070 (16.3%)	0.095	0.009
Liver disease	190 (0.9%)	820 (1.0%)	170 (0.9%)	170 (0.9%)	0.012	0.001
Alcoholism	390 (1.8%)	1,790 (2.3%)	350 (1.9%)	350 (1.8%)	0.029	0.001
Dementia	1,190 (5.6%)	1,220 (1.5%)	800 (4.3%)	770 (4.1%)	0.220	0.007
Cancer 6 months before and including index date	650 (3.0%)	2,140 (2.7%)	580 (3.1%)	610 (3.3%)	0.020	0.009

Platelet inhibitors (excluding heparin)	10,070 (47.3%)	30,840 (39.0%)	8,760 (46.6%)	8,900 (47.3%)	0.170	0.014
Low -dose aspirin	8,640 (40.6%)	27,180 (34.3%)	7,580 (40.3%)	7,690 (40.9%)	0.130	0.012
ADP receptor blockers	2,230 (10.5%)	7,100 (9.0%)	1,940 (10.3%)	2,010 (10.7%)	0.051	0.012
Renin - angiotensin system inhibitors	10,020 (47.1%)	38,070 (48.1%)	8,940 (47.6%)	8,920 (47.5%)	0.020	0.002
Angiotensin - converting enzyme inhibitors	5,210 (24.5%)	20,500 (25.9%)	4,660 (24.8%)	4,660 (24.8%)	0.032	0.001
Angiotensin II antagonists, plain	3,430 (16.1%)	11,850 (15.0%)	3,030 (16.1%)	2,980 (15.9%)	0.031	0.007
Angiotensin II antagonists, combinations	1,410 (6.6%)	5,210 (6.6%)	1,270 (6.8%)	1,290 (6.9%)	0.001	0.003
Beta-blockers	15,110 (71.0%)	56,980 (72.0%)	13,380 (71.2%)	13,380 (71.2%)	0.021	0.000
Proton pump inhibitors	5,960 (28.0%)	17,350 (21.9%)	5,080 (27.0%)	5,240 (27.9%)	0.142	0.019
Non-steroidal anti- inflammatory drugs	1,250 (5.9%)	5,860 (7.4%)	1,140 (6.0%)	1,130 (6.0%)	0.061	0.000
Statins	7,150 (33.6%)	28,740 (36.3%)	6,540 (34.8%)	6,610 (35.2%)	0.057	0.008
Antidiabetic agents	2,390 (11.2%)	10,410 (13.1%)	2,190 (11.6%)	2,240 (11.9%)	0.058	0.009
Loop diuretics	8,030 (37.7%)	22,170 (28.0%)	6,980 (37.2%)	7,040 (37.5%)	0.208	0.006
Non-loop	270 (1.3%)	1,230 (1.6%)	250 (1.3%)	270 (1.4%)	0.024	0.008
diuretics Alpha adrenergic blockers	4,150 (19.5%)	15,810 (20.0%)	3,730 (19.9%)	3,770 (20.0%)	0.024	0.005
Amiodarone	570 (2.7%)	2,560 (3.2%)	520 (2.8%)	530 (2.8%)	0.033	0.003
Dronedarone	60 (0.3%)	600 (0.8%)	50 (0.3%)	40 (0.2%)	0.068	0.016
Antihypertensiv e, combination drugs	1,940 (9.1%)	7,700 (9.7%)	1,760 (9.4%)	1,780 (9.5%)	0.020	0.003
Calcium channel blockers	5,430 (25.5%)	19,680 (24.9%)	4,800 (25.5%)	4,870 (25.9%)	0.015	0.008
Selective serotonin reuptake inhibitors	1,930 (9.1%)	4,790 (6.1%)	1,580 (8.4%)	1,550 (8.2%)	0.114	0.007
Drugs used in alcohol dependence	10 (0.1%)	120 (0.2%)	10 (0.1%)	10 (0.1%)	0.026	0.006
CHA2DS2- VASc, mean(SD)	4.4 (1.50)	3.4 (1.76)	4.3 (1.49)	4.3 (1.54)	0.619	0.006
CHA2DS2- VASc:0 -1	370 (1.7%)	11,520 (14.6%)	370 (2.0%)	450 (2.4%)	0.482	0.030
CHA2DS2- VASc:2 -3	5,430 (25.5%)	30,330 (38.3%)	5,040 (26.8%)	4,890 (26.0%)	0.276	0.018
CHA2DS2- VASc:>=4	15,470 (72.7%)	37,330 (47.1%)	13,380 (71.2%)	13,450 (71.6%)	0.541	0.008
CHADS2, mean(SD)	3.0 (1.44)	2.4 (1.51)	3.0 (1.43)	3.0 (1.44)	0.447	0.006
CHADS2:0	420 (2.0%)	8,300 (10.5%)	420 (2.3%)	440 (2.3%)	0.357	0.005
CHADS2:1 CHADS2:>=2	2,630 (12.4%) 18,220 (85.6%)	15,840 (20.0%) 55,030 (69.5%)	2,360 (12.6%) 16,010 (85.2%)	2,290 (12.2%) 16,060 (85.5%)	0.208 0.394	0.011 0.008
HAS-BLED, mean(SD)	2.4 (0.99)	2.0 (1.05)	2.4 (0.98)	2.4 (0.99)	0.394	0.008
HAS-BLED:<3	12,260 (57.6%)	56,150 (70.9%)	11,060 (58.8%)	10,960 (58.3%)	0.280	0.010
HAS- BLED:>=3	9,020 (42.4%)	23,020 (29.1%)	7,740 (41.2%)	7,830 (41.7%)	0.280	0.010
log_n_hosp,	1	1	ł			

log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.045	0.016
log_n_outpatien t, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.302	0.007

Table 15.45 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Denmark – STANDARD DOSE

					Standardised mea	Standardised mea
	Apixaban (round ed) before	Warfarin (rounde d) before	Apixaban (round ed) after	Warfarin (rounde	n	n
Characteristic	matching	matching	matching	d) after matching	difference	difference
	N= 9709	N=20070	N= 9373	N= 9373	before matching $(max=0.30)$	after matching (max= 0.06)
Time from AF					· · · · · · · · · · · · · · · · · · ·	
diag:< 1 month	6,950 (71.6%)	12,620 (62.9%)	6,660 (71.0%)	6,650 (70.9%)	0.187	0.003
Time from AF	1,100 (11.3%)	2,410 (12.0%)	1,070 (11.4%)	1,050 (11.2%)	0.022	0.006
diag:1 - 6 month	1,100 (11.5%)	2,410 (12.070)	1,070 (11.470)	1,050 (11.270)	0.022	0.000
Time from AF diag:6 - 60	1 660 (17 10/)	5,040 (25.1%)	1 650 (17 60()	1 690 (17 00/)	0.198	0.009
months	1,660 (17.1%)	3,040 (23.1%)	1,650 (17.6%)	1,680 (17.9%)	0.198	0.009
Sex:Female	3,860 (39.7%)	7,950 (39.6%)	3,710 (39.6%)	3,700 (39.5%)	0.002	0.001
Sex:Male	5,850 (60.3%)	12,120 (60.4%)	5,660 (60.4%)	5,670 (60.5%)	0.002	0.001
Age, median(IQR)	71.4 (65.5 - 77.1)	73.3 (66.1 - 80.6)	71.4 (65.5 - 77.3)	71.5 (65.7 - 77.2)	0.155	0.018
Age -group:< 55 years	630 (6.5%)	1,520 (7.6%)	620 (6.7%)	570 (6.0%)	0.043	0.025
Age -group:55- <65 years	1,600 (16.4%)	2,870 (14.3%)	1,550 (16.5%)	1,530 (16.3%)	0.059	0.006
Age -group:65- <75 years	4,230 (43.6%)	6,820 (34.0%)	4,000 (42.7%)	4,070 (43.4%)	0.198	0.014
Age -group:75- <85 years	2,640 (27.2%)	6,280 (31.3%)	2,590 (27.6%)	2,590 (27.7%)	0.089	0.001
Age -group:>= 85 years	610 (6.3%)	2,580 (12.9%)	610 (6.5%)	620 (6.6%)	0.226	0.005
CCI-group:0	4,490 (46.3%)	8,600 (42.8%)	4,400 (46.9%)	4,490 (47.9%)	0.069	0.020
CCI-group:1-2	3,420 (35.3%)	6,000 (29.9%)	3,260 (34.8%)	3,000 (32.0%)	0.114	0.058
CCI-group:>=3	1,790 (18.5%)	5,470 (27.2%)	1,720 (18.3%)	1,880 (20.1%)	0.210	0.044
Prior bleeding (any)	810 (8.3%)	1,940 (9.7%)	790 (8.4%)	780 (8.4%)	0.048	0.001
Prior						
gastrointestinal bleeding	80 (0.8%)	270 (1.4%)	80 (0.9%)	90 (0.9%)	0.051	0.007
Prior intracranial bleeding	90 (0.9%)	140 (0.7%)	90 (0.9%)	80 (0.9%)	0.025	0.002
Prior stroke (any)	1,430 (14.7%)	1,980 (9.8%)	1,240 (13.3%)	1,230 (13.1%)	0.149	0.005
Prior ischaemic stroke	1,400 (14.5%)	1,940 (9.7%)	1,220 (13.0%)	1,200 (12.8%)	0.147	0.005
Prior						
haemorrhagic stroke	60 (0.6%)	90 (0.4%)	60 (0.6%)	60 (0.6%)	0.031	0.001
Prior systemic embolism	40 (0.4%)	110 (0.5%)	40 (0.4%)	40 (0.4%)	0.024	0.005
Prior transient ischaemic attack	380 (3.9%)	600 (3.0%)	340 (3.6%)	320 (3.4%)	0.048	0.008
Chronic kidney disease	180 (1.8%)	1,690 (8.4%)	180 (1.9%)	160 (1.7%)	0.303	0.013
Heart failure	1,280 (13.2%)	3,570 (17.8%)	1,260 (13.4%)	1,300 (13.8%)	0.127	0.012
Coronary artery disease	1,540 (15.8%)	4,590 (22.9%)	1,510 (16.1%)	1,530 (16.3%)	0.179	0.006
Peripheral arterial disease	560 (5.7%)	1,630 (8.1%)	540 (5.8%)	560 (5.9%)	0.094	0.007
Hypertension	5,900 (60.7%)	12,270 (61.1%)	5,650 (60.3%)	5,710 (60.9%)	0.008	0.013
Diabetes	1,590 (16.4%)	3,490 (17.4%)	1,530 (16.3%)	1,540 (16.4%)	0.026	0.003
Chronic obstructive						
pulmonary disease	1,070 (11.0%)	2,570 (12.8%)	1,040 (11.1%)	1,070 (11.4%)	0.055	0.009
Liver disease	100 (1.0%)	240 (1.2%)	90 (1.0%)	100 (1.0%)	0.019	0.002
Alcoholism	340 (3.5%)	590 (2.9%)	310 (3.4%)	320 (3.4%)	0.033	0.004
Dementia	130 (1.3%)	220 (1.1%)	110 (1.2%)	120 (1.3%)	0.019	0.007
Cancer 6 months before and including index date	340 (3.5%)	930 (4.6%)	340 (3.6%)	320 (3.4%)	0.057	0.010

Platelet inhibitors (excluding heparin)	2,750 (28.3%)	6,760 (33.7%)	2,680 (28.6%)	2,740 (29.2%)	0.117	0.014
Low -dose aspirin	1,960 (20.2%)	5,110 (25.5%)	1,930 (20.6%)	2,000 (21.3%)	0.127	0.018
ADP receptor blockers	880 (9.1%)	2,260 (11.2%)	860 (9.1%)	850 (9.1%)	0.071	0.001
Renin - angiotensin system inhibitors	4,130 (42.5%)	8,420 (42.0%)	3,960 (42.3%)	3,950 (42.2%)	0.011	0.002
Angiotensin - converting enzyme inhibitors	1,980 (20.4%)	4,510 (22.5%)	1,930 (20.6%)	1,940 (20.7%)	0.050	0.003
Angiotensin II antagonists, plain	1,240 (12.8%)	2,220 (11.0%)	1,160 (12.4%)	1,120 (12.0%)	0.053	0.012
Angiotensin II antagonists, combinations	680 (7.0%)	1,210 (6.0%)	650 (7.0%)	640 (6.8%)	0.038	0.006
Beta-blockers	6,210 (64.0%)	12,420 (61.9%)	5,980 (63.8%)	5,990 (63.9%)	0.043	0.002
Proton pump inhibitors	1,850 (19.1%)	4,510 (22.5%)	1,790 (19.1%)	1,790 (19.1%)	0.084	0.001
Non-steroidal anti- inflammatory drugs	990 (10.2%)	1,980 (9.9%)	960 (10.2%)	990 (10.6%)	0.012	0.013
Statins	3,360 (34.6%)	6,990 (34.8%)	3,200 (34.1%)	3,230 (34.5%)	0.004	0.007
Antidiabetic	1,270 (13.1%)	2,650 (13.2%)	1,210 (12.9%)	1,220 (13.0%)	0.004	0.003
agents Loop diuretics	1,890 (19.5%)	5,800 (28.9%)	1,870 (20.0%)	1,880 (20.1%)	0.220	0.003
Non-loop diuretics	120 (1.2%)	350 (1.7%)	120 (1.2%)	120 (1.2%)	0.043	0.001
Alpha adrenergic blockers	1,590 (16.4%)	3,670 (18.3%)	1,550 (16.5%)	1,500 (16.0%)	0.050	0.014
Amiodarone	320 (3.3%)	970 (4.9%)	320 (3.4%)	310 (3.3%)	0.081	0.004
Dronedarone	10 (0.1%)	30 (0.1%)	10 (0.1%)	10 (0.1%)	0.013	0.008
Antihypertensive, combination drugs	1,120 (11.5%)	2,110 (10.5%)	1,070 (11.4%)	1,080 (11.5%)	0.031	0.002
Calcium channel blockers	2,160 (22.2%)	4,790 (23.9%)	2,090 (22.3%)	2,120 (22.6%)	0.040	0.007
Selective serotonin reuptake inhibitors	550 (5.7%)	1,150 (5.7%)	520 (5.5%)	490 (5.2%)	0.003	0.011
Drugs used in alcohol dependence	30 (0.3%)	50 (0.2%)	20 (0.2%)	30 (0.3%)	0.007	0.006
CHA2DS2- VASc, mean(SD)	3.0 (1.62)	3.1 (1.67)	2.9 (1.62)	2.9 (1.65)	0.091	0.008
CHA2DS2- VASc:0 -1	1,880 (19.4%)	3,580 (17.8%)	1,850 (19.8%)	1,850 (19.7%)	0.040	0.002
CHA2DS2- VASc:2 -3	4,420 (45.5%)	8,410 (41.9%)	4,310 (45.9%)	4,300 (45.9%)	0.073	0.001
CHA2DS2- VASc:>=4	3,410 (35.1%)	8,080 (40.2%)	3,210 (34.3%)	3,230 (34.4%)	0.107	0.003
CHADS2, mean(SD)	1.6 (1.23)	1.6 (1.21)	1.6 (1.21)	1.6 (1.23)	0.050	0.001
CHADS2:0	1,860 (19.2%)	3,470 (17.3%)	1,830 (19.6%)	1,870 (19.9%)	0.050	0.008
CHADS2:1 CHADS2:>=2	3,320 (34.1%) 4,530 (46.7%)	6,320 (31.5%) 10,280 (51.2%)	3,240 (34.5%) 4,300 (45.9%)	3,200 (34.2%) 4,300 (45.9%)	0.057 0.092	0.007
HAS-BLED,	2.0 (1.11)	2.1 (1.17)	2.0 (1.11)	2.0 (1.12)	0.092	0.000
mean(SD)				. ,		
HAS-BLED:<3 HAS-BLED:>=3	<u>6,490 (66.8%)</u> <u>3,220 (33.2%)</u>	12,660 (63.1%) 7,410 (36.9%)	6,320 (67.5%) 3,050 (32.5%)	6,250 (66.7%) 3,120 (33.3%)	0.078	0.016
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.036	0.008
log_beddays, median(IQR)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.143	0.005
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.074	0.015
income, median(IQR), k€	140.6 (100.7 - 221.9)	122.8 (88.9 - 187.6)	139.1 (100.0 - 218.3)	138.1 (99.5 - 218.2)	0.142	0.004

education:Second ary compulsory	3,240 (33.4%)	8,430 (42.0%)	3,200 (34.1%)	3,200 (34.1%)	0.178	0.000
education:Vocati onal / High school	4,300 (44.3%)	8,140 (40.6%)	4,140 (44.2%)	4,180 (44.6%)	0.076	0.009
education:Higher education	1,960 (20.2%)	2,980 (14.8%)	1,830 (19.5%)	1,780 (19.0%)	0.140	0.014
education:Unkno wn	200 (2.1%)	520 (2.6%)	200 (2.1%)	210 (2.3%)	0.033	0.007
employment:Em ployed or self - employed	2,180 (22.4%)	3,720 (18.5%)	2,090 (22.3%)	2,040 (21.8%)	0.097	0.012
employment:Une mployed	530 (5.5%)	1,190 (5.9%)	520 (5.5%)	490 (5.3%)	0.020	0.012
employment:Reti red	6,890 (71.0%)	15,010 (74.8%)	6,670 (71.1%)	6,750 (72.0%)	0.086	0.018
employment:Unk nown	110 (1.1%)	150 (0.7%)	100 (1.0%)	90 (1.0%)	0.037	0.005




Table 15.46 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Denmark – REDUCED DOSE

Application counsel (b) before marking N=2070 Warfarin (rounde) N=20070 Warfarin (rounde) N=4596 Marking N=4596 n marking N=4596 n marki	8/						I
Image from A^{-1} S-52/1 Image from A^{-1} S-540 (67.1%) 12,620 (62.9%) 3,100 (67.5%) 3,120 (67.8%) 0.0089 0.0066 Time from A^{-1} 570 (10.7%) 2,410 (12.0%) 510 (11.1%) 510 (11.1%) 0.011 0.0091 0.0006 SextFernale 3,250 (67.5%) 7.500 (29.6%) 2,200 (58.4%) 0.2700 (58.7%) 0.453 0.0055 SextFernale 3,250 (67.5%) 7.500 (29.6%) 2,200 (58.4%) 0.4173 0.453 0.0055 SextFernale 85.0 (90.2-980 7-33 (66.1-980) 330 (0.5%) 1.900 (41.2%) 0.451 0.0034 Age_group:5 120 (2.2%) 2.870 (14.3%) 120 (2.5%) 90 (2.0%) 0.451 0.003 Age_group:5 120 (2.2%) 2.801 (1.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age_group:5 120 (2.2%) 2.800 (2.8%) 1.400 (0.7%) 0.004 0.003 Age_group:5 120 (2.8%) 5.240 (10.2%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age_group:5 1.900	Characteristic	d) before) before matching	d) after matching) after matching	difference	difference
Time from AF lage - 1 morius AF lage - 1 morius AF lage - 1 morius AF lage - 6 morius			N=20070	N= 4596	N= 4596		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	diag:< 1 month	3,540 (67.1%)	12,620 (62.9%)	3,100 (67.5%)	3,120 (67.8%)		
		570 (10.7%)	2,410 (12.0%)	510 (11.1%)	510 (11.1%)	0.041	0.000
Sex.Harda 3.259 (n1.7%) 7.950 (30.6%) 2.670 (38.7%) 0.4633 0.005 Sex.Math 2.020 (38.3%) 12.10 (0.4%) 1910 (41.6%) 1900 (41.3%) 0.453 0.005 Age.median(QR) 850 (80.2 - 89.6) 7.33 (66.1 - 80.6) 84.0 (79.4 - 88.2) 84.0 (79.5 - 88.1) 1.181 0.006 Age-groups-5 530 (0.5%) 1.520 (7.6%) 30 (0.5%) 30 (0.5%) 0.368 0.011 Age-groups-5 520 (0.8%) 6.820 (34.0%) 520 (11.3%) 520 (11.4%) 0.610 0.0003 Age-groups-75 1.970 (37.3%) 6.820 (31.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age-groups-12 1.910 (36.3%) 6.620 (22.9%) 1.610 (35.%) 5.200 (2.9%) 0.024 0.014 CC1-group1-2 1.910 (36.3%) 6.400 (22.9%) 1.610 (35.%) 6.200 (29.9%) 1.680 (35.%) 1.520 (32.4%) 0.136 0.070 CC1-group1-2 1.910 (3.7%) 6.000 (29.9%) 1.600 (31.1%) 6.01 (31.1%) 0.124 0.001 Prior 1.820 (4	Time from AF	1,170 (22.2%)	5,040 (25.1%)	980 (21.3%)	970 (21.1%)	0.070	0.006
Age, median(QR) BS.0.(80.2 = 89.6) 73.3 (66.1 = 80.6) 84.0 (79.4 = 88.2) 84.0 (79.5 = 88.1) 1.181 0.006 Age -group:75- Series 100 (2.%) 1.520 (7.6%) 30 (0.5%) 30 (0.7%) 0.368 0.014 Age -group:75- series 120 (2.2%) 2.870 (14.3%) 120 (2.5%) 90 (2.0%) 0.451 0.033 Age -group:75- series 1.970 (37.3%) 6.820 (31.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age -group:7= 1.970 (37.3%) 6.280 (31.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age -group:7= 1.970 (37.3%) 6.280 (31.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 CCL-group:1= 1.910 (5.3%) 6.000 (29.9%) 1.410 (3.7%) 1.490 (32.5%) 0.218 0.034 Prior Incore 1.920 (43.5%) 6.000 (3.1%) 600 (13.1%) 0.014 0.001 (any) 7.20 (1.4%) 1.90 (2.1%) 1.10 (2.1%) 1.10 (2.3%) 0.015 0.015 Grearation (any) 1.10 (2.1%) 1.90	Sex:Female						
Age -group: S3 30 (0.5%) 1.520 (7.6%) 30 (0.5%) 30 (0.7%) 0.368 0.014 Age -group:55- 120 (2.2%) 2.870 (14.3%) 120 (2.5%) 90 (2.0%) 0.451 0.034 Age -group:65- 520 (9.8%) 6.820 (34.0%) 520 (11.3%) 520 (11.4%) 0.610 0.003 Age -group:75- 1.970 (37.3%) 6.280 (31.3%) 1.920 (41.8%) 1.930 (41.9%) 0.128 0.003 Age -group:75 2.640 (50.2%) 2.580 (12.9%) 1.680 (65.5%) 1.520 (32.4%) 0.0288 0.037 CCL-group:1 1.910 (36.3%) 6.000 (29.9%) 1.680 (65.5%) 1.520 (32.4%) 0.159 0.034 Prior 18.80 (43.4%) 5.700 (72.8%) 1.510 (32.8%) 0.136 0.0179 Prior 120 (2.2%) 270 (1.4%) 100 (2.1%) 110 (2.3%) 0.065 0.015 Prior gastrointextinal 1100 (2.1%) 100 (2.1%) 100 (2.9%) 0.016 0.009 Prior instantic 1.000 (0.7%) 1.940 (9.7%) 800 (17.9%) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Age group 55-	Age -group:< 55	, , , , , , , , , , , , , , , , , , ,	, , , ,	, , , , ,			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age -group:55-	120 (2.2%)	2,870 (14.3%)	120 (2.5%)	90 (2.0%)	0.451	0.034
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age -group:65-	520 (9.8%)	6,820 (34.0%)	520 (11.3%)	520 (11.4%)	0.610	0.003
$ \begin{array}{c cccc} Ab years & Define the term of the term of the term of ter$	Age -group:75-					0.128	0.003
years 1-1 </td <td>Age -group:>= 85</td> <td></td> <td></td> <td></td> <td> ,</td> <td></td> <td></td>	Age -group:>= 85				,		
$\begin{array}{c ccccccc} CCLegroup:-2 & 1.910 (36.3\%) & 6.000 (29.9\%) & 1.680 (36.5\%) & 1.520 (33.2\%) & 0.136 & 0.070 \\ CCLegroup:-3 & 1.820 (34.5\%) & 5.470 (27.2\%) & 1.510 (32.8\%) & 1.580 (34.4\%) & 0.159 & 0.034 \\ Prior bleeding & 720 (13.7\%) & 1.940 (9.7\%) & 600 (13.1\%) & 600 (13.1\%) & 0.124 & 0.001 \\ Prior & & & & & & & & & & & & & & & & & & &$, , ,			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			/ / /	/ (/			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $, , ,					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		1,820 (34.3%)		1,510 (52.8%)	1,380 (34.4%)	0.139	0.034
gastrointestinal bleeding 120 (2.2%) 270 (1.4%) 100 (2.1%) 110 (2.3%) 0.065 0.015 Prior intracranial bleeding 110 (2.1%) 140 (0.7%) 80 (1.7%) 80 (1.7%) 0.315 0.009 Prior intracranial bleeding 1.00 (2.1%) 1.980 (9.8%) 830 (18.1%) 820 (17.7%) 0.315 0.009 Prior ischaemic stroke 1.090 (20.7%) 1.940 (9.7%) 820 (17.8%) 800 (17.4%) 0.016 0.009 Prior stroke haemorrhagic 70 (1.3%) 90 (0.4%) 50 (1.1%) 50 (1.0%) 0.096 0.009 Stroke	(any)	720 (13.7%)	1,940 (9.7%)	600 (13.1%)	600 (13.1%)	0.124	0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	gastrointestinal	120 (2.2%)	270 (1.4%)	100 (2.1%)	110 (2.3%)	0.065	0.015
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		· /	140 (0.7%)	80 (1.7%)	80 (1.6%)	0.118	0.003
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		1,110 (21.1%)	1,980 (9.8%)	830 (18.1%)	820 (17.7%)	0.315	0.009
haemorrhagic stroke 70 (1.3%) 90 (0.4%) 50 (1.1%) 50 (1.0%) 0.096 0.009 Prior systemic embolism 30 (0.5%) 110 (0.5%) 30 (0.6%) 30 (0.7%) 0.000 0.011 Prior systemic embolism 230 (4.4%) 600 (3.0%) 200 (4.3%) 170 (3.8%) 0.076 0.025 Chronic kidney disease 420 (8.0%) 1,690 (8.4%) 400 (8.6%) 410 (8.9%) 0.015 0.010 Heart failure 1,090 (20.8%) 3,570 (17.8%) 950 (20.6%) 970 (21.0%) 0.076 0.010 Coronary artery disease 1,180 (22.3%) 4,590 (22.9%) 1,070 (23.2%) 1,070 (23.3%) 0.013 0.004 Peripheral arterial disease 480 (9.2%) 1,630 (8.1%) 440 (9.6%) 460 (10.0%) 0.038 0.015 Hypertension 3,610 (68.5%) 12,270 (61.1%) 3,130 (68.0%) 3,120 (68.0%) 0.123 0.001 Diabetes 920 (17.5%) 3,490 (17.4%) 810 (17.7%) 820 (17.8%) 0.002 0.004 Liver disease 60 (1.2%) 2,5	stroke	1,090 (20.7%)	1,940 (9.7%)	820 (17.8%)	800 (17.4%)	0.310	0.009
embolism 30 (0.5%) 110 (0.5%) 30 (0.6%) 30 (0.7%) 0.000 0.011 Prior transient ischaemic attack 230 (4.4%) 600 (3.0%) 200 (4.3%) 170 (3.8%) 0.076 0.025 Chronic kidney disease 420 (8.0%) 1,690 (8.4%) 400 (8.6%) 410 (8.9%) 0.015 0.010 Heart failure 1,090 (20.8%) 3,570 (17.8%) 950 (20.6%) 970 (21.0%) 0.076 0.010 Coronary artery disease 1,180 (22.3%) 4,590 (22.9%) 1,070 (23.2%) 1,070 (23.3%) 0.013 0.004 Peripheral arterial disease 480 (9.2%) 1,630 (8.1%) 440 (9.6%) 460 (10.0%) 0.038 0.015 Hypertension 3,610 (68.5%) 12,270 (61.1%) 3,130 (68.0%) 0.155 0.001 Diabetes 920 (17.5%) 3,490 (17.4%) 810 (17.7%) 820 (17.8%) 0.003 0.0022 Chronic obstructive 910 (17.2%) 2,570 (12.8%) 790 (17.2%) 810 (17.6%) 0.123 0.011 pulmonary disease 60 (1.2%) 50 (1.2%) <t< td=""><td>haemorrhagic stroke</td><td>70 (1.3%)</td><td>90 (0.4%)</td><td>50 (1.1%)</td><td>50 (1.0%)</td><td>0.096</td><td>0.009</td></t<>	haemorrhagic stroke	70 (1.3%)	90 (0.4%)	50 (1.1%)	50 (1.0%)	0.096	0.009
ischaemic attack 230 (4.4%) 600 (3.0%) 200 (4.3%) 170 (3.8%) 0.076 0.025 Chronic kidney disease 420 (8.0%) 1,690 (8.4%) 400 (8.6%) 410 (8.9%) 0.015 0.010 Heart failure 1,090 (20.8%) 3,570 (17.8%) 950 (20.6%) 970 (21.0%) 0.076 0.010 Coronary artery disease 1,180 (22.3%) 4,590 (22.9%) 1,070 (23.2%) 1,070 (23.3%) 0.013 0.004 Peripheral arterial disease 480 (9.2%) 1,630 (8.1%) 440 (9.6%) 460 (10.0%) 0.038 0.015 Hypertension 3,610 (68.5%) 12,270 (61.1%) 3,130 (68.0%) 3,120 (68.0%) 0.155 0.001 Diabetes 920 (17.5%) 3,490 (17.4%) 810 (17.7%) 820 (17.8%) 0.003 0.002 Ohrnic obstructive 910 (17.2%) 2,570 (12.8%) 790 (17.2%) 810 (17.6%) 0.123 0.011 Liver disease 60 (1.2%) 240 (1.2%) 50 (1.1%) 0.002 0.004 Alcoholism 140 (2.6%) 590 (2.9%) 120 (2.7%) </td <td>-</td> <td>30 (0.5%)</td> <td>110 (0.5%)</td> <td>30 (0.6%)</td> <td>30 (0.7%)</td> <td>0.000</td> <td>0.011</td>	-	30 (0.5%)	110 (0.5%)	30 (0.6%)	30 (0.7%)	0.000	0.011
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		230 (4.4%)	600 (3.0%)	200 (4.3%)	170 (3.8%)	0.076	0.025
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	•	420 (8.0%)	1,690 (8.4%)	400 (8.6%)	410 (8.9%)	0.015	0.010
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heart failure	1,090 (20.8%)	3,570 (17.8%)	950 (20.6%)	970 (21.0%)	0.076	0.010
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	disease	1,180 (22.3%)	4,590 (22.9%)	1,070 (23.2%)	1,070 (23.3%)	0.013	0.004
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		480 (9.2%)	1,630 (8.1%)	440 (9.6%)	460 (10.0%)	0.038	0.015
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $							
obstructive pulmonary disease 910 (17.2%) 2,570 (12.8%) 790 (17.2%) 810 (17.6%) 0.123 0.011 Liver disease 60 (1.2%) 240 (1.2%) 50 (1.2%) 50 (1.1%) 0.002 0.004 Alcoholism 140 (2.6%) 590 (2.9%) 120 (2.7%) 110 (2.5%) 0.018 0.015 Dementia 320 (6.0%) 220 (1.1%) 170 (3.7%) 160 (3.6%) 0.268 0.009 Cancer 6 months before and including index date 250 (4.7%) 930 (4.6%) 230 (5.0%) 240 (5.2%) 0.005 0.010 Platelet inhibitors (excluding 2,120 (40.2%) 6,760 (33.7%) 1,830 (39.9%) 1,840 (40.0%) 0.134 0.003		920 (17.5%)	3,490 (17.4%)	810 (17.7%)	820 (17.8%)	0.003	0.002
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	obstructive	910 (17.2%)	2,570 (12.8%)	790 (17.2%)	810 (17.6%)	0.123	0.011
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		60 (1.2%)	240 (1.2%)	50 (1.2%)	50 (1.1%)	0.002	0.004
Dementia 320 (6.0%) 220 (1.1%) 170 (3.7%) 160 (3.6%) 0.268 0.009 Cancer 6 months before and including index date 250 (4.7%) 930 (4.6%) 230 (5.0%) 240 (5.2%) 0.005 0.010 Platelet inhibitors (excluding 2,120 (40.2%) 6,760 (33.7%) 1,830 (39.9%) 1,840 (40.0%) 0.134 0.003					· · · · ·		
Cancer 6 months before and including index date 250 (4.7%) 930 (4.6%) 230 (5.0%) 240 (5.2%) 0.005 0.010 Platelet inhibitors (excluding 2,120 (40.2%) 6,760 (33.7%) 1,830 (39.9%) 1,840 (40.0%) 0.134 0.003							
Platelet inhibitors (excluding 2,120 (40.2%) 6,760 (33.7%) 1,830 (39.9%) 1,840 (40.0%) 0.134 0.003	Cancer 6 months before and including index		, í	<u> </u>			
	Platelet inhibitors	2,120 (40.2%)	6,760 (33.7%)	1,830 (39.9%)	1,840 (40.0%)	0.134	0.003
Low -dose aspirin 1,460 (27.7%) 5,110 (25.5%) 1,300 (28.3%) 1,300 (28.3%) 0.051 0.000		1,460 (27.7%)	5,110 (25.5%)	1,300 (28.3%)	1,300 (28.3%)	0.051	0.000

ADP receptor						
blockers	800 (15.2%)	2,260 (11.2%)	660 (14.3%)	680 (14.9%)	0.117	0.015
Renin - angiotensin system inhibitors	2,160 (40.9%)	8,420 (42.0%)	1,920 (41.9%)	1,910 (41.6%)	0.021	0.006
Angiotensin - converting enzyme inhibitors	1,110 (21.1%)	4,510 (22.5%)	990 (21.5%)	1,000 (21.8%)	0.034	0.006
Angiotensin II antagonists, plain	680 (12.9%)	2,220 (11.0%)	590 (12.9%)	570 (12.4%)	0.057	0.016
Angiotensin II antagonists, combinations	300 (5.6%)	1,210 (6.0%)	280 (6.0%)	290 (6.3%)	0.019	0.012
Beta-blockers	3,180 (60.4%)	12,420 (61.9%)	2,790 (60.7%)	2,810 (61.0%)	0.031	0.006
Proton pump inhibitors	1,590 (30.1%)	4,510 (22.5%)	1,330 (28.9%)	1,370 (29.9%)	0.174	0.022
Non-steroidal anti-inflammatory drugs	410 (7.8%)	1,980 (9.9%)	380 (8.2%)	380 (8.2%)	0.074	0.002
Statins	1,680 (31.9%)	6,990 (34.8%)	1,530 (33.3%)	1,540 (33.6%)	0.062	0.006
Antidiabetic agents	620 (11.7%)	2,650 (13.2%)	560 (12.2%)	560 (12.1%)	0.047	0.001
Loop diuretics	2,080 (39.5%)	5,800 (28.9%)	1,800 (39.1%)	1,790 (39.0%)	0.225	0.003
Non-loop diuretics	60 (1.1%)	350 (1.7%)	60 (1.2%)	50 (1.2%)	0.052	0.004
Alpha adrenergic blockers	1,070 (20.3%)	3,670 (18.3%)	950 (20.6%)	940 (20.5%)	0.052	0.004
Amiodarone	240 (4.6%)	970 (4.9%)	220 (4.7%)	230 (4.9%)	0.011	0.010
Dronedarone Antihypertensive,	<5	30 (0.1%)	<5	<5	0.030	0.012
combination drugs Calcium channel	490 (9.2%)	2,110 (10.5%)	450 (9.8%)	460 (10.0%)	0.044	0.007
blockers Selective	1,280 (24.2%)	4,790 (23.9%)	1,120 (24.3%)	1,130 (24.5%)	0.008	0.004
serotonin reuptake inhibitors	520 (9.8%)	1,150 (5.7%)	410 (8.9%)	400 (8.8%)	0.152	0.005
Drugs used in alcohol dependence	<5	50 (0.2%)	<5	<5	0.055	0.000
CHA2DS2-VASc, mean(SD)	4.3 (1.45)	3.1 (1.67)	4.2 (1.43)	4.2 (1.47)	0.759	0.004
CHA2DS2- VASc:0 -1	100 (1.9%)	3,580 (17.8%)	100 (2.2%)	120 (2.5%)	0.555	0.024
CHA2DS2- VASc:2 -3	1,440 (27.3%)	8,410 (41.9%)	1,350 (29.5%)	1,320 (28.7%)	0.311	0.016
CHA2DS2- VASc:>=4	3,730 (70.8%)	8,080 (40.2%)	3,140 (68.4%)	3,160 (68.7%)	0.646	0.008
CHADS2, mean(SD)	2.4 (1.20)	1.6 (1.21)	2.3 (1.17)	2.3 (1.19)	0.640	0.002
CHADS2:0	140 (2.6%)	3,470 (17.3%)	140 (3.0%)	160 (3.4%)	0.505	0.023
CHADS2:1 CHADS2:>=2	960 (18.3%) 4,170 (79.1%)	6,320 (31.5%) 10,280 (51.2%)	880 (19.1%) 3,580 (77.9%)	870 (19.0%) 3,570 (77.6%)	0.309 0.612	0.004 0.006
HAS-BLED, mean(SD)	4,170 (79.1%) 2.6 (1.07)	2.1 (1.17)	2.5 (1.07)	2.5 (1.08)	0.406	0.008
HAS-BLED:<3	2,580 (48.9%)	12,660 (63.1%)	2,320 (50.4%)	2,310 (50.3%)	0.288	0.002
HAS-BLED:>=3	2,690 (51.1%)	7,410 (36.9%)	2,280 (49.6%)	2,290 (49.7%)	0.288	0.002
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.327	0.019
log_beddays, median(IQR)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.154	0.002
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.166	0.034
income, median(IQR), k€	97.3 (77.9 - 127.7)	122.8 (88.9 - 187.6)	98.9 (78.3 - 131.0)	97.7 (77.5 - 128.7)	0.301	0.006
education:Seconda ry compulsory	2,570 (48.8%)	8,430 (42.0%)	2,310 (50.3%)	2,340 (50.9%)	0.136	0.011
education:Vocatio nal / High school	1,610 (30.5%)	8,140 (40.6%)	1,450 (31.6%)	1,460 (31.8%)	0.210	0.004
education:Higher education	670 (12.7%)	2,980 (14.8%)	580 (12.6%)	560 (12.2%)	0.063	0.013
education:Unkno	420 (8.0%)	520 (2.6%)	250 (5.4%)	230 (5.1%)	0.244	0.014

employment:Empl oyed or self - employed	150 (2.9%)	3,720 (18.5%)	150 (3.3%)	170 (3.7%)	0.521	0.021
employment:Une mployed	70 (1.3%)	1,190 (5.9%)	70 (1.5%)	60 (1.2%)	0.250	0.021
employment:Retir ed	5,040 (95.7%)	15,010 (74.8%)	4,370 (95.1%)	4,360 (95.0%)	0.615	0.007
employment:Unkn own	10 (0.1%)	150 (0.7%)	10 (0.1%)	10 (0.1%)	0.096	0.000




Table 15.47 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Norway – STANDARD DOSE

	•	[~	
Characteristic	Apixaban (round ed) before matching N=12963	Warfarin (round ed) before matching N=11949	Apixaban (round ed) after matching N= 8456	Warfarin (round ed) after matching N= 8456	Standardised m ean difference before matchin g (max= 0.41)	Standardised m ean difference after matching (max= 0.06)
Time from AF diag:< 1 month	9,440 (72.8%)	6,410 (53.6%)	5,290 (62.5%)	5,280 (62.5%)	0.405	0.001
Time from AF diag:1 - 6 month	910 (7.0%)	1,340 (11.2%)	770 (9.1%)	770 (9.1%)	0.147	0.002
Time from AF diag:6 - 60 months	2,620 (20.2%)	4,200 (35.2%)	2,400 (28.4%)	2,400 (28.4%)	0.339	0.000
Sex:Female	5,110 (39.4%)	4,740 (39.7%)	3,260 (38.5%)	3,260 (38.5%)	0.006	0.000
Sex:Male	7,860 (60.6%)	7,210 (60.3%)	5,200 (61.5%)	5,200 (61.5%)	0.006	0.000
Age, median(IQR)	71.6 (65.5 - 78.0)	75.3 (66.7 - 83.2)	72.7 (65.5 - 80.3)	72.9 (65.6 - 80.2)	0.249	0.004
Age -group:< 55 years	900 (6.9%)	830 (7.0%)	650 (7.6%)	600 (7.1%)	0.002	0.022
Age - group:55-<65 years	2,110 (16.3%)	1,690 (14.2%)	1,340 (15.8%)	1,390 (16.4%)	0.059	0.016
Age - group:65-<75 years	5,310 (40.9%)	3,360 (28.1%)	2,870 (34.0%)	2,890 (34.2%)	0.273	0.005
Age - group:75-<85 years	3,660 (28.2%)	3,860 (32.3%)	2,650 (31.4%)	2,640 (31.3%)	0.088	0.002
Age -group:>= 85 years	990 (7.7%)	2,210 (18.5%)	950 (11.3%)	940 (11.1%)	0.326	0.005
CCI-group:0	5,160 (39.8%)	3,340 (27.9%)	2,900 (34.3%)	2,860 (33.8%)	0.254	0.010
CCI-group:1-2	4,570 (35.2%)	3,810 (31.9%)	3,000 (35.4%)	2,910 (34.4%)	0.071	0.021
CCI- group:>=3	3,230 (24.9%)	4,800 (40.2%)	2,560 (30.2%)	2,680 (31.7%)	0.330	0.032
Prior bleeding (any)	1,380 (10.7%)	1,780 (14.9%)	1,040 (12.3%)	1,040 (12.2%)	0.127	0.002
Prior gastrointestinal bleeding	100 (0.8%)	190 (1.6%)	90 (1.1%)	80 (1.0%)	0.073	0.009
Prior intracranial bleeding	120 (0.9%)	160 (1.3%)	90 (1.1%)	90 (1.1%)	0.039	0.001
Prior stroke (any)	1,370 (10.5%)	1,440 (12.0%)	950 (11.2%)	950 (11.3%)	0.047	0.003
Prior ischaemic stroke	1,330 (10.3%)	1,380 (11.5%)	920 (10.8%)	920 (10.9%)	0.041	0.003
Prior haemorrhagic stroke	70 (0.5%)	110 (0.9%)	60 (0.7%)	60 (0.7%)	0.042	0.004
Prior systemic embolism	50 (0.4%)	140 (1.2%)	50 (0.5%)	40 (0.5%)	0.091	0.007
Prior transient ischaemic attack	470 (3.6%)	460 (3.9%)	330 (3.8%)	310 (3.6%)	0.015	0.011
Chronic kidney disease	520 (4.0%)	1,560 (13.1%)	510 (6.0%)	560 (6.6%)	0.327	0.025
Heart failure	1,980 (15.2%)	3,110 (26.0%)	1,640 (19.3%)	1,680 (19.9%)	0.269	0.013
Coronary artery disease	2,980 (23.0%)	4,410 (36.9%)	2,420 (28.7%)	2,460 (29.1%)	0.307	0.010
Peripheral arterial disease	1,150 (8.9%)	1,370 (11.5%)	810 (9.6%)	840 (9.9%)	0.086	0.010
Hypertension	7,430 (57.3%)	7,270 (60.8%)	4,910 (58.0%)	4,940 (58.4%)	0.072	0.007
Diabetes	1,870 (14.4%)	2,100 (17.6%)	1,320 (15.6%)	1,330 (15.7%)	0.088	0.002
Chronic obstructive pulmonary disease	1,780 (13.7%)	1,850 (15.5%)	1,270 (15.0%)	1,210 (14.4%)	0.050	0.017

Liver disease	110 (0.8%)	150 (1.3%)	90 (1.0%)	80 (0.9%)	0.045	0.010
Alcoholism	260 (2.0%)	170 (1.4%)	140 (1.7%)	140 (1.6%)	0.046	0.003
Dementia	160 (1.2%)	230 (1.9%)	130 (1.5%)	130 (1.5%)	0.054	0.002
Cancer 6 months before and including index date	710 (5.5%)	810 (6.8%)	520 (6.1%)	500 (5.9%)	0.054	0.008
Platelet inhibitors (excluding heparin)	5,020 (38.7%)	5,400 (45.2%)	3,580 (42.4%)	3,600 (42.5%)	0.130	0.004
Low -dose aspirin	4,770 (36.8%)	5,060 (42.4%)	3,380 (40.0%)	3,390 (40.1%)	0.113	0.002
ADP receptor blockers	480 (3.7%)	1,130 (9.5%)	460 (5.4%)	480 (5.6%)	0.234	0.009
Renin - angiotensin system inhibitors	5,790 (44.6%)	5,500 (46.0%)	3,740 (44.2%)	3,790 (44.9%)	0.028	0.014
Angiotensin - converting enzyme inhibitors	1,960 (15.1%)	2,500 (20.9%)	1,470 (17.4%)	1,500 (17.8%)	0.151	0.010
Angiotensin II antagonists, plain	1,920 (14.8%)	1,640 (13.7%)	1,150 (13.6%)	1,180 (14.0%)	0.032	0.009
Angiotensin II antagonists, combinations	1,960 (15.1%)	1,450 (12.2%)	1,150 (13.6%)	1,160 (13.7%)	0.086	0.004
Beta-blockers	8,920 (68.8%)	8,410 (70.4%)	5,860 (69.3%)	5,870 (69.4%)	0.035	0.003
Proton pump inhibitors	2,460 (19.0%)	2,690 (22.5%)	1,670 (19.8%)	1,700 (20.1%)	0.088	0.007
H2-receptor antagonists	150 (1.2%)	170 (1.4%)	100 (1.2%)	110 (1.2%)	0.018	0.002
Non-steroidal anti- inflammatory drugs	1,280 (9.9%)	910 (7.6%)	740 (8.8%)	730 (8.6%)	0.081	0.007
Statins	4,960 (38.3%)	5,020 (42.0%)	3,340 (39.5%)	3,380 (40.0%)	0.076	0.009
Antidiabetic agents	1,280 (9.9%)	1,400 (11.7%)	890 (10.5%)	900 (10.7%)	0.060	0.005
Loop diuretics	1,970 (15.2%)	3,390 (28.4%)	1,690 (20.0%)	1,710 (20.2%)	0.323	0.007
Non-loop diuretics	200 (1.6%)	230 (1.9%)	150 (1.7%)	140 (1.6%)	0.029	0.006
Alpha adrenergic blockers	770 (5.9%)	960 (8.0%)	570 (6.8%)	600 (7.1%)	0.083	0.015
Amiodarone	480 (3.7%)	700 (5.9%)	420 (4.9%)	410 (4.8%)	0.102	0.007
Dronedarone	240 (1.9%)	130 (1.1%)	110 (1.3%)	120 (1.4%)	0.064	0.007
Antihypertensi ve, combination drugs	2,260 (17.5%)	1,740 (14.6%)	1,350 (16.0%)	1,360 (16.1%)	0.079	0.004
Calcium channel blockers	2,700 (20.9%)	2,640 (22.1%)	1,770 (21.0%)	1,780 (21.1%)	0.031	0.002
Selective serotonin reuptake inhibitors	490 (3.8%)	530 (4.5%)	340 (4.1%)	340 (4.0%)	0.035	0.004
Drugs used in alcohol dependence	20 (0.2%)	20 (0.1%)	10 (0.1%)	10 (0.2%)	0.010	0.006
CHA2DS2- VASc, mean(SD)	2.7 (1.63)	3.3 (1.86)	2.9 (1.70)	2.9 (1.77)	0.309	0.010
CHA2DS2- VASc:0 -1	3,120 (24.1%)	2,240 (18.7%)	1,800 (21.3%)	1,910 (22.5%)	0.131	0.031
CHA2DS2- VASc:2 -3	6,020 (46.5%)	4,370 (36.6%)	3,740 (44.3%)	3,470 (41.1%)	0.201	0.065
CHA2DS2- VASc:>=4	3,820 (29.4%)	5,340 (44.7%)	2,920 (34.5%)	3,080 (36.4%)	0.320	0.040
CHADS2, mean(SD)	1.3 (1.22)	1.7 (1.35)	1.5 (1.26)	1.5 (1.28)	0.301	0.003

CHADS2:0	3,900 (30.1%)	2,530 (21.1%)	2,130 (25.1%)	2,210 (26.1%)	0.207	0.022
CHADS2:1	4,370 (33.7%)	3,480 (29.1%)	2,820 (33.4%)	2,700 (31.9%)	0.099	0.032
CHADS2:>=2	4,690 (36.1%)	5,940 (49.7%)	3,510 (41.5%)	3,560 (42.0%)	0.277	0.011
HAS-BLED, mean(SD)	1.8 (1.14)	2.1 (1.26)	1.9 (1.18)	1.9 (1.20)	0.245	0.006
HAS- BLED:<3	9,430 (72.7%)	7,410 (62.0%)	5,880 (69.5%)	5,760 (68.1%)	0.230	0.029
HAS- BLED:>=3	3,540 (27.3%)	4,540 (38.0%)	2,580 (30.5%)	2,690 (31.9%)	0.230	0.029
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.279	0.002
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.003	0.001
log_n_outpatie nt, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.155	0.005




Table 15.48 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating <u>apixaban</u> or warfarin and standardised mean differences before and aftermatching, Norway – REDUCED DOSE

	Apixaban (round	Warfarin (rounde	Apixaban (round	Warfarin (rounde	Standardised mea	Standardised mea
Characteristic	ed) before matching N= 4817	d) before matching N=11949	ed) after matching N= 4215	d) after matching N= 4215	difference before matching (max= 0.90)	difference after matching (max= 0.08)
Time from AF diag:< 1 month	3,250 (67.5%)	6,410 (53.6%)	2,740 (65.0%)	2,730 (64.7%)	0.286	0.006
Time from AF diag:1 - 6 month	570 (11.9%)	1,340 (11.2%)	530 (12.5%)	520 (12.4%)	0.021	0.002
Time from AF diag:6 - 60 months	1,000 (20.7%)	4,200 (35.2%)	950 (22.6%)	970 (23.0%)	0.327	0.009
Sex:Female	2,800 (58.0%)	4,740 (39.7%)	2,320 (55.1%)	2,300 (54.5%)	0.374	0.012
Sex:Male	2,020 (42.0%)	7,210 (60.3%)	1,890 (44.9%)	1,920 (45.5%)	0.374	0.012
Age, median(IQR)	84.8 (79.6 - 89.3)	75.3 (66.7 - 83.2)	83.9 (78.6 - 88.2)	83.8 (78.4 - 88.1)	0.899	0.006
Age -group:< 55 years	40 (0.8%)	830 (7.0%)	40 (0.9%)	40 (0.9%)	0.321	0.002
Age -group:55- <65 years	150 (3.1%)	1,690 (14.2%)	150 (3.6%)	150 (3.5%)	0.401	0.005
Age -group:65- <75 years	530 (11.0%)	3,360 (28.1%)	530 (12.5%)	500 (11.8%)	0.442	0.020
Age -group:75- <85 years	1,750 (36.3%)	3,860 (32.3%)	1,690 (40.0%)	1,750 (41.6%)	0.086	0.031
Age -group:>= 85 years	2,350 (48.8%)	2,210 (18.5%)	1,810 (43.0%)	1,780 (42.2%)	0.675	0.015
CCI-group:0	1,110 (23.1%)	3,340 (27.9%)	970 (23.0%)	910 (21.6%)	0.110	0.032
CCI-group:1-2	1,520 (31.6%)	3,810 (31.9%)	1,330 (31.6%)	1,360 (32.3%)	0.008	0.014
CCI-group:>=3	2,180 (45.3%)	4,800 (40.2%)	1,920 (45.4%)	1,940 (46.1%)	0.104	0.014
Prior bleeding (any)	930 (19.3%)	1,780 (14.9%)	780 (18.5%)	780 (18.5%)	0.117	0.001
Prior gastrointestinal bleeding	90 (1.9%)	190 (1.6%)	80 (1.9%)	90 (2.1%)	0.024	0.014
Prior intracranial bleeding	100 (2.1%)	160 (1.3%)	80 (1.9%)	80 (1.8%)	0.060	0.005
Prior stroke (any)	770 (15.9%)	1,440 (12.0%)	650 (15.3%)	650 (15.4%)	0.113	0.004
Prior ischaemic stroke	750 (15.5%)	1,380 (11.5%)	630 (14.9%)	630 (14.9%)	0.117	0.000
Prior haemorrhagic stroke	70 (1.4%)	110 (0.9%)	50 (1.1%)	50 (1.2%)	0.047	0.016
Prior systemic embolism	40 (0.8%)	140 (1.2%)	40 (0.9%)	50 (1.1%)	0.039	0.024
Prior transient ischaemic attack	250 (5.2%)	460 (3.9%)	210 (4.9%)	230 (5.4%)	0.063	0.020
Chronic kidney disease	810 (16.8%)	1,560 (13.1%)	710 (16.7%)	750 (17.7%)	0.105	0.026
Heart failure	1,300 (27.1%)	3,110 (26.0%)	1,160 (27.4%)	1,170 (27.7%)	0.024	0.006
Coronary artery disease	1,640 (33.9%)	4,410 (36.9%)	1,490 (35.4%)	1,520 (35.9%)	0.062	0.010
Peripheral arterial disease	580 (12.1%)	1,370 (11.5%)	520 (12.3%)	540 (12.8%)	0.018	0.016
Hypertension	3,110 (64.5%)	7,270 (60.8%)	2,710 (64.4%)	2,740 (65.0%)	0.076	0.013
Diabetes Chronic obstructive pulmonary disease	760 (15.8%) 850 (17.6%)	2,100 (17.6%) 1,850 (15.5%)	690 (16.5%) 750 (17.8%)	710 (16.9%) 770 (18.3%)	0.048	0.012
Liver disease	50 (1.0%)	150 (1.3%)	40 (0.9%)	40 (0.9%)	0.032	0.005
Alcoholism	80 (1.7%)	170 (1.4%)	60 (1.5%)	70 (1.7%)	0.032	0.013
Dementia	200 (4.1%)	230 (1.9%)	150 (3.4%)	160 (3.7%)	0.130	0.015
Cancer 6 months before and including index date	330 (6.9%)	810 (6.8%)	290 (6.9%)	310 (7.4%)	0.004	0.019

Platelet inhibitors						
(excluding heparin)	2,450 (50.9%)	5,400 (45.2%)	2,110 (50.2%)	2,120 (50.3%)	0.115	0.004
Low -dose aspirin	2,310 (47.9%)	5,060 (42.4%)	1,980 (47.1%)	1,990 (47.2%)	0.111	0.002
ADP receptor blockers	410 (8.6%)	1,130 (9.5%)	390 (9.2%)	400 (9.4%)	0.031	0.009
Renin - angiotensin system inhibitors	2,180 (45.3%)	5,500 (46.0%)	1,930 (45.9%)	1,910 (45.3%)	0.016	0.012
Angiotensin - converting enzyme inhibitors	970 (20.1%)	2,500 (20.9%)	870 (20.5%)	860 (20.5%)	0.021	0.001
Angiotensin II antagonists, plain	690 (14.4%)	1,640 (13.7%)	600 (14.3%)	580 (13.8%)	0.020	0.016
Angiotensin II antagonists, combinations	580 (12.0%)	1,450 (12.2%)	510 (12.2%)	510 (12.0%)	0.004	0.004
Beta-blockers	3,430 (71.2%)	8,410 (70.4%)	3,030 (71.8%)	3,000 (71.1%)	0.018	0.015
Proton pump inhibitors	1,350 (27.9%)	2,690 (22.5%)	1,130 (26.8%)	1,200 (28.4%)	0.124	0.036
H2-receptor antagonists	80 (1.6%)	170 (1.4%)	60 (1.5%)	70 (1.6%)	0.015	0.010
Non-steroidal anti-inflammatory drugs	330 (6.9%)	910 (7.6%)	290 (6.9%)	300 (7.1%)	0.026	0.009
Statins	1,840 (38.2%)	5,020 (42.0%)	1,680 (40.0%)	1,680 (39.7%)	0.078	0.004
Antidiabetic agents	470 (9.8%)	1,400 (11.7%)	440 (10.3%)	440 (10.3%)	0.061	0.001
Loop diuretics Non-loop	1,600 (33.3%)	3,390 (28.4%)	1,420 (33.8%)	1,440 (34.2%)	0.106	0.009
diuretics Alpha adrenergic	80 (1.7%)	230 (1.9%)	70 (1.8%)	80 (1.9%)	0.015	0.007
blockers	380 (8.0%)	960 (8.0%)	340 (8.1%)	360 (8.6%)	0.002	0.017
Amiodarone	210 (4.3%)	700 (5.9%)	190 (4.5%)	180 (4.2%)	0.070	0.014
Dronedarone	20 (0.4%)	130 (1.1%)	20 (0.4%)	20 (0.4%)	0.082	0.004
Antihypertensive, combination drugs	690 (14.3%)	1,740 (14.6%)	610 (14.4%)	600 (14.3%)	0.006	0.005
Calcium channel blockers	1,130 (23.5%)	2,640 (22.1%)	980 (23.1%)	990 (23.5%)	0.033	0.009
Selective serotonin reuptake inhibitors	310 (6.4%)	530 (4.5%)	250 (5.9%)	240 (5.6%)	0.085	0.012
Drugs used in alcohol dependence	10 (0.1%)	20 (0.1%)	10 (0.1%)	10 (0.1%)	0.006	0.000
CHA2DS2- VASc, mean(SD)	4.0 (1.54)	3.3 (1.86)	4.0 (1.55)	4.1 (1.58)	0.459	0.037
CHA2DS2- VASc:0 -1	170 (3.4%)	2,240 (18.7%)	170 (3.9%)	180 (4.2%)	0.503	0.013
CHA2DS2- VASc:2 -3	1,740 (36.0%)	4,370 (36.6%)	1,540 (36.5%)	1,390 (32.9%)	0.012	0.076
CHA2DS2- VASc:>=4	2,920 (60.6%)	5,340 (44.7%)	2,510 (59.6%)	2,650 (63.0%)	0.322	0.069
CHADS2, mean(SD)	2.1 (1.26)	1.7 (1.35)	2.1 (1.26)	2.2 (1.26)	0.346	0.042
CHADS2:0	250 (5.1%)	2,530 (21.1%)	250 (5.9%)	240 (5.7%)	0.487	0.008
CHADS2:1 CHADS2:>=2	1,490 (30.8%) 3,080 (64.0%)	3,480 (29.1%) 5,940 (49.7%)	1,300 (30.8%) 2,670 (63.3%)	1,180 (27.9%) 2,800 (66.4%)	0.037 0.291	0.065
HAS-BLED, mean(SD)	2.5 (1.16)	2.1 (1.26)	2.5 (1.16)	2.5 (1.16)	0.308	0.033
HAS-BLED:<3	2,510 (52.2%)	7,410 (62.0%)	2,240 (53.0%)	2,170 (51.4%)	0.200	0.032
HAS-BLED:>=3	2,300 (47.8%)	4,540 (38.0%)	1,980 (47.0%)	2,050 (48.6%)	0.200	0.032
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.145	0.020
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.031	0.008
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.132	0.005




Table 15.49 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Sweden – STANDARD DOSE

	Apixaban (round	Warfarin (rounde	Anivahan (round	Warfarin (rounda	Standardised mea	Standardised mea
Characteristic	ed) before matching N=27638	d) before matching N=47152	Apixaban (round ed) after matching N=24843	Warfarin (rounde d) after matching N=24843	n difference before matching (max= 0.35)	n difference after matching (max= 0.04)
Time from AF diag:< 1 month	19,250 (69.7%)	28,530 (60.5%)	16,980 (68.4%)	16,940 (68.2%)	0.193	0.004
Time from AF diag:1 - 6 month	1,980 (7.2%)	4,220 (9.0%)	1,830 (7.4%)	1,850 (7.5%)	0.066	0.004
Time from AF diag:6 - 60 months	6,410 (23.2%)	14,400 (30.5%)	6,030 (24.3%)	6,050 (24.4%)	0.167	0.002
Sex:Female	11,100 (40.1%)	20,290 (43.0%)	10,010 (40.3%)	9,830 (39.6%)	0.059	0.015
Sex:Male	16,540 (59.9%)	26,860 (57.0%)	14,830 (59.7%)	15,010 (60.4%)	0.059	0.015
Age, median(IQR)	72.0 (65.9 - 77.9)	75.6 (68.4 - 82.6)	72.4 (66.1 - 78.4)	72.2 (66.2 - 78.2)	0.322	0.019
Age -group:< 55 years	1,690 (6.1%)	2,130 (4.5%)	1,470 (5.9%)	1,480 (6.0%)	0.072	0.001
Age -group:55-<65 years	4,280 (15.5%)	5,540 (11.8%)	3,730 (15.0%)	3,820 (15.4%)	0.109	0.010
Age -group:65-<75 years Age -group:75-<85	11,430 (41.4%)	14,880 (31.6%)	9,940 (40.0%)	10,030 (40.4%)	0.205	0.007
Age -group:////////////////////////////////////	8,290 (30.0%)	16,570 (35.1%)	7,760 (31.3%)	7,690 (30.9%)	0.110	0.007
years	1,940 (7.0%)	8,030 (17.0%)	1,930 (7.8%)	1,830 (7.4%)	0.311	0.015
CCI-group:0	13,310 (48.2%)	17,670 (37.5%)	11,670 (47.0%)	11,860 (47.8%)	0.217	0.016
CCI-group:1-2	9,290 (33.6%)	15,790 (33.5%)	8,450 (34.0%)	8,260 (33.3%)	0.003	0.016
CCI-group:>=3 Prior bleeding (any)	5,040 (18.2%) 2,480 (9.0%)	13,700 (29.0%) 5,150 (10.9%)	4,720 (19.0%) 2,250 (9.1%)	4,720 (19.0%) 2,260 (9.1%)	0.257 0.065	0.001
Prior gastrointestinal bleeding	150 (0.5%)	360 (0.8%)	140 (0.6%)	160 (0.6%)	0.026	0.008
Prior intracranial bleeding	240 (0.9%)	410 (0.9%)	200 (0.8%)	200 (0.8%)	0.000	0.001
Prior stroke (any)	3,000 (10.9%)	6,200 (13.1%)	2,740 (11.0%)	2,720 (11.0%)	0.070	0.003
Prior ischaemic stroke	2,900 (10.5%)	6,080 (12.9%)	2,660 (10.7%)	2,640 (10.6%)	0.075	0.002
Prior haemorrhagic stroke	210 (0.8%)	330 (0.7%)	180 (0.7%)	180 (0.7%)	0.007	0.000
Prior systemic embolism	130 (0.5%)	510 (1.1%)	130 (0.5%)	120 (0.5%)	0.068	0.004
Prior transient ischaemic attack	1,000 (3.6%)	2,050 (4.3%)	920 (3.7%)	910 (3.7%)	0.037	0.003
Chronic kidney disease	470 (1.7%)	3,280 (7.0%)	470 (1.9%)	430 (1.7%)	0.260	0.011
Heart failure	4,220 (15.3%)	11,330 (24.0%)	3,980 (16.0%)	3,900 (15.7%)	0.222	0.009
Coronary artery disease	4,790 (17.3%)	12,460 (26.4%)	4,550 (18.3%)	4,490 (18.1%)	0.221	0.006
Peripheral arterial disease	1,280 (4.6%)	3,030 (6.4%)	1,190 (4.8%)	1,190 (4.8%)	0.079	0.001
Hypertension	19,060 (69.0%) 4,550 (16.5%)	34,570 (73.3%)	17,250 (69.4%) 4,170 (16.8%)	17,250 (69.4%)	0.096	0.000
Diabetes Chronic obstructive pulmonary disease	2,880 (10.4%)	9,090 (19.3%) 5,700 (12.1%)	2,650 (10.7%)	4,180 (16.8%) 2,600 (10.5%)	0.073 0.053	0.001 0.006
Liver disease	210 (0.8%)	430 (0.9%)	190 (0.8%)	210 (0.8%)	0.015	0.006
Alcoholism	780 (2.8%)	1,030 (2.2%)	670 (2.7%)	660 (2.6%)	0.040	0.004
Dementia Cancer 6 months before and including	350 (1.3%) 160 (0.6%)	770 (1.6%) 400 (0.9%)	320 (1.3%) 150 (0.6%)	310 (1.3%) 150 (0.6%)	0.031	0.000
index date Platelet inhibitors		. ,				
(excluding heparin) Low -dose aspirin	9,020 (32.6%) 8,220 (29.7%)	18,680 (39.6%) 17,010 (36.1%)	8,370 (33.7%) 7,650 (30.8%)	8,510 (34.3%) 7,770 (31.3%)	0.146	0.012
ADP receptor blockers	1,270 (4.6%)	3,710 (7.9%)	1,190 (4.8%)	1,210 (4.9%)	0.135	0.004
Renin -angiotensin system inhibitors	13,340 (48.2%)	24,140 (51.2%)	12,100 (48.7%)	12,040 (48.5%)	0.059	0.005
Angiotensin - converting enzyme inhibitors	6,730 (24.4%)	13,490 (28.6%)	6,240 (25.1%)	6,240 (25.1%)	0.096	0.000
Angiotensin II antagonists, plain	4,640 (16.8%)	8,000 (17.0%)	4,120 (16.6%)	4,100 (16.5%)	0.005	0.002
Angiotensin II antagonists, combinations	1,770 (6.4%)	2,540 (5.4%)	1,560 (6.3%)	1,530 (6.2%)	0.043	0.004

Beta-blockers	21,290 (77.0%)	36,150 (76.7%)	19,030 (76.6%)	19,010 (76.5%)	0.009	0.002
Proton pump inhibitors	5,360 (19.4%)	10,150 (21.5%)	4,830 (19.5%)	4,760 (19.2%)	0.052	0.008
H2-receptor antagonists	100 (0.4%)	210 (0.4%)	90 (0.4%)	100 (0.4%)	0.015	0.006
Non-steroidal anti- inflammatory drugs	2,100 (7.6%)	2,970 (6.3%)	1,870 (7.5%)	1,860 (7.5%)	0.051	0.001
Statins	9,080 (32.8%)	16,730 (35.5%)	8,230 (33.1%)	8,210 (33.0%)	0.056	0.002
Antidiabetic agents	3,290 (11.9%)	6,350 (13.5%)	2,990 (12.0%)	3,000 (12.1%)	0.048	0.001
Loop diuretics	4,600 (16.6%)	12,990 (27.5%)	4,410 (17.7%)	4,310 (17.4%)	0.265	0.010
Non-loop diuretics	310 (1.1%)	650 (1.4%)	290 (1.2%)	270 (1.1%)	0.023	0.007
Alpha adrenergic blockers	6,030 (21.8%)	11,180 (23.7%)	5,500 (22.1%)	5,500 (22.1%)	0.046	0.000
Amiodarone	330 (1.2%)	890 (1.9%)	320 (1.3%)	310 (1.2%)	0.057	0.003
Dronedarone	370 (1.3%)	440 (0.9%)	310 (1.2%)	310 (1.3%)	0.038	0.002
Antihypertensive, combination drugs	2,610 (9.4%)	3,850 (8.2%)	2,310 (9.3%)	2,290 (9.2%)	0.045	0.002
Calcium channel blockers	6,710 (24.3%)	12,240 (26.0%)	6,080 (24.5%)	6,150 (24.7%)	0.039	0.006
Selective serotonin reuptake inhibitors	1,650 (6.0%)	3,110 (6.6%)	1,500 (6.0%)	1,460 (5.9%)	0.026	0.006
Drugs used in alcohol dependence	50 (0.2%)	60 (0.1%)	40 (0.2%)	40 (0.2%)	0.016	0.000
CHA2DS2-VASc, mean(SD)	3.0 (1.64)	3.6 (1.75)	3.1 (1.65)	3.0 (1.66)	0.319	0.018
CHA2DS2-VASc:0 -1	5,040 (18.2%)	5,700 (12.1%)	4,340 (17.5%)	4,420 (17.8%)	0.172	0.008
CHA2DS2-VASc:2 -3	12,560 (45.4%)	17,540 (37.2%)	11,090 (44.6%)	11,120 (44.7%)	0.168	0.002
CHA2DS2- VASc:>=4	10,040 (36.3%)	23,910 (50.7%)	9,410 (37.9%)	9,310 (37.5%)	0.293	0.008
CHADS2, mean(SD)	2.4 (1.40)	2.9 (1.47)	2.5 (1.41)	2.5 (1.41)	0.297	0.013
CHADS2:0	1,820 (6.6%)	2,300 (4.9%)	1,550 (6.2%)	1,810 (7.3%)	0.073	0.041
CHADS2:1	5,510 (19.9%)	6,040 (12.8%)	4,760 (19.1%)	4,480 (18.0%)	0.193	0.029
CHADS2:>=2	20,320 (73.5%)	38,810 (82.3%)	18,540 (74.6%)	18,560 (74.7%)	0.213	0.002
HAS-BLED, mean(SD)	1.7 (0.87)	1.9 (0.92)	1.7 (0.87)	1.7 (0.88)	0.224	0.008
HAS-BLED:<3	23,200 (83.9%)	36,080 (76.5%)	20,720 (83.4%)	20,750 (83.5%)	0.187	0.003
HAS-BLED:>=3	4,440 (16.1%)	11,080 (23.5%)	4,120 (16.6%)	4,090 (16.5%)	0.187	0.003
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.200	0.015
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.089	0.007
log_n_outpatient, median(IQR)	0.7 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.353	0.025
income, median(IQR), k€	57.4 (44.1 - 87.9)	49.8 (40.5 - 72.3)	55.9 (43.5 - 85.0)	55.9 (43.5 - 84.2)	0.129	0.006
education:Secondary compulsory	8,870 (32.1%)	18,850 (40.0%)	8,260 (33.3%)	8,170 (32.9%)	0.164	0.008
education:Vocationa 1 / High school	11,280 (40.8%)	18,480 (39.2%)	10,170 (40.9%)	10,290 (41.4%)	0.033	0.010
education:Higher education	7,260 (26.3%)	9,340 (19.8%)	6,200 (25.0%)	6,160 (24.8%)	0.154	0.003
education:Unknown	230 (0.8%)	490 (1.0%)	210 (0.8%)	230 (0.9%)	0.022	0.006




Table 15.50 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>apixaban</u> or warfarin and standardised mean differences before and after matching, Sweden – REDUCED DOSE

Characteristic	Apixaban (rounded) before matching N=11187	Warfarin (rounded) before matching N=47152	Apixaban (rounded) after matching N= 9983	Warfarin (rounded) after matching N= 9983	Standardised mean difference before matching (max= 1.10)	Standardised mean difference after matching (max= 0.05)
Time from AF diag:< 1 month	6,810 (60.9%)	28,530 (60.5%)	6,060 (60.7%)	5,990 (60.0%)	0.007	0.015
Time from AF diag:1 - 6 month	1,060 (9.5%)	4,220 (9.0%)	950 (9.5%)	990 (9.9%)	0.019	0.014
Time from AF diag:6 - 60 months	3,320 (29.7%)	14,400 (30.5%)	2,970 (29.8%)	3,010 (30.1%)	0.020	0.007
Sex:Female	6,800 (60.8%)	20,290 (43.0%)	5,890 (59.0%)	5,790 (58.0%)	0.362	0.019
Sex:Male	4,380 (39.2%)	26,860 (57.0%)	4,100 (41.0%)	4,190 (42.0%)	0.362	0.019
Age, median(IQR)	85.8 (81.2 - 89.9)	75.6 (68.4 - 82.6)	85.0 (80.5 - 89.0)	85.0 (80.7 - 88.9)	1.097	0.004
Age -group:< 55 years	40 (0.4%)	2,130 (4.5%)	40 (0.4%)	30 (0.3%)	0.271	0.020
Age -group:55-<65 years	160 (1.5%)	5,540 (11.8%)	160 (1.6%)	170 (1.7%)	0.423	0.008
Age -group:65-<75 years	870 (7.8%)	14,880 (31.6%)	870 (8.7%)	850 (8.6%)	0.627	0.006
Age -group:75-<85 years	4,020 (35.9%)	16,570 (35.1%)	3,920 (39.3%)	3,960 (39.7%)	0.016	0.008
Age -group:>= 85 years CCI-group:0	6,100 (54.5%)	8,030 (17.0%) 17,670 (37.5%)	4,980 (49.9%)	4,960 (49.7%)	0.849	0.004
CCI-group:0 CCI-group:1-2	2,790 (25.0%) 3,830 (34.2%)	15,790 (33.5%)	2,620 (26.3%) 3,430 (34.4%)	2,710 (27.2%) 3,290 (33.0%)	0.272	0.020
CCI-group:>=3	4,570 (40.8%)	13,700 (29.0%)	3,930 (39.4%)	3,980 (39.8%)	0.249	0.029
Prior bleeding (any)	1,700 (15.2%)	5,150 (10.9%)	1,470 (14.7%)	1,480 (14.8%)	0.127	0.003
Prior gastrointestinal bleeding	120 (1.1%)	360 (0.8%)	100 (1.0%)	100 (1.0%)	0.037	0.002
Prior intracranial bleeding	240 (2.1%)	410 (0.9%)	180 (1.8%)	180 (1.8%)	0.103	0.005
Prior stroke (any)	2,370 (21.2%)	6,200 (13.1%)	2,000 (20.1%)	1,980 (19.8%)	0.214	0.006
Prior ischaemic stroke	2,270 (20.3%)	6,080 (12.9%)	1,930 (19.4%)	1,920 (19.2%)	0.200	0.003
Prior haemorrhagic stroke	220 (1.9%)	330 (0.7%)	170 (1.7%)	170 (1.7%)	0.109	0.002
Prior systemic embolism	110 (1.0%)	510 (1.1%)	110 (1.1%)	110 (1.1%)	0.010	0.002
Prior transient ischaemic attack	770 (6.9%)	2,050 (4.3%)	650 (6.5%)	620 (6.2%)	0.109	0.011
Chronic kidney disease Heart failure	1,110 (9.9%) 3,780 (33.7%)	3,280 (7.0%)	970 (9.7%)	1,040 (10.4%)	0.107	0.025
Coronary artery	5,780 (55.7%)	11,330 (24.0%)	3,240 (32.5%)	3,210 (32.2%)	0.216	0.006
disease Peripheral arterial	3,460 (31.0%)	12,460 (26.4%)	3,080 (30.8%)	3,160 (31.7%)	0.100	0.018
disease Hypertension	790 (7.1%) 8,680 (77.6%)	3,030 (6.4%) 34,570 (73.3%)	710 (7.2%) 7,750 (77.6%)	690 (7.0%) 7,800 (78.2%)	0.025	0.008
Diabetes	2,090 (18.7%)	9,090 (19.3%)	1,890 (18.9%)	1,940 (19.5%)	0.014	0.014
Chronic obstructive pulmonary disease	1,670 (14.9%)	5,700 (12.1%)	1,460 (14.6%)	1,490 (14.9%)	0.083	0.007
Liver disease	90 (0.8%)	430 (0.9%)	80 (0.8%)	80 (0.8%)	0.014	0.002
Alcoholism	170 (1.5%)	1,030 (2.2%)	160 (1.6%)	160 (1.6%)	0.046	0.001
Dementia	670 (6.0%)	770 (1.6%)	490 (4.9%)	450 (4.5%)	0.230	0.015
Cancer 6 months before and including index date	70 (0.6%)	400 (0.9%)	70 (0.7%)	70 (0.7%)	0.030	0.001
Platelet inhibitors (excluding heparin)	5,500 (49.2%)	18,680 (39.6%)	4,820 (48.2%)	4,930 (49.4%)	0.193	0.024
Low -dose aspirin	4,870 (43.5%)	17,010 (36.1%)	4,290 (43.0%)	4,400 (44.1%)	0.153	0.022
ADP receptor blockers	1,010 (9.1%)	3,710 (7.9%)	890 (8.9%)	930 (9.3%)	0.043	0.013
Renin -angiotensin system inhibitors	5,680 (50.8%)	24,140 (51.2%)	5,080 (50.9%)	5,100 (51.1%)	0.009	0.003
Angiotensin - converting enzyme inhibitors	3,130 (28.0%)	13,490 (28.6%)	2,800 (28.1%)	2,800 (28.0%)	0.013	0.001
Angiotensin II antagonists, plain	2,060 (18.4%)	8,000 (17.0%)	1,830 (18.4%)	1,830 (18.4%)	0.037	0.000
Angiotensin II antagonists, combinations	530 (4.8%)	2,540 (5.4%)	490 (4.9%)	490 (4.9%)	0.029	0.004
Beta-blockers	8,490 (75.9%)	36,150 (76.7%)	7,560 (75.7%)	7,580 (75.9%)	0.017	0.004
Proton pump inhibitors	3,030 (27.1%)	10,150 (21.5%)	2,620 (26.3%)	2,670 (26.7%)	0.130	0.011
H2-receptor antagonists	50 (0.5%)	210 (0.4%)	50 (0.5%)	50 (0.5%)	0.004	0.003

Non-steroidal anti- inflammatory drugs	510 (4.5%)	2,970 (6.3%)	470 (4.7%)	450 (4.5%)	0.078	0.007
Statins	3,630 (32.4%)	16,730 (35.5%)	3,320 (33.3%)	3,390 (34.0%)	0.065	0.015
Antidiabetic agents	1,300 (11.6%)	6,350 (13.5%)	1,190 (11.9%)	1,250 (12.5%)	0.056	0.018
Loop diuretics	4,340 (38.8%)	12,990 (27.5%)	3,760 (37.7%)	3,810 (38.1%)	0.241	0.009
Non-loop diuretics	130 (1.2%)	650 (1.4%)	120 (1.2%)	140 (1.4%)	0.020	0.014
Alpha adrenergic blockers	2,700 (24.1%)	11,180 (23.7%)	2,440 (24.5%)	2,460 (24.7%)	0.009	0.005
Amiodarone	120 (1.1%)	890 (1.9%)	120 (1.2%)	130 (1.3%)	0.068	0.009
Dronedarone	40 (0.3%)	440 (0.9%)	40 (0.4%)	20 (0.2%)	0.077	0.024
Antihypertensive, combination drugs	770 (6.8%)	3,850 (8.2%)	700 (7.0%)	720 (7.2%)	0.050	0.006
Calcium channel blockers	3,020 (27.0%)	12,240 (26.0%)	2,700 (27.1%)	2,750 (27.5%)	0.023	0.010
Selective serotonin reuptake inhibitors	1,100 (9.9%)	3,110 (6.6%)	920 (9.3%)	910 (9.1%)	0.119	0.006
Drugs used in alcohol dependence	10 (0.1%)	60 (0.1%)	10 (0.1%)	<5	0.019	0.013
CHA2DS2-VASc, mean(SD)	4.6 (1.47)	3.6 (1.75)	4.6 (1.47)	4.5 (1.52)	0.659	0.006
CHA2DS2-VASc:0 -1	110 (0.9%)	5,700 (12.1%)	110 (1.1%)	160 (1.6%)	0.463	0.047
CHA2DS2-VASc:2 -3	2,260 (20.2%)	17,540 (37.2%)	2,150 (21.5%)	2,190 (21.9%)	0.383	0.010
CHA2DS2- VASc:>=4	8,820 (78.9%)	23,910 (50.7%)	7,730 (77.4%)	7,640 (76.5%)	0.617	0.022
CHADS2, mean(SD)	3.7 (1.26)	2.9 (1.47)	3.7 (1.25)	3.7 (1.28)	0.621	0.004
CHADS2:0	40 (0.3%)	2,300 (4.9%)	40 (0.4%)	40 (0.4%)	0.289	0.006
CHADS2:1	190 (1.7%)	6,040 (12.8%)	190 (1.9%)	250 (2.5%)	0.441	0.042
CHADS2:>=2	10,970 (98.0%)	38,810 (82.3%)	9,760 (97.8%)	9,700 (97.1%)	0.547	0.041
HAS-BLED, mean(SD)	2.3 (0.84)	1.9 (0.92)	2.3 (0.83)	2.3 (0.85)	0.396	0.006
HAS-BLED:<3	7,170 (64.1%)	36,080 (76.5%)	6,510 (65.2%)	6,480 (64.9%)	0.275	0.005
HAS-BLED:>=3	4,020 (35.9%)	11,080 (23.5%)	3,480 (34.8%)	3,500 (35.1%)	0.275	0.005
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.291	0.011
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.086	0.028
log_n_outpatient, median(IQR)	0.7 (0.0 - 1.1)	0.0 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.581	0.007
income, median(IQR), k€	45.9 (39.3 - 56.5)	49.8 (40.5 - 72.3)	45.9 (39.1 - 56.8)	46.1 (39.3 - 56.8)	0.127	0.010
education:Secondar y compulsory	5,770 (51.6%)	18,850 (40.0%)	5,080 (50.9%)	5,040 (50.5%)	0.235	0.008
education:Vocation al / High school	3,510 (31.3%)	18,480 (39.2%)	3,180 (31.9%)	3,190 (31.9%)	0.165	0.000
education:Higher education	1,720 (15.3%)	9,340 (19.8%)	1,550 (15.5%)	1,590 (15.9%)	0.118	0.011
education:Unknown	200 (1.7%)	490 (1.0%)	170 (1.7%)	170 (1.7%)	0.060	0.000




Table 15.51 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – STANDARD DOSE

Characteristic	Dabigatran (rounded) before matching N=20478	Warfarin (rounded) before matching N=79171	Dabigatran (rounded) after matching N=18701	Warfarin (rounded) after matching N=18701	Standardised mean difference before matching	Standardised mean difference after matching
in ten	7.020 (29.7%)	25,000 (44,20/)	7 240 (20 20()	7 200 (20 50()	(max = 0.78)	(max = 0.04)
index_year:2013	7,920 (38.7%)	35,000 (44.2%)	7,340 (39.3%)	7,390 (39.5%)	0.112 0.114	0.005 0.004
index_year:2014	7,130 (34.8%)	23,330 (29.5%)	6,350 (34.0%)	6,310 (33.8%)		
index_year:2015	2,820 (13.8%)	13,390 (16.9%)	2,750 (14.7%)	2,730 (14.6%)	0.087	0.003
index_year:2016	2,610 (12.7%)	7,460 (9.4%)	2,260 (12.1%)	2,270 (12.2%)	0.106	0.002
Time from AF diag:< 1 month	13,600 (66.4%)	47,550 (60.1%)	12,120 (64.8%)	11,980 (64.1%)	0.132	0.015
Time from AF diag:1 - 6 month	1,540 (7.5%)	7,970 (10.1%)	1,490 (8.0%)	1,530 (8.2%)	0.090	0.007
Time from AF diag:6 - 60 months	5,340 (26.1%)	23,650 (29.9%)	5,090 (27.2%)	5,190 (27.8%)	0.085	0.012
Sex:Female	6,560 (32.1%)	32,980 (41.7%)	6,110 (32.7%)	6,050 (32.4%)	0.200	0.007
Sex:Male	13,910 (67.9%)	46,190 (58.3%)	12,590 (67.3%)	12,650 (67.6%)	0.200	0.007
Age, median(IQR)	67.6 (61.5 - 72.4)	75.0 (67.5 - 82.2)	67.9 (61.7 - 72.7)	67.9 (61.7 - 72.8)	0.775	0.001
Age -group:< 55 years	2,330 (11.4%)	4,480 (5.7%)	2,110 (11.3%)	2,130 (11.4%)	0.206	0.003
Age -group:55-<65 years	5,240 (25.6%)	10,100 (12.8%)	4,610 (24.7%)	4,640 (24.8%)	0.330	0.003
Age -group:65-<75 years	10,030 (49.0%)	25,060 (31.6%)	9,120 (48.8%)	9,040 (48.3%)	0.359	0.009
Age -group:75-<85 years	2,760 (13.5%)	26,700 (33.7%)	2,740 (14.7%)	2,780 (14.9%)	0.490	0.006
Age -group:>= 85 years	120 (0.6%)	12,830 (16.2%)	120 (0.6%)	120 (0.6%)	0.588	0.000
CCI-group:0	11,480 (56.1%)	29,610 (37.4%)	10,150 (54.3%)	10,100 (54.0%)	0.381	0.005
CCI-group:1-2	6,410 (31.3%)	25,600 (32.3%)	6,030 (32.2%)	5,840 (31.2%)	0.022	0.022
CCI-group:>=3	2,590 (12.6%)	23,960 (30.3%)	2,530 (13.5%)	2,770 (14.8%)	0.440	0.037
Prior bleeding (any)	1,430 (7.0%)	8,870 (11.2%)	1,360 (7.3%)	1,380 (7.4%)	0.147	0.005
Prior gastrointestinal bleeding	100 (0.5%)	820 (1.0%)	100 (0.5%)	80 (0.4%)	0.066	0.003
Prior intracranial bleeding	120 (0.6%)	710 (0.9%)	110 (0.6%)	120 (0.6%)	0.038	0.006
Prior stroke (any)	1,650 (8.1%)	9,610 (12.1%)	1,550 (8.3%)	1,540 (8.2%)	0.135	0.001
Prior ischaemic stroke	1,620 (7.9%)	9,400 (11.9%)	1,520 (8.1%)	1,510 (8.1%)	0.133	0.001
Prior haemorrhagic stroke	70 (0.4%)	520 (0.7%)	70 (0.4%)	80 (0.4%)	0.042	0.003
Prior systemic embolism	50 (0.2%)	760 (1.0%)	50 (0.2%)	40 (0.2%)	0.096	0.003
Prior transient ischaemic attack	570 (2.8%)	3,120 (3.9%)	530 (2.8%)	500 (2.7%)	0.066	0.009
Chronic kidney disease	180 (0.9%)	6,530 (8.2%)	180 (1.0%)	180 (0.9%)	0.358	0.003
Heart failure	2,300 (11.2%)	18,010 (22.7%)	2,240 (12.0%)	2,280 (12.2%)	0.311	0.006
Coronary artery disease	2,870 (14.0%)	21,450 (27.1%)	2,810 (15.0%)	2,850 (15.2%)	0.327	0.005
Peripheral arterial disease	840 (4.1%)	6,030 (7.6%)	810 (4.3%)	840 (4.5%)	0.151	0.009
Hypertension	11,580 (56.6%)	54,110 (68.3%)	10,730 (57.4%)	10,670 (57.1%)	0.245	0.007
Diabetes	2,630 (12.8%)	14,680 (18.5%)	2,520 (13.5%)	2,550 (13.7%)	0.157	0.006
Chronic obstructive pulmonary disease	1,750 (8.5%)	10,120 (12.8%)	1,670 (8.9%)	1,660 (8.9%)	0.138	0.001
Liver disease	170 (0.8%)	820 (1.0%)	170 (0.9%)	170 (0.9%)	0.020	0.001
Alcoholism	630 (3.1%)	1,790 (2.3%)	580 (3.1%)	610 (3.2%)	0.050	0.001
Dementia	80 (0.4%)	1,220 (1.5%)	80 (0.4%)	70 (0.4%)	0.118	0.009
Cancer 6 months before and including index date	480 (2.3%)	2,140 (2.7%)	460 (2.4%)	430 (2.3%)	0.024	0.008
Platelet inhibitors (excluding heparin)	5,740 (28.0%)	30,840 (39.0%)	5,400 (28.9%)	5,500 (29.4%)	0.234	0.012
Low -dose aspirin	5,180 (25.3%)	27,180 (34.3%)	4,860 (26.0%)	4,930 (26.4%)	0.198	0.009
ADP receptor blockers	720 (3.5%)	7,100 (9.0%)	720 (3.8%)	740 (4.0%)	0.226	0.006
Renin -angiotensin system inhibitors	8,250 (40.3%)	38,070 (48.1%)	7,650 (40.9%)	7,640 (40.8%)	0.158	0.001
Angiotensin - converting enzyme inhibitors	3,690 (18.0%)	20,500 (25.9%)	3,550 (19.0%)	3,570 (19.1%)	0.191	0.003
Angiotensin II antagonists, plain	2,430 (11.9%)	11,850 (15.0%)	2,240 (12.0%)	2,170 (11.6%)	0.091	0.011
Angiotensin II antagonists, combinations	1,810 (8.8%)	5,210 (6.6%)	1,560 (8.4%)	1,560 (8.3%)	0.084	0.000
Beta-blockers	14,670 (71.6%)	56,980 (72.0%)	13,310 (71.2%)	13,170 (70.4%)	0.008	0.016

Proton pump inhibitors	2,770 (13.5%)	17,350 (21.9%)	2,660 (14.2%)	2,660 (14.2%)	0.221	0.001
Non-steroidal anti- inflammatory drugs	2,090 (10.2%)	5,860 (7.4%)	1,840 (9.8%)	1,880 (10.0%)	0.099	0.006
Statins	6,110 (29.8%)	28,740 (36.3%)	5,710 (30.5%)	5,750 (30.7%)	0.138	0.005
Antidiabetic agents	1,910 (9.3%)	10,410 (13.1%)	1,840 (9.9%)	1,870 (10.0%)	0.122	0.004
Loop diuretics	2,490 (12.2%)	22,170 (28.0%)	2,460 (13.1%)	2,460 (13.1%)	0.404	0.001
Non-loop diuretics	230 (1.1%)	1,230 (1.6%)	210 (1.1%)	200 (1.1%)	0.039	0.005
Alpha adrenergic blockers	2,690 (13.2%)	15,810 (20.0%)	2,600 (13.9%)	2,620 (14.0%)	0.184	0.003
Amiodarone	350 (1.7%)	2,560 (3.2%)	350 (1.9%)	350 (1.9%)	0.098	0.001
Dronedarone	70 (0.4%)	600 (0.8%)	70 (0.4%)	80 (0.4%)	0.054	0.003
Antihypertensive, combination drugs	2,540 (12.4%)	7,700 (9.7%)	2,240 (12.0%)	2,250 (12.0%)	0.086	0.002
Calcium channel blockers	3,960 (19.3%)	19,680 (24.9%)	3,760 (20.1%)	3,760 (20.1%)	0.133	0.001
Selective serotonin reuptake inhibitors	810 (3.9%)	4,790 (6.1%)	770 (4.1%)	760 (4.1%)	0.097	0.002
Drugs used in alcohol dependence	60 (0.3%)	120 (0.2%)	50 (0.3%)	50 (0.3%)	0.033	0.001
CHA2DS2-VASc, mean(SD)	2.2 (1.48)	3.4 (1.76)	2.3 (1.48)	2.3 (1.52)	0.732	0.004
CHA2DS2-VASc:0 - 1	7,010 (34.2%)	11,520 (14.6%)	6,020 (32.2%)	6,200 (33.1%)	0.471	0.020
CHA2DS2-VASc:2 - 3	9,810 (47.9%)	30,330 (38.3%)	9,120 (48.8%)	8,820 (47.2%)	0.195	0.032
CHA2DS2- VASc:>=4	3,660 (17.8%)	37,330 (47.1%)	3,560 (19.0%)	3,680 (19.7%)	0.659	0.016
CHADS2, mean(SD)	1.3 (1.21)	2.4 (1.51)	1.4 (1.22)	1.4 (1.24)	0.769	0.009
CHADS2:0	5,800 (28.3%)	8,300 (10.5%)	4,850 (25.9%)	5,090 (27.2%)	0.463	0.029
CHADS2:1	7,070 (34.5%)	15,840 (20.0%)	6,510 (34.8%)	6,300 (33.7%)	0.331	0.024
CHADS2:>=2	7,610 (37.1%)	55,030 (69.5%)	7,340 (39.3%)	7,320 (39.1%)	0.686	0.003
HAS-BLED, mean(SD)	1.6 (1.03)	2.0 (1.05)	1.6 (1.03)	1.6 (1.05)	0.428	0.008
HAS-BLED:<3	16,950 (82.8%)	56,150 (70.9%)	15,340 (82.0%)	15,250 (81.5%)	0.284	0.013
HAS-BLED:>=3	3,530 (17.2%)	23,020 (29.1%)	3,360 (18.0%)	3,450 (18.5%)	0.284	0.013
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.308	0.003
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.054	0.010
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.126	0.001

Table 15.52 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – REDUCED DOSE

	Dabigatran (rounded) before matching N=10731	before matching N=79171	Dabigatran (rounded) after matching N=10669	after matching N=10669	difference before matching	dised m ean
	N=10731	N=79171	N=10669	N=10669		ean
						11.00
					(max= 0.62)	differen
1						ce after ma
						tching
						(max=0)
						.07)
index_year:2013	4,640 (43.3%)	35,000 (44.2%)	4,600 (43.1%)	4,660 (43.7%)	0.019	0.011
index_year:2014	3,340 (31.2%)	23,330 (29.5%)	3,330 (31.2%)	3,260 (30.5%)	0.037	0.015
index_year:2015	1,400 (13.0%)	13,390 (16.9%)	1,400 (13.1%)	1,420 (13.3%)	0.109	0.006
index_year:2016	1,350 (12.6%)	7,460 (9.4%)	1,340 (12.5%)	1,340 (12.5%)	0.101	0.001
Time from AF diag:< 1 month	6,560 (61.1%)	47,550 (60.1%)	6,530 (61.2%)	6,480 (60.7%)	0.022	0.010
Time from AF diag:1 - 6 month	1,100 (10.3%)	7,970 (10.1%)	1,100 (10.3%)	1,140 (10.6%)	0.007	0.012
Time from AF diag:6 - 60 months	3,070 (28.6%)	23,650 (29.9%)	3,050 (28.5%)	3,060 (28.7%)	0.028	0.003
Sex:Female	5,700 (53.1%)	32,980 (41.7%)	5,650 (52.9%)	5,710 (53.5%)	0.230	0.012
Sex:Male	5,030 (46.9%)	46,190 (58.3%)	5,020 (47.1%)	4,960 (46.5%)	0.230	0.012
Age, median(IQR)	81.3 (75.9 - 85.7)	75.0 (67.5 - 82.2)	81.3 (75.9 - 85.7)	81.4 (76.2 - 85.9)	0.617	0.007
Age -group:< 55 years	110 (1.0%)	4,480 (5.7%)	110 (1.0%)	120 (1.1%)	0.263	0.014
Age -group:55-<65 years	500 (4.6%)	10,100 (12.8%)	500 (4.7%)	510 (4.8%)	0.291	0.004
Age -group:65-<75 years	1,760 (16.4%)	25,060 (31.6%)	1,760 (16.5%)	1,700 (15.9%)	0.362	0.016
Age -group:75-<85 years	5,310 (49.5%)	26,700 (33.7%)	5,280 (49.5%)	5,200 (48.7%)	0.324	0.016
Age -group:>= 85 years	3,050 (28.4%)	12,830 (16.2%)	3,020 (28.3%)	3,150 (29.5%)	0.297	0.026
CCI-group:0	3,850 (35.9%)	29,610 (37.4%)	3,840 (36.0%)	3,820 (35.8%)	0.031	0.004
CCI-group:1-2	3,880 (36.1%)	25,600 (32.3%)	3,860 (36.1%)	3,740 (35.0%)	0.080	0.023
CCI-group:>=3	3,000 (28.0%)	23,960 (30.3%)	2,980 (27.9%)	3,120 (29.2%)	0.050	0.029
Prior bleeding (any)	1,380 (12.9%)	8,870 (11.2%)	1,370 (12.8%)	1,430 (13.4%)	0.051	0.017
Prior gastrointestinal bleeding	150 (1.4%)	820 (1.0%)	150 (1.4%)	170 (1.5%)	0.031	0.016
Prior intracranial bleeding	170 (1.6%)	710 (0.9%)	160 (1.5%)	160 (1.5%)	0.060	0.004
Prior stroke (any)	1,730 (16.1%)	9,610 (12.1%)	1,710 (16.0%)	1,730 (16.2%)	0.114	0.006
Prior ischaemic stroke	1,680 (15.6%)	9,400 (11.9%)	1,660 (15.5%)	1,680 (15.7%)	0.109	0.006
Prior haemorrhagic stroke	130 (1.2%)	520 (0.7%)	130 (1.2%)	130 (1.2%)	0.057	0.001
Prior systemic embolism	90 (0.8%)	760 (1.0%)	90 (0.8%)	80 (0.8%)	0.016	0.006
Prior transient ischaemic attack	590 (5.5%)	3,120 (3.9%)	580 (5.4%)	570 (5.3%)	0.074	0.005
Chronic kidney disease	370 (3.5%)	6,530 (8.2%)	370 (3.5%)	390 (3.7%)	0.204	0.009
Heart failure	2,040 (19.0%)	18,010 (22.7%)	2,030 (19.0%)	2,070 (19.4%)	0.093	0.009
Coronary artery disease Peripheral arterial	2,640 (24.6%) 790 (7.4%)	21,450 (27.1%) 6,030 (7.6%)	2,630 (24.7%) 790 (7.4%)	2,680 (25.1%) 790 (7.4%)	0.058 0.009	0.010
disease	5 000 (10 01)	51 110 (-0 A	5.040 (10.011)	5 0 40 4 - 0 0 - 11	0.011	0.001
Hypertension Diabetes	7,390 (68.9%)	54,110 (68.3%)	7,340 (68.8%)	7,340 (68.8%)	0.011 0.082	0.001
Chronic obstructive	1,660 (15.5%) 1,520 (14.2%)	14,680 (18.5%) 10,120 (12.8%)	1,650 (15.5%) 1,510 (14.1%)	1,670 (15.7%) 1,560 (14.6%)	0.082	0.005
pulmonary disease	1,520 (14.270)	10,120 (12.070)	1,510 (14.170)	1,500 (14.070)	0.040	0.012
Liver disease	90 (0.8%)	820 (1.0%)	90 (0.8%)	90 (0.9%)	0.021	0.004
Alcoholism	230 (2.1%)	1,790 (2.3%)	220 (2.1%)	220 (2.1%)	0.008	0.001
Dementia	340 (3.1%)	1,220 (1.5%)	320 (3.0%)	310 (2.9%)	0.106	0.002
Cancer 6 months before and including index	400 (3.7%)	2,140 (2.7%)	400 (3.8%)	420 (3.9%)	0.059	0.009
date Platelet inhibitors	4,620 (43.0%)	30,840 (39.0%)	4,580 (42.9%)	4,570 (42.8%)	0.083	0.002
(excluding heparin) Low -dose aspirin	3,990 (37.2%)	27,180 (34.3%)	3,960 (37.1%)	3,950 (37.0%)	0.060	0.003
ADP receptor blockers	920 (8.6%)	7,100 (9.0%)	910 (8.6%)	<u>3,950 (37.0%)</u> 920 (8.7%)	0.060	0.003
Renin -angiotensin system inhibitors	4,800 (44.7%)	38,070 (48.1%)	4,770 (44.7%)	4,730 (44.3%)	0.068	0.004
Angiotensin - converting enzyme	2,280 (21.3%)	20,500 (25.9%)	2,270 (21.3%)	2,180 (20.4%)	0.109	0.022
inhibitore	1.520 (14.20()	11,850 (15.0%)	1,520 (14.2%)	1,580 (14.8%)	0.020	0.016
inhibitors Angiotensin II antagonists, plain	1,530 (14.3%)	11,050 (15.070)	, , , , , , , , , , , , , , , , , , ,			
	920 (8.5%)	5,210 (6.6%)	910 (8.5%)	910 (8.5%)	0.074	0.001

Proton pump inhibitors	2,410 (22.5%)	17,350 (21.9%)	2,400 (22.5%)	2,470 (23.2%)	0.013	0.015
Non-steroidal anti-	900 (8.4%)	5,860 (7.4%)	890 (8.3%)	880 (8.3%)	0.038	0.003
inflammatory drugs						
Statins	3,740 (34.9%)	28,740 (36.3%)	3,730 (35.0%)	3,760 (35.2%)	0.030	0.005
Antidiabetic agents	1,160 (10.8%)	10,410 (13.1%)	1,160 (10.8%)	1,140 (10.7%)	0.072	0.003
Loop diuretics	2,880 (26.9%)	22,170 (28.0%)	2,880 (27.0%)	2,900 (27.2%)	0.026	0.005
Non-loop diuretics	150 (1.4%)	1,230 (1.6%)	150 (1.4%)	140 (1.3%)	0.014	0.002
Alpha adrenergic blockers	1,920 (17.9%)	15,810 (20.0%)	1,910 (17.9%)	1,900 (17.8%)	0.054	0.003
Amiodarone	290 (2.7%)	2,560 (3.2%)	290 (2.7%)	280 (2.7%)	0.033	0.003
Dronedarone	20 (0.2%)	600 (0.8%)	20 (0.2%)	20 (0.2%)	0.078	0.002
Antihypertensive, combination drugs	1,270 (11.8%)	7,700 (9.7%)	1,260 (11.8%)	1,250 (11.7%)	0.067	0.001
Calcium channel blockers	2,750 (25.6%)	19,680 (24.9%)	2,730 (25.6%)	2,730 (25.6%)	0.018	0.000
Selective serotonin reuptake inhibitors	740 (6.9%)	4,790 (6.1%)	730 (6.8%)	720 (6.8%)	0.034	0.002
Drugs used in alcohol dependence	20 (0.2%)	120 (0.2%)	20 (0.2%)	20 (0.2%)	0.006	0.002
CHA2DS2-VASc, mean(SD)	3.9 (1.53)	3.4 (1.76)	3.9 (1.53)	3.9 (1.60)	0.303	0.012
CHA2DS2-VASc:0-1	470 (4.4%)	11,520 (14.6%)	470 (4.4%)	630 (5.9%)	0.352	0.068
CHA2DS2-VASc:2 -3	3,970 (37.0%)	30,330 (38.3%)	3,960 (37.1%)	3,650 (34.2%)	0.027	0.061
CHA2DS2-VASc:>=4	6,290 (58.6%)	37,330 (47.1%)	6,240 (58.5%)	6,390 (59.9%)	0.231	0.029
CHADS2, mean(SD)	2.4 (1.38)	2.4 (1.51)	2.4 (1.38)	2.4 (1.41)	0.034	0.007
CHADS2:0	510 (4.7%)	8,300 (10.5%)	510 (4.7%)	650 (6.1%)	0.219	0.061
CHADS2:1	2,360 (22.0%)	15,840 (20.0%)	2,350 (22.0%)	2,160 (20.3%)	0.049	0.044
CHADS2:>=2	7,860 (73.3%)	55,030 (69.5%)	7,810 (73.2%)	7,850 (73.6%)	0.083	0.009
HAS-BLED, mean(SD)	2.3 (0.98)	2.0 (1.05)	2.3 (0.97)	2.3 (1.01)	0.270	0.000
HAS-BLED:<3	6,580 (61.3%)	56,150 (70.9%)	6,560 (61.5%)	6,460 (60.5%)	0.204	0.020
HAS-BLED:>=3	4,150 (38.7%)	23,020 (29.1%)	4,110 (38.5%)	4,210 (39.5%)	0.204	0.020
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.017	0.017
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.056	0.016
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.091	0.004

Table 15.53 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Denmark – STANDARD DOSE

	Debiestres (mar 1	Wonforin (Dahiastran (arrant	Wonforin (1-1)	Standardised mean	Standardised mean
Characteristic	Dabigatran (rounde d) before matching N= 7853	Warfarin (rounded) before matching N=20070	Dabigatran (rounde d) after matching N= 7338	Warfarin (rounded) after matching N= 7338	difference before matching (max= 0.66)	difference after matching (max= 0.04)
index_year:2013	3,330 (42.4%)	6,810 (33.9%)	3,080 (41.9%)	3,060 (41.6%)	0.175	(max = 0.04) 0.006
index_year:2013	2,810 (35.8%)	5,400 (26.9%)	2,550 (34.8%)	2,590 (35.3%)	0.173	0.000
index_year:2014	1,030 (13.1%)	4,580 (22.8%)	1,030 (14.0%)	1.020 (13.9%)	0.256	0.003
index_year:2015	680 (8.7%)	3,280 (16.4%)	680 (9.3%)	680 (9.2%)	0.230	0.003
Time from AF diag:< 1 month	5,440 (69.2%)	12,620 (62.9%)	4,960 (67.6%)	4,890 (66.7%)	0.134	0.019
Time from AF diag:1 - 6 month	680 (8.7%)	2,410 (12.0%)	680 (9.2%)	710 (9.6%)	0.110	0.014
Time from AF diag:6 - 60 months	1,740 (22.1%)	5,040 (25.1%)	1,710 (23.2%)	1,740 (23.7%)	0.071	0.011
Sex:Female	2,510 (32.0%)	7,950 (39.6%)	2,390 (32.5%)	2,380 (32.5%)	0.159	0.001
Sex:Male	5,340 (68.0%)	12,120 (60.4%)	4,950 (67.5%)	4,960 (67.5%)	0.159	0.001
Age, median(IQR)	67.3 (61.2 - 71.9)	73.3 (66.1 - 80.6)	67.6 (61.5 - 72.2)	67.8 (61.6 - 72.4)	0.656	0.014
Age -group:< 55 years	900 (11.4%)	1,520 (7.6%)	840 (11.4%)	820 (11.2%)	0.132	0.006
Age -group:55-<65 years	2,100 (26.7%)	2,870 (14.3%)	1,870 (25.5%)	1,840 (25.0%)	0.311	0.012
Age -group:65-<75 years	3,900 (49.6%)	6,820 (34.0%)	3,670 (50.0%)	3,700 (50.4%)	0.321	0.007
Age -group:75-<85 years	950 (12.1%)	6,280 (31.3%)	950 (12.9%)	970 (13.2%)	0.479	0.010
Age -group:>= 85 years	10 (0.2%)	2,580 (12.9%)	10 (0.2%)	10 (0.2%)	0.533	0.003
CCI-group:0	4,620 (58.8%)	8,600 (42.8%)	4,210 (57.3%)	4,180 (56.9%)	0.324	0.009
CCI-group:1-2	2,340 (29.7%)	6,000 (29.9%)	2,240 (30.6%)	2,180 (29.7%)	0.004	0.020
CCI-group:>=3	900 (11.4%)	5,470 (27.2%)	890 (12.1%)	980 (13.4%)	0.409	0.040
Prior bleeding (any)	490 (6.3%)	1,940 (9.7%)	470 (6.4%)	480 (6.5%)	0.127	0.004
Prior gastrointestinal bleeding	40 (0.5%)	270 (1.4%)	40 (0.5%)	40 (0.5%)	0.090	0.004
Prior intracranial bleeding	30 (0.4%)	140 (0.7%)	30 (0.4%)	40 (0.5%)	0.036	0.006
Prior stroke (any)	620 (7.8%)	1,980 (9.8%)	580 (7.9%)	580 (8.0%)	0.071	0.004
Prior ischaemic stroke	610 (7.7%)	1,940 (9.7%)	570 (7.8%)	580 (7.9%)	0.069	0.004
Prior haemorrhagic stroke	20 (0.3%)	90 (0.4%)	20 (0.3%)	20 (0.3%)	0.029	0.008
Prior systemic embolism	10 (0.2%)	110 (0.5%)	10 (0.2%)	10 (0.2%)	0.062	0.000
Prior transient ischaemic attack	210 (2.7%)	600 (3.0%)	190 (2.6%)	190 (2.6%)	0.020	0.001
Chronic kidney disease	50 (0.7%)	1,690 (8.4%)	50 (0.7%)	50 (0.7%)	0.377	0.008
Heart failure	850 (10.8%)	3,570 (17.8%)	830 (11.3%)	860 (11.7%)	0.202	0.014
Coronary artery disease	1,060 (13.5%)	4,590 (22.9%)	1,040 (14.2%)	1,050 (14.3%)	0.244	0.004
Peripheral arterial disease	320 (4.1%)	1,630 (8.1%)	320 (4.3%)	320 (4.4%)	0.169	0.005
Hypertension	4,360 (55.5%)	12,270 (61.1%)	4,090 (55.7%)	4,080 (55.5%)	0.113	0.004
Diabetes	1,010 (12.8%)	3,490 (17.4%)	980 (13.3%)	990 (13.5%)	0.128	0.006
Chronic obstructive pulmonary disease	590 (7.5%)	2,570 (12.8%)	580 (7.9%)	570 (7.7%)	0.177	0.007
Liver disease	70 (0.9%)	240 (1.2%)	70 (0.9%)	60 (0.8%)	0.029	0.010
Alcoholism	290 (3.7%)	590 (2.9%)	270 (3.7%)	280 (3.9%)	0.040	0.011
Dementia	40 (0.5%)	220 (1.1%)	40 (0.6%)	30 (0.4%)	0.062	0.015
Cancer 6 months before and including index date	200 (2.6%)	930 (4.6%)	200 (2.8%)	190 (2.6%)	0.108	0.012
Platelet inhibitors (excluding heparin)	1,860 (23.7%)	6,760 (33.7%)	1,800 (24.5%)	1,840 (25.1%)	0.223	0.014
Low -dose aspirin	1,490 (19.0%)	5,110 (25.5%)	1,440 (19.6%)	1,460 (19.8%)	0.156	0.006
ADP receptor blockers	420 (5.4%)	2,260 (11.2%)	420 (5.7%)	430 (5.9%)	0.213	0.006
Renin -angiotensin system inhibitors	3,080 (39.3%)	8,420 (42.0%)	2,890 (39.4%)	2,930 (39.9%)	0.055	0.009
Angiotensin - converting enzyme inhibitors	1,530 (19.5%)	4,510 (22.5%)	1,460 (19.9%)	1,460 (19.9%)	0.074	0.001
Angiotensin II antagonists, plain	770 (9.8%)	2,220 (11.0%)	720 (9.8%)	710 (9.7%)	0.041	0.004
Angiotensin II antagonists, combinations	550 (7.0%)	1,210 (6.0%)	490 (6.7%)	510 (6.9%)	0.037	0.007

Beta-blockers	5,310 (67.6%)	12,420 (61.9%)	4,890 (66.6%)	4,820 (65.6%)	0.120	0.021
Proton pump						
inhibitors Non-steroidal anti-	1,060 (13.5%)	4,510 (22.5%)	1,040 (14.2%)	1,010 (13.8%)	0.234	0.011
inflammatory drugs	890 (11.3%)	1,980 (9.9%)	800 (11.0%)	820 (11.2%)	0.046	0.007
Statins	2,340 (29.8%)	6,990 (34.8%)	2,230 (30.4%)	2,240 (30.5%)	0.107	0.002
Antidiabetic agents	810 (10.3%)	2,650 (13.2%)	790 (10.8%)	800 (10.9%)	0.090	0.006
Loop diuretics	1,150 (14.7%)	5,800 (28.9%)	1,140 (15.5%)	1,150 (15.7%)	0.349	0.005
Non-loop diuretics	90 (1.2%)	350 (1.7%)	90 (1.2%)	80 (1.1%)	0.047	0.009
Alpha adrenergic blockers	1,140 (14.5%)	3,670 (18.3%)	1,100 (14.9%)	1,110 (15.1%)	0.101	0.003
Amiodarone	200 (2.6%)	970 (4.9%)	200 (2.8%)	210 (2.8%)	0.119	0.004
Dronedarone	10 (0.1%)	30 (0.1%)	10 (0.1%)	<5	0.020	0.006
Antihypertensive, combination drugs	930 (11.8%)	2,110 (10.5%)	850 (11.5%)	870 (11.9%)	0.042	0.012
Calcium channel blockers	1,600 (20.4%)	4,790 (23.9%)	1,520 (20.7%)	1,520 (20.7%)	0.084	0.002
Selective serotonin reuptake inhibitors	340 (4.3%)	1,150 (5.7%)	330 (4.4%)	310 (4.2%)	0.067	0.012
Drugs used in alcohol dependence	30 (0.4%)	50 (0.2%)	30 (0.4%)	30 (0.4%)	0.029	0.000
CHA2DS2-VASc, mean(SD)	2.2 (1.41)	3.1 (1.67)	2.3 (1.42)	2.3 (1.46)	0.573	0.010
CHA2DS2-VASc:0 -1	2,580 (32.8%)	3,580 (17.8%)	2,310 (31.5%)	2,350 (32.0%)	0.350	0.012
CHA2DS2-VASc:2 -3	3,940 (50.1%)	8,410 (41.9%)	3,720 (50.7%)	3,600 (49.1%)	0.165	0.032
CHA2DS2- VASc:>=4	1,340 (17.1%)	8,080 (40.2%)	1,310 (17.9%)	1,390 (18.9%)	0.530	0.027
CHADS2, mean(SD)	1.1 (1.01)	1.6 (1.21)	1.1 (1.01)	1.1 (1.03)	0.484	0.006
CHADS2:0	2,320 (29.5%)	3,470 (17.3%)	2,110 (28.7%)	2,140 (29.1%)	0.292	0.009
CHADS2:1	3,330 (42.4%)	6,320 (31.5%)	3,100 (42.3%)	3,050 (41.6%)	0.228	0.014
CHADS2:>=2	2,200 (28.0%)	10,280 (51.2%)	2,130 (29.0%)	2,150 (29.3%)	0.488	0.006
HAS-BLED, mean(SD)	1.7 (1.08)	2.1 (1.17)	1.7 (1.08)	1.7 (1.09)	0.383	0.010
HAS-BLED:<3	6,110 (77.8%)	12,660 (63.1%)	5,660 (77.2%)	5,560 (75.7%)	0.327	0.034
HAS-BLED:>=3	1,740 (22.2%)	7,410 (36.9%)	1,680 (22.8%)	1,780 (24.3%)	0.327	0.034
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.226	0.003
log_beddays, median(IQR)	0.7 (0.0 - 1.6)	1.1 (0.0 - 1.9)	0.7 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.305	0.015
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.012	0.007
income, median(IQR), k€	168.7 (113.9 - 268.2)	122.8 (88.9 - 187.6)	162.3 (111.7 - 258.8)	161.2 (111.2 - 255.0)	0.252	0.009
education:Secondar y compulsory	2,250 (28.7%)	8,430 (42.0%)	2,190 (29.9%)	2,180 (29.7%)	0.282	0.004
education:Vocation al / High school	3,660 (46.7%)	8,140 (40.6%)	3,420 (46.6%)	3,460 (47.2%)	0.123	0.012
education:Higher education	1,780 (22.6%)	2,980 (14.8%)	1,570 (21.4%)	1,540 (21.0%)	0.200	0.010
education:Unknown	160 (2.1%)	520 (2.6%)	150 (2.1%)	150 (2.1%)	0.034	0.002
employment:Emplo yed or self - employed	2,800 (35.7%)	3,720 (18.5%)	2,470 (33.6%)	2,400 (32.6%)	0.394	0.020
employment:Unem ployed	620 (7.8%)	1,190 (5.9%)	590 (8.1%)	600 (8.1%)	0.074	0.002
employment:Retire d	4,350 (55.4%)	15,010 (74.8%)	4,210 (57.3%)	4,270 (58.1%)	0.415	0.017
employment:Unkno	80 (1.0%)	150 (0.7%)	80 (1.0%)	80 (1.1%)	0.031	0.007




Table 15.54 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Denmark – REDUCED DOSE

Characteristic	Dabigatran (rounde d) before matching N= 4593	Warfarin (rounded) before matching N=20070	Dabigatran (rounde d) after matching N= 4556	Warfarin (rounded) after matching N= 4556	Standardised mean difference before matching (max= 0.78)	Standardised mean difference after matching (max= 0.08)
index_year:2013	2,050 (44.7%)	6,810 (33.9%)	2,020 (44.4%)	2,020 (44.3%)	0.221	0.001
index_year:2014	1,560 (34.1%)	5,400 (26.9%)	1,560 (34.2%)	1,520 (33.3%)	0.156	0.019
index_year:2015	600 (13.0%)	4,580 (22.8%)	600 (13.1%)	630 (13.7%)	0.258	0.017
index_year:2016	380 (8.3%)	3,280 (16.4%)	380 (8.3%)	400 (8.7%)	0.248	0.013
Time from AF	500 (0.570)	5,200 (10.470)	566 (8.576)	400 (0.770)	0.240	0.015
diag:< 1 month Time from AF	3,040 (66.2%)	12,620 (62.9%)	3,020 (66.3%)	3,020 (66.4%)	0.069	0.001
diag:1 - 6 month	450 (9.9%)	2,410 (12.0%)	450 (9.9%)	450 (9.9%)	0.069	0.001
Time from AF diag:6 - 60 months	1,100 (24.0%)	5,040 (25.1%)	1,080 (23.8%)	1,080 (23.7%)	0.027	0.001
Sex:Female	2,480 (53.9%)	7,950 (39.6%)	2,450 (53.7%)	2,500 (54.8%)	0.289	0.021
Sex:Male	2,120 (46.1%)	12,120 (60.4%)	2,110 (46.3%)	2,060 (45.2%)	0.289	0.021
Age, median(IQR)	81.3 (76.2 - 85.7)	73.3 (66.1 - 80.6)	81.3 (76.2 - 85.7)	81.4 (76.5 - 85.9)	0.780	0.012
Age -group:< 55 years	50 (1.0%)	1,520 (7.6%)	50 (1.0%)	50 (1.2%)	0.329	0.017
Age -group:55-<65 years	200 (4.4%)	2,870 (14.3%)	200 (4.4%)	200 (4.4%)	0.346	0.001
Age -group:65-<75 years	700 (15.3%)	6,820 (34.0%)	700 (15.5%)	670 (14.8%)	0.443	0.019
Age -group:75-<85	2,340 (50.9%)	6,280 (31.3%)	2,320 (51.0%)	2,260 (49.7%)	0.408	0.026
years Age -group:>= 85	1,300 (28.3%)	2,580 (12.9%)	1,280 (28.1%)	1,370 (30.0%)	0.390	0.041
years						
CCI-group:0	1,830 (39.8%)	8,600 (42.8%)	1,820 (40.0%)	1,830 (40.1%)	0.063	0.002
CCI-group:1-2	1,620 (35.2%)	6,000 (29.9%)	1,610 (35.3%)	1,580 (34.6%)	0.112	0.013
CCI-group:>=3	1,150 (25.1%)	5,470 (27.2%)	1,130 (24.8%)	1,150 (25.3%)	0.049	0.013
Prior bleeding (any)	510 (11.0%)	1,940 (9.7%)	500 (11.0%)	520 (11.5%)	0.045	0.017
Prior gastrointestinal bleeding	70 (1.5%)	270 (1.4%)	70 (1.5%)	70 (1.6%)	0.016	0.007
Prior intracranial bleeding	70 (1.4%)	140 (0.7%)	60 (1.3%)	60 (1.3%)	0.071	0.004
Prior stroke (any)	660 (14.3%)	1,980 (9.8%)	650 (14.2%)	630 (13.8%)	0.137	0.009
Prior ischaemic stroke	640 (14.0%)	1,940 (9.7%)	630 (13.8%)	620 (13.5%)	0.134	0.009
Prior haemorrhagic	30 (0.7%)	90 (0.4%)	30 (0.7%)	30 (0.7%)	0.042	0.003
stroke Prior systemic	20 (0.4%)	110 (0.5%)	20 (0.4%)	10 (0.3%)	0.017	0.026
embolism Prior transient	220 (4.7%)	600 (3.0%)	210 (4.6%)	210 (4.5%)	0.088	0.002
ischaemic attack Chronic kidney	120 (2.5%)	1,690 (8.4%)	120 (2.6%)	120 (2.7%)	0.260	0.008
disease						0.004
Heart failure Coronary artery	750 (16.4%) 980 (21.4%)	3,570 (17.8%) 4,590 (22.9%)	750 (16.4%) 980 (21.4%)	750 (16.5%)	0.038	0.004
disease Peripheral arterial		, , , ,		, , , ,		
disease Hypertension	300 (6.6%) 3,080 (67.1%)	1,630 (8.1%) 12,270 (61.1%)	300 (6.6%) 3,050 (67.0%)	300 (6.7%) 3,070 (67.4%)	0.059	0.002
Diabetes	680 (14.9%)	3,490 (17.4%)	670 (14.8%)	700 (15.3%)	0.068	0.003
Chronic obstructive	660 (14.4%)	2,570 (12.8%)	650 (14.4%)	660 (14.5%)	0.047	0.003
pulmonary disease	30 (0.6%)	240 (1.2%)	30 (0.6%)	30 (0.6%)	0.058	0.006
Liver disease	. ,					
Alcoholism	120 (2.6%)	590 (2.9%)	110 (2.5%)	110 (2.4%)	0.021	0.004
Dementia Cancer 6 months before and including index date	160 (3.5%) 180 (4.0%)	220 (1.1%) 930 (4.6%)	140 (3.1%) 180 (4.0%)	130 (2.7%) 190 (4.3%)	0.161	0.022
Platelet inhibitors (excluding heparin)	1,750 (38.1%)	6,760 (33.7%)	1,730 (38.1%)	1,740 (38.2%)	0.093	0.003
Low -dose aspirin	1,320 (28.7%)	5,110 (25.5%)	1,310 (28.7%)	1,320 (28.9%)	0.073	0.004
ADP receptor	560 (12.2%)	2,260 (11.2%)	560 (12.2%)	570 (12.5%)	0.031	0.009
blockers Renin -angiotensin	1,940 (42.2%)	8,420 (42.0%)	1,920 (42.2%)	1,900 (41.6%)	0.005	0.012
system inhibitors Angiotensin - converting enzyme inhibitors	970 (21.0%)	4,510 (22.5%)	960 (21.0%)	930 (20.4%)	0.036	0.015
Angiotensin II antagonists, plain	560 (12.2%)	2,220 (11.0%)	550 (12.2%)	570 (12.6%)	0.037	0.013
Angiotensin II antagonists,	330 (7.3%)	1,210 (6.0%)	330 (7.2%)	330 (7.2%)	0.049	0.003
combinations						

			1			
Proton pump inhibitors	1,050 (22.9%)	4,510 (22.5%)	1,050 (23.0%)	1,060 (23.3%)	0.012	0.007
Non-steroidal anti- inflammatory drugs	460 (9.9%)	1,980 (9.9%)	450 (9.9%)	450 (9.8%)	0.001	0.004
Statins	1,560 (34.1%)	6,990 (34.8%)	1,560 (34.2%)	560 (34.2%) 1,570 (34.4%)		0.006
Antidiabetic agents	500 (10.8%)	2,650 (13.2%)	490 (10.8%)	500 (11.0%)	0.075	0.006
Loop diuretics	1,350 (29.3%)	5,800 (28.9%)	1,340 (29.4%)	1,360 (29.8%)	0.009	0.008
Non-loop diuretics	70 (1.6%)	350 (1.7%)	70 (1.5%)	80 (1.7%)	0.012	0.012
Alpha adrenergic blockers	990 (21.6%)	3,670 (18.3%)	990 (21.7%)	980 (21.4%)	0.084	0.006
Amiodarone	190 (4.1%)	970 (4.9%)	190 (4.1%)	190 (4.1%)	0.037	0.000
Dronedarone	<5	30 (0.1%)	<5	10 (0.1%)	0.012	0.007
Antihypertensive, combination drugs	530 (11.4%)	2,110 (10.5%)	520 (11.4%)	510 (11.1%)	0.029	0.010
Calcium channel blockers	1,210 (26.4%)	4,790 (23.9%)	1,200 (26.4%)	1,230 (27.0%)	0.058	0.014
Selective serotonin reuptake inhibitors	350 (7.6%)	1,150 (5.7%)	340 (7.5%)	330 (7.3%)	0.076	0.010
Drugs used in alcohol dependence	10 (0.2%)	50 (0.2%)	10 (0.2%)	10 (0.2%)	0.001	0.005
CHA2DS2-VASc, mean(SD)	3.9 (1.45)	3.1 (1.67)	3.9 (1.45)	3.9 (1.51)	0.487	0.021
CHA2DS2-VASc:0 - 1	170 (3.7%)	3,580 (17.8%)	170 (3.8%)	230 (5.0%)	0.467	0.062
CHA2DS2-VASc:2 - 3	1,710 (37.2%)	8,410 (41.9%)	1,710 (37.4%)	1,570 (34.5%)	0.096	0.061
CHA2DS2- VASc:>=4	2,710 (59.0%)	8,080 (40.2%)	2,680 (58.8%)	2,750 (60.4%)	0.383	0.034
CHADS2, mean(SD)	2.1 (1.14)	1.6 (1.21)	2.1 (1.13)	2.1 (1.18)	0.407	0.009
CHADS2:0	190 (4.2%)	3,470 (17.3%)	190 (4.2%)	270 (6.0%)	0.434	0.081
CHADS2:1	1,150 (25.0%)	6,320 (31.5%)	1,150 (25.1%)	1,040 (22.7%)	0.145	0.057
CHADS2:>=2	3,260 (70.9%)	10,280 (51.2%)	3,220 (70.7%)	3,250 (71.3%)	0.411	0.014
HAS-BLED, mean(SD)	2.4 (0.99)	2.1 (1.17)	2.4 (0.99)	2.4 (1.03)	0.240	0.007
HAS-BLED:<3	2,570 (56.0%)	12,660 (63.1%)	2,560 (56.1%)	2,530 (55.5%)	0.145	0.014
HAS-BLED:>=3	2,020 (44.0%)	7,410 (36.9%)	2,000 (43.9%)	2,030 (44.5%)	0.145	0.014
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.046	0.023
log_beddays, median(IQR)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.193	0.023
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.040	0.012
income, median(IQR), k€	104.2 (78.7 - 144.1)	122.8 (88.9 - 187.6)	104.3 (78.8 - 144.5)	104.1 (78.1 - 144.9)	0.240	0.006
education:Secondary compulsory	2,150 (46.8%)	8,430 (42.0%)	2,140 (47.0%)	2,180 (47.7%)	0.096	0.015
education:Vocationa 1/High school	1,590 (34.6%)	8,140 (40.6%)	1,580 (34.6%)	1,550 (34.0%)	0.124	0.012
education:Higher education	630 (13.7%)	2,980 (14.8%)	620 (13.6%)	620 (13.6%)	0.033	0.001
education:Unknown	230 (5.0%)	520 (2.6%)	220 (4.8%)	210 (4.7%)	0.126	0.007
employment:Employ ed or self -employed	270 (5.8%)	3,720 (18.5%)	270 (5.8%)	250 (5.5%)	0.398	0.014
employment:Unempl oyed	90 (2.0%)	1,190 (5.9%)	90 (2.0%)	110 (2.3%)	0.202	0.020
employment:Retired	4,220 (91.9%)	15,010 (74.8%)	4,190 (91.9%)	4,190 (91.9%)	0.472	0.001
employment:Unkno						





Table 15.55 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Norway – STANDARD DOSE

	Dabigatran (round ed) before	Warfarin (rounded)	Dabigatran (round	Warfarin (rounded)	Standardised mean difference	Standardised mean difference
Characteristic	matching	before matching N=11949	ed) after matching N= 4590	after matching N= 4590	before matching (max= 0.77)	after matching
index_year:2013	N= 5630 2,570 (45.7%)	5,810 (48.6%)	2,240 (48.9%)	2,260 (49.2%)	0.058	(max= 0.09) 0.006
index_year:2013	1,960 (34.8%)	3,450 (28.8%)	1,450 (31.5%)	1,430 (31.0%)	0.128	0.000
index_year:2014	620 (11.0%)	1,760 (14.8%)	540 (11.8%)	550 (11.9%)	0.1120	0.003
index_year:2016	480 (8.6%)	930 (7.8%)	360 (7.8%)	360 (7.9%)	0.028	0.003
Time from AF						
diag:< 1 month Time from AF	3,610 (64.1%)	6,410 (53.6%)	2,750 (60.0%)	2,670 (58.2%)	0.213	0.035
diag:1 - 6 month Time from AF	380 (6.7%)	1,340 (11.2%)	340 (7.4%)	350 (7.6%)	0.160	0.007
diag:6 - 60 months	1,650 (29.3%)	4,200 (35.2%)	1,500 (32.6%)	1,570 (34.2%)	0.127	0.033
Sex:Female	1,690 (30.1%)	4,740 (39.7%)	1,420 (31.0%)	1,390 (30.4%)	0.202	0.013
Sex:Male	3,940 (69.9%)	7,210 (60.3%)	3,170 (69.0%)	3,200 (69.6%)	0.202	0.013
Age, median(IQR) Age -group:< 55	67.4 (61.1 - 71.9)	75.3 (66.7 - 83.2)	67.7 (61.2 - 72.8)	67.7 (61.1 - 72.9)	0.746	0.004
years	680 (12.1%)	830 (7.0%)	570 (12.4%)	560 (12.3%)	0.177	0.003
Age -group:55-<65 years	1,460 (25.9%)	1,690 (14.2%)	1,130 (24.6%)	1,170 (25.6%)	0.296	0.022
Age -group:65-<75 years	2,760 (49.1%)	3,360 (28.1%)	2,190 (47.6%)	2,120 (46.3%)	0.442	0.027
Age -group:75-<85 years	680 (12.1%)	3,860 (32.3%)	660 (14.5%)	690 (14.9%)	0.501	0.014
Age -group:>= 85 years	40 (0.8%)	2,210 (18.5%)	40 (1.0%)	50 (1.0%)	0.630	0.002
CCI-group:0	2,880 (51.1%)	3,340 (27.9%)	2,110 (45.9%)	2,140 (46.5%)	0.487	0.011
CCI-group:1-2	1,920 (34.0%)	3,810 (31.9%)	1,690 (36.8%)	1,590 (34.6%)	0.045	0.045
CCI-group:>=3	840 (14.9%)	4,800 (40.2%)	790 (17.3%)	870 (18.9%)	0.590	0.041
Prior bleeding (any)	450 (8.0%)	1,780 (14.9%)	410 (8.9%)	420 (9.1%)	0.219	0.006
Prior gastrointestinal	30 (0.6%)	190 (1.6%)	30 (0.7%)	20 (0.5%)	0.100	0.032
bleeding Prior intracranial	30 (0.5%)	160 (1.3%)	30 (0.6%)	40 (0.8%)	0.086	0.021
bleeding Prior stroke (any)	410 (7.2%)	1,440 (12.0%)	360 (7.8%)	360 (7.8%)	0.163	0.002
Prior ischaemic stroke	400 (7.1%)	1,380 (11.5%)	350 (7.7%)	350 (7.6%)	0.154	0.004
Prior haemorrhagic stroke	20 (0.3%)	110 (0.9%)	20 (0.4%)	20 (0.4%)	0.076	0.007
Prior systemic embolism	20 (0.3%)	140 (1.2%)	20 (0.3%)	20 (0.4%)	0.105	0.004
Prior transient ischaemic attack	130 (2.3%)	460 (3.9%)	120 (2.6%)	110 (2.3%)	0.089	0.021
Chronic kidney disease	80 (1.4%)	1,560 (13.1%)	80 (1.7%)	70 (1.6%)	0.464	0.009
Heart failure	620 (10.9%)	3,110 (26.0%)	590 (12.8%)	580 (12.7%)	0.396	0.003
Coronary artery disease	960 (17.1%)	4,410 (36.9%)	920 (20.1%)	920 (20.0%)	0.457	0.004
Peripheral arterial disease	300 (5.3%)	1,370 (11.5%)	270 (5.9%)	290 (6.3%)	0.226	0.017
Hypertension	2,910 (51.7%)	7,270 (60.8%)	2,440 (53.2%)	2,410 (52.5%)	0.184	0.014
Diabetes Chronia obstructivo	650 (11.5%)	2,100 (17.6%)	580 (12.7%)	590 (12.9%)	0.172	0.006
Chronic obstructive pulmonary disease	600 (10.7%)	1,850 (15.5%)	540 (11.7%)	540 (11.8%)	0.143	0.002
Liver disease	50 (0.9%)	150 (1.3%)	50 (1.0%)	50 (1.0%)	0.037	0.000
Alcoholism	120 (2.1%)	170 (1.4%)	100 (2.1%)	100 (2.1%)	0.055	0.003
Dementia	10 (0.2%)	230 (1.9%)	10 (0.3%)	10 (0.2%)	0.163	0.013
Cancer 6 months before and including index date	230 (4.1%)	810 (6.8%)	220 (4.7%)	210 (4.6%)	0.115	0.003
Platelet inhibitors (excluding heparin)	1,850 (32.8%)	5,400 (45.2%)	1,620 (35.3%)	1,640 (35.7%)	0.254	0.008
Low -dose aspirin	1,800 (32.0%)	5,060 (42.4%)	1,570 (34.3%)	1,590 (34.7%)	0.216	0.009
ADP receptor blockers	100 (1.8%)	1,130 (9.5%)	100 (2.2%)	100 (2.1%)	0.340	0.009
Renin -angiotensin system inhibitors	2,180 (38.7%)	5,500 (46.0%)	1,830 (39.8%)	1,800 (39.3%)	0.149	0.012
Angiotensin - converting enzyme inhibitors	690 (12.3%)	2,500 (20.9%)	640 (13.8%)	630 (13.7%)	0.234	0.004
Angiotensin II antagonists, plain	690 (12.3%)	1,640 (13.7%)	570 (12.4%)	540 (11.9%)	0.042	0.016

Angiotensin II antagonists, combinations	800 (14.2%)	1,450 (12.2%)	630 (13.6%)	620 (13.5%)	0.060	0.004
Beta-blockers	3,900 (69.2%)	8,410 (70.4%)	3,130 (68.1%)	3,090 (67.2%)	0.026	0.019
Proton pump inhibitors	680 (12.0%)	2,690 (22.5%)	610 (13.3%)	620 (13.4%)	0.280	0.004
H2-receptor antagonists	60 (1.1%)	170 (1.4%)	50 (1.1%)	50 (1.2%)	0.029	0.006
Non-steroidal anti- inflammatory drugs	620 (11.0%)	910 (7.6%)	470 (10.1%)	470 (10.3%)	0.119	0.004
Statins	1,800 (32.0%)	5,020 (42.0%)	1,560 (34.0%)	1,530 (33.3%)	0.208	0.015
Antidiabetic agents	420 (7.5%)	1,400 (11.7%)	390 (8.5%)	400 (8.7%)	0.144	0.006
Loop diuretics	530 (9.3%)	3,390 (28.4%)	510 (11.2%)	490 (10.8%)	0.502	0.013
Non-loop diuretics	70 (1.3%)	230 (1.9%)	60 (1.4%)	60 (1.2%)	0.048	0.013
Alpha adrenergic blockers	240 (4.3%)	960 (8.0%)	220 (4.8%)	220 (4.9%)	0.156	0.004
Amiodarone	100 (1.8%)	700 (5.9%)	100 (2.2%)	90 (2.0%)	0.215	0.009
Dronedarone	30 (0.5%)	130 (1.1%)	30 (0.6%)	30 (0.7%)	0.073	0.011
Antihypertensive, combination drugs	910 (16.2%)	1,740 (14.6%)	720 (15.8%)	720 (15.8%)	0.046	0.001
Calcium channel blockers	850 (15.1%)	2,640 (22.1%)	770 (16.8%)	780 (16.9%)	0.181	0.003
Selective serotonin reuptake inhibitors	170 (3.0%)	530 (4.5%)	140 (3.1%)	160 (3.5%)	0.077	0.022
Drugs used in alcohol dependence	20 (0.3%)	20 (0.1%)	10 (0.2%)	10 (0.2%)	0.035	0.005
CHA2DS2-VASc, mean(SD)	2.0 (1.43)	3.3 (1.86)	2.1 (1.46)	2.1 (1.56)	0.775	0.026
CHA2DS2-VASc:0 -1	2,300 (40.8%)	2,240 (18.7%)	1,690 (36.7%)	1,830 (39.8%)	0.498	0.063
CHA2DS2-VASc:2 -3	2,550 (45.3%)	4,370 (36.6%)	2,160 (47.1%)	1,950 (42.4%)	0.178	0.094
CHA2DS2- VASc:>=4	780 (13.9%)	5,340 (44.7%)	740 (16.2%)	820 (17.8%)	0.720	0.043
CHADS2, mean(SD)	0.9 (1.01)	1.7 (1.35)	1.0 (1.04)	0.9 (1.09)	0.683	0.029
CHADS2:0	2,540 (45.1%)	2,530 (21.1%)	1,850 (40.4%)	2,030 (44.2%)	0.527	0.079
CHADS2:1	1,860 (33.1%)	3,480 (29.1%)	1,600 (34.9%)	1,450 (31.6%)	0.085	0.070
CHADS2:>=2	1,230 (21.8%)	5,940 (49.7%)	1,130 (24.7%)	1,110 (24.1%)	0.609	0.013
HAS-BLED, mean(SD)	1.5 (1.09)	2.1 (1.26)	1.6 (1.11)	1.5 (1.14)	0.543	0.031
HAS-BLED:<3	4,620 (82.0%)	7,410 (62.0%)	3,660 (79.7%)	3,650 (79.6%)	0.456	0.003
HAS-BLED:>=3	1,010 (18.0%)	4,540 (38.0%)	930 (20.3%)	940 (20.4%)	0.456	0.003
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.7 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.508	0.005
log_beddays, median(IQR)	1.1 (0.7 - 1.6)	1.4 (0.7 - 1.8)	1.1 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.131	0.007
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.089	0.005



PFIZER CONFIDENTIAL Page 167 of 253

Table 15.56 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating dabigatranor warfarin and standardised mean differences before and aftermatching, Norway – REDUCED DOSE

Characteristic	Dabigatran (r ounded) before matching N= 3054	Warfarin (rou nded) before matching N=11949	Dabigatran (r ounded) after matching N= 3035	Warfarin (rou nded) after matching N= 3035	Standardised mean difference before matchi ng (max= 0.57)	Standardised mean difference after matching (max= 0.10)
index_year:2013	1,590 (52.2%)	5,810 (48.6%)	1,580 (52.1%)	1,580 (52.0%)	0.072	0.003
index_year:2014	890 (29.2%)	3,450 (28.8%)	890 (29.4%)	890 (29.4%)	0.009	0.000
index_year:2015	310 (10.2%)	1,760 (14.8%)	310 (10.2%)	320 (10.7%)	0.139	0.014
index_year:2016	260 (8.4%)	930 (7.8%)	250 (8.3%)	240 (8.0%)	0.022	0.011
Time from AF diag:< 1 month	1,760 (57.8%)	6,410 (53.6%)	1,750 (57.7%)	1,720 (56.7%)	0.083	0.020
Time from AF diag:1 - 6 month	340 (11.2%)	1,340 (11.2%)	340 (11.1%)	350 (11.5%)	0.001	0.014
Time from AF diag:6 - 60 months	950 (31.1%)	4,200 (35.2%)	950 (31.2%)	960 (31.7%)	0.087	0.012
Sex:Female	1,620 (52.9%)	4,740 (39.7%)	1,600 (52.7%)	1,610 (53.1%)	0.269	0.009
Sex:Male	1,440 (47.1%)	7,210 (60.3%)	1,440 (47.3%)	1,420 (46.9%)	0.269	0.009
Age, median(IQR)	81.1 (75.6 - 85.7)	75.3 (66.7 - 83.2)	81.1 (75.5 - 85.7)	81.3 (75.8 - 85.8)	0.572	0.003
Age -group:< 55 years	40 (1.2%)	830 (7.0%)	40 (1.2%)	40 (1.3%)	0.296	0.012
Age -group:55-<65 years	140 (4.6%)	1,690 (14.2%)	140 (4.6%)	170 (5.5%)	0.333	0.041
Age -group:65-<75 years	540 (17.5%)	3,360 (28.1%)	540 (17.6%)	490 (16.0%)	0.254	0.043
Age -group:75-<85 years	1,490 (48.8%)	3,860 (32.3%)	1,480 (48.7%)	1,460 (48.2%)	0.341	0.009
Age -group:>= 85 years	850 (27.9%)	2,210 (18.5%)	850 (27.9%)	880 (29.0%)	0.224	0.023
CCI-group:0	1,000 (32.6%)	3,340 (27.9%)	990 (32.5%)	950 (31.1%)	0.103	0.030
CCI-group:1-2	1,090 (35.8%)	3,810 (31.9%)	1,090 (35.8%)	1,100 (36.1%)	0.082	0.006
CCI-group:>=3	960 (31.6%)	4,800 (40.2%)	960 (31.7%)	1,000 (32.8%)	0.180	0.023
Prior bleeding (any)	460 (14.9%)	1,780 (14.9%)	450 (14.9%)	480 (15.8%)	0.001	0.026
Prior gastrointestinal bleeding	50 (1.5%)	190 (1.6%)	50 (1.5%)	60 (1.8%)	0.005	0.026
Prior intracranial bleeding	50 (1.5%)	160 (1.3%)	50 (1.5%)	50 (1.7%)	0.017	0.013
Prior stroke (any)	410 (13.3%)	1,440 (12.0%)	410 (13.3%)	430 (14.3%)	0.040	0.028
Prior ischaemic stroke	390 (12.9%)	1,380 (11.5%)	390 (12.9%)	420 (13.9%)	0.041	0.030
Prior haemorrhagic stroke	30 (1.1%)	110 (0.9%)	30 (1.1%)	40 (1.2%)	0.023	0.006
Prior systemic embolism	30 (1.0%)	140 (1.2%)	30 (1.0%)	30 (0.9%)	0.018	0.007
Prior transient ischaemic attack	170 (5.6%)	460 (3.9%)	160 (5.4%)	170 (5.5%)	0.080	0.007
Chronic kidney disease	180 (5.7%)	1,560 (13.1%)	180 (5.8%)	180 (6.0%)	0.253	0.010
Heart failure	610 (19.8%)	3,110 (26.0%)	610 (19.9%)	600 (19.6%)	0.148	0.008
Coronary artery disease Peripheral arterial disease	880 (28.9%) 270 (8.8%)	4,410 (36.9%) 1,370 (11.5%)	880 (29.1%) 270 (8.8%)	870 (28.7%) 250 (8.3%)	0.171 0.090	0.009 0.020
Hypertension	1,990 (65.2%)	7,270 (60.8%)	1,980 (65.1%)	2,000 (65.8%)	0.090	0.020
Diabetes	440 (14.3%)	2,100 (17.6%)	440 (14.4%)	440 (14.4%)	0.091	0.001
Chronic obstructive pulmonary	· · · · · · · · · · · · · · · · · · ·		Ì	, í		
disease	460 (15.0%)	1,850 (15.5%)	460 (15.0%)	450 (14.9%)	0.014	0.004
Liver disease	30 (0.9%)	150 (1.3%)	30 (0.9%)	30 (1.1%)	0.039	0.023
Alcoholism	40 (1.3%)	170 (1.4%)	40 (1.4%)	40 (1.3%)	0.007	0.009
Dementia	90 (3.0%)	230 (1.9%)	90 (3.0%)	100 (3.3%)	0.071	0.021
Cancer 6 months before and including index date	200 (6.4%)	810 (6.8%)	200 (6.5%)	210 (6.8%)	0.014	0.012
Platelet inhibitors (excluding heparin)	1,480 (48.6%)	5,400 (45.2%)	1,470 (48.3%)	1,420 (46.9%)	0.068	0.028
Low -dose aspirin	1,430 (47.0%)	5,060 (42.4%)	1,420 (46.7%)	1,380 (45.5%)	0.092	0.023
ADP receptor blockers	130 (4.3%)	1,130 (9.5%)	130 (4.3%)	120 (4.1%)	0.208	0.012
Renin -angiotensin system inhibitors	1,370 (44.7%)	5,500 (46.0%)	1,350 (44.6%)	1,350 (44.6%)	0.027	0.000
Angiotensin -converting enzyme inhibitors	530 (17.4%)	2,500 (20.9%)	530 (17.4%)	500 (16.5%)	0.089	0.025
Angiotensin II antagonists, plain	440 (14.3%)	1,640 (13.7%)	430 (14.3%)	440 (14.4%)	0.017	0.004
Angiotensin II antagonists, combinations	420 (13.6%)	1,450 (12.2%)	410 (13.5%)	430 (14.0%)	0.042	0.015
Beta-blockers	2,060 (67.4%)	8,410 (70.4%)	2,050 (67.5%)	2,020 (66.5%)	0.065	0.020
Proton pump inhibitors	620 (20.3%)	2,690 (22.5%)	620 (20.3%)	640 (20.9%)	0.056	0.015
H2-receptor antagonists	50 (1.5%)	170 (1.4%)	50 (1.5%)	40 (1.2%)	0.008	0.023
Non-steroidal anti-inflammatory drugs	260 (8.6%)	910 (7.6%)	260 (8.4%)	250 (8.2%)	0.037	0.010
Statins	1,130 (37.0%)	5,020 (42.0%)	1,130 (37.2%)	1,120 (37.0%)	0.102	0.003
Antidiabetic agents	310 (10.0%)	1,400 (11.7%)	310 (10.0%)	310 (10.3%)	0.056	0.010
Loop diuretics	700 (23.1%)	3,390 (28.4%)	700 (23.2%)	680 (22.2%)	0.122	0.022
Non-loop diuretics	50 (1.7%)	230 (1.9%)	50 (1.6%)	40 (1.4%)	0.019	0.022

Alaba adapancia blo altera	240 (7.8%)	960 (8.0%)	240 (7.8%)	230 (7.7%)	0.009	0.004
Alpha adrenergic blockers	× /					
Amiodarone	70 (2.3%)	700 (5.9%)	70 (2.3%)	70 (2.1%)	0.182	0.011
Dronedarone	10 (0.3%)	130 (1.1%)	10 (0.3%)	10 (0.2%)	0.102	0.007
Antihypertensive, combination drugs	500 (16.2%)	1,740 (14.6%)	490 (16.1%)	510 (16.7%)	0.047	0.016
Calcium channel blockers	750 (24.5%)	2,640 (22.1%)	740 (24.3%)	740 (24.3%)	0.056	0.001
Selective serotonin reuptake inhibitors	160 (5.2%)	530 (4.5%)	160 (5.1%)	170 (5.5%)	0.036	0.015
Drugs used in alcohol dependence	<5	20 (0.1%)	<5	<5	0.002	0.010
CHA2DS2-VASc, mean(SD)	3.7 (1.54)	3.3 (1.86)	3.7 (1.54)	3.7 (1.66)	0.247	0.013
CHA2DS2-VASc:0-1	180 (5.7%)	2,240 (18.7%)	180 (5.8%)	250 (8.2%)	0.405	0.095
CHA2DS2-VASc:2 -3	1,320 (43.1%)	4,370 (36.6%)	1,310 (43.1%)	1,160 (38.3%)	0.133	0.097
CHA2DS2-VASc:>=4	1,560 (51.2%)	5,340 (44.7%)	1,550 (51.1%)	1,620 (53.5%)	0.130	0.048
CHADS2, mean(SD)	1.9 (1.24)	1.7 (1.35)	1.9 (1.24)	1.9 (1.27)	0.174	0.019
CHADS2:0	270 (8.8%)	2,530 (21.1%)	270 (8.9%)	320 (10.6%)	0.350	0.058
CHADS2:1	1,060 (34.6%)	3,480 (29.1%)	1,050 (34.5%)	950 (31.2%)	0.117	0.070
CHADS2:>=2	1,730 (56.6%)	5,940 (49.7%)	1,720 (56.6%)	1,770 (58.2%)	0.138	0.032
HAS-BLED, mean(SD)	2.3 (1.06)	2.1 (1.26)	2.3 (1.06)	2.3 (1.11)	0.126	0.001
HAS-BLED:<3	1,850 (60.7%)	7,410 (62.0%)	1,850 (60.8%)	1,790 (59.1%)	0.028	0.036
HAS-BLED:>=3	1,200 (39.3%)	4,540 (38.0%)	1,190 (39.2%)	1,240 (40.9%)	0.028	0.036
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.193	0.012
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.103	0.016
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.014	0.010




Table 15.57 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Sweden – STANDARD DOSE

Characteristic	Dabigatran (r ounded) before matching N= 6995	Warfarin (rou nded) before matching N=47152	Dabigatran (r ounded) after matching N= 6773	Warfarin (rou nded) after matching N= 6773	Standardised mean difference before matchi ng (max= 0.79)	Standardised mean difference after matching (max= 0.03)
index_year:2013	2,020 (28.9%)	22,380 (47.5%)	2,020 (29.8%)	2,080 (30.6%)	0.389	0.017
index_year:2014	2,350 (33.7%)	14,490 (30.7%)	2,350 (34.8%)	2,300 (33.9%)	0.063	0.017
index_year:2015	1,180 (16.8%)	7,040 (14.9%)	1,180 (17.4%)	1,160 (17.2%)	0.052	0.006
index_year:2016	1,440 (20.6%)	3,240 (6.9%)	1,220 (18.0%)	1,240 (18.3%)	0.407	0.006
Time from AF diag:< 1 month	4,560 (65.1%)	28,530 (60.5%)	4,410 (65.1%)	4,420 (65.2%)	0.096	0.003
Time from AF diag:1 - 6 month	490 (6.9%)	4,220 (9.0%)	480 (7.0%)	470 (7.0%)	0.074	0.002
Time from AF diag:6 - 60 months	1,950 (27.9%)	14,400 (30.5%)	1,890 (27.9%)	1,880 (27.8%)	0.058	0.002
Sex:Female	2,360 (33.7%)	20,290 (43.0%)	2,300 (34.0%)	2,280 (33.6%)	0.193	0.008
Sex:Male	4,640 (66.3%)	26,860 (57.0%)	4,470 (66.0%)	4,500 (66.4%)	0.193	0.008
Age, median(IQR)	68.3 (62.1 - 73.2)	75.6 (68.4 - 82.6)	68.4 (62.1 - 73.4)	68.3 (62.0 - 73.3)	0.794	0.009
Age -group:< 55 years	750 (10.7%)	2,130 (4.5%)	710 (10.5%)	740 (11.0%)	0.234	0.016
Age -group:55-<65 years	1,680 (24.1%)	5,540 (11.8%)	1,610 (23.8%)	1,630 (24.1%)	0.326	0.007
Age -group:65-<75 years	3,370 (48.2%)	14,880 (31.6%)	3,260 (48.2%)	3,220 (47.5%)	0.344	0.013
Age -group:75-<85 years	1,140 (16.2%)	16,570 (35.1%)	1,130 (16.7%)	1,120 (16.6%)	0.444	0.003
Age -group:>= 85 years	60 (0.9%)	8,030 (17.0%)	60 (0.9%)	60 (0.9%)	0.591	0.000
CCI-group:0	3,990 (57.0%)	17,670 (37.5%)	3,830 (56.5%)	3,780 (55.9%)	0.398	0.014
CCI-group:1-2	2,160 (30.9%)	15,790 (33.5%)	2,100 (31.0%)	2,070 (30.6%)	0.056	0.008
CCI-group:>=3	850 (12.2%)	13,700 (29.0%)	850 (12.5%)	920 (13.5%)	0.427	0.032
Prior bleeding (any)	490 (7.0%)	5,150 (10.9%)	480 (7.0%)	480 (7.1%)	0.136	0.004
Prior gastrointestinal bleeding	30 (0.4%)	360 (0.8%)	30 (0.4%)	20 (0.3%)	0.054	0.008
Prior intracranial bleeding	50 (0.8%)	410 (0.9%)	50 (0.8%)	50 (0.7%)	0.011	0.003
Prior stroke (any)	630 (9.0%)	6,200 (13.1%)	610 (9.0%)	600 (8.9%)	0.132	0.004 0.004
Prior ischaemic stroke Prior haemorrhagic stroke	620 (8.8%) 40 (0.5%)	6,080 (12.9%) 330 (0.7%)	590 (8.8%) 40 (0.5%)	590 (8.7%) 30 (0.5%)	0.132 0.024	0.004
Prior systemic embolism	20 (0.2%)	510 (1.1%)	20 (0.3%)	10 (0.2%)	0.104	0.002
Prior transient ischaemic attack	220 (3.2%)	2,050 (4.3%)	210 (3.1%)	200 (3.0%)	0.060	0.009
Chronic kidney disease	50 (0.7%)	3,280 (7.0%)	50 (0.7%)	60 (0.8%)	0.329	0.008
Heart failure	840 (11.9%)	11,330 (24.0%)	830 (12.2%)	840 (12.4%)	0.319	0.004
Coronary artery disease	850 (12.1%)	12,460 (26.4%)	840 (12.5%)	880 (13.0%)	0.368	0.015
Peripheral arterial disease	220 (3.2%)	3,030 (6.4%)	220 (3.2%)	230 (3.3%)	0.154	0.005
Hypertension	4,310 (61.6%)	34,570 (73.3%)	4,200 (62.0%)	4,180 (61.8%)	0.252	0.005
Diabetes	970 (13.9%)	9,090 (19.3%)	960 (14.1%)	970 (14.3%)	0.144	0.006
Chronic obstructive pulmonary disease	560 (8.0%)	5,700 (12.1%)	550 (8.1%)	560 (8.2%)	0.137	0.002
Liver disease	50 (0.7%)	430 (0.9%)	50 (0.7%)	60 (0.9%)	0.019	0.015
Alcoholism	220 (3.1%)	1,030 (2.2%)	210 (3.2%)	230 (3.4%)	0.060	0.012
Dementia	20 (0.3%)	770 (1.6%)	20 (0.4%)	30 (0.4%)	0.131	0.002
Cancer 6 months before and including index date	40 (0.6%)	400 (0.9%)	40 (0.6%)	30 (0.5%)	0.035	0.012
Platelet inhibitors (excluding heparin)	2,030 (29.0%)	18,680 (39.6%)	1,980 (29.3%)	2,020 (29.8%)	0.225	0.013
Low -dose aspirin	1,890 (27.0%)	17,010 (36.1%)	1,850 (27.2%)	1,880 (27.8%)	0.196	0.012
ADP receptor blockers	200 (2.9%)	3,710 (7.9%)	200 (2.9%)	210 (3.1%)	0.223	0.012
Renin -angiotensin system inhibitors	2,980 (42.7%)	24,140 (51.2%)	2,920 (43.1%)	2,910 (42.9%)	0.172	0.004

Angiotensin -converting enzyme		13,490		[[
inhibitors	1,470 (21.0%)	(28.6%)	1,450 (21.5%)	1,480 (21.9%)	0.177	0.010
Angiotensin II antagonists, plain	970 (13.9%)	8,000 (17.0%)	950 (14.0%)	920 (13.5%)	0.085	0.015
Angiotensin II antagonists, combinations	460 (6.6%)	2,540 (5.4%)	440 (6.6%)	440 (6.4%)	0.049	0.005
Beta-blockers	5,460 (78.1%)	36,150 (76.7%)	5,290 (78.1%)	5,270 (77.8%)	0.034	0.008
Proton pump inhibitors	1,030 (14.7%)	10,150 (21.5%)	1,020 (15.0%)	1,030 (15.2%)	0.177	0.005
H2-receptor antagonists	20 (0.2%)	210 (0.4%)	20 (0.2%)	20 (0.2%)	0.038	0.003
Non-steroidal anti-inflammatory drugs	590 (8.4%)	2,970 (6.3%)	570 (8.4%)	590 (8.6%)	0.079	0.007
Statins	1,960 (28.1%)	16,730 (35.5%)	1,910 (28.3%)	1,980 (29.2%)	0.160	0.021
Antidiabetic agents	680 (9.6%)	6,350 (13.5%)	660 (9.8%)	670 (9.8%)	0.120	0.001
Loop diuretics	810 (11.6%)	12,990 (27.5%)	800 (11.9%)	810 (12.0%)	0.411	0.004
Non-loop diuretics	60 (0.9%)	650 (1.4%)	60 (0.8%)	60 (0.9%)	0.049	0.006
Alpha adrenergic blockers	1,310 (18.7%)	11,180 (23.7%)	1,280 (18.9%)	1,290 (19.0%)	0.122	0.003
Amiodarone	50 (0.7%)	890 (1.9%)	50 (0.7%)	50 (0.7%)	0.109	0.007
Dronedarone	40 (0.6%)	440 (0.9%)	40 (0.6%)	40 (0.6%)	0.040	0.002
Antihypertensive, combination drugs	700 (10.0%)	3,850 (8.2%)	670 (9.9%)	650 (9.6%)	0.063	0.009
Calcium channel blockers	1,510 (21.6%)	12,240 (26.0%)	1,470 (21.7%)	1,460 (21.6%)	0.103	0.002
Selective serotonin reuptake inhibitors	300 (4.3%)	3,110 (6.6%)	300 (4.4%)	290 (4.3%)	0.100	0.007
Drugs used in alcohol dependence	20 (0.2%)	60 (0.1%)	10 (0.2%)	10 (0.2%)	0.023	0.000
CHA2DS2-VASc, mean(SD)	2.4 (1.55)	3.6 (1.75)	2.4 (1.55)	2.4 (1.55)	0.706	0.004
CHA2DS2-VASc:0-1	2,130 (30.5%)	5,700 (12.1%)	2,030 (29.9%)	2,020 (29.9%)	0.461	0.001
CHA2DS2-VASc:2 -3	3,330 (47.6%)	17,540 (37.2%)	3,240 (47.8%)	3,280 (48.4%)	0.211	0.011
CHA2DS2-VASc:>=4	1,540 (21.9%)	23,910 (50.7%)	1,510 (22.3%)	1,480 (21.8%)	0.627	0.012
CHADS2, mean(SD)	1.9 (1.32)	2.9 (1.47)	1.9 (1.32)	1.9 (1.33)	0.666	0.011
CHADS2:0	940 (13.4%)	2,300 (4.9%)	880 (13.0%)	920 (13.5%)	0.299	0.014
CHADS2:1	1,880 (26.9%)	6,040 (12.8%)	1,810 (26.7%)	1,800 (26.5%)	0.358	0.004
CHADS2:>=2	4,180 (59.7%)	38,810 (82.3%)	4,080 (60.3%)	4,060 (60.0%)	0.514	0.006
HAS-BLED, mean(SD)	1.5 (0.91)	1.9 (0.92)	1.5 (0.90)	1.5 (0.91)	0.498	0.013
HAS-BLED:<3	6,220 (89.0%)	36,080 (76.5%)	6,020 (88.9%)	6,040 (89.1%)	0.334	0.008
HAS-BLED:>=3	770 (11.0%)	11,080 (23.5%)	750 (11.1%)	740 (10.9%)	0.334	0.008
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.363	0.007
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.097	0.009
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.056	0.003
income, median(IQR), k€	70.7 (47.2 - 104.2)	49.8 (40.5 - 72.3)	69.1 (46.9 - 102.9)	69.4 (47.1 - 100.3)	0.261	0.001
education:Secondary compulsory	1,690 (24.1%)	18,850 (40.0%)	1,670 (24.6%)	1,670 (24.7%)	0.345	0.002
education:Vocational / High school	2,890 (41.3%)	18,480 (39.2%)	2,820 (41.7%)	2,810 (41.5%)	0.044	0.004
education:Higher education	2,360 (33.7%)	9,340 (19.8%)	2,230 (32.9%)	2,230 (32.9%)	0.318	0.000
education:Unknown	60 (0.8%)	490 (1.0%)	60 (0.8%)	60 (0.9%)	0.021	0.008




Table 15.58 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>dabigatran</u> or warfarin and standardised mean differences before and after matching, Sweden – REDUCED DOSE

Characteristic	Dabigatran (r ounded) before matching N= 3084	Warfarin (rou nded) before matching N=47152	Dabigatran (r ounded) after matching N= 3078	Warfarin (rou nded) after matching N= 3078	Standardised mean difference before matchi ng	Standardised mean difference after matching (max= 0.07)
index_year:2013	1,000 (32.4%)	22,380 (47.5%)	1,000 (32.5%)	1,060 (34.5%)	(max= 0.56) 0.312	0.044
index_year:2014	890 (28.7%)	14,490 (30.7%)	890 (28.8%)	850 (27.6%)	0.044	0.025
index_year:2015	490 (15.8%)	7,040 (14.9%)	490 (15.9%)	470 (15.2%)	0.025	0.017
index_year:2016	710 (23.1%)	3,240 (6.9%)	710 (22.9%)	700 (22.6%)	0.466	0.008
Time from AF diag:< 1 month	1,760 (56.9%)	28,530 (60.5%)	1,760 (57.1%)	1,730 (56.2%)	0.072	0.017
Time from AF diag:1 - 6 month	310 (10.0%)	4,220 (9.0%)	310 (10.0%)	340 (10.9%)	0.036	0.030
Time from AF diag:6 - 60 months	1,020 (33.0%)	14,400 (30.5%)	1,020 (33.0%)	1,010 (32.9%)	0.054	0.001
Sex:Female	1,600 (52.0%)	20,290 (43.0%)	1,600 (52.0%)	1,600 (52.0%)	0.181	0.001
Sex:Male	1,480 (48.0%)	26,860 (57.0%)	1,480 (48.0%)	1,480 (48.0%)	0.181	0.001
Age, median(IQR)	81.4 (75.8 -	75.6 (68.4 -	81.4 (75.8 -	81.6 (75.9 -	0.564	0.003
	85.8)	82.6)	85.8)	85.7)		
Age -group:< 55 years	20 (0.8%)	2,130 (4.5%)	20 (0.8%)	30 (0.9%)	0.234	0.011
Age -group:55-<65 years	160 (5.1%)	5,540 (11.8%)	160 (5.1%)	140 (4.6%)	0.242	0.024
Age -group:65-<75 years	520 (17.0%)	14,880 (31.6%)	520 (17.0%)	540 (17.6%)	0.345	0.015
Age -group:75-<85 years	1,480 (48.1%)	16,570 (35.1%)	1,480 (48.1%)	1,470 (47.7%)	0.265	0.008
Age -group:>= 85 years	900 (29.1%)	8,030 (17.0%)	890 (29.0%)	900 (29.3%)	0.288	0.006
CCI-group:0	1,030 (33.4%)	17,670 (37.5%)	1,030 (33.4%)	1,050 (34.0%)	0.086	0.011
CCI-group:1-2	1,170 (37.8%)	15,790 (33.5%)	1,160 (37.8%)	1,070 (34.6%)	0.091	0.066
CCI-group:>=3	890 (28.8%)	13,700 (29.0%)	890 (28.8%)	970 (31.4%)	0.006	0.057
Prior bleeding (any)	420 (13.5%)	5,150 (10.9%)	410 (13.4%)	420 (13.7%)	0.080	0.008
Prior gastrointestinal bleeding	30 (0.9%)	360 (0.8%)	30 (0.9%)	40 (1.1%)	0.020	0.019
Prior intracranial bleeding	50 (1.8%)	410 (0.9%)	50 (1.7%)	50 (1.5%)	0.078	0.021
Prior stroke (any)	660 (21.5%)	6,200 (13.1%)	660 (21.3%)	670 (21.7%)	0.222	0.008
Prior ischaemic stroke	640 (20.7%)	6,080 (12.9%)	630 (20.6%)	640 (20.8%)	0.210	0.004
Prior haemorrhagic stroke Prior systemic embolism	60 (2.0%)	330 (0.7%)	60 (1.9%) 40 (1.2%)	60 (1.9%) 40 (1.3%)	0.111 0.013	0.005
Prior transient ischaemic attack	40 (1.2%) 210 (6.7%)	510 (1.1%) 2,050 (4.3%)	210 (6.7%)	190 (6.2%)	0.102	0.009
Chronic kidney disease	80 (2.7%)	3,280 (7.0%)	80 (2.7%)	90 (2.8%)	0.202	0.018
Heart failure	680 (22.0%)	11,330 (24.0%)	680 (22.1%)	720 (23.5%)	0.047	0.033
Coronary artery disease	770 (25.0%)	12,460 (26.4%)	770 (25.1%)	760 (24.8%)	0.032	0.006
Peripheral arterial disease	220 (7.2%)	3,030 (6.4%)	220 (7.1%)	240 (7.7%)	0.032	0.020
Hypertension	2,320 (75.1%)	34,570 (73.3%)	2,310 (75.1%)	2,270 (73.7%)	0.041	0.032
Diabetes	540 (17.5%)	9,090 (19.3%)	540 (17.5%)	540 (17.5%)	0.046	0.001
Chronic obstructive pulmonary disease	400 (13.0%)	5,700 (12.1%)	400 (13.0%)	450 (14.5%)	0.027	0.042
Liver disease	30 (1.1%)	430 (0.9%)	30 (1.1%)	30 (1.0%)	0.017	0.003
Alcoholism	70 (2.3%)	1,030 (2.2%)	70 (2.3%)	70 (2.4%)	0.007	0.009
Dementia	90 (2.8%)	770 (1.6%)	90 (2.8%)	90 (2.8%)	0.077	0.004
Cancer 6 months before and including index date	20 (0.7%)	400 (0.9%)	20 (0.7%)	20 (0.7%)	0.016	0.000
Platelet inhibitors (excluding heparin)	1,380 (44.9%)	18,680 (39.6%)	1,380 (44.8%)	1,410 (45.7%)	0.107	0.018
Low -dose aspirin	1,240 (40.2%)	17,010 (36.1%)	1,240 (40.3%)	1,250 (40.6%)	0.086	0.008

Renin -angiotensin system inhibitors	1,490 (48.3%)	24,140 (51.2%)	1,490 (48.4%)	1,480 (48.0%)	0.057	0.008
Angiotensin -converting enzyme inhibitors	790 (25.5%)	13,490 (28.6%)	790 (25.5%)	750 (24.3%)	0.070	0.029
Angiotensin II antagonists, plain	530 (17.3%)	8,000 (17.0%)	530 (17.3%)	570 (18.5%)	0.008	0.031
Angiotensin II antagonists, combinations	170 (5.4%)	2,540 (5.4%)	170 (5.5%)	160 (5.1%)	0.002	0.016
Beta-blockers	2,190 (71.0%)	36,150 (76.7%)	2,190 (71.1%)	2,170 (70.5%)	0.130	0.012
Proton pump inhibitors	740 (23.9%)	10,150 (21.5%)	740 (23.9%)	770 (25.1%)	0.058	0.028
H2-receptor antagonists	10 (0.2%)	210 (0.4%)	10 (0.2%)	<5	0.045	0.026
Non-steroidal anti-inflammatory drugs	190 (6.0%)	2,970 (6.3%)	180 (5.9%)	190 (6.1%)	0.013	0.007
Statins	1,050 (34.0%)	16,730 (35.5%)	1,050 (34.0%)	1,070 (34.6%)	0.032	0.013
Antidiabetic agents	360 (11.6%)	6,350 (13.5%)	360 (11.7%)	330 (10.8%)	0.055	0.029
Loop diuretics	830 (27.0%)	12,990 (27.5%)	830 (27.1%)	870 (28.1%)	0.011	0.024
Non-loop diuretics	30 (0.8%)	650 (1.4%)	30 (0.8%)	20 (0.8%)	0.055	0.004
Alpha adrenergic blockers	690 (22.2%)	11,180 (23.7%)	690 (22.3%)	690 (22.4%)	0.035	0.002
Amiodarone	30 (1.0%)	890 (1.9%)	30 (1.0%)	30 (1.0%)	0.076	0.000
Dronedarone	10 (0.4%)	440 (0.9%)	10 (0.4%)	10 (0.3%)	0.072	0.006
Antihypertensive, combination drugs	250 (7.9%)	3,850 (8.2%)	250 (8.0%)	240 (7.7%)	0.008	0.008
Calcium channel blockers	790 (25.7%)	12,240 (26.0%)	790 (25.7%)	770 (24.9%)	0.007	0.019
Selective serotonin reuptake inhibitors	230 (7.4%)	3,110 (6.6%)	230 (7.4%)	220 (7.3%)	0.031	0.005
Drugs used in alcohol dependence	<5	60 (0.1%)	<5	10 (0.2%)	0.003	0.009
CHA2DS2-VASc, mean(SD)	4.2 (1.59)	3.6 (1.75)	4.2 (1.59)	4.2 (1.66)	0.360	0.001
CHA2DS2-VASc:0-1	130 (4.1%)	5,700 (12.1%)	130 (4.1%)	160 (5.0%)	0.298	0.047
CHA2DS2-VASc:2 -3	940 (30.6%)	17,540 (37.2%)	940 (30.7%)	910 (29.6%)	0.140	0.023
CHA2DS2-VASc:>=4	2,020 (65.3%)	23,910 (50.7%)	2,010 (65.3%)	2,010 (65.4%)	0.300	0.002
CHADS2, mean(SD)	3.4 (1.37)	2.9 (1.47)	3.4 (1.37)	3.4 (1.40)	0.369	0.004
CHADS2:0	50 (1.5%)	2,300 (4.9%)	50 (1.5%)	60 (1.9%)	0.196	0.035
CHADS2:1	160 (5.2%)	6,040 (12.8%)	160 (5.2%)	180 (5.8%)	0.270	0.029
CHADS2:>=2	2,880 (93.4%)	38,810 (82.3%)	2,870 (93.4%)	2,840 (92.3%)	0.344	0.043
HAS-BLED, mean(SD)	2.1 (0.83)	1.9 (0.92)	2.1 (0.83)	2.1 (0.85)	0.227	0.012
HAS-BLED:<3	2,150 (69.8%)	36,080 (76.5%)	2,150 (69.9%)	2,140 (69.4%)	0.151	0.013
HAS-BLED:>=3	930 (30.2%)	11,080 (23.5%)	930 (30.1%)	940 (30.6%)	0.151	0.013
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.043	0.015
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.046	0.032
log_n_outpatient, median(IQR)	0.7 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.168	0.004
income, median(IQR), k€	48.0 (40.0 - 66.2)	49.8 (40.5 - 72.3)	48.0 (40.1 - 66.2)	47.6 (39.6 - 66.0)	0.024	0.023
education:Secondary compulsory	1,280 (41.3%)	18,850 (40.0%)	1,270 (41.4%)	1,290 (41.9%)	0.028	0.011
education:Vocational / High school	1,100 (35.7%)	18,480 (39.2%)	1,100 (35.7%)	1,100 (35.8%)	0.071	0.001
education:Higher education	660 (21.3%)	9,340 (19.8%)	660 (21.3%)	630 (20.4%)	0.037	0.022
education:Unknown	50 (1.6%)	490 (1.0%)	50 (1.6%)	60 (1.9%)	0.050	0.025




Table 15.59 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – STANDARD DOSE

Characteristic	Rivaroxaban (Warfarin (rou	Rivaroxaban (Warfarin (rou	Standardised	Standardised
	rounded) before	nded) before	rounded) after	nded) after	mean	mean
	matching	matching N=79171	matching N=23703	matching N=23703	difference before matchi	difference after matching
	N=28366	11-79171	11-23703	11-23703	ng	(max=0.06)
	N=28500				(max = 0.62)	(max = 0.00)
index_year:2013	4,760 (16.8%)	35,000	4,760 (20.1%)	4,680 (19.7%)	0.624	0.008
mdex_year.2015	1,700 (10.070)	(44.2%)	1,700 (20.170)	1,000 (19.770)	0.021	0.000
index_year:2014	5,960 (21.0%)	23,330	5,800 (24.5%)	5,680 (24.0%)	0.196	0.012
: 1	0.500 (20.20()	(29.5%)	7.000 (21.10()	5 500 (21 50()	0.210	0.012
index_year:2015	8,590 (30.3%)	13,390	7,380 (31.1%)	7,520 (31.7%)	0.319	0.013
in ter	0.070 (22.00()	(16.9%)	5 770 (24 20/)	5 820 (24 (0))	0.570	0.000
index_year:2016 Time from AF diag:< 1 month	9,070 (32.0%) 17,990	7,460 (9.4%) 47,550	5,770 (24.3%)	5,820 (24.6%)	0.579	0.006
Time from AF diag:< 1 month	(63.4%)	47,550 (60.1%)	14,760 (62.3%)	14,630 (61.7%)	0.069	0.011
Time from AF diag:1 - 6 month	2,720 (9.6%)	7,970 (10.1%)	2,370 (10.0%)	2,510 (10.6%)	0.016	0.019
Time from AF diag:6 - 60 months	7,650 (27.0%)	23,650	6,570 (27.7%)	6,560 (27.7%)	0.064	0.001
This from AF diag.0 - 00 months	7,030 (27.070)	(29.9%)	0,570 (27.770)	0,500 (27.770)	0.004	0.001
Sex:Female	11,690	32,980	9,810 (41.4%)	9,830 (41.5%)	0.009	0.001
Soxii emare	(41.2%)	(41.7%)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.009	0.001
Sex:Male	16,680	46,190	13,890	13,880	0.009	0.001
Sommale	(58.8%)	(58.3%)	(58.6%)	(58.5%)	01000	01001
Age, median(IQR)	71.8 (65.8 -	75.0 (67.5 -	72.5 (66.0 -	72.7 (66.1 -	0.225	0.021
	78.5)	82.2)	79.4)	79.7)		
Age -group:< 55 years	1,690 (6.0%)	4,480 (5.7%)	1,470 (6.2%)	1,400 (5.9%)	0.013	0.012
Age -group:55-<65 years	4,570 (16.1%)	10,100	3,620 (15.3%)	3,670 (15.5%)	0.095	0.005
	,	(12.8%)				
Age -group:65-<75 years	11,460	25,060	9,020 (38.1%)	8,850 (37.3%)	0.183	0.015
	(40.4%)	(31.6%)				
Age -group:75-<85 years	8,070 (28.4%)	26,700	7,110 (30.0%)	7,170 (30.2%)	0.114	0.006
		(33.7%)				
Age -group:>= 85 years	2,580 (9.1%)	12,830	2,480 (10.5%)	2,620 (11.0%)	0.215	0.018
		(16.2%)				
CCI-group:0	13,380	29,610	10,770	10,750	0.199	0.002
	(47.2%)	(37.4%)	(45.4%)	(45.4%)		
CCI-group:1-2	9,640 (34.0%)	25,600	8,120 (34.3%)	7,710 (32.5%)	0.035	0.037
		(32.3%)				
CCI-group:>=3	5,350 (18.9%)	23,960	4,810 (20.3%)	5,240 (22.1%)	0.267	0.045
	0.5.00 (0.000)	(30.3%)	0.000 (0.40()	0.050 (0.50)	0.050	0.000
Prior bleeding (any)	2,560 (9.0%)	8,870 (11.2%)	2,230 (9.4%)	2,250 (9.5%)	0.072	0.003
Prior gastrointestinal bleeding	180 (0.6%)	820 (1.0%)	170 (0.7%)	170 (0.7%)	0.043	0.002
Prior intracranial bleeding	270 (0.9%)	710 (0.9%)	230 (1.0%)	230 (1.0%)	0.004	0.000
Prior stroke (any)	3,270 (11.5%)	9,610 (12.1%)	2,780 (11.7%)	2,800 (11.8%)	0.019	0.002
Prior ischaemic stroke	3,180 (11.2%)	9,400 (11.9%)	2,710 (11.4%)	2,730 (11.5%)	0.021	0.003
Prior haemorrhagic stroke	190 (0.7%)	520 (0.7%)	160 (0.7%)	150 (0.6%)	0.000 0.058	0.005
Prior systemic embolism	130 (0.5%)	760 (1.0%)	130 (0.5%) 860 (3.6%)	130 (0.5%)	0.038	0.000 0.005
Prior transient ischaemic attack	1,010 (3.5%)	3,120 (3.9%)		880 (3.7%)		
Chronic kidney disease Heart failure	450 (1.6%)	6,530 (8.2%)	450 (1.9%) 3,510 (14.8%)	530 (2.2%)	0.312	0.025
neart failure	3,770 (13.3%)	18,010 (22.7%)	3,310 (14.8%)	3,550 (15.0%)	0.248	0.005
Coronary artery disease	4,930 (17.4%)	21,450	4,450 (18.8%)	4,510 (19.0%)	0.236	0.007
Coronary artery disease	4,930 (17.4%)	(27.1%)	4,430 (10.0%)	4,510 (19.0%)	0.230	0.007
Peripheral arterial disease	1,650 (5.8%)	6,030 (7.6%)	1,440 (6.1%)	1,480 (6.2%)	0.072	0.006
Hypertension	17,780	54,110	15,060	15,190	0.119	0.000
riperension	(62.7%)	(68.3%)	(63.5%)	(64.1%)	0.117	0.012
Diabetes	4,240 (14.9%)	14,680	3,700 (15.6%)	3,780 (15.9%)	0.096	0.009
	.,(11)/0)	(18.5%)	-,	-,	5.070	0.007
Chronic obstructive pulmonary	3,300 (11.6%)	10,120	2,820 (11.9%)	2,920 (12.3%)	0.035	0.012
disease		(12.8%)				-
Liver disease	240 (0.8%)	820 (1.0%)	210 (0.9%)	220 (0.9%)	0.021	0.004
Alcoholism	820 (2.9%)	1,790 (2.3%)	690 (2.9%)	660 (2.8%)	0.040	0.006
Dementia	460 (1.6%)	1,220 (1.5%)	400 (1.7%)	410 (1.7%)	0.007	0.006
Cancer 6 months before and	870 (3.1%)	2,140 (2.7%)	740 (3.1%)	760 (3.2%)	0.022	0.005
including index date	</td <td>, , , ,</td> <td></td> <td></td> <td></td> <td></td>	, , , ,				
Platelet inhibitors (excluding	9,850 (34.7%)	30,840	8,370 (35.3%)	8,590 (36.2%)	0.087	0.019

Low -dose aspirin	8,660 (30.5%)	27,180 (34.3%)	7,290 (30.8%)	7,460 (31.5%)	0.081	0.015
ADP receptor blockers	1,490 (5.3%)	7,100 (9.0%)	1,400 (5.9%)	1,440 (6.1%)	0.145	0.008
Renin -angiotensin system inhibitors	12,190 (43.0%)	38,070 (48.1%)	10,330 (43.6%)	10,350 (43.7%)	0.102	0.001
Angiotensin -converting enzyme inhibitors	5,260 (18.6%)	20,500 (25.9%)	4,760 (20.1%)	4,730 (20.0%)	0.177	0.002
Angiotensin II antagonists, plain	3,940 (13.9%)	11,850 (15.0%)	3,290 (13.9%)	3,340 (14.1%)	0.031	0.007
Angiotensin II antagonists, combinations	2,610 (9.2%)	5,210 (6.6%)	1,960 (8.3%)	1,950 (8.2%)	0.097	0.003
Beta-blockers	18,990 (67.0%)	56,980 (72.0%)	16,070 (67.8%)	15,940 (67.2%)	0.109	0.012
Proton pump inhibitors	5,150 (18.2%)	17,350 (21.9%)	4,500 (19.0%)	4,490 (19.0%)	0.094	0.001
Non-steroidal anti-inflammatory drugs	2,460 (8.7%)	5,860 (7.4%)	1,960 (8.3%)	1,910 (8.1%)	0.046	0.007
Statins	9,290 (32.8%)	28,740 (36.3%)	7,870 (33.2%)	7,950 (33.5%)	0.075	0.007
Antidiabetic agents	3,070 (10.8%)	10,410 (13.1%)	2,670 (11.3%)	2,740 (11.5%)	0.072	0.009
Loop diuretics	4,600 (16.2%)	22,170 (28.0%)	4,310 (18.2%)	4,410 (18.6%)	0.287	0.011
Non-loop diuretics	320 (1.1%)	1,230 (1.6%)	270 (1.1%)	280 (1.2%)	0.038	0.005
Alpha adrenergic blockers	4,380 (15.4%)	15,810 (20.0%)	3,930 (16.6%)	3,960 (16.7%)	0.119	0.002
Amiodarone	490 (1.7%)	2,560 (3.2%)	480 (2.0%)	510 (2.1%)	0.097	0.009
Dronedarone	120 (0.4%)	600 (0.8%)	110 (0.5%)	110 (0.5%)	0.043	0.001
Antihypertensive, combination drugs	3,580 (12.6%)	7,700 (9.7%)	2,800 (11.8%)	2,780 (11.7%)	0.092	0.003
Calcium channel blockers	6,340 (22.4%)	19,680 (24.9%)	5,390 (22.7%)	5,410 (22.8%)	0.059	0.002
Selective serotonin reuptake inhibitors	1,510 (5.3%)	4,790 (6.1%)	1,300 (5.5%)	1,290 (5.4%)	0.032	0.002
Drugs used in alcohol dependence	70 (0.2%)	120 (0.2%)	50 (0.2%)	50 (0.2%)	0.019	0.002
CHA2DS2-VASc, mean(SD)	2.9 (1.63)	3.4 (1.76)	3.0 (1.65)	3.0 (1.70)	0.293	0.013
CHA2DS2-VASc:0 -1	5,750 (20.3%)	11,520 (14.6%)	4,370 (18.5%)	4,620 (19.5%)	0.151	0.026
CHA2DS2-VASc:2 -3	13,100 (46.2%)	30,330 (38.3%)	10,780 (45.5%)	10,130 (42.7%)	0.160	0.055
CHA2DS2-VASc:>=4	9,520 (33.6%)	37,330 (47.1%)	8,550 (36.1%)	8,960 (37.8%)	0.279	0.036
CHADS2, mean(SD)	1.8 (1.39)	2.4 (1.51)	1.9 (1.40)	1.9 (1.43)	0.383	0.010
CHADS2:0 CHADS2:1	4,980 (17.5%) 8,230 (29.0%)	8,300 (10.5%) 15,840	3,530 (14.9%) 6,680 (28.2%)	3,960 (16.7%) 6,040 (25.5%)	0.204 0.210	0.050
CHADS2:>=2	15,160	(20.0%) 55,030	13,500	13,710	0.335	0.018
	(53.4%)	(69.5%)	(56.9%)	(57.8%)	0.152	0.007
HAS-BLED, mean(SD)	1.9 (1.01)	2.0 (1.05)	1.9 (1.01)	1.9 (1.04)	0.152	0.007
HAS-BLED:<3	21,630 (76.2%)	56,150 (70.9%)	17,900 (75.5%)	17,570 (74.1%)	0.121	0.033
HAS-BLED:>=3	6,740 (23.8%)	23,020 (29.1%)	5,800 (24.5%)	6,140 (25.9%)	0.121	0.033
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.221	0.012
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.006	0.011
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.001	0.001

Table 15.60 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin in Denmark, Norway, or Sweden and standardised mean differences before and after matching – **REDUCED DOSE**

Characteristic	Rivaroxaban (rounded) before matching N= 9214	Warfarin (rou nded) before matching N=79171	Rivaroxaban (rounded) after matching N= 9088	Warfarin (rou nded) after matching N= 9088	Standardised mean difference before matchi ng (max= 0.74)	Standardised mean difference after matching (max= 0.05)
index_year:2013	2,190 (23.8%)	35,000 (44.2%)	2,180 (24.0%)	2,150 (23.6%)	0.442	0.009
index_year:2014	2,330 (25.3%)	23,330 (29.5%)	2,330 (25.6%)	2,320 (25.5%)	0.094	0.002
index_year:2015	2,510 (27.2%)	13,390 (16.9%)	2,480 (27.3%)	2,540 (27.9%)	0.250	0.014
index_year:2016	2,190 (23.7%)	7,460 (9.4%)	2,100 (23.1%)	2,090 (23.0%)	0.393	0.003
Time from AF diag:< 1 month	5,250 (57.0%)	47,550 (60.1%)	5,190 (57.1%)	5,160 (56.8%)	0.063	0.006
Time from AF diag:1 - 6 month	1,010 (11.0%)	7,970 (10.1%)	1,000 (11.0%)	1,050 (11.5%)	0.029	0.016
Time from AF diag:6 - 60 months	2,960 (32.1%)	23,650 (29.9%)	2,900 (31.9%)	2,880 (31.7%)	0.048	0.005
Sex:Female	4,990 (54.1%)	32,980 (41.7%)	4,890 (53.8%)	4,860 (53.4%)	0.252	0.006
Sex:Male	4,230 (45.9%)	46,190 (58.3%)	4,200 (46.2%)	4,230 (46.6%)	0.252	0.006
Age, median(IQR)	83.1 (76.2 - 88.3)	75.0 (67.5 - 82.2)	82.9 (76.0 - 88.1)	82.9 (76.0 - 88.0)	0.735	0.004
Age -group:< 55 years	80 (0.9%)	4,480 (5.7%)	80 (0.9%)	80 (0.9%)	0.270	0.002
Age -group:55-<65 years	400 (4.3%)	10,100 (12.8%)	400 (4.4%)	400 (4.4%)	0.307	0.003
Age -group:65-<75 years	1,570 (17.0%)	25,060 (31.6%)	1,570 (17.2%)	1,550 (17.1%)	0.346	0.004
Age -group:75-<85 years	3,390 (36.8%)	26,700 (33.7%)	3,390 (37.3%)	3,460 (38.0%)	0.065	0.015
Age -group:>= 85 years	3,770 (41.0%)	12,830 (16.2%)	3,650 (40.2%)	3,600 (39.6%)	0.570	0.013
CCI-group:0	2,670 (28.9%)	29,610 (37.4%)	2,640 (29.1%)	2,760 (30.3%)	0.180	0.027
CCI-group:1-2	3,120 (33.8%)	25,600 (32.3%)	3,070 (33.7%)	2,870 (31.6%)	0.031	0.046
CCI-group:>=3	3,430 (37.2%)	23,960 (30.3%)	3,380 (37.2%)	3,460 (38.1%)	0.148	0.020
Prior bleeding (any)	1,310 (14.2%)	8,870 (11.2%)	1,300 (14.3%)	1,270 (14.0%)	0.089	0.008
Prior gastrointestinal bleeding Prior intracranial bleeding	150 (1.6%) 150 (1.6%)	820 (1.0%) 710 (0.9%)	150 (1.6%) 150 (1.6%)	140 (1.6%) 140 (1.5%)	0.047 0.067	0.002 0.007
Prior stroke (any)	1,590 (17.2%)	9,610 (12.1%)	1,540 (17.0%)	1,570 (17.3%)	0.067	0.007
Prior ischaemic stroke	1,540 (16.7%)	9,400 (11.9%)	1,490 (16.4%)	1,530 (16.9%)	0.138	0.012
Prior haemorrhagic stroke	110 (1.2%)	520 (0.7%)	110 (1.2%)	110 (1.2%)	0.056	0.002
Prior systemic embolism	90 (1.0%)	760 (1.0%)	90 (1.0%)	80 (0.9%)	0.001	0.006
Prior transient ischaemic attack	460 (5.0%)	3,120 (3.9%)	460 (5.0%)	430 (4.8%)	0.052	0.011
Chronic kidney disease Heart failure	880 (9.5%) 2,390 (25.9%)	6,530 (8.2%) 18,010	870 (9.6%) 2,350 (25.9%)	980 (10.7%) 2,360 (25.9%)	0.044	0.039
Coronary artery disease	2,610 (28.3%)	(22.7%) 21,450 (27.1%)	2,580 (28.4%)	2,560 (28.1%)	0.027	0.006
Peripheral arterial disease	810 (8.8%)	6,030 (7.6%)	810 (8.9%)	740 (8.1%)	0.044	0.028
Hypertension	6,550 (71.1%)	54,110 (68.3%)	6,460 (71.1%)	6,410 (70.6%)	0.060	0.012
Diabetes	1,750 (19.0%)	14,680 (18.5%)	1,730 (19.1%)	1,760 (19.4%)	0.011	0.008
Chronic obstructive pulmonary disease	1,320 (14.3%)	10,120 (12.8%)	1,310 (14.4%)	1,340 (14.7%)	0.046	0.009
Liver disease	90 (1.0%)	820 (1.0%)	90 (1.0%)	90 (1.0%)	0.005	0.002
Alcoholism	210 (2.3%)	1,790 (2.3%)	200 (2.2%)	210 (2.3%)	0.000	0.002
Dementia	440 (4.7%)	1,220 (1.5%)	400 (4.4%)	430 (4.7%)	0.184	0.013
Cancer 6 months before and including index date	370 (4.1%)	2,140 (2.7%)	370 (4.1%)	370 (4.1%)	0.075	0.001
Platelet inhibitors (excluding heparin)	4,260 (46.2%)	30,840 (39.0%)	4,190 (46.1%)	4,240 (46.7%)	0.147	0.011

		27,180				
Low -dose aspirin	3,670 (39.8%)	(34.3%)	3,620 (39.8%)	3,650 (40.2%)	0.113	0.008
ADP receptor blockers	880 (9.6%)	7,100 (9.0%)	860 (9.4%)	880 (9.7%)	0.022	0.007
Renin -angiotensin system inhibitors	4,290 (46.5%)	38,070 (48.1%)	4,240 (46.7%)	4,260 (46.8%)	0.031	0.003
Angiotensin -converting enzyme inhibitors	2,050 (22.2%)	20,500 (25.9%)	2,030 (22.3%)	2,020 (22.2%)	0.085	0.003
Angiotensin II antagonists, plain	1,380 (14.9%)	11,850 (15.0%)	1,360 (15.0%)	1,350 (14.9%)	0.001	0.003
Angiotensin II antagonists, combinations	810 (8.8%)	5,210 (6.6%)	800 (8.8%)	790 (8.7%)	0.084	0.005
Beta-blockers	6,200 (67.3%)	56,980 (72.0%)	6,130 (67.5%)	6,140 (67.6%)	0.102	0.003
Proton pump inhibitors	2,350 (25.5%)	17,350 (21.9%)	2,320 (25.5%)	2,380 (26.2%)	0.085	0.016
Non-steroidal anti-inflammatory drugs	650 (7.1%)	5,860 (7.4%)	650 (7.1%)	630 (6.9%)	0.012	0.008
Statins	3,240 (35.2%)	28,740 (36.3%)	3,200 (35.3%)	3,220 (35.4%)	0.024	0.003
Antidiabetic agents	1,210 (13.2%)	10,410 (13.1%)	1,200 (13.2%)	1,190 (13.1%)	0.001	0.003
Loop diuretics	3,240 (35.2%)	22,170 (28.0%)	3,170 (34.9%)	3,190 (35.1%)	0.154	0.004
Non-loop diuretics	130 (1.4%)	1,230 (1.6%)	130 (1.4%)	140 (1.6%)	0.011	0.012
Alpha adrenergic blockers	1,780 (19.3%)	15,810 (20.0%)	1,760 (19.3%)	1,760 (19.3%)	0.016	0.001
Amiodarone	240 (2.6%)	2,560 (3.2%)	230 (2.6%)	230 (2.6%)	0.040	0.001
Dronedarone	40 (0.4%)	600 (0.8%)	40 (0.4%)	30 (0.3%)	0.047	0.013
Antihypertensive, combination drugs	1,100 (11.9%)	7,700 (9.7%)	1,090 (12.0%)	1,110 (12.2%)	0.071	0.008
Calcium channel blockers	2,260 (24.5%)	19,680 (24.9%)	2,230 (24.5%)	2,260 (24.8%)	0.008	0.008
Selective serotonin reuptake inhibitors	800 (8.7%)	4,790 (6.1%)	780 (8.6%)	790 (8.6%)	0.101	0.002
Drugs used in alcohol dependence	10 (0.1%)	120 (0.2%)	10 (0.1%)	10 (0.1%)	0.022	0.000
CHA2DS2-VASc, mean(SD)	4.1 (1.61)	3.4 (1.76)	4.1 (1.61)	4.1 (1.64)	0.413	0.006
CHA2DS2-VASc:0 -1	410 (4.4%)	11,520 (14.6%)	410 (4.5%)	490 (5.4%)	0.351	0.043
CHA2DS2-VASc:2 -3	2,920 (31.7%)	30,330 (38.3%)	2,910 (32.0%)	2,810 (30.9%)	0.138	0.023
CHA2DS2-VASc:>=4	5,880 (63.8%)	37,330 (47.1%)	5,780 (63.5%)	5,790 (63.7%)	0.341	0.003
CHADS2, mean(SD)	2.7 (1.45)	2.4 (1.51)	2.7 (1.45)	2.7 (1.47)	0.190	0.002
CHADS2:0	450 (4.9%)	8,300 (10.5%)	450 (5.0%)	530 (5.9%)	0.209	0.039
CHADS2:1	1,540 (16.7%)	15,840 (20.0%)	1,530 (16.8%)	1,530 (16.9%)	0.085	0.002
CHADS2:>=2	7,220 (78.3%)	55,030 (69.5%)	7,110 (78.2%)	7,020 (77.2%)	0.202	0.023
HAS-BLED, mean(SD)	2.4 (1.02)	2.0 (1.05)	2.4 (1.02)	2.4 (1.05)	0.344	0.001
HAS-BLED:<3	5,430 (58.9%)	56,150 (70.9%)	5,380 (59.2%)	5,330 (58.7%)	0.253	0.010
HAS-BLED:>=3	3,780 (41.1%)	23,020 (29.1%)	3,710 (40.8%)	3,760 (41.3%)	0.253	0.010
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.100	0.015
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.6)	0.030	0.001
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.057	0.007

Table 15.61 Baseline characteristics of patients with non-valvular atrial fibrillationinitiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and aftermatching, Denmark – STANDARD DOSE

6/					Standardised	0, 1 ¹
	Rivaroxaban (Warfarin (rou	Rivaroxaban (Warfarin (rou	mean	Standardised
<u>Channa stanistis</u>	rounded) before	nded) before	rounded) after	nded) after	difference	mean difference
Characteristic	matching	matching	matching	matching	before matchi	after matching
	N=9559	N=20070	N= 8362	N= 8362	ng	(max = 0.07)
					(max= 0.58)	· · · ·
index_year:2013	1,540 (16.1%)	6,810 (33.9%)	1,540 (18.4%)	1,460 (17.5%)	0.421	0.023
index_year:2014	1,330 (13.9%)	5,400 (26.9%)	1,330 (15.9%)	1,350 (16.2%)	0.326	0.007
index_year:2015	2,720 (28.5%)	4,580 (22.8%)	2,630 (31.5%)	2,740 (32.8%)	0.129	0.028
index_year:2016	3,970 (41.5%)	3,280 (16.4%)	2,860 (34.2%)	2,810 (33.6%)	0.578	0.014
Time from AF diag:< 1 month	6,420 (67.1%)	12,620 (62.9%)	5,520 (66.0%)	5,480 (65.5%)	0.090	0.011
Time from AF diag:1 - 6 month	1,130 (11.8%)	2,410 (12.0%)	1,000 (11.9%)	1,040 (12.4%)	0.005	0.016
Time from AF diag:6 - 60 months	2,010 (21.0%)	5,040 (25.1%)	1,840 (22.1%)	1,850 (22.1%)	0.098	0.000
Sex:Female	3,980 (41.6%)	7,950 (39.6%)	3,450 (41.3%)	3,480 (41.6%)	0.041	0.006
Sex:Male	5,580 (58.4%)	12,120 (60.4%)	4,910 (58.7%)	4,890 (58.4%)	0.041	0.006
Age, median(IQR)	71.7 (65.7 - 78.5)	73.3 (66.1 - 80.6)	72.0 (65.7 - 78.9)	72.2 (65.8 - 79.1)	0.086	0.012
Age -group:< 55 years	600 (6.2%)	1,520 (7.6%)	560 (6.7%)	580 (6.9%)	0.053	0.010
Age -group:55-<65 years	1,560 (16.3%)	2,870 (14.3%)	1,330 (15.9%)	1,300 (15.6%)	0.056	0.008
Age -group:65-<75 years	3,850 (40.3%)	6,820 (34.0%)	3,260 (39.0%)	3,190 (38.1%)	0.130	0.018
Age -group:75-<85 years	2,680 (28.0%)	6,280 (31.3%)	2,390 (28.6%)	2,440 (29.1%)	0.071	0.013
Age -group:>= 85 years	880 (9.2%)	2,580 (12.9%)	830 (9.9%)	860 (10.3%)	0.119	0.012
CCI-group:0	4,810 (50.4%)	8,600 (42.8%)	4,130 (49.4%)	4,230 (50.6%)	0.151	0.024
CCI-group:1-2	3,190 (33.3%)	6,000 (29.9%)	2,800 (33.4%)	2,530 (30.3%)	0.073	0.068
CCI-group:>=3	1,560 (16.3%)	5,470 (27.2%)	1,430 (17.1%)	1,600 (19.1%)	0.267	0.050
Prior bleeding (any)	730 (7.7%)	1,940 (9.7%)	660 (7.9%)	670 (8.0%)	0.071	0.006
Prior gastrointestinal bleeding	70 (0.7%)	270 (1.4%)	60 (0.8%)	70 (0.8%)	0.067	0.005
Prior intracranial bleeding	80 (0.8%)	140 (0.7%)	70 (0.8%)	70 (0.8%)	0.014	0.001
Prior stroke (any)	1,150 (12.1%)	1,980 (9.8%)	950 (11.3%)	940 (11.2%)	0.071	0.004
Prior ischaemic stroke	1,130 (11.8%)	1,940 (9.7%)	930 (11.1%)	920 (11.0%)	0.068	0.003
Prior haemorrhagic stroke	50 (0.5%)	90 (0.4%)	40 (0.5%)	40 (0.5%)	0.013	0.002
Prior systemic embolism	30 (0.3%)	110 (0.5%)	30 (0.3%)	20 (0.3%)	0.043	0.002
Prior transient ischaemic attack	300 (3.2%)	600 (3.0%)	270 (3.2%)	270 (3.2%)	0.009	0.001
Chronic kidney disease	110 (1.1%)	1,690 (8.4%)	110 (1.3%)	120 (1.4%)	0.346	0.012
Heart failure	1,120 (11.7%)	3,570 (17.8%)	1,050 (12.6%)	1,040 (12.4%)	0.172	0.005
Coronary artery disease	1,390 (14.6%)	4,590 (22.9%)	1,300 (15.6%)	1,300 (15.6%)	0.214	0.000
Peripheral arterial disease	510 (5.3%)	1,630 (8.1%)	480 (5.7%)	500 (5.9%)	0.113	0.009
Hypertension	5,690 (59.5%)	12,270 (61.1%)	4,950 (59.1%)	4,980 (59.6%)	0.033	0.009
Diabetes	1,360 (14.2%)	3,490 (17.4%)	1,230 (14.7%)	1,260 (15.0%)	0.086	0.009
Chronic obstructive pulmonary disease	1,050 (11.0%)	2,570 (12.8%)	940 (11.2%)	1,000 (11.9%)	0.055	0.022
Liver disease	80 (0.8%)	240 (1.2%)	80 (0.9%)	80 (1.0%)	0.040	0.006
Alcoholism	310 (3.3%)	590 (2.9%)	280 (3.4%)	270 (3.2%)	0.018	0.009
Dementia	150 (1.6%)	220 (1.1%)	130 (1.5%)	120 (1.5%)	0.041	0.003
Cancer 6 months before and including index date	350 (3.7%)	930 (4.6%)	330 (3.9%)	330 (4.0%)	0.048	0.001
Platelet inhibitors (excluding heparin)	2,660 (27.8%)	6,760 (33.7%)	2,390 (28.6%)	2,420 (29.0%)	0.128	0.008
Low -dose aspirin	1,960 (20.5%)	5,110 (25.5%)	1,770 (21.1%)	1,770 (21.1%)	0.117	0.000
ADP receptor blockers	760 (7.9%)	2,260 (11.2%)	690 (8.3%)	710 (8.5%)	0.113	0.006
Renin -angiotensin system inhibitors	3,790 (39.7%)	8,420 (42.0%)	3,330 (39.8%)	3,300 (39.4%)	0.047	0.007
Angiotensin -converting enzyme inhibitors	1,850 (19.3%)	4,510 (22.5%)	1,660 (19.9%)	1,630 (19.5%)	0.078	0.011
Angiotensin II antagonists, plain	1,020 (10.6%)	2,220 (11.0%)	870 (10.5%)	890 (10.7%)	0.013	0.008
Angiotensin II antagonists, combinations	700 (7.3%)	1,210 (6.0%)	570 (6.8%)	550 (6.6%)	0.049	0.011
Beta-blockers	5,980 (62.6%)	12,420 (61.9%)	5,190 (62.1%)	5,090 (60.8%)	0.014	0.027
Proton pump inhibitors	1,760 (18.4%)	4,510 (22.5%)	1,600 (19.2%)	1,550 (18.5%)	0.101	0.017
Non-steroidal anti-inflammatory drugs	990 (10.3%)	1,980 (9.9%)	820 (9.8%)	830 (9.9%)	0.016	0.003
Statins	3,100 (32.4%)	6,990 (34.8%)	2,710 (32.5%)	2,690 (32.2%)	0.052	0.006
				980 (11.7%)	0.067	0.013
Antidiabetic agents	1,050 (11.0%)	2,650 (13.2%)	950 (11.3%)	980(11.7%)	0.007	0.015

Non-loop diuretics	110 (1.1%)	350 (1.7%)	100 (1.2%)	110 (1.3%)	0.050	0.007
Alpha adrenergic blockers	1,600 (16.7%)	3,670 (18.3%)	1,420 (17.0%)	1,420 (16.9%)	0.040	0.002
Amiodarone	230 (2.4%)	970 (4.9%)	220 (2.7%)	240 (2.8%)	0.133	0.010
Dronedarone	20 (0.2%)	30 (0.1%)	10 (0.2%)	20 (0.2%)	0.011	0.003
Antihypertensive, combination drugs	1,110 (11.6%)	2,110 (10.5%)	950 (11.3%)	920 (11.0%)	0.035	0.012
Calcium channel blockers	2,180 (22.8%)	4,790 (23.9%)	1,890 (22.7%)	1,930 (23.1%)	0.026	0.011
Selective serotonin reuptake inhibitors	540 (5.6%)	1,150 (5.7%)	470 (5.6%)	480 (5.7%)	0.005	0.006
Drugs used in alcohol dependence	30 (0.3%)	50 (0.2%)	20 (0.3%)	20 (0.3%)	0.009	0.007
CHA2DS2-VASc, mean(SD)	2.9 (1.58)	3.1 (1.67)	2.9 (1.59)	2.9 (1.64)	0.133	0.008
CHA2DS2-VASc:0 -1	1,880 (19.6%)	3,580 (17.8%)	1,620 (19.3%)	1,690 (20.2%)	0.046	0.021
CHA2DS2-VASc:2 -3	4,530 (47.4%)	8,410 (41.9%)	3,940 (47.1%)	3,720 (44.5%)	0.111	0.053
CHA2DS2-VASc:>=4	3,150 (32.9%)	8,080 (40.2%)	2,810 (33.5%)	2,950 (35.3%)	0.152	0.038
CHADS2, mean(SD)	1.5 (1.18)	1.6 (1.21)	1.5 (1.17)	1.5 (1.20)	0.115	0.007
CHADS2:0	1,880 (19.6%)	3,470 (17.3%)	1,600 (19.1%)	1,740 (20.8%)	0.061	0.044
CHADS2:1	3,450 (36.0%)	6,320 (31.5%)	3,010 (36.0%)	2,720 (32.5%)	0.097	0.075
CHADS2:>=2	4,240 (44.3%)	10,280 (51.2%)	3,750 (44.9%)	3,900 (46.7%)	0.139	0.036
HAS-BLED, mean(SD)	2.0 (1.06)	2.1 (1.17)	2.0 (1.07)	2.0 (1.11)	0.131	0.006
HAS-BLED:<3	6,670 (69.8%)	12,660 (63.1%)	5,830 (69.7%)	5,700 (68.2%)	0.142	0.033
HAS-BLED:>=3	2,890 (30.2%)	7,410 (36.9%)	2,540 (30.3%)	2,660 (31.8%)	0.142	0.033
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.113	0.007
log_beddays, median(IQR)	1.1 (0.0 - 1.6)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.198	0.007
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.053	0.009
income, median(IQR), k€	137.1 (96.7 - 218.8)	122.8 (88.9 - 187.6)	132.8 (94.8 - 210.0)	131.8 (94.4 - 209.4)	0.094	0.011
education:Secondary compulsory	3,480 (36.4%)	8,430 (42.0%)	3,160 (37.8%)	3,170 (37.9%)	0.114	0.003
education:Vocational / High school	3,990 (41.8%)	8,140 (40.6%)	3,490 (41.7%)	3,450 (41.3%)	0.024	0.009
education:Higher education	1,870 (19.6%)	2,980 (14.8%)	1,520 (18.1%)	1,540 (18.4%)	0.126	0.007
education:Unknown	210 (2.2%)	520 (2.6%)	200 (2.3%)	200 (2.4%)	0.024	0.001
employment:Employed or self - employed	2,070 (21.6%)	3,720 (18.5%)	1,750 (20.9%)	1,720 (20.6%)	0.078	0.009
employment:Unemployed	520 (5.5%)	1,190 (5.9%)	460 (5.5%)	460 (5.5%)	0.020	0.001
employment:Retired	6,890 (72.1%)	15,010 (74.8%)	6,090 (72.8%)	6,120 (73.2%)	0.062	0.009
employment:Unknown	80 (0.8%)	150 (0.7%)	70 (0.8%)	70 (0.8%)	0.010	0.005





Table 15.62 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Denmark – REDUCED DOSE

Characteristic	Rivaroxaban (Warfarin (rou	Rivaroxaban (Warfarin (rou	Standardised	Standardised
	rounded)	nded) before	rounded) after	nded) after	mean	mean
	before	matching	matching	matching	difference	difference
	matching N= 3123	N=20070	N= 3010	N= 3010	before matchi	after matching (max= 0.09)
	N= 5125				ng (max= 0.89)	(IIIax = 0.09)
index_year:2013	810 (26.0%)	6,810 (33.9%)	800 (26.6%)	780 (25.9%)	0.174	0.017
index_year:2014	550 (17.6%)	5,400 (26.9%)	550 (18.2%)	540 (17.9%)	0.225	0.008
index_year:2015	790 (25.2%)	4,580 (22.8%)	770 (25.4%)	790 (26.2%)	0.056	0.018
index_year:2016	980 (31.3%)	3,280 (16.4%)	900 (29.7%)	900 (30.0%)	0.355	0.005
Time from AF diag:< 1 month	1,950 (62.4%)	12,620 (62.9%)	1,890 (62.8%)	1,880 (62.4%)	0.010	0.009
Time from AF diag:1 - 6 month	340 (10.8%)	2,410 (12.0%)	330 (11.1%)	360 (12.1%)	0.037	0.032
Time from AF diag:6 - 60 months	840 (26.8%)	5,040 (25.1%)	790 (26.1%)	770 (25.5%)	0.038	0.014
Sex:Female	1,730 (55.4%)	7,950 (39.6%)	1,640 (54.4%)	1,650 (54.8%)	0.320	0.009
Sex:Male	1,390 (44.6%)	12,120 (60.4%)	1,370 (45.6%)	1,360 (45.2%)	0.320	0.009
Age, median(IQR)	83.4 (76.3 -	73.3 (66.1 -	82.9 (76.0 -	82.9 (76.1 -	0.892	0.003
1 igo, incomm(r.c.r.)	88.6)	80.6)	88.2)	88.0)	0.072	01002
Age -group:< 55 years	40 (1.2%)	1,520 (7.6%)	40 (1.2%)	30 (1.1%)	0.319	0.009
Age -group:55-<65 years	140 (4.4%)	2,870 (14.3%)	140 (4.6%)	110 (3.5%)	0.344	0.054
Age -group:65-<75 years	520 (16.6%)	6,820 (34.0%)	520 (17.2%)	530 (17.6%)	0.409	0.012
Age -group:75-<85 years	1,080 (34.7%)	6,280 (31.3%)	1,080 (35.8%)	1,130 (37.5%)	0.073	0.034
Age -group:>= 85 years	1,350 (43.2%)	2,580 (12.9%)	1,240 (41.2%)	1,210 (40.3%)	0.717	0.019
CCI-group:0	940 (29.9%)	8,600 (42.8%)	910 (30.4%)	1,010 (33.7%)	0.271	0.071
CCI-group:1-2	1,100 (35.1%)	6,000 (29.9%)	1,050 (35.0%)	930 (30.8%)	0.111	0.089
CCI-group:>=3	1,090 (35.0%)	5,470 (27.2%)	1,040 (34.6%)	1,070 (35.5%)	0.167	0.019
Prior bleeding (any)	360 (11.7%)	1,940 (9.7%)	360 (11.9%)	340 (11.3%)	0.064	0.018
Prior gastrointestinal bleeding Prior intracranial bleeding	60 (2.0%) 50 (1.5%)	270 (1.4%) 140 (0.7%)	60 (2.1%) 40 (1.4%)	60 (2.1%) 40 (1.2%)	0.051 0.074	0.002 0.018
Prior stroke (any)	590 (18.9%)	1,980 (9.8%)	40 (1.4%) 540 (18.0%)	40 (1.2%) 560 (18.5%)	0.259	0.018
Prior ischaemic stroke	580 (18.5%)	1,940 (9.7%)	530 (17.7%)	550 (18.3%)	0.259	0.012
Prior haemorrhagic stroke	30 (0.9%)	90 (0.4%)	30 (0.8%)	20 (0.8%)	0.058	0.004
Prior systemic embolism	20 (0.6%)	110 (0.5%)	20 (0.6%)	10 (0.4%)	0.014	0.028
Prior transient ischaemic attack	120 (3.8%)	600 (3.0%)	110 (3.8%)	110 (3.6%)	0.042	0.012
Chronic kidney disease	250 (8.0%)	1,690 (8.4%)	240 (8.0%)	280 (9.3%)	0.016	0.044
Heart failure	730 (23.4%)	3,570 (17.8%)	690 (23.0%)	700 (23.3%)	0.139	0.006
Coronary artery disease	740 (23.8%)	4,590 (22.9%)	720 (23.9%)	710 (23.5%)	0.022	0.009
Peripheral arterial disease	270 (8.7%)	1,630 (8.1%)	270 (8.9%)	270 (8.8%)	0.020	0.005
Hypertension	2,140 (68.4%)	12,270 (61.1%)	2,060 (68.3%)	2,000 (66.5%)	0.152	0.038
Diabetes	610 (19.4%)	3,490 (17.4%)	590 (19.6%)	580 (19.4%)	0.051	0.006
Chronic obstructive pulmonary disease	490 (15.6%)	2,570 (12.8%)	480 (15.9%)	500 (16.5%)	0.080	0.017
Liver disease	40 (1.1%)	240 (1.2%)	30 (1.1%)	30 (0.9%)	0.006	0.023
Alcoholism	100 (3.2%)	590 (2.9%)	90 (3.1%)	80 (2.8%)	0.013	0.020
Dementia	160 (5.2%)	220 (1.1%)	140 (4.5%)	130 (4.4%)	0.236	0.005
Cancer 6 months before and including index date	160 (5.0%)	930 (4.6%)	160 (5.2%)	150 (5.0%)	0.019	0.008
Platelet inhibitors (excluding	1,300 (41.7%)	6,760 (33.7%)	1,240 (41.3%)	1,260 (41.8%)	0.165	0.010
heparin) Low -dose aspirin	950 (30.4%)	5,110 (25.5%)	910 (30.3%)	910 (30.1%)	0.109	0.003
ADP receptor blockers	440 (14.1%)	2,260 (11.2%)	420 (13.8%)	450 (15.0%)	0.087	0.003
Renin -angiotensin system inhibitors	1,380 (44.1%)	8,420 (42.0%)	1,330 (44.3%)	1,310 (43.6%)	0.042	0.014
Angiotensin -converting enzyme inhibitors	700 (22.5%)	4,510 (22.5%)	680 (22.7%)	680 (22.6%)	0.001	0.002
Angiotensin II antagonists, plain	390 (12.4%)	2,220 (11.0%)	380 (12.5%)	340 (11.2%)	0.043	0.040
Angiotensin II antagonists,	220 (7.0%)	1,210 (6.0%)	210 (7.0%)	200 (6.7%)	0.039	0.012
combinations Beta-blockers	1,900 (60.8%)	12,420	1,840 (61.1%)	1,830 (60.7%)	0.022	0.007
Droton nymn int-it-it-	860 (27 50/)	(61.9%)	820 (27 (0/)	850 (20 10/)	0.117	0.010
Proton pump inhibitors Non-steroidal anti-inflammatory	860 (27.5%) 290 (9.1%)	4,510 (22.5%)	830 (27.6%) 280 (9.4%)	850 (28.1%) 260 (8.6%)	0.117 0.025	0.010 0.028
drugs		1,980 (9.9%)				
Statins	1,070 (34.4%)	6,990 (34.8%)	1,040 (34.7%)	1,050 (34.9%)	0.010	0.006
Antidiabetic agents	450 (14.4%)	2,650 (13.2%)	440 (14.7%)	430 (14.4%)	0.036	0.008

Loop diuretics	1,290 (41.3%)	5,800 (28.9%)	1,230 (40.7%)	1,230 (41.0%)	0.262	0.005
Non-loop diuretics	50 (1.5%)	350 (1.7%)	40 (1.5%)	50 (1.5%)	0.020	0.005
Alpha adrenergic blockers	680 (21.6%)	3,670 (18.3%)	650 (21.6%)	640 (21.2%)	0.084	0.011
Amiodarone	140 (4.5%)	970 (4.9%)	140 (4.6%)	140 (4.7%)	0.016	0.006
Dronedarone	<5	30 (0.1%)	<5	<5	0.033	0.000
Antihypertensive, combination	360 (11.6%)	2,110 (10.5%)	350 (11.7%)	360 (12.0%)	0.034	0.008
drugs	· · · ·		· · · · ·	×		
Calcium channel blockers	760 (24.3%)	4,790 (23.9%)	730 (24.4%)	730 (24.1%)	0.010	0.005
Selective serotonin reuptake	290 (9.2%)	1,150 (5.7%)	270 (8.9%)	270 (8.9%)	0.132	0.000
inhibitors						
Drugs used in alcohol dependence	<5	50 (0.2%)	<5	<5	0.036	0.026
CHA2DS2-VASc, mean(SD)	4.1 (1.53)	3.1 (1.67)	4.1 (1.52)	4.1 (1.58)	0.628	0.002
CHA2DS2-VASc:0 -1	120 (3.9%)	3,580 (17.8%)	120 (4.1%)	140 (4.5%)	0.458	0.020
CHA2DS2-VASc:2 -3	950 (30.3%)	8,410 (41.9%)	930 (31.0%)	940 (31.4%)	0.245	0.009
CHA2DS2-VASc:>=4	2,060 (65.8%)	8,080 (40.2%)	1,960 (65.0%)	1,930 (64.2%)	0.530	0.017
CHADS2, mean(SD)	2.3 (1.23)	1.6 (1.21)	2.3 (1.22)	2.3 (1.26)	0.552	0.013
CHADS2:0	150 (4.7%)	3,470 (17.3%)	150 (4.9%)	180 (6.1%)	0.412	0.054
CHADS2:1	590 (19.0%)	6,320 (31.5%)	580 (19.4%)	610 (20.2%)	0.290	0.019
CHADS2:>=2	2,380 (76.3%)	10,280	2,280 (75.7%)	2,220 (73.8%)	0.540	0.046
		(51.2%)				
HAS-BLED, mean(SD)	2.5 (1.06)	2.1 (1.17)	2.5 (1.06)	2.5 (1.10)	0.367	0.008
HAS-BLED:<3	1,570 (50.2%)	12,660	1,530 (50.7%)	1,520 (50.6%)	0.262	0.002
		(63.1%)				
HAS-BLED:>=3	1,560 (49.8%)	7,410 (36.9%)	1,480 (49.3%)	1,490 (49.4%)	0.262	0.002
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.193	0.014
log_beddays, median(IQR)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.9)	1.1 (0.0 - 1.8)	1.1 (0.0 - 1.8)	0.169	0.007
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	0.097	0.015
income, median(IQR), k€	99.5 (77.7 -	122.8 (88.9 -	100.7 (78.1 -	100.0 (77.7 -	0.242	0.018
	134.3)	187.6)	135.6)	136.8)		
education:Secondary compulsory	1,520 (48.6%)	8,430 (42.0%)	1,460 (48.6%)	1,490 (49.6%)	0.132	0.019
education:Vocational / High school	990 (31.7%)	8,140 (40.6%)	970 (32.2%)	960 (31.9%)	0.184	0.008
education:Higher education	380 (12.3%)	2,980 (14.8%)	370 (12.4%)	370 (12.1%)	0.074	0.009
education:Unknown	230 (7.4%)	520 (2.6%)	200 (6.7%)	190 (6.4%)	0.222	0.012
employment:Employed or self -	180 (5.6%)	3,720 (18.5%)	170 (5.8%)	180 (6.0%)	0.405	0.010
employed						
employment:Unemployed	70 (2.1%)	1,190 (5.9%)	70 (2.2%)	50 (1.8%)	0.194	0.033
employment:Retired	2,880 (92.1%)	15,010	2,760 (91.8%)	2,770 (91.9%)	0.478	0.004
		(74.8%)				
employment:Unknown	10 (0.2%)	150 (0.7%)	10 (0.2%)	10 (0.3%)	0.086	0.028



PFIZER CONFIDENTIAL Page 183 of 253

Table 15.63 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Norway – STANDARD DOSE

Characteristic	Rivaroxaban (Warfarin (rou	Rivaroxaban (Warfarin (rou	Standardised	Standardised
	rounded)	nded) before	rounded) after	nded) after	mean	mean
	before	matching	matching	matching	difference	difference
	matching N= 7916	N=11949	N= 5466	N= 5466	before matchi	after matching $(max = 0.08)$
	N= /910				ng (max= 0.55)	(max= 0.08)
index_year:2013	1,840 (23.3%)	5,810 (48.6%)	1,840 (33.6%)	1,790 (32.7%)	0.547	0.019
index_year:2014	1,880 (23.8%)	3,450 (28.8%)	1,730 (31.6%)	1,710 (31.2%)	0.115	0.008
index_year:2015	2,210 (27.9%)	1,760 (14.8%)	1,250 (22.9%)	1,240 (22.7%)	0.324	0.004
index_year:2016	1,990 (25.1%)	930 (7.8%)	650 (11.9%)	730 (13.4%)	0.480	0.043
Time from AF diag:< 1 month	4,960 (62.6%)	6,410 (53.6%)	3,160 (57.9%)	3,200 (58.5%)	0.182	0.011
Time from AF diag:1 - 6 month	660 (8.4%)	1,340 (11.2%)	530 (9.7%)	550 (10.1%)	0.095	0.014
Time from AF diag:6 - 60 months	2,300 (29.0%)	4,200 (35.2%)	1,770 (32.4%)	1,720 (31.4%)	0.132	0.021
Sex:Female	3,150 (39.8%)	4,740 (39.7%)	2,210 (40.5%)	2,230 (40.8%)	0.003	0.007
Sex:Male Age, median(IQR)	4,760 (60.2%) 71.2 (65.3 -	7,210 (60.3%) 75.3 (66.7 -	3,260 (59.5%) 72.4 (65.3 -	3,240 (59.2%) 72.5 (65.6 -	0.003 0.261	0.007 0.024
Age, median(IQK)	71.2 (03.3 - 77.8)	83.2)	72.4 (63.3 - 79.7)	80.1)	0.201	0.024
Age -group:< 55 years	530 (6.6%)	830 (7.0%)	400 (7.3%)	370 (6.7%)	0.013	0.024
Age -group:55-<65 years	1,390 (17.5%)	1,690 (14.2%)	910 (16.6%)	920 (16.8%)	0.092	0.004
Age -group:65-<75 years	3,240 (41.0%)	3,360 (28.1%)	1,930 (35.3%)	1,920 (35.2%)	0.273	0.003
Age -group:75-<85 years	2,090 (26.4%)	3,860 (32.3%)	1,600 (29.2%)	1,600 (29.2%)	0.129	0.001
Age -group:>= 85 years	670 (8.5%)	2,210 (18.5%)	630 (11.5%)	660 (12.1%)	0.296	0.019
CCI-group:0	3,320 (42.0%)	3,340 (27.9%)	2,030 (37.0%)	2,040 (37.3%)	0.298	0.005
CCI-group:1-2	2,870 (36.2%)	3,810 (31.9%)	2,020 (37.0%)	1,900 (34.7%)	0.090	0.048
CCI-group:>=3	1,730 (21.9%)	4,800 (40.2%)	1,420 (25.9%)	1,530 (28.0%)	0.404	0.047
Prior bleeding (any)	820 (10.4%)	1,780 (14.9%)	640 (11.7%)	670 (12.2%)	0.137	0.016
Prior gastrointestinal bleeding	70 (0.9%)	190 (1.6%)	60 (1.1%)	70 (1.2%)	0.061	0.012
Prior intracranial bleeding	70 (0.9%)	160 (1.3%)	60 (1.0%)	70 (1.2%)	0.045	0.016
Prior stroke (any) Prior ischaemic stroke	870 (11.0%) 860 (10.8%)	1,440 (12.0%) 1,380 (11.5%)	670 (12.3%) 660 (12.0%)	660 (12.1%) 640 (11.8%)	0.030	0.007
Prior haemorrhagic stroke	40 (0.5%)	110 (0.9%)	40 (0.7%)	40 (0.7%)	0.024	0.000
Prior systemic embolism	30 (0.4%)	140 (1.2%)	30 (0.6%)	30 (0.6%)	0.048	0.000
Prior transient ischaemic attack	290 (3.7%)	460 (3.9%)	220 (4.0%)	210 (3.9%)	0.009	0.002
Chronic kidney disease	200 (2.5%)	1,560 (13.1%)	200 (3.6%)	240 (4.3%)	0.404	0.039
Heart failure	970 (12.2%)	3,110 (26.0%)	830 (15.2%)	860 (15.7%)	0.358	0.012
Coronary artery disease	1,660 (20.9%)	4,410 (36.9%)	1,360 (24.8%)	1,420 (25.9%)	0.358	0.025
Peripheral arterial disease	660 (8.4%)	1,370 (11.5%)	500 (9.2%)	500 (9.1%)	0.104	0.003
Hypertension	4,520 (57.1%)	7,270 (60.8%)	3,180 (58.3%)	3,190 (58.3%)	0.076	0.001
Diabetes	1,080 (13.6%)	2,100 (17.6%)	790 (14.4%)	800 (14.7%)	0.111	0.007
Chronic obstructive pulmonary disease	1,030 (13.0%)	1,850 (15.5%)	750 (13.7%)	760 (14.0%)	0.070	0.008
Liver disease	80 (1.0%)	150 (1.3%)	60 (1.0%)	60 (1.0%)	0.031	0.002
Alcoholism	190 (2.5%)	170 (1.4%)	120 (2.2%)	110 (2.1%)	0.075	0.005
Dementia	100 (1.2%)	230 (1.9%)	80 (1.5%)	80 (1.5%)	0.054	0.000
Cancer 6 months before and including index date	440 (5.6%)	810 (6.8%)	340 (6.2%)	360 (6.5%)	0.048	0.015
Platelet inhibitors (excluding	3,160 (39.9%)	5,400 (45.2%)	2,270 (41.6%)	2,300 (42.1%)	0.107	0.011
heparin)						
Low -dose aspirin	3,040 (38.4%)	5,060 (42.4%)	2,180 (39.8%)	2,190 (40.1%)	0.080	0.005
ADP receptor blockers	190 (2.4%)	1,130 (9.5%)	190 (3.4%)	220 (3.9%)	0.303	0.029
Renin -angiotensin system inhibitors	3,250 (41.1%)	5,500 (46.0%)	2,280 (41.7%)	2,290 (41.8%)	0.101	0.003
Angiotensin -converting enzyme inhibitors	950 (12.0%)	2,500 (20.9%)	770 (14.2%)	800 (14.6%)	0.241	0.012
Angiotensin II antagonists, plain	1,080 (13.6%)	1,640 (13.7%)	740 (13.5%)	730 (13.4%)	0.002	0.003
Angiotensin II antagonists, combinations	1,220 (15.4%)	1,450 (12.2%)	770 (14.1%)	760 (13.9%)	0.094	0.007
Beta-blockers	4,980 (62.9%)	8,410 (70.4%)	3,540 (64.8%)	3,570 (65.3%)	0.159	0.010
Proton pump inhibitors	1,340 (16.9%)	2,690 (22.5%)	1,000 (18.3%)	1,020 (18.6%)	0.143	0.008
H2-receptor antagonists	110 (1.4%)	170 (1.4%)	70 (1.3%)	80 (1.4%)	0.003	0.009
Non-steroidal anti-inflammatory	750 (9.5%)	910 (7.6%)	490 (8.9%)	460 (8.4%)	0.069	0.020
drugs						
Statins	2,790 (35.2%)	5,020 (42.0%)	2,010 (36.8%)	2,030 (37.1%)	0.140	0.006
Antidiabetic agents	730 (9.2%)	1,400 (11.7%)	530 (9.7%)	550 (10.1%)	0.082	0.013
Loop diuretics	1,010 (12.8%)	3,390 (28.4%)	880 (16.1%)	910 (16.7%)	0.393	0.017
Non-loop diuretics	100(1.3%)	230 (1.9%)	80 (1.4%)	70 (1.3%)	0.048	0.005
Alpha adrenergic blockers	390 (4.9%)	960 (8.0%)	300 (5.5%)	310 (5.7%)	0.127	0.010

Amiodarone	160 (2.0%)	700 (5.9%)	150 (2.8%)	160 (3.0%)	0.197	0.011
Dronedarone	50 (0.7%)	130 (1.1%)	50 (0.9%)	40 (0.7%)	0.048	0.017
Antihypertensive, combination drugs	1,410 (17.8%)	1,740 (14.6%)	910 (16.6%)	900 (16.4%)	0.087	0.004
Calcium channel blockers	1,580 (20.0%)	2,640 (22.1%)	1,110 (20.3%)	1,100 (20.1%)	0.052	0.007
Selective serotonin reuptake inhibitors	310 (3.9%)	530 (4.5%)	230 (4.2%)	220 (4.0%)	0.027	0.008
Drugs used in alcohol dependence	20 (0.2%)	20 (0.1%)	10 (0.2%)	10 (0.2%)	0.027	0.004
CHA2DS2-VASc, mean(SD)	2.7 (1.64)	3.3 (1.86)	2.9 (1.68)	2.9 (1.79)	0.345	0.000
CHA2DS2-VASc:0 -1	2,030 (25.7%)	2,240 (18.7%)	1,200 (21.9%)	1,330 (24.4%)	0.168	0.058
CHA2DS2-VASc:2 -3	3,670 (46.3%)	4,370 (36.6%)	2,470 (45.1%)	2,250 (41.1%)	0.199	0.080
CHA2DS2-VASc:>=4	2,220 (28.0%)	5,340 (44.7%)	1,800 (33.0%)	1,880 (34.5%)	0.352	0.032
CHADS2, mean(SD)	1.3 (1.21)	1.7 (1.35)	1.4 (1.24)	1.4 (1.29)	0.333	0.016
CHADS2:0	2,490 (31.5%)	2,530 (21.1%)	1,420 (26.0%)	1,590 (29.1%)	0.236	0.071
CHADS2:1	2,680 (33.8%)	3,480 (29.1%)	1,860 (34.1%)	1,690 (31.0%)	0.100	0.066
CHADS2:>=2	2,750 (34.8%)	5,940 (49.7%)	2,180 (40.0%)	2,180 (39.9%)	0.307	0.002
HAS-BLED, mean(SD)	1.8 (1.12)	2.1 (1.26)	1.9 (1.14)	1.9 (1.19)	0.253	0.007
HAS-BLED:<3	5,850 (73.9%)	7,410 (62.0%)	3,880 (71.0%)	3,800 (69.4%)	0.256	0.035
HAS-BLED:>=3	2,070 (26.1%)	4,540 (38.0%)	1,580 (29.0%)	1,670 (30.6%)	0.256	0.035
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.7 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.7 - 1.1)	0.421	0.019
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.049	0.003
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.079	0.002




Table 15.64 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Norway – REDUCED DOSE

	Rivaroxaban (rounded)	Warfarin (rou	Rivaroxaban (Warfarin (rou	Standardised mean	Standardised mean
Characteristic	before matching	nded) before matching N=11949	rounded) after matching N= 2641	nded) after matching N= 2641	difference before matchi ng	difference after matching
	N= 2649	11-11717	11-2011	11-2011	$(\max = 0.61)$	(max= 0.08)
index_year:2013	860 (32.6%)	5,810 (48.6%)	860 (32.7%)	860 (32.6%)	0.329	0.002
index_year:2014	710 (26.8%)	3,450 (28.8%)	710 (26.9%)	680 (25.8%)	0.045	0.025
index_year:2015	640 (24.2%)	1,760 (14.8%)	640 (24.2%)	670 (25.3%)	0.241	0.026
index_year:2016	430 (16.3%)	930 (7.8%)	430 (16.2%)	430 (16.2%)	0.263	0.001
Time from AF diag:< 1 month	1,480 (55.9%)	6,410 (53.6%)	1,480 (56.0%)	1,490 (56.4%)	0.046	0.008
Time from AF diag:1 - 6 month	290 (11.0%)	1,340 (11.2%)	290 (11.0%)	290 (10.8%)	0.006	0.005
Time from AF diag:6 - 60 months	880 (33.0%)	4,200 (35.2%)	870 (33.0%)	870 (32.8%)	0.045	0.005
Sex:Female	1,360 (51.3%)	4,740 (39.7%)	1,350 (51.3%)	1,330 (50.2%)	0.236	0.020
Sex:Male	1,290 (48.7%) 82.0 (74.7 -	7,210 (60.3%)	1,290 (48.7%)	1,310 (49.8%)	0.236	0.020
Age, median(IQR)	82.0 (74.7 - 87.6)	75.3 (66.7 - 83.2)	82.0 (74.7 - 87.6)	82.1 (74.3 - 87.6)	0.608	0.010
Age -group:< 55 years	30 (1.1%)	830 (7.0%)	30 (1.1%)	30 (1.0%)	0.304	0.004
Age -group:55-<65 years	140 (5.2%)	1,690 (14.2%)	140 (5.2%)	170 (6.3%)	0.306	0.046
Age -group:65-<75 years	510 (19.4%)	3,360 (28.1%)	510 (19.5%)	500 (19.0%)	0.205	0.011
Age -group:75-<85 years	1,000 (37.6%)	3,860 (32.3%)	1,000 (37.7%)	1,000 (37.7%)	0.111	0.000
Age -group:>= 85 years	970 (36.8%)	2,210 (18.5%)	970 (36.6%)	950 (36.0%)	0.417	0.013
CCI-group:0	720 (27.3%)	3,340 (27.9%)	720 (27.3%)	720 (27.1%)	0.015	0.004
CCI-group:1-2	880 (33.3%)	3,810 (31.9%)	880 (33.2%)	810 (30.5%)	0.030	0.058
CCI-group:>=3	1,050 (39.4%)	4,800 (40.2%)	1,040 (39.5%)	1,120 (42.4%)	0.015	0.059
Prior bleeding (any)	440 (16.4%)	1,780 (14.9%)	440 (16.5%)	450 (16.8%)	0.042	0.010
Prior gastrointestinal bleeding	50 (1.8%)	190 (1.6%)	50 (1.9%)	50 (1.9%)	0.019	0.000
Prior intracranial bleeding	40 (1.5%)	160 (1.3%)	40 (1.6%)	50 (1.8%)	0.018	0.021
Prior stroke (any)	390 (14.6%)	1,440 (12.0%)	390 (14.7%)	400 (15.3%)	0.077	0.018
Prior ischaemic stroke	370 (14.0%)	1,380 (11.5%)	370 (14.0%)	390 (14.6%)	0.073	0.016
Prior haemorrhagic stroke	30 (1.1%)	110 (0.9%)	30 (1.1%)	30 (1.3%)	0.017	0.021
Prior systemic embolism	20 (0.9%)	140 (1.2%)	20 (0.9%)	20 (0.6%)	0.030	0.031
Prior transient ischaemic attack	140 (5.3%)	460 (3.9%)	140 (5.3%)	130 (5.0%)	0.069	0.012
Chronic kidney disease Heart failure	380 (14.5%) 640 (24.1%)	1,560 (13.1%) 3,110 (26.0%)	380 (14.5%) 640 (24.1%)	440 (16.7%) 610 (23.0%)	0.042 0.045	0.058 0.026
Coronary artery disease	860 (32.4%)	4,410 (36.9%)	860 (32.4%)	840 (31.9%)	0.043	0.026
Peripheral arterial disease	310 (11.5%)	1,370 (11.5%)	300 (32.4%)	270 (10.3%)	0.090	0.040
Hypertension	1,740 (65.6%)	7,270 (60.8%)	1,730 (65.6%)	1,750 (66.1%)	0.100	0.040
Diabetes	410 (15.5%)	2,100 (17.6%)	410 (15.5%)	410 (15.6%)	0.057	0.003
Chronic obstructive pulmonary disease	390 (14.9%)	1,850 (15.5%)	390 (14.9%)	400 (15.0%)	0.017	0.002
Liver disease	30 (1.2%)	150 (1.3%)	30 (1.2%)	40 (1.4%)	0.011	0.017
Alcoholism	50 (2.0%)	170 (1.4%)	50 (2.0%)	50 (2.0%)	0.045	0.000
Dementia	90 (3.2%)	230 (1.9%)	90 (3.2%)	100 (3.7%)	0.086	0.027
Cancer 6 months before and including index date	200 (7.4%)	810 (6.8%)	190 (7.3%)	200 (7.6%)	0.024	0.010
Platelet inhibitors (excluding heparin)	1,300 (48.9%)	5,400 (45.2%)	1,290 (48.8%)	1,260 (47.8%)	0.075	0.020
Low -dose aspirin	1,230 (46.5%)	5,060 (42.4%)	1,220 (46.3%)	1,200 (45.4%)	0.083	0.018
ADP receptor blockers	140 (5.3%)	1,130 (9.5%)	140 (5.3%)	140 (5.5%)	0.160	0.005
Renin -angiotensin system inhibitors	1,180 (44.7%)	5,500 (46.0%)	1,180 (44.6%)	1,190 (44.9%)	0.028	0.005
Angiotensin -converting enzyme inhibitors	440 (16.6%)	2,500 (20.9%)	440 (16.7%)	440 (16.5%)	0.110	0.004
Angiotensin II antagonists, plain	380 (14.3%)	1,640 (13.7%)	380 (14.4%)	390 (14.8%)	0.019	0.013
Angiotensin II antagonists, combinations	380 (14.3%)	1,450 (12.2%)	380 (14.3%)	380 (14.2%)	0.064	0.002
Beta-blockers	1,750 (66.0%)	8,410 (70.4%)	1,750 (66.1%)	1,750 (66.3%)	0.094	0.005
Proton pump inhibitors	650 (24.5%)	2,690 (22.5%)	650 (24.5%)	690 (25.9%)	0.047	0.032
H2-receptor antagonists	40 (1.5%)	170 (1.4%)	40 (1.5%)	50 (1.8%)	0.011	0.021
Non-steroidal anti-inflammatory drugs	200 (7.7%)	910 (7.6%)	200 (7.7%)	210 (8.0%)	0.004	0.011
Statins	1,020 (38.4%)	5,020 (42.0%)	1,010 (38.4%)	1,010 (38.3%)	0.074	0.001
Antidiabetic agents	270 (10.2%)	1,400 (11.7%)	270 (10.3%)	270 (10.0%)	0.048	0.008
Loop diuretics	740 (28.0%)	3,390 (28.4%)	740 (28.1%)	730 (27.5%)	0.008	0.014
Non-loop diuretics	50 (1.8%)	230 (1.9%)	50 (1.8%)	60 (2.1%)	0.011	0.025
Alpha adrenergic blockers	220 (8.4%)	960 (8.0%)	220 (8.3%)	240 (9.2%)	0.013	0.031

Amiodarone	60 (2.4%)	700 (5.9%)	60 (2.4%)	60 (2.2%)	0.174	0.015
Dronedarone	20 (0.7%)	130 (1.1%)	20 (0.7%)	20 (0.6%)	0.041	0.019
Antihypertensive, combination drugs	440 (16.7%)	1,740 (14.6%)	440 (16.7%)	450 (16.8%)	0.060	0.005
Calcium channel blockers	610 (23.0%)	2,640 (22.1%)	610 (22.9%)	600 (22.7%)	0.022	0.005
Selective serotonin reuptake inhibitors	180 (6.6%)	530 (4.5%)	180 (6.6%)	180 (6.6%)	0.095	0.000
Drugs used in alcohol dependence	<5	20 (0.1%)	<5	<5	0.031	0.000
CHA2DS2-VASc, mean(SD)	3.8 (1.62)	3.3 (1.86)	3.8 (1.62)	3.7 (1.70)	0.283	0.012
CHA2DS2-VASc:0 -1	180 (6.9%)	2,240 (18.7%)	180 (6.9%)	240 (9.0%)	0.359	0.078
CHA2DS2-VASc:2 -3	1,020 (38.6%)	4,370 (36.6%)	1,020 (38.5%)	970 (36.8%)	0.042	0.035
CHA2DS2-VASc:>=4	1,440 (54.5%)	5,340 (44.7%)	1,440 (54.5%)	1,430 (54.1%)	0.197	0.008
CHADS2, mean(SD)	2.0 (1.29)	1.7 (1.35)	2.0 (1.29)	2.0 (1.32)	0.209	0.004
CHADS2:0	280 (10.5%)	2,530 (21.1%)	280 (10.6%)	310 (11.8%)	0.294	0.040
CHADS2:1	790 (29.9%)	3,480 (29.1%)	790 (29.8%)	770 (29.3%)	0.016	0.010
CHADS2:>=2	1,580 (59.6%)	5,940 (49.7%)	1,580 (59.7%)	1,560 (58.9%)	0.199	0.016
HAS-BLED, mean(SD)	2.4 (1.15)	2.1 (1.26)	2.4 (1.15)	2.4 (1.20)	0.219	0.017
HAS-BLED:<3	1,510 (56.9%)	7,410 (62.0%)	1,500 (56.8%)	1,440 (54.4%)	0.106	0.049
HAS-BLED:>=3	1,140 (43.1%)	4,540 (38.0%)	1,140 (43.2%)	1,210 (45.6%)	0.106	0.049
log_n_hosp, median(IQR)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.7 (0.7 - 1.1)	0.111	0.025
log_beddays, median(IQR)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	1.4 (0.7 - 1.8)	0.080	0.006
log_n_outpatient, median(IQR)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.027	0.008

\




Table 15.65 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Sweden – STANDARD DOSE

Characteristic	Rivaroxaban (rounded) before matching N=10891	Warfarin (rou nded) before matching N=47152	Rivaroxaban (rounded) after matching N= 9875	Warfarin (rou nded) after matching N= 9875	Standardised mean difference before matchi ng (max= 0.82)	Standardised mean difference after matching (max= 0.05)
index_year:2013	1,380 (12.7%)	22,380 (47.5%)	1,380 (14.0%)	1,430 (14.5%)	0.820	0.014
index_year:2014	2,740 (25.2%)	14,490 (30.7%)	2,740 (27.7%)	2,620 (26.5%)	0.124	0.027
index_year:2015	3,660 (33.6%)	7,040 (14.9%)	3,500 (35.5%)	3,540 (35.8%)	0.446	0.008
index_year:2016	3,110 (28.5%)	3,240 (6.9%)	2,250 (22.8%)	2,290 (23.2%)	0.592	0.008
Time from AF diag:< 1 month	6,620 (60.8%)	28,530 (60.5%)	6,080 (61.5%)	5,960 (60.4%)	0.006	0.024
Time from AF diag:1 - 6 month	930 (8.5%)	4,220 (9.0%)	840 (8.5%)	920 (9.3%)	0.016	0.025
Time from AF diag:6 - 60 months	3,350 (30.7%)	14,400 (30.5%)	2,960 (29.9%)	3,000 (30.4%)	0.004	0.010
Sex:Female	4,550 (41.8%)	20,290 (43.0%)	4,150 (42.0%)	4,120 (41.7%)	0.025	0.006
Sex:Male	6,340 (58.2%)	26,860 (57.0%)	5,720 (58.0%)	5,750 (58.3%)	0.025	0.006
Age, median(IQR)	72.4 (66.4 - 79.1)	75.6 (68.4 - 82.6)	72.9 (66.7 - 79.6)	73.2 (66.8 - 80.0)	0.245	0.026
Age -group:< 55 years	570 (5.2%)	2,130 (4.5%)	510 (5.2%)	460 (4.6%)	0.033	0.026
Age -group:55-<65 years	1,620 (14.9%)	5,540 (11.8%)	1,390 (14.1%)	1,450 (14.7%)	0.092	0.017
Age -group:65-<75 years	4,370 (40.1%)	14,880 (31.6%)	3,830 (38.8%)	3,740 (37.9%)	0.179	0.018
Age -group:75-<85 years	3,300 (30.3%)	16,570 (35.1%)	3,120 (31.6%)	3,140 (31.8%)	0.104	0.003
Age -group:>= 85 years	1,030 (9.5%)	8,030 (17.0%)	1,030 (10.4%)	1,090 (11.1%)	0.224	0.023
CCI-group:0	5,240 (48.1%)	17,670 (37.5%)	4,620 (46.7%)	4,480 (45.4%)	0.217	0.027
CCI-group:1-2	3,590 (33.0%)	15,790 (33.5%)	3,300 (33.4%)	3,280 (33.2%)	0.011	0.005
CCI-group:>=3	2,060 (18.9%)	13,700 (29.0%)	1,960 (19.8%)	2,120 (21.4%)	0.239	0.039
Prior bleeding (any)	1,010 (9.2%)	5,150 (10.9%)	930 (9.4%)	910 (9.2%)	0.056	0.006
Prior gastrointestinal bleeding	40 (0.4%)	360 (0.8%)	40 (0.4%)	40 (0.4%)	0.048	0.013
Prior intracranial bleeding	120 (1.1%)	410 (0.9%)	100 (1.0%)	90 (1.0%)	0.021	0.009
Prior stroke (any)	1,240 (11.4%)	6,200 (13.1%)	1,160 (11.7%)	1,200 (12.1%)	0.053	0.012
Prior ischaemic stroke	1,200 (11.0%)	6,080 (12.9%)	1,130 (11.4%)	1,170 (11.8%)	0.058	0.013
Prior haemorrhagic stroke	100 (0.9%)	330 (0.7%)	80 (0.8%)	80 (0.8%)	0.022	0.009
Prior systemic embolism	80 (0.7%)	510 (1.1%)	70 (0.7%)	70 (0.7%)	0.041	0.002
Prior transient ischaemic attack	410 (3.8%)	2,050 (4.3%)	370 (3.8%)	400 (4.1%)	0.030	0.015
Chronic kidney disease	140 (1.3%)	3,280 (7.0%)	140 (1.4%)	170 (1.7%)	0.286	0.023
Heart failure	1,690 (15.5%)	11,330 (24.0%)	1,630 (16.5%)	1,660 (16.8%)	0.216	0.008
Coronary artery disease	1,880 (17.3%)	12,460 (26.4%)	1,790 (18.1%)	1,800 (18.2%)	0.223	0.002
Peripheral arterial disease	480 (4.4%)	3,030 (6.4%)	460 (4.7%)	480 (4.9%)	0.090	0.010
Hypertension	7,580 (69.6%)	34,570 (73.3%)	6,930 (70.2%)	7,030 (71.1%)	0.083	0.021
Diabetes	1,810 (16.6%)	9,090 (19.3%)	1,680 (17.0%)	1,720 (17.4%)	0.070	0.010
Chronic obstructive pulmonary disease	1,220 (11.2%)	5,700 (12.1%)	1,140 (11.5%)	1,160 (11.7%)	0.028	0.006
Liver disease	80 (0.8%)	430 (0.9%)	80 (0.8%)	80 (0.8%)	0.014	0.002
Alcoholism	310 (2.9%)	1,030 (2.2%)	290 (2.9%)	280 (2.8%)	0.045	0.004
Dementia	220 (2.0%)	770 (1.6%)	190 (1.9%)	210 (2.1%)	0.026	0.014
Cancer 6 months before and including index date	70 (0.7%)	400 (0.9%)	70 (0.7%)	70 (0.7%)	0.020	0.000
Platelet inhibitors (excluding heparin)	4,040 (37.1%)	18,680 (39.6%)	3,700 (37.5%)	3,860 (39.1%)	0.052	0.033
Low -dose aspirin	3,660 (33.6%)	17,010 (36.1%)	3,350 (33.9%)	3,500 (35.5%)	0.052	0.033

ADP receptor blockers	540 (5.0%)	3,710 (7.9%)	520 (5.2%)	520 (5.3%)	0.118	0.000
Renin -angiotensin system inhibitors	5,150 (47.3%)	24,140 (51.2%)	4,730 (47.9%)	4,770 (48.3%)	0.078	0.008
Angiotensin -converting enzyme inhibitors	2,470 (22.6%)	13,490 (28.6%)	2,320 (23.5%)	2,310 (23.4%)	0.137	0.002
Angiotensin II antagonists, plain	1,850 (17.0%)	8,000 (17.0%)	1,680 (17.0%)	1,720 (17.4%)	0.000	0.012
Angiotensin II antagonists, combinations	700 (6.4%)	2,540 (5.4%)	620 (6.3%)	640 (6.5%)	0.043	0.009
Beta-blockers	8,030 (73.7%)	36,150 (76.7%)	7,330 (74.3%)	7,280 (73.7%)	0.068	0.012
Proton pump inhibitors	2,050 (18.9%)	10,150 (21.5%)	1,900 (19.2%)	1,930 (19.5%)	0.066	0.008
H2-receptor antagonists	40 (0.4%)	210 (0.4%)	40 (0.4%)	40 (0.4%)	0.014	0.003
Non-steroidal anti-inflammatory drugs	710 (6.6%)	2,970 (6.3%)	650 (6.6%)	620 (6.3%)	0.010	0.010
Statins	3,410 (31.3%)	16,730 (35.5%)	3,150 (31.9%)	3,230 (32.7%)	0.088	0.017
Antidiabetic agents	1,290 (11.8%)	6,350 (13.5%)	1,190 (12.1%)	1,200 (12.2%)	0.050	0.003
Loop diuretics	1,850 (17.0%)	12,990 (27.5%)	1,800 (18.2%)	1,870 (18.9%)	0.255	0.017
Non-loop diuretics	110 (1.0%)	650 (1.4%)	100 (1.0%)	110 (1.1%)	0.039	0.010
Alpha adrenergic blockers	2,390 (21.9%)	11,180 (23.7%)	2,210 (22.4%)	2,230 (22.6%)	0.042	0.004
Amiodarone	100 (0.9%)	890 (1.9%)	100 (1.0%)	110 (1.1%)	0.080	0.007
Dronedarone Antihypertensive, combination	50 (0.5%)	440 (0.9%)	50 (0.5%)	60 (0.6%)	0.053	0.008
Antinypertensive, combination drugs	1,070 (9.8%)	3,850 (8.2%)	950 (9.6%)	970 (9.8%)	0.057	0.007
Calcium channel blockers	2,580 (23.7%)	12,240 (26.0%)	2,390 (24.2%)	2,390 (24.2%)	0.053	0.000
Selective serotonin reuptake inhibitors	660 (6.1%)	3,110 (6.6%)	600 (6.1%)	590 (6.0%)	0.021	0.005
Drugs used in alcohol dependence	20 (0.2%)	60 (0.1%)	20 (0.2%)	10 (0.1%)	0.015	0.016
CHA2DS2-VASc, mean(SD)	3.1 (1.65)	3.6 (1.75)	3.2 (1.66)	3.2 (1.69)	0.274	0.025
CHA2DS2-VASc:0-1	1,840 (16.8%)	5,700 (12.1%)	1,560 (15.8%)	1,600 (16.2%)	0.135	0.010
CHA2DS2-VASc:2 -3	4,900 (45.0%)	17,540 (37.2%)	4,380 (44.3%)	4,160 (42.1%)	0.159	0.044
CHA2DS2-VASc:>=4	4,160 (38.2%)	23,910 (50.7%)	3,940 (39.9%)	4,120 (41.7%)	0.255	0.036
CHADS2, mean(SD)	2.5 (1.41)	2.9 (1.47)	2.6 (1.41)	2.6 (1.44)	0.251	0.026
CHADS2:0	610 (5.6%)	2,300 (4.9%)	510 (5.2%)	620 (6.3%)	0.031	0.047
CHADS2:1 CHADS2:>=2	2,110 (19.4%) 8,180 (75.1%)	6,040 (12.8%) 38,810 (82.3%)	1,800 (18.3%) 7,560 (76.6%)	1,630 (16.5%) 7,620 (77.2%)	0.179	0.046 0.015
HAS-BLED, mean(SD)	1.8 (0.86)	1.9 (0.92)	1.8 (0.86)	1.8 (0.87)	0.197	0.018
HAS-BLED:<3	9,110 (83.6%)	36,080 (76.5%)	8,190 (83.0%)	8,070 (81.8%)	0.179	0.032
HAS-BLED:>=3	1,780 (16.4%)	11,080 (23.5%)	1,680 (17.0%)	1,800 (18.2%)	0.179	0.032
log_n_hosp, median(IQR)	0.7 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.275	0.024
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.075	0.022
log_n_outpatient, median(IQR)	0.7 (0.0 - 0.7)	0.0 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.7 (0.0 - 0.7)	0.229	0.000
income, median(IQR), k€	55.0 (43.0 - 84.6)	49.8 (40.5 - 72.3)	54.1 (42.6 - 81.9)	53.7 (42.4 - 81.5)	0.078	0.004
education:Secondary compulsory	3,710 (34.1%)	18,850 (40.0%)	3,460 (35.0%)	3,450 (34.9%)	0.122	0.002
education:Vocational / High school	4,330 (39.7%)	18,480 (39.2%)	3,950 (40.0%)	3,920 (39.7%)	0.011	0.008
education:Higher education	2,750 (25.3%)	9,340 (19.8%)	2,380 (24.1%)	2,410 (24.4%)	0.131	0.009
education:Unknown	100 (0.9%)	490 (1.0%)	90 (0.9%)	100 (1.0%)	0.013	0.009




Table 15.66 Baseline characteristics of patients with non-valvular atrial fibrillation initiating <u>rivaroxaban</u> or warfarin and standardised mean differences before and after matching, Sweden – REDUCED DOSE

Characteristic	Rivaroxaban (rounded) before matching N= 3442	Warfarin (rou nded) before matching N=47152	Rivaroxaban (rounded) after matching N= 3437	Warfarin (rou nded) after matching N= 3437	Standardised mean difference before matchi ng (max= 0.76)	Standardised mean difference after matching (max= 0.04)
index_year:2013	520 (15.0%)	22,380 (47.5%)	520 (15.0%)	500 (14.6%)	0.749	0.010
index_year:2014	1,070 (31.1%)	14,490 (30.7%)	1,070 (31.1%)	1,100 (32.0%)	0.007	0.019
index_year:2015	1,080 (31.3%)	7,040 (14.9%)	1,080 (31.4%)	1,080 (31.4%)	0.396	0.001
index_year:2016	780 (22.7%)	3,240 (6.9%)	780 (22.5%)	760 (22.0%)	0.457	0.013
Time from AF diag:< 1 month	1,820 (52.8%)	28,530 (60.5%)	1,820 (52.9%)	1,790 (52.2%)	0.155	0.014
Time from AF diag:1 - 6 month	380 (11.0%)	4,220 (9.0%)	380 (11.0%)	400 (11.6%)	0.069	0.018
Time from AF diag:6 - 60 months	1,250 (36.2%)	14,400 (30.5%)	1,240 (36.1%)	1,240 (36.2%)	0.119	0.002
Sex:Female	1,900 (55.2%)	20,290 (43.0%)	1,900 (55.1%)	1,880 (54.7%)	0.245	0.009
Sex:Male	1,540 (44.8%)	26,860 (57.0%)	1,540 (44.9%)	1,560 (45.3%)	0.245	0.009
Age, median(IQR)	83.5 (77.1 - 88.4)	75.6 (68.4 - 82.6)	83.5 (77.1 - 88.4)	83.4 (77.1 - 88.2)	0.755	0.004
Age -group:< 55 years	20 (0.6%)	2,130 (4.5%)	20 (0.6%)	20 (0.6%)	0.254	0.008
Age -group:55-<65 years	120 (3.5%)	5,540 (11.8%)	120 (3.5%)	130 (3.8%)	0.315	0.016
Age -group:65-<75 years	540 (15.6%)	14,880 (31.6%)	540 (15.6%)	520 (15.1%)	0.384	0.013
Age -group:75-<85 years	1,320 (38.2%)	16,570 (35.1%)	1,320 (38.3%)	1,330 (38.8%)	0.063	0.010
Age -group:>= 85 years	1,450 (42.2%)	8,030 (17.0%)	1,450 (42.1%)	1,430 (41.7%)	0.573	0.008
CCI-group:0	1,010 (29.3%)	17,670 (37.5%)	1,010 (29.4%)	1,030 (29.9%)	0.173	0.011
CCI-group:1-2	1,140 (33.1%)	15,790 (33.5%)	1,140 (33.1%)	1,140 (33.1%)	0.009	0.000
CCI-group:>=3	1,290 (37.6%)	13,700 (29.0%)	1,290 (37.6%)	1,270 (37.1%)	0.182	0.010
Prior bleeding (any)	510 (14.7%)	5,150 (10.9%)	500 (14.7%)	490 (14.1%)	0.114	0.016
Prior gastrointestinal bleeding	30 (1.0%)	360 (0.8%)	30 (1.0%)	30 (0.9%)	0.022	0.003
Prior intracranial bleeding	70 (1.9%)	410 (0.9%)	70 (1.9%)	60 (1.6%)	0.088	0.020
Prior stroke (any)	610 (17.8%)	6,200 (13.1%)	610 (17.8%)	610 (17.8%)	0.128	0.001
Prior ischaemic stroke	590 (17.1%)	6,080 (12.9%)	590 (17.1%)	600 (17.3%)	0.118	0.005
Prior haemorrhagic stroke	50 (1.6%) 50 (1.3%)	330 (0.7%)	50 (1.6%)	50 (1.5%)	0.082 0.023	0.007 0.019
Prior systemic embolism Prior transient ischaemic attack	200 (5.9%)	510 (1.1%) 2,050 (4.3%)	50 (1.3%) 200 (5.8%)	50 (1.6%) 190 (5.6%)	0.023	0.009
Chronic kidney disease	240 (7.0%)	3,280 (7.0%)	240 (7.0%)	260 (7.4%)	0.003	0.009
Heart failure	1,020 (29.7%)	11,330 (24.0%)	1,020 (29.7%)	1,050 (30.4%)	0.129	0.016
Coronary artery disease	1,010 (29.3%)	12,460 (26.4%)	1,010 (29.3%)	1,010 (29.3%)	0.063	0.000
Peripheral arterial disease	240 (6.9%)	3,030 (6.4%)	240 (6.9%)	200 (5.9%)	0.017	0.041
Hypertension	2,680 (77.8%)	34,570 (73.3%)	2,670 (77.7%)	2,660 (77.5%)	0.104	0.006
Diabetes	730 (21.3%)	9,090 (19.3%)	730 (21.3%)	760 (22.2%)	0.050	0.022
Chronic obstructive pulmonary disease	440 (12.8%)	5,700 (12.1%)	440 (12.8%)	450 (13.0%)	0.021	0.007
Liver disease	20 (0.7%)	430 (0.9%)	20 (0.7%)	30 (0.8%)	0.023	0.013
Alcoholism	60 (1.6%)	1,030 (2.2%)	60 (1.6%)	70 (2.0%)	0.040	0.028
Dementia	190 (5.4%)	770 (1.6%)	180 (5.4%)	200 (5.8%)	0.207	0.018
Cancer 6 months before and including index date	20 (0.6%)	400 (0.9%)	20 (0.6%)	20 (0.5%)	0.025	0.015
Platelet inhibitors (excluding heparin)	1,660 (48.3%)	18,680 (39.6%)	1,660 (48.3%)	1,720 (50.0%)	0.176	0.036
Low -dose aspirin	1,490 (43.2%)	17,010 (36.1%)	1,480 (43.1%)	1,550 (45.0%)	0.146	0.038
ADP receptor blockers	300 (8.8%)	3,710 (7.9%)	300 (8.8%)	280 (8.3%)	0.033	0.019

Renin -angiotensin system inhibitors	1,730 (50.2%)	24,140	1,730 (50.3%)	1,760 (51.1%)	0.020	0.016
Angiotensin -converting enzyme inhibitors	910 (26.3%)	(51.2%) 13,490 (28.6%)	910 (26.4%)	900 (26.3%)	0.051	0.002
Angiotensin II antagonists, plain	610 (17.6%)	8,000 (17.0%)	610 (17.7%)	620 (18.2%)	0.018	0.013
Angiotensin II antagonists, combinations	210 (6.2%)	2,540 (5.4%)	210 (6.2%)	210 (6.2%)	0.034	0.001
Beta-blockers	2,550 (74.1%)	36,150 (76.7%)	2,550 (74.1%)	2,560 (74.5%)	0.060	0.011
Proton pump inhibitors	840 (24.4%)	10,150 (21.5%)	840 (24.4%)	850 (24.8%)	0.069	0.009
H2-receptor antagonists	20 (0.6%)	210 (0.4%)	20 (0.6%)	20 (0.6%)	0.026	0.011
Non-steroidal anti-inflammatory drugs	160 (4.8%)	2,970 (6.3%)	160 (4.8%)	160 (4.7%)	0.067	0.004
Statins	1,150 (33.4%)	16,730 (35.5%)	1,150 (33.4%)	1,160 (33.6%)	0.043	0.005
Antidiabetic agents	490 (14.3%)	6,350 (13.5%)	490 (14.3%)	500 (14.4%)	0.024	0.003
Loop diuretics	1,210 (35.1%)	12,990 (27.5%)	1,210 (35.1%)	1,230 (35.8%)	0.163	0.015
Non-loop diuretics	40 (1.1%)	650 (1.4%)	40 (1.1%)	40 (1.2%)	0.026	0.005
Alpha adrenergic blockers	880 (25.7%)	11,180 (23.7%)	880 (25.7%)	880 (25.5%)	0.046	0.005
Amiodarone	30 (0.9%)	890 (1.9%)	30 (0.9%)	30 (1.0%)	0.083	0.009
Dronedarone Antihypertensive, combination	20 (0.5%)	440 (0.9%)	20 (0.5%)	10 (0.4%)	0.052	0.013
drugs	290 (8.5%)	3,850 (8.2%)	290 (8.6%)	310 (8.9%)	0.014	0.011
Calcium channel blockers	890 (25.8%)	12,240 (26.0%)	890 (25.8%)	930 (27.1%)	0.003	0.028
Selective serotonin reuptake inhibitors	340 (9.8%)	3,110 (6.6%)	340 (9.8%)	340 (9.9%)	0.117	0.005
Drugs used in alcohol dependence	<5	60 (0.1%)	<5	10 (0.1%)	0.010	0.017
CHA2DS2-VASc, mean(SD)	4.3 (1.62)	3.6 (1.75)	4.3 (1.62)	4.3 (1.60)	0.464	0.005
CHA2DS2-VASc:0 -1 CHA2DS2-VASc:2 -3	100 (2.9%) 960 (27.8%)	5,700 (12.1%) 17,540 (37.2%)	100 (2.9%) 960 (27.8%)	120 (3.4%) 890 (25.9%)	0.353	0.027
CHA2DS2-VASc:>=4	2,390 (69.3%)	23,910 (50.7%)	2,380 (69.2%)	2,430 (70.7%)	0.386	0.032
CHADS2, mean(SD)	3.5 (1.35)	2.9 (1.47)	3.5 (1.35)	3.5 (1.34)	0.455	0.001
CHADS2:0	30 (0.8%)	2,300 (4.9%)	30 (0.8%)	40 (1.1%)	0.244	0.029
CHADS2:1	160 (4.5%)	6,040 (12.8%)	160 (4.5%)	150 (4.5%)	0.297	0.004
CHADS2:>=2	3,260 (94.6%)	38,810 (82.3%)	3,250 (94.6%)	3,250 (94.4%)	0.393	0.009
HAS-BLED, mean(SD)	2.2 (0.83)	1.9 (0.92)	2.2 (0.83)	2.2 (0.83)	0.294	0.014
HAS-BLED:<3	2,360 (68.4%)	36,080 (76.5%)	2,350 (68.5%)	2,370 (69.1%)	0.181	0.013
HAS-BLED:>=3	1,090 (31.6%)	11,080 (23.5%)	1,080 (31.5%)	1,060 (30.9%)	0.181	0.013
log_n_hosp, median(IQR)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.080	0.009
log_beddays, median(IQR)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.7 (0.0 - 1.4)	0.023	0.005
log_n_outpatient, median(IQR)	0.7 (0.0 - 1.1)	0.0 (0.0 - 0.7)	0.7 (0.0 - 1.1)	0.7 (0.0 - 1.1)	0.324	0.005
income, median(IQR), k€	46.3 (39.4 - 59.8)	49.8 (40.5 - 72.3)	46.3 (39.4 - 59.8)	46.5 (39.7 - 59.3)	0.042	0.002
education:Secondary compulsory	1,640 (47.5%)	18,850 (40.0%)	1,630 (47.5%)	1,650 (47.9%)	0.152	0.008
education:Vocational / High school	1,150 (33.3%)	18,480 (39.2%)	1,140 (33.3%)	1,100 (32.1%)	0.123	0.025
education:Higher education	590 (17.0%)	9,340 (19.8%)	580 (17.0%)	610 (17.7%)	0.072	0.020
education:Unknown	80 (2.2%)	490 (1.0%)	80 (2.2%)	80 (2.3%)	0.094	0.002




Table 15.67 Sensitivity analysis (after re -matching within subgroups defined by initial dose): pairwise propensity -score matched adjusted hazard ratios of the <u>primary</u> <u>endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country

		Any stroke or	SE	Any bleeding at an acute he	ospitalization	Secondary cor	nposite outcom	e
		HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	1	P-int
All countrie	es All	0.92(0.84 - 1.01)		0.73(0.68 - 0.78)		1.09(1.04 - 1.14)	-	_
	Dose		0.549		0.210			<.001
	Standard	0.88(0.78 - 1.00)		0.75(0.69 - 0.83)		0.93(0.87 - 0.99)	-	
	Reduced	0.96(0.83 - 1.10)	-	0.68(0.61 - 0.76)		1.18(1.12 - 1.25)	+	
Denmark	All	1.05(0.88 - 1.24)	-	0.83(0.73 - 0.95)		1.26(1.16 - 1.36)		
	Dose		0.739		0.126			0.001
	Standard	1.05(0.84 - 1.32)	-	0.90(0.75 - 1.09)		1.08(0.96 - 1.22)		
	Reduced	1.01(0.78 - 1.31)	_	0.72(0.59 - 0.87)		1.31(1.18 - 1.45)		
Norway	All	0.77(0.62 - 0.95)		0.71(0.62 - 0.82)	1	0.89(0.80 - 0.98)		-
	Dose		0.952		0.554	i I		0.019
	Standard	0.76(0.58 - 1.01)		0.76(0.62 - 0.92)		0.82(0.71 - 0.95)		-
	Reduced	0.78(0.57 - 1.07)		0.66(0.54 - 0.82)		0.96(0.84 - 1.10)	-	-
Sweden	All	0.91(0.80 - 1.03)		0.68(0.61 - 0.75)		1.07(1.00 - 1.14)	-	
	Dose		0.241		0.609			<.001
	Standard	0.83(0.69 - 0.98)		0.69(0.60 - 0.78)		0.87(0.80 - 0.96)		
	Reduced	0.98(0.82 - 1.18)	-	0.65(0.56 - 0.77)		1.19(1.10 - 1.29)	-	
		0.5 1 Favors apixaban	2 Favors Warfarin	0.5 1 Favors apixaban	2 Favors Warfarin	0.5 Ewor	1 apixaban Favors Warf	2 forin
	l	ravois apixaban	avois wanann	ravois apixadan	ravora wanann	Pavors	process ravors wan	

CI confidence interval; HR hazard ratio; NVAV non-valvular atrial fibrillation; SE systemic embolism

Table 15.68 Sensitivity subgroup analysis for initial dose: pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary</u> <u>endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country

		Any stroke or SE	3	Any bleeding at an acute	hospitalization	Secondary cor	nposite outcor	ne
		HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)		P-int
All countrie	s All	0.93(0.83 - 1.04)		0.87(0.80 - 0.94)		1.02(0.96 - 1.08)	-	_
	Dose		0.648		0.007			0.649
	Standard	0.95(0.80 - 1.12)	1	0.75(0.66 - 0.85)		0.98(0.89 - 1.09)	-	
	Reduced	0.90(0.76 - 1.05)	1	0.95(0.85 - 1.07)	-	1.02(0.94 - 1.09)	-	
Denmark	All	0.98(0.82 - 1.17)		0.93(0.81 - 1.06)	-	1.13(1.04 - 1.24)		
	Dose		0.511		0.107			0.340
	Standard	0.91(0.70 - 1.17)		0.80(0.65 - 0.98)		1.04(0.90 - 1.21)		
	Reduced	1.01(0.80 - 1.28)	-	0.99(0.84 - 1.17)		1.13(1.02 - 1.26)		
Norway	All	0.81(0.64 - 1.04)	-	0.87(0.75 - 1.02)		0.88(0.78 - 1.00)		
	Dose		0.463		0.207	1		0.410
	Standard	0.91(0.62 - 1.34)		0.77(0.60 - 0.98)		0.94(0.77 - 1.15)	-	
	Reduced	0.75(0.55 - 1.04)		0.95(0.78 - 1.17)	-	0.85(0.73 - 0.99)		
Sweden	All	0.94(0.77 - 1.15)		0.78(0.66 - 0.92)		0.96(0.86 - 1.08)	-	
	Dose		0.403		0.115	1		0.757
	Standard	1.02(0.77 - 1.34)	-	0.68(0.53 - 0.85)	1	0.94(0.79 - 1.12)		1
	Reduced	0.86(0.64 - 1.14)	1	0.89(0.70 - 1.12)		0.97(0.84 - 1.13)		1
		0.5 1	2	0.5 1	1 2	0.5	1	2
	l	Favors dabigatran	Favors Warfarin	Favors dabigatran	Favors Warfarin	Favors d	abigatran Favors W	anann

CI confidence interval; HR hazard ratio; NVAV non-valvular atrial fibrillation; SE systemic embolism

Table 15.69 Sensitivity subgroup analysis for initial dose: pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary</u> <u>endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country

	_	Any stroke or S	SE	Any bleeding at an a	acute hospital	lization	Secondary com	posite outcom	ie
		HR (95% CI)	P-int	HR (95% CI)	I	P-int	HR (95% CI)	1	P-int
All countrie	s All	0.97(0.88 - 1.07)		1.11(1.03 - 1.20)	-		1.15(1.09 - 1.20)	-	
	Dose		0.802			0.479			0.008
	Standard	0.96(0.85 - 1.09)	-	1.09(0.99 - 1.20)			1.08(1.01 - 1.15)		
	Reduced	0.98(0.83 - 1.16)	-	1.15(1.02 - 1.29)			1.23(1.15 - 1.32)	+	
Denmark	All	0.92(0.77 - 1.09)	-	1.08(0.95 - 1.23)			1.31(1.21 - 1.42)		
	Dose		0.644			0.255			0.260
	Standard	0.94(0.76 - 1.18)	-	1.01(0.86 - 1.19)	-		1.24(1.11 - 1.39)		
	Reduced	0.87(0.66 - 1.14)	-	1.19(0.96 - 1.48)			1.36(1.21 - 1.53)		
Norway	All	1.19(0.98 - 1.45)		1.12(0.98 - 1.28)			1.04(0.94 - 1.16)		
	Dose		0.434			0.882			0.231
	Standard	1.12(0.88 - 1.44)	-	1.12(0.95 - 1.33)	+		0.99(0.86 - 1.13)	-	
	Reduced	1.32(0.95 - 1.82)		1.13(0.92 - 1.38)			1.12(0.97 - 1.30)		
Sweden	All	0.89(0.76 - 1.04)		1.13(1.00 - 1.28)			1.07(0.99 - 1.15)	-	
	Dose		0.801			0.989			0.035
	Standard	0.88(0.73 - 1.08)		1.14(0.97 - 1.33)			1.00(0.90 - 1.10)		1
	Reduced	0.90(0.69 - 1.17)	-	1.12(0.91 - 1.39)		 	1.17(1.04 - 1.32)		1
		0.5 1	2	0.5	1	2	0.5	1	2
		Favors rivaroxaban	Favors Warf	Favors riv:	aroxaban Favors V	Warf	Favors riv	aroxaban Favors W	arf

CI confidence interval; HR hazard ratio; NVAV non-valvular atrial fibrillation; SE systemic embolism

Table 15.70 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Denmark (propensity -score matched population) cost_EP_year=1

Endpoint	apixaban: #patients available for year		apixaban: proportion of patients with any	apixaban: proportion of patients with >1	apixaban: proportion of patients with >5 -	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	8092	0.047(0.282)	3.39%	0.95%	0.00%	11024	0.065(0.352)	4.39%	1.46%	0.03%
Bleeding BedDays	8092	0.252(4.586)	2.88%	2.19%	1.01%	11024	0.255(2.193)	3.80%	2.88%	1.31%
Bleeding hospitalisation costs	8092	135(2464)				11024	137(1178)			
Bleeding outpat. visits	8092	0.029(0.191)	2.60%	0.30%	0.00%	11024	0.037(0.220)	3.24%	0.42%	0.00%
Bleeding outpat. costs	8092	3(18)				11024	4(21)			
Stroke/se hospitalisations	8092	0.029(0.215)	2.21%	0.48%	0.00%	11024	0.030(0.214)	2.23%	0.60%	0.00%
Stroke/se BedDays	8092	0.176(1.933)	2.04%	1.74%	0.93%	11024	0.183(2.081)	2.02%	1.64%	0.93%
Stroke/se hospitalisation costs	8092	95(1038)				11024	98(1118)			
Stroke/se outpat. visits	8092	0.032(0.211)	2.63%	0.54%	0.00%	11024	0.026(0.191)	2.20%	0.36%	0.00%
Stroke/se outpat. costs	8092	3(20)				11024	2(18)			

Endpoint	apixaban: #patients available for year		apixaban: proportion of patients with any	apixaban: proportion of patients with >1	apixaban: proportion of patients with >5 ·	warfarin: #patients available for . year	warfarin: mean (SD)	warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	2157	0.032(0.245)	2.23%	0.65%	0.00%	3413	0.041(0.280)	2.75%	0.94%	0.00%
Bleeding BedDays	2157	0.163(1.743)	1.95%	1.62%	0.93%	3413	0.149(1.486)	2.31%	1.73%	0.94%
Bleeding hospitalisation costs	2157	87(937)				3413	80(798)			
Bleeding outpat. visits	2157	0.022(0.179)	1.85%	0.28%	0.00%	3413	0.030(0.194)	2.61%	0.26%	0.00%
Bleeding outpat. costs	2157	2(17)		-		3413	3(18)			
Stroke/se hospitalisations	2157	0.017(0.170)	1.21%	0.42%	0.00%	3413	0.014(0.145)	1.08%	0.29%	0.00%
Stroke/se BedDays	2157	0.136(2.366)	1.16%	1.02%	0.60%	3413	0.080(1.078)	0.97%	0.82%	0.44%
Stroke/se hospitalisation costs	2157	73(1271)				3413	43(579)			
Stroke/se outpat. visits	2157	0.011(0.117)	0.97%	0.14%	0.00%	3413	0.008(0.109)	0.70%	0.12%	0.00%
Stroke/se outpat. costs	2157	1(11)				3413	1(10)			

Table 15.71 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Denmark (propensity -score matched population) cost_EP_year=1

Endpoint	dabigatran: #patients available for year	dabigatran: mean (SD)	dabigatran: proportion of patients with any	dabigatran: proportion of patients with >1	dabigatran: proportion of patients with >5	warfarin: #patients available for - year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	10402	0.045(0.277)	3.27%	0.96%	0.00%	10403	0.057(0.334)	3.81%	1.30%	0.03%
Bleeding BedDays	10402	0.150(1.363)	2.76%	2.11%	0.91%	10403	0.225(2.128)	3.25%	2.51%	1.14%
Bleeding hospitalisation costs	10402	81(733)				10403	121(1143)			
Bleeding outpat. visits	10402	0.033(0.199)	2.91%	0.37%	0.00%	10403	0.038(0.227)	3.24%	0.46%	0.00%
Bleeding outpat. costs	10402	3(19)				10403	4(21)			
Stroke/se hospitalisations	10402	0.024(0.202)	1.78%	0.47%	0.01%	10403	0.025(0.195)	1.85%	0.56%	0.00%
Stroke/se BedDays	10402	0.126(1.612)	1.62%	1.34%	0.70%	10403	0.156(1.968)	1.68%	1.43%	0.83%
Stroke/se hospitalisation costs	10402	67(866)				10403	84(1057)			
Stroke/se outpat. visits	10402	0.021(0.173)	1.75%	0.34%	0.00%	10403	0.023(0.181)	1.86%	0.37%	0.00%
Stroke/se outpat. costs	10402	2(16)				10403	2(17)			

Endpoint	dabigatran: #patients available for year		dabigatran: proportion of patients with any	dabigatran: proportion of patients with >1	dabigatran: proportion of patients with >5	-	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	4941	0.033(0.265)	2.21%	0.67%	0.02%		3929	0.031(0.238)	2.21%	0.56%	0.00%
Bleeding BedDays	4941	0.097(1.040)	1.76%	1.32%	0.57%		3929	0.112(1.331)	1.86%	1.27%	0.61%
Bleeding hospitalisation costs	4941	52(559)					3929	60(715)			
Bleeding outpat. visits	4941	0.028(0.188)	2.39%	0.32%	0.00%		3929	0.031(0.196)	2.72%	0.28%	0.00%
Bleeding outpat. costs	4941	3(18)					3929	3(19)			
Stroke/se hospitalisations	4941	0.013(0.139)	0.97%	0.22%	0.00%		3929	0.012(0.137)	0.94%	0.23%	0.00%
Stroke/se BedDays	4941	0.076(1.279)	0.97%	0.75%	0.45%		3929	0.063(0.925)	0.87%	0.74%	0.36%
Stroke/se hospitalisation costs	4941	41(687)					3929	34(497)			
Stroke/se outpat. visits	4941	0.006(0.083)	0.51%	0.06%	0.00%		3929	0.006(0.097)	0.51%	0.10%	0.00%
Stroke/se outpat. costs	4941	1(8)					3929	1(9)			

Table 15.72 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Denmark (propensity -score matched population) **cost_EP_year=1**

Endpoint	rivaroxaban: #patients available for year	rivaroxaban:	rivaroxaban: proportion of patients with any	rivaroxaban: proportion of patients with >1	rivaroxaban: proportion of patients with >5	warfarin: #patients available for - year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	7389	0.064(0.363)	4.11%	1.52%	0.05%	7494	0.066(0.376)	4.20%	1.44%	0.05%
Bleeding BedDays	7389	0.238(1.907)	3.63%	2.99%	1.37%	7494	0.246(2.125)	3.67%	2.80%	1.32%
Bleeding hospitalisation costs	7389	128(1024)				7494	132(1142)			
Bleeding outpat. visits	7389	0.042(0.239)	3.56%	0.57%	0.00%	7494	0.039(0.228)	3.34%	0.49%	0.00%
Bleeding outpat. costs	7389	4(23)				7494	4(21)	-		
Stroke/se hospitalisations	7389	0.027(0.207)	2.02%	0.49%	0.00%	7494	0.032(0.224)	2.39%	0.71%	0.00%
Stroke/se BedDays	7389	0.158(1.915)	1.83%	1.39%	0.76%	7494	0.195(2.088)	2.26%	1.77%	1.03%
Stroke/se hospitalisation costs	7389	85(1029)				7494	105(1122)	-		
Stroke/se outpat. visits	7389	0.018(0.144)	1.60%	0.15%	0.00%	7494	0.028(0.200)	2.30%	0.44%	0.00%
Stroke/se outpat. costs	7389	2(14)				7494	3(19)			

Endpoint	rivaroxaban: #patients available for year	rivaroxaban: mean (SD)	rivaroxaban: proportion of patients with any	rivaroxaban: proportion of patients with >1	rivaroxaban: proportion of patients with >5 -	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	2544	0.048(0.284)	3.50%	0.98%	0.00%	1735	0.036(0.242)	2.71%	0.58%	0.00%
Bleeding BedDays	2544	0.119(0.945)	2.87%	2.24%	0.59%	1735	0.139(1.403)	2.36%	1.61%	0.98%
Bleeding hospitalisation costs	2544	64(508)		-		1735	75(754)			
Bleeding outpat. visits	2544	0.037(0.222)	3.07%	0.47%	0.00%	1735	0.029(0.191)	2.59%	0.29%	0.00%
Bleeding outpat. costs	2544	3(21)				1735	3(18)			
Stroke/se hospitalisations	2544	0.020(0.173)	1.65%	0.24%	0.00%	1735	0.011(0.129)	0.86%	0.17%	0.00%
Stroke/se BedDays	2544	0.119(1.618)	1.65%	1.30%	0.51%	1735	0.080(1.160)	0.81%	0.69%	0.40%
Stroke/se hospitalisation costs	2544	64(869)				1735	43(623)			
Stroke/se outpat. visits	2544	0.006(0.084)	0.59%	0.04%	0.00%	1735	0.009(0.110)	0.69%	0.17%	0.00%
Stroke/se outpat. costs	2544	1(8)		•		1735	1(10)			

Table 15.73 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Norway (propensity -score matched population)

Exploratory analysis - costs. Country no. Comparing drug apixaban with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed -day=1627.99 € and price per outpatient visit=54.03 €.

cost_EP_year=1

	apixaban: #patients available for	apixaban:	apixaban: proportion of patients with	apixaban: proportion of patients with	apixaban: proportion of patients with	warfarin: #patients available for	warfarin:	warfarin: proportion of patients with	warfarin: proportion of patients with	warfarin: proportion of patients with
Endpoint	year	mean (SD)	any	>1	>5 -	year	mean (SD)	any	>1	>5
Bleeding hospitalisations	5980	0.054(0.308)	3.86%	1.07%	0.00%	9759	0.076(0.393)	5.09%	1.46%	0.07%
Bleeding BedDays	5980	0.463(4.176)	3.86%	3.46%	2.22%	9759	0.548(4.076)	5.09%	4.57%	2.78%
Bleeding hospitalisation costs	5980	753(6798)				9759	892(6635)	-		
Bleeding outpat. visits	5980	0.052(0.315)	3.60%	1.02%	0.03%	9759	0.055(0.329)	3.87%	0.99%	0.04%
Bleeding outpat. costs	5980	3(17)				9759	3(18)			
Stroke/se hospitalisations	5980	0.027(0.193)	2.27%	0.33%	0.00%	9759	0.026(0.194)	2.11%	0.30%	0.00%
Stroke/se BedDays	5980	0.238(2.691)	2.27%	2.09%	1.27%	9759	0.237(2.651)	2.11%	2.00%	1.25%
Stroke/se hospitalisation costs	5980	388(4381)				9759	386(4316)			
Stroke/se outpat. visits	5980	0.028(0.290)	1.81%	0.42%	0.03%	9759	0.024(0.316)	1.39%	0.40%	0.05%
Stroke/se outpat. costs	5980	2(16)				9759	1(17)			

Endpoint	apixaban: #patients available for year		apixaban: proportion of patients with any	apixaban: proportion of patients with >1	apixaban: proportion of patients with >5 -	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	1458	0.047(0.300)	3.29%	0.82%	0.00%	3530	0.051(0.328)	3.34%	1.08%	0.06%
Bleeding BedDays	1458	0.374(3.330)	3.29%	3.09%	1.99%	3530	0.338(2.901)	3.34%	3.06%	2.04%
Bleeding hospitalisation costs	1458	609(5421)				3530	550(4723)			
Bleeding outpat. visits	1458	0.046(0.270)	3.57%	0.69%	0.00%	3530	0.050(0.300)	3.60%	0.88%	0.00%
Bleeding outpat. costs	1458	2(15)				3530	3(16)			
Stroke/se hospitalisations	1458	0.017(0.163)	1.37%	0.21%	0.00%	3530	0.016(0.147)	1.36%	0.23%	0.00%
Stroke/se BedDays	1458	0.139(1.529)	1.37%	1.23%	0.89%	3530	0.117(1.278)	1.36%	1.22%	0.85%
Stroke/se hospitalisation costs	1458	226(2489)				3530	191(2080)			-
Stroke/se outpat. visits	1458	0.003(0.052)	0.27%	0.00%	0.00%	3530	0.002(0.053)	0.20%	0.03%	0.00%
Stroke/se outpat. costs	1458	0(3)				3530	0(3)			

Table 15.74 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Norway (propensity -score matched population)

Exploratory analysis - costs. Country no. Comparing drug dabigatran with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed -day=1627.99 € and price per outpatient visit=54.03 €. cost_EP_year=1

Endpoint	dabigatran: #patients available for year		dabigatran: proportion of patients with any		dabigatran: proportion of patients with >5 -	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	6634	0.047(0.281)	3.56%	0.80%	0.02%	6663	0.057(0.325)	4.07%	1.08%	0.02%
Bleeding BedDays	6634	0.345(2.857)	3.56%	3.33%	1.85%	6663	0.418(3.489)	4.07%	3.60%	2.15%
Bleeding hospitalisation costs	6634	562(4651)			-	6663	680(5681)	-		-
Bleeding outpat. visits	6634	0.045(0.281)	3.33%	0.71%	0.02%	6663	0.051(0.314)	3.62%	0.92%	0.05%
Bleeding outpat. costs	6634	2(15)				6663	3(17)	-		-
Stroke/se hospitalisations	6634	0.023(0.206)	1.67%	0.36%	0.02%	6663	0.022(0.181)	1.80%	0.27%	0.00%
Stroke/se BedDays	6634	0.191(2.410)	1.67%	1.61%	1.01%	6663	0.194(2.521)	1.80%	1.68%	1.01%
Stroke/se hospitalisation costs	6634	311(3924)			-	6663	315(4104)	-		-
Stroke/se outpat. visits	6634	0.030(0.340)	1.67%	0.50%	0.06%	6663	0.025(0.358)	1.34%	0.36%	0.08%
Stroke/se outpat. costs	6634	2(18)				6663	1(19)			

cost_EP_year=2

Endpoint	dabigatran: #patients available for year		dabigatran: proportion of patients with any	dabigatran: proportion of patients with >1	dabigatran: proportion of patients with >5	warfarin: #patients available for - year	warfarin: mean (SD)	warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	3009	0.041(0.338)	2.59%	0.70%	0.10%	2622	0.041(0.298)	2.48%	0.99%	0.00%
Bleeding BedDays	3009	0.278(2.489)	2.59%	2.39%	1.40%	2622	0.286(2.858)	2.48%	2.29%	1.60%
Bleeding hospitalisation costs	3009	453(4051)				2622	465(4652)			-
Bleeding outpat. visits	3009	0.042(0.276)	3.22%	0.56%	0.07%	2622	0.045(0.291)	3.28%	0.76%	0.00%
Bleeding outpat. costs	3009	2(15)				2622	2(16)			
Stroke/se hospitalisations	3009	0.012(0.118)	1.10%	0.10%	0.00%	2622	0.013(0.127)	1.11%	0.11%	0.00%
Stroke/se BedDays	3009	0.092(1.157)	1.10%	1.00%	0.56%	2622	0.102(1.245)	1.11%	1.03%	0.72%
Stroke/se hospitalisation costs	3009	150(1883)				2622	166(2026)			
Stroke/se outpat. visits	3009	0.007(0.105)	0.53%	0.13%	0.00%	2622	0.002(0.055)	0.19%	0.04%	0.00%
Stroke/se outpat. costs	3009	0(6)		•		2622	0(3)			

PFIZER CONFIDENTIAL Page 202 of 253

Table 15.75 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Norway (propensity -score matched population)

Exploratory analysis - costs. Country no. Comparing drug rivaroxaban with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed -day=1627.99 € and price per outpatient visit=54.03 €.

Endpoint	rivaroxaban: #patients available for year	rivaroxaban: mean (SD)	rivaroxaban: proportion of patients with any	rivaroxaban: proportion of patients with >1	rivaroxaban: proportion of patients with >5	warfarin: #patients available for - year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	6484	0.077(0.378)	5.41%	1.60%	0.03%	6421	0.067(0.359)	4.67%	1.28%	0.03%
Bleeding BedDays	6484	0.539(3.821)	5.41%	4.86%	2.87%	6421	0.456(3.132)	4.67%	4.16%	2.59%
Bleeding hospitalisation costs	6484	877(6220)				6421	743(5099)	-	-	
Bleeding outpat. visits	6484	0.066(0.380)	4.66%	1.08%	0.09%	6421	0.059(0.349)	4.13%	1.03%	0.06%
Bleeding outpat. costs	6484	4(21)				6421	3(19)			
Stroke/se hospitalisations	6484	0.032(0.221)	2.56%	0.52%	0.00%	6421	0.023(0.180)	1.98%	0.23%	0.00%
Stroke/se BedDays	6484	0.328(3.741)	2.56%	2.27%	1.48%	6421	0.200(2.212)	1.98%	1.90%	1.09%
Stroke/se hospitalisation costs	6484	534(6090)				6421	326(3600)			
Stroke/se outpat. visits	6484	0.031(0.309)	2.02%	0.43%	0.05%	6421	0.025(0.256)	1.59%	0.42%	0.05%
Stroke/se outpat. costs	6484	2(17)				6421	1(14)			

cost_EP_year=1

Endpoint	rivaroxaban: #patients available for year	rivaroxaban:	rivaroxaban: proportion of patients with any	rivaroxaban: proportion of patients with >1	rivaroxaban: proportion of patients with >5 -	warfarin: #patients available for year		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalisations	3174	0.055(0.302)	4.06%	1.07%	0.00%	2187	0.054(0.339)	3.34%	1.37%	0.05%
Bleeding BedDays	3174	0.335(2.301)	4.06%	3.62%	2.11%	2187	0.375(3.199)	3.34%	3.16%	2.15%
Bleeding hospitalisation costs	3174	545(3745)				2187	610(5209)			
Bleeding outpat. visits	3174	0.059(0.316)	4.47%	1.07%	0.03%	2187	0.052(0.305)	3.70%	0.96%	0.00%
Bleeding outpat. costs	3174	3(17)				2187	3(16)			
Stroke/se hospitalisations	3174	0.022(0.186)	1.70%	0.32%	0.00%	2187	0.018(0.156)	1.55%	0.23%	0.00%
Stroke/se BedDays	3174	0.203(2.607)	1.70%	1.61%	0.95%	2187	0.138(1.372)	1.55%	1.42%	1.01%
Stroke/se hospitalisation costs	3174	330(4244)				2187	224(2234)			
Stroke/se outpat. visits	3174	0.012(0.224)	0.57%	0.32%	0.03%	2187	0.003(0.064)	0.27%	0.05%	0.00%
Stroke/se outpat. costs	3174	1(12)				2187	0(3)			

Table 15.76 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with apixaban and warfarin, Sweden (propensity -score matched population)

Exploratory analysis - costs. Country se. Comparing drug apixaban with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed-day=1009.83 € and price per outpatient visit=36.87 €.

cost_ep_type_text		apixaban: mean (sd)	apixaban: proportion of patients with any		of patients		warfarin: mean (sd)	warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalizations	18315	0.035(0.238)	2.79%	0.52%	0.01%	29240	0.046(0.283)	3.45%	0.76%	0.01%
Bleeding BedDays	18315	0.254(2.274)	2.77%	2.68%	1.44%	29240	0.323(2.548)	3.44%	3.35%	1.80%
Bleeding hospitalization costs	18315	257(2296)				29240	326(2573)			
Bleeding outpat. visits	18315	0.063(0.352)	4.24%	1.34%	0.02%	29240	0.073(0.404)	4.70%	1.46%	0.08%
Bleeding outpat. costs	18315	2(13)				29240	3(15)			
Stroke/se hospitalizations	18315	0.022(0.171)	1.90%	0.28%	0.00%	29240	0.024(0.186)	1.96%	0.35%	0.00%
Stroke/se BedDays	18315	0.226(2.233)	1.93%	1.90%	1.24%	29240	0.251(2.530)	2.00%	1.97%	1.29%
Stroke/se hospitalization costs	18315	229(2255)			•	29240	253(2555)			
Stroke/se outpat. visits	18315	0.035(0.287)	2.41%	0.54%	0.04%	29240	0.039(0.606)	2.15%	0.52%	0.08%
Stroke/se outpat. costs	18315	1(11)	•		•	29240	1(22)		•	

cost_ep_type_text		apixaban: mean (sd)	apixaban: proportion of patients with any	proportion of patients	proportion of patients		warfarin: mean (sd)	warfarin: proportion of patients with any		warfarin: proportion of patients with >5
Bleeding hospitalizations	5086	0.027(0.194)	2.26%	0.28%	0.00%	12679	0.035(0.247)	2.63%	0.56%	0.02%
Bleeding BedDays	5086	0.188(1.678)	2.24%	2.14%	1.04%	12679	0.242(2.314)	2.59%	2.50%	1.30%
Bleeding hospitalization costs	5086	190(1695)				12679	244(2336)			
Bleeding outpat. visits	5086	0.050(0.303)	3.58%	0.88%	0.02%	12679	0.062(0.363)	4.05%	1.25%	0.05%
Bleeding outpat. costs	5086	2(11)				12679	2(13)			
Stroke/se hospitalizations	5086	0.012(0.125)	1.00%	0.16%	0.00%	12679	0.011(0.118)	0.91%	0.13%	0.00%
Stroke/se BedDays	5086	0.126(1.770)	0.96%	0.96%	0.65%	12679	0.095(1.293)	0.88%	0.88%	0.62%
Stroke/se hospitalization costs	5086	127(1787)				12679	96(1305)			
Stroke/se outpat. visits	5086	0.011(0.148)	0.90%	0.06%	0.02%	12679	0.008(0.106)	0.63%	0.09%	0.00%
Stroke/se outpat. costs	5086	0(5)			•	12679	0(4)	•	•	

Table 15.77 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with dabigatran and warfarin, Sweden (propensity -score matched population)

Exploratory analysis - costs. Country se. Comparing drug dabigatran with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed-day=1009.83 € and price per outpatient visit=36.87 €.

cost_ep_type_text			dabigatran: proportion of patients with any	dabigatran: proportion of patients with >1	dabigatran: proportion of patients with >5	available		warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalizations	7926	0.031(0.233)	2.31%	0.57%	0.01%	7890	0.036(0.256)	2.66%	0.61%	0.03%
Bleeding BedDays	7926	0.254(2.657)	2.31%	2.23%	1.31%	7890	0.240(2.146)	2.64%	2.55%	1.29%
Bleeding hospitalization costs	7926	257(2684)				7890	243(2167)			
Bleeding outpat. visits	7926	0.062(0.387)	3.86%	1.30%	0.08%	7890	0.069(0.411)	4.35%	1.36%	0.08%
Bleeding outpat. costs	7926	2(14)				7890	3(15)			
Stroke/se hospitalizations	7926	0.019(0.160)	1.59%	0.26%	0.00%	7890	0.020(0.178)	1.58%	0.27%	0.00%
Stroke/se BedDays	7926	0.169(1.973)	1.64%	1.64%	1.01%	7890	0.198(2.174)	1.56%	1.55%	1.03%
Stroke/se hospitalization costs	7926	170(1993)				7890	200(2196)			
Stroke/se outpat. visits	7926	0.054(0.536)	2.75%	0.86%	0.16%	7890	0.054(0.947)	2.17%	0.66%	0.14%
Stroke/se outpat. costs	7926	2(20)				7890	2(35)			

cost_ep_type_text			dabigatran: proportion of patients with any	dabigatran: proportion of patients with >1	dabigatran: proportion of patients with >5			warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalizations	3750	0.021(0.200)	1.55%	0.35%	0.03%	3443	0.025(0.187)	2.03%	0.32%	0.00%
Bleeding BedDays	3750	0.149(1.994)	1.52%	1.44%	0.88%	3443	0.138(1.280)	2.00%	1.92%	0.78%
Bleeding hospitalization costs	3750	150(2013)				3443	139(1292)			
Bleeding outpat. visits	3750	0.047(0.292)	3.41%	0.80%	0.03%	3443	0.067(0.420)	4.04%	1.28%	0.12%
Bleeding outpat. costs	3750	2(11)				3443	2(15)			
Stroke/se hospitalizations	3750	0.008(0.098)	0.72%	0.08%	0.00%	3443	0.007(0.101)	0.61%	0.09%	0.00%
Stroke/se BedDays	3750	0.074(1.115)	0.72%	0.72%	0.45%	3443	0.064(1.096)	0.61%	0.61%	0.38%
Stroke/se hospitalization costs	3750	75(1126)				3443	64(1106)			
Stroke/se outpat. visits	3750	0.007(0.094)	0.56%	0.11%	0.00%	3443	0.018(0.365)	0.73%	0.26%	0.06%
Stroke/se outpat. costs	3750	0(3)	•			3443	1(13)	•	•	

Table 15.78 Health care resource utilisation (HCRU) and associated costs related to bleeding and stroke/systemic embolism among patients with NVAF treated with rivaroxaban and warfarin, Sweden (propensity -score matched population)

Exploratory analysis - costs. Country se. Comparing drug rivaroxaban with warfarin For patients included at least 1 and 2 years before end of study, (and for the latter not censored before start of that year). Using price per hospital bed-day=1009.83 € and price per outpatient visit=36.87 €.


cost_ep_type_text			rivaroxaban: proportion of patients with any		rivaroxaban: proportion of patients with >5		warfarin: mean (sd)	warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalizations	10177	0.048(0.265)	3.85%	0.72%	0.00%	10137	0.043(0.286)	3.22%	0.65%	0.02%
Bleeding BedDays	10177	0.308(2.260)	3.83%	3.67%	1.78%	10137	0.284(2.279)	3.24%	3.18%	1.63%
Bleeding hospitalization costs	10177	311(2282)			•	10137	287(2301)		•	
Bleeding outpat. visits	10177	0.108(0.490)	7.04%	2.10%	0.13%	10137	0.075(0.407)	4.89%	1.40%	0.08%
Bleeding outpat. costs	10177	4(18)				10137	3(15)			
Stroke/se hospitalizations	10177	0.023(0.180)	1.84%	0.34%	0.00%	10137	0.021(0.168)	1.81%	0.26%	0.00%
Stroke/se BedDays	10177	0.218(2.307)	1.85%	1.81%	1.18%	10137	0.207(2.208)	1.82%	1.81%	1.09%
Stroke/se hospitalization costs	10177	220(2330)				10137	209(2230)	•	•	•
Stroke/se outpat. visits	10177	0.037(0.569)	2.02%	0.44%	0.07%	10137	0.040(0.513)	2.39%	0.47%	0.07%
Stroke/se outpat. costs	10177	1(21)				10137	1(19)			

cost_ep_type_text	rivaroxaban: #patients available for year	rivaroxaban:	rivaroxaban: proportion of patients with any		proportion of	# 2		warfarin: mean (sd)	warfarin: proportion of patients with any	warfarin: proportion of patients with >1	warfarin: proportion of patients with >5
Bleeding hospitalizations	3955	0.034(0.229)	2.73%	0.53%	0.00%		3014	0.032(0.233)	2.36%	0.53%	0.00%
Bleeding BedDays	3955	0.221(1.854)	2.68%	2.58%	1.39%		3014	0.189(1.922)	2.42%	2.32%	1.00%
Bleeding hospitalization costs	3955	223(1872)	•	•			3014	191(1941)			
Bleeding outpat. visits	3955	0.089(0.436)	5.94%	1.77%	0.08%		3014	0.069(0.389)	4.35%	1.46%	0.03%
Bleeding outpat. costs	3955	3(16)			-		3014	3(14)			
Stroke/se hospitalizations	3955	0.018(0.172)	1.39%	0.30%	0.00%		3014	0.008(0.103)	0.66%	0.13%	0.00%
Stroke/se BedDays	3955	0.145(1.650)	1.37%	1.29%	0.94%		3014	0.079(1.146)	0.70%	0.70%	0.56%
Stroke/se hospitalization costs	3955	146(1666)					3014	79(1157)	•		•
Stroke/se outpat. visits	3955	0.010(0.117)	0.88%	0.13%	0.00%		3014	0.007(0.085)	0.63%	0.03%	0.00%
Stroke/se outpat. costs	3955	0(4)					3014	0(3)	•		

Figure 15.1 Flow diagram of identification of the study population (all countries combined)

Persons ages \geq 18 years alive and with a dispensing of a study OAC 01.01.2013 -31.12.2016 N=781,093 (100%)

AF diagnosis 5 years before to 60 days after index date N=450,969 (58%)



vitamin K antagonist


Figure 15.2 Flow diagram of identification of the study population (Denmark)

Persons ages \geq 18 years alive and with a dispensing of a study OAC

01.01.2013 -31.12.2016 N=207,572 (100%)

AF diagnosis 5 years before to 60 days after index date

N=114,381 (55%)



Abbreviations: AF atrial fibrillation, DVT deep vein thrombosis, OAC oral anticoagulant, PE pulmonary embolism, VKA vitamin K antagonist


Figure 15.3 Flow diagram of identification of the study population (Norway)

Persons ages ≥ 18 years alive and with a dispensing of a study OAC

01.01.2013 -31.12.2016 N=181,883 (100%)

AF diagnosis 5 years before to 60 days after index date

N=104,344 (57%)



Abbreviations: AF atrial fibrillation, DVT deep vein thrombosis, OAC oral anticoagulant, PE pulmonary embolism, VKA vitamin K antagonist


Figure 15.4 Flow diagram of identification of the study population (Sweden)

Persons ages ≥ 18 years alive and with a dispensing of a study OAC

01.01.2013 -31.12.2016 N=391,638 (100%)

AF diagnosis 5 years before to 60 days after index date

N=232,244 (59%)



Abbreviations: AF atrial fibrillation, DVT deep vein thrombosis, OAC oral anticoagulant, PE pulmonary embolism, VKA vitamin K antagonist









Figure 15.5 Crude cumulative incidence of any stroke or systemic embolism at an acute hospitalisation with an overnight stay among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country




















Cumulative incidence of Gastro

0.03

0.01

0.00

DrugG


12

24

Follow-up (Months)

dabigatran

36



0.03

0.02

0.01

0.00

DrugGrou

12


24


Follow-up (Months)


abigatrar


36


48












*Country-specific data too sparse to report











Figure 15.14 Crude cumulative incidence of ischaemic stroke at an acute hospitalisation with an overnight stay, systemic embolism at an acute hospitalisation with an overnight stay, acute myocardial infarction at an acute hospitalisation with an overnight stay, or death of any cause among patients with NVAF initiating apixaban, dabigatran, rivaroxaban, or warfarin, overall and by country

















	Any stroke or	SE	Any bleeding at acu	te hospitalization	Secondary con	nposite outcome	
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	1	P-int
All Age		0.365		0.830	1.12(1.07 - 1.17)	-	0.147
<pre><65 years 65 - <75 years 75 - <85 years</pre>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.72(0.54 - 0.96) 0.72(0.61 - 0.84) 0.72(0.62 - 0.82)	-	1.00(0.81 - 1.23) 1.03(0.92 - 1.16) 1.07(0.99 - 1.16) 1.15(1.07 - 1.23)		
>= 85 years		0.255		0.025	1.15(1.07 - 1.23) 1.16(1.09 - 1.24)	+	0.009
Female Male CHA2DS2VASc		0.582	0.66(0.59 - 0.75) 0.78(0.71 - 0.86)	0.617	1.08(1.01 - 1.15)		0.011
2-3 =4 CHADS2	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	- 0.815	0.36(0.58 - 0.75)	0.991	0.97 0.88 - 1.06 1.13(1.07 - 1.20)	-#-	0.725
0	[60events/ 6df] 0.86(0.63 - 1.18) 0.95(0.86 - 1.06)	0.815	0.74(0.51 - 1.07) 0.68(0.56 - 0.83)	. 0.991	1.00(0.72 - 1.39) 0.92(0.86 - 1.14)		10.725
HAS-BLED	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.027	0.72(0.66 - 0.78)	0.243	1.12(1.06 - 1.17) 1.11(1.04 - 1.18) 1.08(1.01 - 1.16)	+	0.708
Chronic kidney disease	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.396	0.73(0.63 - 0.81)	0.045	1.08(1.01 - 1.16) 1.16(1.10 - 1.22) 0.88(0.78 - 1.00)	+	0.004
Yes Diabetes No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.949		0.086	· · · · ·	+	0.029
Yes Heart failure		0.660	0.72(0.66 - 0.78) 0.77(0.66 - 0.91)	0.332	1.17(1.11 - 1.23) 1.00(0.91 - 1.10)		0.052
Yes Coronary artery disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.360	0.71(0.65 - 0.78) 0.75(0.65 - 0.87)	- 0.631	1.09(1.03 - 1.15) 1.15(1.07 - 1.25) 1.16(1.09 - 1.23)		0.241
Yes Peripheral arterial disase	$\begin{array}{c c} 0.99(0.88 - 1.12) \\ 0.88(0.73 - 1.05) \end{array} \longrightarrow$	0.323	0.74(0.67 - 0.81) 0.71(0.62 - 0.81)	0.290	1.16(1.09 - 1.23) 1.07(0.99 - 1.15)		0.089
Yes Prior ischaemic stroke	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.541	$\begin{array}{c c} 0.72(0.66 - 0.78) \\ 0.79(0.63 - 0.99) \\ 0.72(0.66 - 0.78) \\ \end{array}$	0.748	1.13(1.08 - 1.19) 1.08(0.95 - 1.23)		0.986
Yes Prior haemorrhagic stroke	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.298	$\begin{array}{c c} 0.72(\ 0.66 - \ 0.78) \\ 0.73(\ 0.61 - \ 0.86) \end{array} \right $		1.09(1.03 - 1.15) 1.12(1.01 - 1.23)	*	0.098
No Yes Prior stroke (any)	0.96(0.87 - 1.07) [60events/13df] ?	0.457	0.73(0.67 - 0.79) [60events/13df]	??	$1.12(1.07 - 1.18)^{+}_{-}_{-}_{-}_{-}_{-}_{-}_{-}_{-}_{-}_{-$		0.810
No Yes Prior transient ishaemic attac	0.89(0.78 - 1.01)	0.928	0.71(0.66 - 0.78)	- 0.775	1.08(1.03 - 1.15)	*	0.588
Prior systemic embolism	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.633	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.195	1.12(1.07 - 1.17) 1.07(0.88 - 1.30)	-	0.922
Prior gastointestinal bleeding	0.96(0.87 - 1.06) [40events/18df] ?	0.551	0.72(0.67 - 0.78) [40events/18df]	??	1.12(1.07 - 1.17) [150events/18df]	??	0.336
No	0.96(0.87 - 1.06)	0.766	$\begin{array}{c} 0.72(\ 0.67\ -\ 0.78)\\ 0.98(\ 0.59\ -\ 1.63)\end{array} $	0.893	1.12(1.07 - 1.17) 1.32(0.95 - 1.84)	+	- 0.506
Prior intracranial bleeding No Yes	0.96(0.87 - 1.07) [70events/10df] ?	0.766	0.73(0.68 - 0.79) [70events/10df]	??	1.12(1.07 - 1.18)	*	0.506
	0.5 1	2	0.5	1 2	0.5	1	2
	Favors apixaban	Favors Warfarin	Favors apixa	ban Favors Warfarin	Favors a	pixaban Favors Warfari	ın
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	er than 10 events pr degr	ee of freedom - no Cox regression run]				

Figure 15.18 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin overall and in the subgroups – all countries combined

	Any stroke or S	SE	Any bleeding at ac	ute hospitalization	Secondary con	mposite outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age		0.117	0.89(0.82 - 0.97)		1.03(0.97 - 1.10)	0.906
<pre><65 years 65 - <75 years 75 - <85 years ->= 85 years</pre>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.63(0.47 - 0.84) 0.70(0.59 - 0.82) 0.95(0.82 - 1.09) 1.14(0.95 - 1.37)		$\begin{array}{c} 0.95(\ 0.78\ -\ 1.17)\\ 1.05(\ 0.93\ -\ 1.19)\\ 1.01(\ 0.91\ -\ 1.11)\\ 0.99(\ 0.89\ -\ 1.11) \end{array}$	
Sex Female Male CHA2DS2VASc	0.90(0.76 - 1.07)	0.971	0.95(0.83 - 1.09) 0.85(0.76 - 0.95)	0.285	1.03(0.94 - 1.13) 1.03(0.95 - 1.11)	0.950
CHA2DS2VASc	0.62(0.20 1.00)	0.430	0.72(0.52 - 1.01)	0.035	1.03(0.95 - 1.11) 1.21(0.95 - 1.54)	0.198
2-3 CHADS2	0.86(0.74 - 1.00)	0.471	0.78(0.68 - 0.89) - 0.97(0.86 - 1.10)	0.454	0.99(0.89 - 1.10)	0.243
$\stackrel{0}{\stackrel{1}{\scriptstyle >=2}}$	0.59(0.34 - 1.01) 0.95(0.72 - 1.25) 0.87(0.76 - 0.99)		0.69(0.50 - 0.97)		1.19(0.91 - 1.57) 0.98(0.86 - 1.13) 0.99(0.92 - 1.06)	
HAS-BLED	0.94(0.80 - 1.10)	- 0.269	0.88(0.79 - 0.99) 0.90(0.78 - 1.03)	0.996	1:03(0:92 - 1:12)	0.846
Chronic kidney disease	0.89(0.79 - 1.00)	0.301	0.89(0.82 - 0.98) [80events/20df]	0.819	1.05(0.99 - 1.12) [180events/20df]	0.020
Yes Diabetes No	0.89(0.78 - 1.01)	0.889	0.87(0.79 - 0.96) 1.00(0.81 - 1.24)		1.05(0.98 - 1.13) 0.96(0.84 - 1.09)	0.213
Yes Heart failure No		0.133	· · · · ·	0.306		0.757
Yes Coronary artery disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.127	0.87(0.79 - 0.96) 0.98(0.81 - 1.19) 0.92(0.83 - 1.01)	0.243	1.01(0.94 - 1.09) 1.05(0.93 - 1.18) 1.08(1.01 - 1.17)	0.003
Yes Peripheral arterial disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.776	$\begin{array}{c} 0.92(\ 0.83 - 1.01) \\ 0.82(\ 0.69 - 0.98) \\ 0.87(\ 0.80 - 0.06) \end{array}$	0.171	1.08(1.01 - 1.17) 0.90(0.81 - 1.01)	0.804
Yes Prior ischaemic stroke	$\begin{array}{c} 0.90(0.79 - 1.01) \\ 0.86(0.57 - 1.30) \end{array}$	0.494	$\begin{array}{c} 0.87(\ 0.80 - \ 0.96) \\ 1.13(\ 0.84 - \ 1.51) \end{array}$	0.363	1.03(0.96 - 1.10)	0.946
No Yes Prior haemorrhagic stroke	0.90(0.78 - 1.04)	0.993	$\begin{array}{c} 0.90(0.82 - 0.99) \\ 0.82(0.66 - 1.02) \end{array}$	0.601	1.02(0.95 - 1.09) 1.03(0.91 - 1.18)	0.976
Prior stroke (any)	0.89(0.80 - 1.01) [30events/20df] ??	0.400	0.89(0.82 - 0.98) [30events/20df]	??	1.03(0.97 - 1.10) [50events/20df]	??
NO Yes	0.91(0.79 - 1.05)	0.719	$\begin{array}{c} 0.90(\ 0.82 \ \ 0.99) \\ 0.83(\ 0.67 \ \ 1.02) \end{array} \right \qquad$	0.419	1.02(0.96 - 1.10)	0.340
Prior transient ishaemic attac	K 0.90(0.80 - 1.01)		$ \begin{array}{c} 0.89(\ 0.81 \ - \ 0.97) \\ 1.02(\ 0.68 \ - \ 1.52) \end{array} $	<u> </u>	1.03(0.96 - 1.09) 1.14(0.88 - 1.49)	
Prior systemic embolism	0.90(0.80 - 1.01)	0.784	0.89(0.81 - 0.97) [20events/29df]		1.03(0.97 - 1.10) [40events/29df]	0.493
Prior gastointestinal bleeding	0.90(0.80 - 1.01) [20events/27df]	0.174	0.89(0.82 - 0.97) [40events/27df]		1.03(0.97 - 1.09) [60events/27df]	0.522
Prior intracranial bleeding	0.90(0.80 - 1.01)	0.728	0.90(0.82 - 0.98) [30events/19df]	0.319	[00events/27/di] 1.03(0.97 - 1.10) [50events/19df]	0.893
Yes	[30events/19dī]		[30events/19df]		[SUevents/19df]	
	0.5 1	2	0.5	1 2	0.5	1 2
* Subaroun actimates converting -11	Favors dabigatran	Favors Warfarin	Favors dab	·	Favors o	dabigatran Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of fewe	er than 10 events pr degre	ee of freedom - no Cox regression ru	nj		

Figure 15.19 Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin overall and in the subgroups – all countries combined

	Any stroke or SE		Any bleeding at ac	cute hospitalization	Secondary comp	oosite outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age		0.190	1.15(1.07 - 1.25)	0.679	1.20(1.14 - 1.26)	
<pre><65 years 65 - <75 years 75 - <85 years >= 85 years</pre>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	_	0.95(0.70 - 1.29) - 1.09(0.93 - 1.27) - 1.09(0.93 - 1.27) - 1.18(1.04 - 1.33) - 1.17(1.02 - 1.35) - 1.17(1.02 -		1.03(0.83 - 1.28) 1.16(1.03 - 1.31) 1.13(1.04 - 1.23) 1.24(1.15 - 1.35)	
Sex Female	$\begin{array}{c} 1.07(0.92 - 1.24) \\ 0.98(0.84 - 1.13) \end{array}$	0.359	1.10(0.97 - 1.24) 1.21(1.09 - 1.33)	0.171	1.22(1.13 - 1.32) 1.16(1.08 - 1.25)	
CHA2DS2VASc 0-1 2-3	$\begin{bmatrix} 70 \text{ events}/11 \text{ df} \\ 1.04(0.84 - 1.78) \end{bmatrix} = \begin{bmatrix} 2? \\ 2? \\ 3.001(0.88 - 1.78) \end{bmatrix}$	0.961	1.21(1.09 - 1.55) 1.09(0.78 - 1.52) 1.10(0.97 - 1.25)	0.782	1.16(1.08 - 1.23) 1.26(0.95 - 1.67) 1.18(1.07 - 1.30)	0.395
CHADS2		0.502	1.16(1.05 - 1.28)	0.279	1.16(1.09 - 1.23)	0.254
HAS-BLED	[50events/6df] 0.92(0.69 - 1.23) 1.01(0.90 - 1.13)		1.02(0.85 - 1.23) 1.02(0.85 - 1.23) 1.15(1.05 - 1.25)		1.23(0.94 - 1.07) 1.12(0.98 - 1.28) 1.17(1.11 - 1.24)	+
≤ 3	1.04(0.90 - 1.22)	0.575	1.17(1.05 - 1.29)	0.562	1.25(1.16 - 1.34) 1.12(1.04 - 1.21)	0.028
Chronic kidney disease	1.04(0.93 - 1.15) [90events/15df]	0.425	1.17(1.08 - 1.27) 1.01(0.75 - 1.34)	0.059	1.24(1.17 - 1.31) 0.72(0.60 - 0.86)	
Yes Diabetes No Yes	0.98(0.87 - 1.10)	0.074	1.10(1.01 - 1.20)	0.009	1.21(1.14 - 1.28) 1.18(1.06 - 1.31)	— 0.647
Heart failure	0.98(0.87 - 1.10)	0.060	1.11(1.02 - 1.22)	0.195	1.17(1.12 - 1.26)	
Yes Coronary artery disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.763	1.27(1.09 - 1.19) 1.13(1.03 - 1.23) 1.22(1.06 - 1.41)	0.370	1.26(1.19 - 1.35) 1.06(0.97 - 1.16)	<.001
Peripheral arterial disase	1.04(0.93 - 1.22)	0.496	1.22(1.00 - 1.41) 1.16(1.07 - 1.26) 1.16(0.91 - 1.47)	0.658	1.00(0.97 - 1.10) 1.21(1.14 - 1.27) 1.15(1.00 - 1.33)	0.405
Yes Prior ischaemic stroke	$\begin{array}{c} 1.05(\ 0.92 - 1.19) \\ 0.95(\ 0.80 - 1.13) \end{array}$	0.219	1.18(1.08 - 1.29) 1.03(0.86 - 1.23)	0.143	1.17(1.11 - 1.24) 1.23(1.10 - 1.37)	
Prior haemorrhagic stroke No Yes	1.04(0.93 - 1.15) [30events/17df]	0.089	1.05(0.86 - 1.25) 1.16(1.07 - 1.25) [40events/17df]	22	1.20(1.14 - 1.26) [80events/17df]	22
Yes Prior stroke (any) No Ves	1.05(0.92 - 1.20)	0.177	1.18(1.08 - 1.28) 1.04(0.88 - 1.24)	0.193	1.17(1.11 - 1.24)	0.647
Prior transient ishaemic attac No Yes	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.958	1.0(0.00 - 1.21) 1.16(1.07 - 1.25) 1.02(0.72 - 1.45)	0.648	1.20(1.14 - 1.27) 1.06(0.85 - 1.32)	0.271
Prior systemic embolism	1.02(0.92 - 1.14) [50events/18df]	0.532	1.15(1.07 - 1.25) [30events/18df]	22	1.20(1.14 - 1.26) [100events/18df]	 0.491
Yes Prior gastointestinal bleeding	1.03(0.93 - 1.14) [20events/22df]	0.554	1.15(1.06 - 1.24) [50events/22df]	0.331	1.19(1.13 - 1.26) [100events/22df]	22 - 0.958
Prior intracranial bleeding No Yes	1.03(0.93 - 1.15) [40events/12df] ??	0.339	1.16(1.07 - 1.25) [60events/12df]	??	1.19(1.13 - 1.26) [110events/12df]	??
	0.5 1	2	0.5	1 2	0.5	1 2
	Favors rivaroxaban Fav	ors Warfarin	Favors rive	aroxaban Favors Warfarin	Favors rivard	oxaban Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of fewer that	in 10 events pr degr	ee of freedom - no Cox regression n	ın]		

Figure 15.20 Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin overall and in the subgroups – all countries combined

	Any stroke or	SE	Any bleeding at acut	e hospitalization	Secondary composite	e outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age	1.15(0.96 - 1.39)	0.592	0.73(0.64 - 0.85)	0.225	1.26(1.15 - 1.37)	0.467
<pre><65 years 65 - <75 years 75 - <85 years ->= 85 years</pre>	[60events/ 8df] 1.22(0.84 - 1.75) 1.01(0.76 - 1.34) 1.12(0.77 - 1.64)		$\begin{bmatrix} 70 \text{events} / 8 \text{df} \\ 0.84 (\ 0.64 - 1.10) \\ 0.62 (\ 0.50 - 0.78) \\ 0.73 (\ 0.56 - 0.95) \end{bmatrix}$	<u> </u>	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Sex	1.09(0.83 - 1.43)	0.746	0.67(0.54 - 0.83)	0.379	1.33(1.18 - 1.50)	0.141
Female Male CHA2DS2VASc 0-1		0.429	· · · · / ·	22		0.639
2-3 ≥=4 CHADS2	$\begin{bmatrix} 30 \text{events}/10 \text{df} \\ 1.26(0.83 - 1.82) \\ 1.03(0.83 - 1.27) \end{bmatrix} \xrightarrow{?}$	0.837	[60events/10df] 0.75(0.60 - 0.95) 0.67(0.56 - 0.81)	0.710	$\begin{bmatrix} 90 \text{events}/10 \text{df} \\ 1.22 \{ 1.05 - 1.42 \} \\ 1.17 \{ 1.06 - 1.30 \} \end{bmatrix}$	0.518
	$\begin{array}{c c} [20 \text{events} / 6df] \\ 1.05(0.65 - 1.68) \\ 1.14(0.93 - 1.40) \end{array} \end{array} - \begin{array}{c} ? \\ - \end{array}$	0.037	0.67(0.41 - 1.11)		1.27(0.83 - 1.94) 1.15(0.94 - 1.40)	0.510
HAS-BLED	1.14(0.93 - 1.40)	0.797	0.70(0.59 - 0.83)	0.440	1.21(1.10 - 1.34) 1.35(1.19 - 1.52) 1.12(1.00 - 1.26)	0.025
>=3 Chronic kidney disease		0.598		<.001	· · · · · · · · · · · · · · · · · · ·	<.001
Yes Diabetes	1.18(0.97 - 1.43) [40events/21df] 2.121(0.08 - 1.50)	0.542	0.79(0.68 - 0.92) [80events/21df]	??	$\begin{array}{c} 1.32(1.21 - 1.44) \\ 0.71(0.55 - 0.93) \\ 1.20(1.18 - 1.43) \\ \end{array}$	0.171
Yes Heart failure		0.602	0.72(0.61 - 0.84)	0.810	1.30(1.18 - 1.43)	0.125
No Yes Coroṇary artery disase	1.12(0.91 - 1.37) [100events/11df] ?	0.010	$\begin{array}{c} 0.72(\ 0.61 - \ 0.84) \\ 0.79(\ 0.56 - \ 1.10) \end{array}$	0.017	1.28(1.16 - 1.41) 1.17(0.99 - 1.38)	0.082
No Yes Peripheral arterial disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.163	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.914	1.29(1.17 - 1.43) 1.19(1.01 - 1.40)	0.049
Prior ischaemic stroke	1:18(0.97 - 1:44)		0.74(0.64 - 0.87)	<u> </u>	1.29(1.18 - 1.42)	i
No Yes	1.21(0.94 - 1.55)	0.237	0.71(0.61 - 0.83)	0.553	1.27(1.15 - 1.40) 1.15(0.96 - 1.38)	0.132
Prior haemorrhagic stroke	1.15(0.95 - 1.39) [10events/37df]	0.890	0.73(0.63 - 0.84) [10events/37df]	0.855	1.25(1.15 - 1.36) [20events/37df] ?	
Prior stroke (any)	1.18(0.92 - 1.51)	0.370	0.70(0.60 - 0.82)	0.396	1.27(1.15 - 1.40) 1.15(0.96 - 1.38)	0.158
Prior transient ishaemic attac		0.784	0.83(0.59 - 1.17) 0.75(0.65 - 0.86) [40events/26df]	0.165	1.15(0.96 - 1.38) 1.27(1.16 - 1.38) [140 events/26 df]	0.259
Yes Prior systemic embolism	1	0.729		0.643		0.076
Yes Prior gastointestinal bleeding	1.16(0.96 - 1.40) [10events/42df] ?	0.051	0.73(0.64 - 0.85) [10events/42df]	??	1.25(1.15 - 1.36) [20events/42df] ?	0.163
Prior intracranial bleeding No	1.18(0.98 - 1.43) [10events/33df] ?	0.520	0.73(0.63 - 0.84) [20events/33df]	?? 0.541	1.26(1.16 - 1.38) [70events/33df] ?	0.010
No Yes	1.14(0.95 - 1.38) [20events/31df] ?	?	0.74(0.64 - 0.85) [10events/31df]	??	1.24(1.14 - 1.36) [30events/31df] ?	?
	0.5 1	2	0.5	1 2	0.5	1 2
	Favors apixaban	Favors Warfarin	Favors apixat	ban Favors Warfarin	Favors apixaban	Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	ver than 10 events pr degr	ee of freedom - no Cox regression run]			

Figure 15.21 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – Denmark

	Any stroke or	SE	Any bleeding at acu	te hospitalization	Secondary compo	osite outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age		0.346		0.113	1.15(1.05 - 1.26)	0.878
65 years 65 - 75 years 75 - 85 years ->= 85 years	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.69(0.45 - 1.06)		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Sex Female	1.06(0.81 - 1.38)	0.415	0.96(0.73 - 1.18)	0.791	1.17(1.03 - 1.30)	0.670
CHA2DS2VASc 0-1		0.330	0.91(0.77 - 1.08)	0.189	1.12(1.00 - 1.26)	0.835
2-3 CHADS2	$\begin{bmatrix} 30 \text{ events} / 4df \\ 1.09(0.79 - 1.51) \\ 0.91(0.73 - 1.14) \end{bmatrix} \xrightarrow{??}$	0.260	$ \begin{array}{c} 0.83(0.67 - 1.02) \\ 1.00(0.83 - 1.20) \end{array} $	0.094	1.11(0.96 - 1.30) 1.09(0.97 - 1.23)	0.861
	[30events/ 4df] 1.11(0.75 - 1.66) 0.94(0.76 - 1.16)		0.56(0.34 - 0.92)		1.19(0.81 - 1.76) 1.08(0.90 - 1.31)	
HAS-BLED	0.94(0.76 - 1.16) 0.96(0.74 - 1.24)	0.954	0.99(0.84 - 1.16) 0.98(0.82 - 1.18) 0.87(0.72 - 1.05)	0.302	1.11(1.00 - 1.23) 1.11(0.99 - 1.26) 1.17(1.03 - 1.33)	0.554
>=3 Chronic kidney disease		0.894		0.279	· · · · · · · · · · · · · · · · · · ·	0.148
Yes Diabetes	0.97(0.81 - 1.16) [10events/36df] ??	0.252	0.94(0.82 - 1.08) [30events/36df]	?? 0.149	1.16(1.06 - 1.27) [60events/36df]	??0.640
Yes Heart failure		0.320	0.88(0.76 - 1.03) 1.14(0.84 - 1.55)	0.455	1.16(1.05 - 1.28) 1.09(0.89 - 1.33)	0.626
No Yes Coronary artery disase	$\begin{array}{c} 0.93(0.77 - 1.13) \\ 1.28(0.80 - 2.04) \end{array}$	0.105	$ \begin{array}{c} 0.90(\ 0.78 \ - \ 1.05) \\ 1.07(\ 0.78 \ - \ 1.47) \end{array} $	0.071	1.15(1.04 - 1.27) 1.16(0.97 - 1.39)	0.055
No Yes Peripheral arterial disase	1.05(0.86 - 1.29)	0.405	$\begin{array}{c} 0.99(\ 0.85 \ - \ 1.16) \\ 0.76(\ 0.58 \ - \ 0.99) \end{array}$	0.997	1.21(1.09 - 1.34) 1.00(0.84 - 1.19)	0.269
Prior ischaemic stroke	0.99(0.82 - 1.19) [40events/9df] ??	0.352	0.93(0.80 - 1.06) [80events/ 9df]	??	1.17(1.06 - 1.28) 1.10(0.83 - 1.47)	0.209
No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		1.14(1.03 - 1.25) 1.21(0.99 - 1.48)	
Prior haemorrhagic stroke No Yes	0.98(0.81 - 1.17) [10events/38df]	0.691	0.93(0.81 - 1.06) [10events/38df]	22	1.15(1.05 - 1.25) [10events/38df]	22
Prior stroke (any) No Vas	1.00(0.80 - 1.25)	0.359	0.91(0.79 - 1.05) 1.06(0.75 - 1.52)	0.578	1.13(1.03 - 1.25) 1.22(1.00 - 1.48)	0.830
Prior transient ishaemic attac	k 0.99(0.82 - 1.19)	0.492	0.93(0.81 - 1.07) [40events/19df]	0.793	1.15(1.05 - 1.26) [100events/19df]	0.933
Prior systemic embolism	0.97(0.81 - 1.17)	0.838	0.92(0.81 - 1.06) [0events/39df]	0.235	[100events/19d1] 1.15(1.05 - 1.25) [10events/39df]	0.123
Prior gastointestinal bleeding	[10events/39df] 22 0.98(0.81 - 1,17)	0.552	[0events/39df] 0.94(0.82 - 1.07) [20events/40df]	0.288	[10events/39df] 1.15(1.05 - 1.25) [40events/40df]	0.622
Yes Prior intracranial bleeding No	1	0.865		0.860		0.048
Yes	0.97(0.81 - 1.17) [10events/26df] ??	· · · · · · · · · · · · · · · · · · ·	0.93(0.81 - 1.06) [10events/26df]	??	1.14(1.04 - 1.25) [20events/26df]	??
	0.5 1	2	0.5	1 2	0.5	1 2
	Favors dabigatran	Favors Warfarin	Favors dabig		Favors dabig:	atran Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	er than 10 events pr degre	ee of freedom - no Cox regression run			

Figure 15.22 Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin overall and in the subgroups – *Denmark*

	Any stroke or SE		Any bleeding at a	cute hospitalization	Secondary comp	oosite outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age	0.97(0.81 - 1.17)	0.214	1.09(0.95 - 1.25)	0.191	1.34(1.23 - 1.46)	0.627
<pre><65 years 65 - <75 years 75 - <85 years</pre>	[40events/10df] 1.19(0.82 - 1.72) 0.73(0.55 - 0.98) 1.07(0.75 - 1.51)		[70events/10df] 1.28(0.98 - 1.67) 0.88(0.70 - 1.10) 1.08(0.84 - 1.39)		$ \begin{array}{c} 1.53(1.05 - 2.24) \\ 1.31(1.08 - 1.59) \\ 1.21(1.06 - 1.40) \\ 1.30(1.13 - 1.50) \end{array} $	
>= 85 years Sex Female		0.845		0.012		0.905
CHA2DS2VASc	0.97(0.75 - 1.27)	0.378	0.90(0.72 - 1.11) 1.26(1.06 - 1.50)	0.565	1.35(1.19 - 1.53) 1.32(1.18 - 1.49)	0.487
2-3 CHADS2	[20events/11df] 1.18(0.81 - 1.74) 0.86(0.69 - 1.06)		[50events/11df] 1.13(0.91 - 1.40) 1.00(0.84 - 1.20)		[70events/11df] 1.39(1.19 - 1.62) 1.24(1.12 - 1.38)	
	[20events/ 3df] 1.02(0.65 - 1.61) 0.91(0.74 - 1.11)	0.284	1.48(0.90 - 2.46) 1.00(0.75 - 1.32)	0.379	1.58(1.00 - 2.48) 1.37(1.13 - 1.67) 1.29(1.17 - 1.42)	0.523
HAS-BLED		0.355	1.07(0.91 - 1.25) 1 16(0.96 - 1.41)	0.217	1.2)(1.1) 1.12)	0.036
Chronic kidney disease		0.175	1.16(0.96 - 1.41) 1.02(0.85 - 1.23)	0.055	1.46(1.29 - 1.66) 1.22(1.09 - 1.37) 1.38(1.26 - 1.50)	0.014
Yes Diabetes	1.00(0.83 - 1.21) [30events/29df] ??	0.930	1.12(0.98 - 1.29) [60events/29df]	??	1.38(1.26 - 1.50) [170events/29df]	??
Yes Heart failure No	$\begin{array}{c} 0.98(0.80 - 1.21) \\ 0.93(0.64 - 1.35) \end{array}$	0.084	1.04(0.90 - 1.21) 1.35(0.98 - 1.86)	0.244	1.36(1.23 - 1.49) 1.33(1.11 - 1.60)	0.530
Yes Coronary artery disase	$\begin{array}{c} 0.91(0.75 - 1.11) \\ 1.38(0.88 - 2.16) \end{array}$	0.286	1.04(0.90 - 1.21) 1.35(0.98 - 1.87)	0.945	1.32(1.20 - 1.46) 1.40(1.17 - 1.67)	0.265
No Yes Peripheral arterial disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.067	1.08(0.93 - 1.27) 1.10(0.85 - 1.43)	0.229	$\begin{array}{c} 1.38(1.25 - 1.53) \\ 1.24(1.05 - 1.46) \end{array}$	0.141
No Yes Prior ischaemic stroke	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.269	1.12(0.97 - 1.29) 0.85(0.56 - 1.31)	0.674	1.38(1.26 - 1.51) 1.14(0.90 - 1.44)	0.898
No Yes Prior haemorrhagic stroke	1.02(0.79 - 1.31) 0.88(0.68 - 1.15)	0.236	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.692	1.32(1.20 - 1.46) 1.38(1.16 - 1.64)	0.899
Prior stroke (any)	0.98(0.82 - 1.18) ?	i i	1.09(0.95 - 1.25) [10events/37df]	22	1.34(1.23 - 1.46) [20events/37df]	22
NO		0.290	1.10(0.95 - 1.28) 1.01(0.74 - 1.40)	0.693	1.32(1.20 - 1.45) 1.39(1.17 - 1.66)	0.894
Yes Prior transient ishaemic attac No Yes	k 1.01(0.83 - 1.22)	0.231	1.09(0.95 - 1.25) [30events/20df]	22	1.37(1.25 - 1.49) [100events/20df]	2?
Prior systemic embolism	0.98(0.81 - 1.17)	0.815	1.09(0.95 - 1.25) [10events/39df]	0.931	1.34(1.23 - 1.46) [20events/39df]	2 - 0.115
Yes Prior gastointestinal bleeding	0.99(0.83 - 1.19) [10events/35df]	0.120	1.06(0.93 - 1.22) [20events/35df]	0.081	1.35(1.24 - 1.47) [50events/35df]	0.368
Prior intracranial bleeding No Yes	0.99(0.82 - 1.18) [10events/28df]	0.301	1.09(0.95 - 1.24) [20events/28df]	0.996	1.34(1.23 - 1.46) [30events/28df]	0.368
105				• •		
	0.5 1 Favors rivaroxaban Fav	2 ors Warfarin	0.5 Favors riv	1 2 varoxaban Favors Warfarin	0.5 Favors rivaro	1 2 oxaban Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of fewer that				a	

Figure 15.23 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – Denmark

	Any stroke or	SE	Any bleeding at acut	e hospitalization	Secondary composite	e outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age		0.191		0.851	0.97(0.87 - 1.09)	0.053
<pre><65 years 65 - <75 years 75 - <85 years >= 85 years</pre>	[30events/17df] ? 1.19(0.72 - 1.99) . 0.67(0.45 - 0.98) . 1.16(0.74 - 1.82) .	<u> </u>	$\begin{bmatrix} 60events/17df \\ 0.76(0.53 - 1.10) \\ 0.69(0.53 - 0.89) \\ 0.61(0.45 - 0.81) \\ 0.61(0.45 - 0.81) \\ \end{bmatrix}$		[120events/17df] 0.98(0.75 - 1.30) 0.80(0.66 - 0.96) 1.13(0.94 - 1.36)	
Sex Female	0.96(0.66 - 1.39)	0.818	$0.64(0.48 - 0.84)^{-1}$	0.107	0.95(0.80 - 1.14)	0.776
CHA2DS2VASc 0-1		0.077	· · · · · · · · · · · · · · · · · · ·	2?		0.085
2-3 ≥=4 CHADS2	$\begin{array}{c c} 20 \text{events}/12 \text{df} \\ 0.75 \{0.47 \\ 0.98 \{0.73 \\ 0.73 \\ 1.31 \} \end{array} $	0.375	[50events/12df] 0.63(0.48 - 0.84) 0.69(0.56 - 0.85)	0.919	$\begin{bmatrix} 60 \text{events}/12 \text{df} \\ 0.77(0.62 - 0.96) \\ 1.02(0.89 - 1.17) \end{bmatrix} = \boxed{\begin{tabular}{ll} & \begin{tabular}{ll} & \begin{tabular}{$	0.860
	[30events/10df] 1.09(0.62 - 1.91) 0.89(0.67 - 1.17)	<u> </u>	[60events/10df] 0.67(0.49 - 0.93) 0.66(0.54 - 0.80)	-??	[90events/10df] 0.96(0.75 - 1.23) 0.96(0.84 - 1.09)	?
HAS-BLED	0.91(0.61 - 1.35)	0.682	0.69(0.53 - 0.89)	0.602	0.95(0.80 - 1.12)	0.794
Chronic kidney disease	0.92(0.71 - 1.20)	0.718	0.72(0.60 - 0.87)	- 0.750	1.00(0.88 - 1.14) 0.94(0.74 - 1.20)	0.929
Yes Diabetes No	$\begin{bmatrix} 0.094(0.72 - 1.24) \\ 1.05(0.59 - 1.87) \end{bmatrix}$	0.278	0.67(0.48 - 0.97)	0.913	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.577
Yes Heart failure		0.105		0.463	· · · · · ·	<.001
Yes Coronary artery disase	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.776	0.72(0.59 - 0.89) 0.65(0.49 - 0.85)	0.004	$\begin{array}{c} 0.85(\ 0.73 - 0.98) \\ 1.18(\ 0.98 - 1.41) \\ 0.88(\ 0.75 - 1.03)^{1} \end{array}$	0.046
Yes Peripheral arterial disase	0.90(0.66 - 1.24) 1.07(0.73 - 1.58)	0.117	0.59(0.47 - 0.74)	0.772	$\begin{array}{c} 0.88(\ 0.75 - 1.03) \\ 1.13(\ 0.96 - 1.33) \\ 0.02(\ 0.01 - 1.05) \\ \end{array}$	0.220
Yes Prior ischaemic stroke	$\begin{array}{c} 0.85(0.65 - 1.10) \\ 2.27(1.04 - 4.99) \end{array}$	0.614	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.007	$\begin{array}{c} 0.92(\ 0.81\ -\ 1.05)\\ 1.27(\ 0.96\ -\ 1.69) \end{array}$	0.630
No Yes Prior haemorrhagic stroke	0.90(0.67 - 1.22) 1.09(0.71 - 1.68)	0.738	$\begin{array}{c} 0.73(\ 0.61 - \ 0.88) \\ 0.53(\ 0.35 - \ 0.79) \\ \end{array}$		$\begin{array}{c} 0.93(\ 0.82\ -\ 1.06)\\ 1.17(\ 0.90\ -\ 1.53) \end{array}$	0.253
No Yes Prior stroke (any)	0.95(0.74 - 1.22) ?	2.0.634	0.70(0.59 - 0.83) [10events/34df]	??	0.97(0.87 - 1.09) [30events/34df]	2 0.826
NO Yes	0.90(0.67 - 1.21)	I	0.73(0.61 - 0.88)	- ; ;	0.93(0.82 - 1.06) 1.20(0.93 - 1.56)	
Prior transient ishaemic attac No Yes	k 0.98(0.76 - 1.26)	0.207	0.67(0.57 - 0.80)	0.233	0.97(0.86 - 1.09)	0.835
Prior systemic embolism	0.94(0.73 - 1.20)	0.266	0.69(0.58 - 0.81) [10events/37df]	0.175	0.97(0.87 - 1.09) [30events/37df]	0.548
Yes Prior gastointestinal bleeding No	0.96(0.74 - 1.23)	0.988	0.70(0.59 - 0.82)	0.514	0.97(0.86 - 1.09)	0.055
Prior intracranial bleeding		0.833		0.665		0.096
Yes	0.96(0.75 - 1.23) [10events/36df] ?	?	0.71(0.60 - 0.84) [20events/36df]	??	0.98(0.87 - 1.10) [40events/36df] ?	?
	0.5 1	2	0.5	1 2	0.5	1 2
	Favors apixaban	Favors Warfarin	Favors apixab		Favors apixaban	Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	ver than 10 events pr degr	ee of freedom - no Cox regression run]			

Figure 15.24 Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin overall and in the subgroups – *Norway*

	Any stroke or S	SE	Any bleeding at acute	e hospitalization	Secondary composit	te outcome
	HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
All Age		0.225		0.039		0.347
$\begin{array}{c} 45 \text{ years} \\ 65 - 75 \text{ years} \\ 75 - 85 \text{ years} \\ >= 85 \text{ years} \end{array}$	20events/18df] 0.84(0.54 - 1.32) 0.71(0.48 - 1.05) 60events/6df] 2? 0.76(0.53 - 1.10) 2?	0.840	50events/18df] 0.70(0.51 - 0.97) 0.83(0.64 - 1.07) 1.25(0.92 - 1.70)	0.235	[80events/18df] 1.12(0.87 - 1.45) 0.87(0.71 - 1.06) 0.81(0.64 - 1.03) 0.90(0.75 - 1.09)	0.576
CHA2DS2VASc 0-1 2-3	$\begin{array}{c c} 0.76(0.53 - 1.10) \\ \hline \\ 0.76(0.56 - 1.09) \\ \hline \\ 0.89(0.61 - 1.32) \\ 0.67(0.48 - 0.93) \\ \hline \end{array}$	0.524	1.02(0.80 - 1.30) 50events/5dfl 990(0.70 - 1.10)	<u>??</u> 0.914	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.081
CHADS2 0 1 =2	0.67(0.48 = 0.93) [20events/4df] 1.12(0.69 = 1.81) 0.63(0.46 = 0.85)	.130	0.88(0.70 - 1.10)	0.712	1.26(0.84 - 1.90)	0.118
HAS-BLED 3 Chronic kidney disease	1.03(0.73 - 1.44)	0.031	$8.87(8.68 \pm 1.12)$	0.436	0.87(0.85 - 1.14)	0.321
Yes Diabetes No Yes	0.77(0.60 - 0.99) [10events/27df] 0.73(0.56 - 0.95) [40events/ 4df] ??	0.216	0.90(0.77 - 1.06) [40events/27df] 0.93(0.78 - 1.10) 0.78(0.51 - 1.21)	?? 0.570	0.97(0.85 - 1.10) [80events/27df] 0.92(0.80 - 1.06) 0.92(0.69 - 1.22)	?? 0.975
Heart failure No Yes Coronary artery disase No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.607	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.556	0.87(0.75 - 1.01) 1.05(0.84 - 1.33) 0.89(0.76 - 1.03) 1.00(0.81 - 1.24)	0.140
Yes Peripheral arterial disase No Yes Prior ischaemic stroke	0.75(0.58 - 0.97)	0.399	0.87(0.74 - 1.03) [60events/12df]	0.171 ??	0.88(0.77 - 1.01) [110events/12df]	0.043 ??
No Yes Prior haemorrhagic stroke No Yes	0.83(0.61 - 1,11) [80events/9df] 0.77(0.60 - 0.98) [10events/26df] 2?	0.505	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.431	0.91(0.79 - 1.04) 1.00(0.74 - 1.36) 0.93(0.82 - 1.05) 10events/26df]	0.840
Yes Prior stroke (any) No Yes Prior transient ishaemic attac	0.84(0.62 - 1.12) [80events/9df] ??	0.360	1.01(0.85 - 1.20)	0.004	8:99(8:73 - 1:05)	0.689
Yes Prior systemic embolism Yes Prior gastointestinal bleeding	0.79(0.61 - 1.02) [20events/21df] 0.77(0.60 - 0.98) [0events/39df] ??	0.254	0.90(0.76 - 1.06) [30events/21df] 0.90(0.77 - 1.06) 0events/39df]	?? 	0.91(0.80 - 1.04) [60events/21df] 0.92(0.81 - 1.04) [10events/39df]	?? 0.069 ?? 0.368
Prior intracranial bleeding No Prior intracranial bleeding Yes	0.79(0.62 - 1.02) [10events/34df] 0.76(0.59 - 0.97) [10events/34df] ??	0.326	0.89(0.76 - 1.05) [20events/34df] 0.92(0.78 - 1.08) [10events/34df]	22 0.505	0.92(0.81 - 1.04) [20events/34df] 0.93(0.82 - 1.05) [20events/34df]	2? 0.696
105	0.5 1 Favors dabigatran	2 Favors Warfarin	0.5	1 2 ran Favors Warfarin	0.5 Favors dabigatran	1 2 Favors Warfarin
L * Subgroup estimates conventionally ac	ljusted in case of imbalance. [In case of few		, i i i i i i i i i i i i i i i i i i i	avois waitain	r avois dauganai	a u, 013 Walialii

Figure 15.25 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin overall and in the subgroups – Norway

	Any stroke or	SE	Any bleeding at	acute hospitalizati	ion	Secondary con	posite outcome	
	HR (95% CI)	P-int	HR (95% CI)		P-int	HR (95% CI)	1	P-int
All Age		0.209	1.18(1.03 - 1.35)		0.759			0.549
<pre>65 years 65 - <75 years 75 - <85 years >= 85 years</pre>	[20events/20df] ? 0.97(0.63 - 1.49) . 1.4(0.83 - 1.57) . .08(0.74 - 1.57) .		[50events/20df] 1.15(0.87 - 1.53) 1.11(0.90 - 1.37) 1.19(0.92 - 1.54)		1	[90events/20df] 1.15(0.91 - 1.46) 0.98(0.83 - 1.17) 1.00(0.84 - 1.18)		
Sex Female Male	1.36(1.01 - 1.84)	0.132	1.23(1.00 - 1.51) 1.15(0.96 - 1.38)		0.787	1.03(0.88 - 1.20) 1.09(0.94 - 1.25)	_ <u>+</u>	0.428
CHA2DS2VASc 0-1 2-3	[10events/15df] 0.95(0.65 - 1.38) 1.16(0.90 - 1.48)	0.142	[50events/15df] 1.22(0.97 - 1.54) 1.15(0.97 - 1.38)	??	0.940	[70events/15df] [0.99(0.82 - 1.19)] 1.04(0.91 - 1.18)]	??	0.032
CHADS2		0.709	1.15(0.97 - 1.38)		0.743	1.04(0.91 - 1.18)		0.347
1 HAS-BLED	[30events/ 7df] 0.96(0.60 - 1.54) 1.18(0.93 - 1.49)	0.466	1.16(0.89 - 1.52)		0.510	0.95(0.76 - 1.18) 1.04(0.92 - 1.18)		0.214
Chronic kidney disease	1.22(0.89 - 1.67)		1:18(8:97 - 1:44)			1.08(0.93 - 1.25) 1.01(0.87 - 1.17)	=	1
NO	1.17(0.94 - 1.45) [40events/12df]	0.752	1.22(1.05 - 1.41) [110events/12df]	??	0.270	1.14(1.01 - 1.27)	_	0.002
Yes Diabetes No Yes	1.01(0.80 - 1.26) 2.22(1.33 - 3.69)	0.004	1.11(0.95 - 1.29)		0.042	1.08(0.96 - 1.22) 1.02(0.82 - 1.27)		0.508
Yes Heart failure	$\frac{1.11(0.88 - 1.39)}{1.32(0.83 - 2.09)} =$	0.349	1.18(1.00 - 1.39) 1.15(0.89 - 1.48)		0.931	1.04(0.92 - 1.18) 1.03(0.85 - 1.24)		0.824
Yes Coronary artery disase No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.811	1.10(0.89 - 1.48) 1.10(0.93 - 1.30) 1.39(1.10 - 1.75)		0.138	1.09(0.85 - 1.24) 1.09(0.95 - 1.24) 1.04(0.88 - 1.23)		0.576
Yes Peripheral arterial disase		0.198			0.656			0.242
Yes Prior ischaemic stroke	1.11(0.89 - 1.38) [50events/14df] ?	0.508	1.17(1.01 - 1.35) [110events/14df]	??	0.144	1.03(0.92 - 1.16) 1.27(0.96 - 1.68)		0.323
Yes Prior haemorrhagic stroke	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.494	1.24(1.06 - 1.44) 0.95(0.69 - 1.30)		0.199	1.03(0.92 - 1.16) 1.14(0.89 - 1.45)		0.812
No Yes Prior stroke (any)	1.15(0.93 - 1.41) [10events/32df] ?	0.583	1.20(1.04 - 1.37) [10events/32df]	??	0.136	1.06(0.96 - 1.18) [20events/32df]	??	0.262
No Yes Prior transient ishaemic attac	1.19(0.93 - 1.53)	0.771	1.24(1.07 - 1.45) 0.95(0.69 - 1.29)		0.749	1.03(0.91 - 1.16) 1.11(0.88 - 1.41)		0.931
Prior systemic embolism	1.17(0.94 - 1.44) [40events/13df]	2 0.165	1.19(1.03 - 1.37) [50events/13df]	??	0.400	1.06(0.95 - 1.18) [90events/13df]	??	0.301
NO Ves	1.13(0.92 - 1.39) [10events/32df]	<u> </u>	1.18(1.03 - 1.35) [10events/32df]	??		1.06(0.95 - 1.17) [20events/32df]	??	
Prior gastointestinal bleeding	1.15(0.94 - 1.42) [10events/35df]	0.731	1.17(1.02 - 1.35) [20events/35df]	??	0.532	1.06(0.96 - 1.18) [30events/35df]	??	0.939
Prior intracranial bleeding No Yes	1.15(0.93 - 1.41) [10events/24df]	0.580	1.20(1.04 - 1.38) [20events/24df]	??	0.260	1.06(0.96 - 1.18) [40events/24df]	??	0.781
	0.5 1	2	0.5		2	0.5	1	2
	Favors rivaroxaban	Favors Warfarin		rivaroxaban Favors Warfar	-	Favors riv.	aroxaban Favors Warfa	-
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	ver than 10 events pr degree	ee of freedom - no Cox regression	run]				

Figure 15.26 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of rivaroxaban vs. warfarin overall and in the subgroups – Norway

Age	HR (95% CI)					
All Age		P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
		0.652		0.528	1.09(1.02 - 1.16)	0.088
<65 years 65 - <75 years 75 - <85 years $\geq = 85$ years	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.88(0.65 - 1.20) 0.95(0.80 - 1.13) 1.09(0.98 - 1.21) 1.13(1.03 - 1.25)	
Sex Female	0.80(0.66 - 0.98)	0.362	$\begin{array}{c} 0.76(\ 0.03\ -\ 0.92)\\ 0.68(\ 0.57\ -\ 0.80)\\ 0.78(\ 0.68\ -\ 0.90) \end{array} \right \qquad $	0.156	1.13(1.03 - 1.23) 1.13(1.03 - 1.24) 1.04(0.95 - 1.14)	0.027
CHA2DS2VASc I	[50events/ 8df] 0.61(0.46 - 0.83) 0.94(0.80 - 1.09)	0.029	0.90(0.54 - 1.49) 0.62(0.50 - 0.75)		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	<.001
CHADS2	[10events/7df] ?	0.259	0.77(0.68 - 0.88)	??	1.11(1.00 1.22)	??
HAS-BLED	0.44(0.23 - 0.84) 0.88(0.77 - 1.01)	0.005	[30events/ 7df] 0.54(0.34 - 0.84) 0.75(0.67 - 0.83)	0.054	[30events/ 7df] 0.62(0.42 - 0.92) 1.10(1.03 - 1.18) 1.05(0.97 - 1.14)	0.156
Chronic kidney disease	0.74(0.62 - 0.89) 0.94(0.78 - 1.14)	0.134	0.67(0.58 - 0.77) 0.80(0.68 - 0.96)	0.991	1.05(0.97 - 1.14) 1.08(0.98 - 1.20)	0.497
Diabetes	0.87(0.76 - 1.01) 80events/11df 0.87(0.74 - 1.02) .84(0.64 - 1.09)	0.972	$\begin{array}{c c} 0.73(0.66 - 0.82) \\ 0.87(0.62 - 1.22) \\ 0.72(0.64 - 0.82) \\ 0.79(0.63 - 0.99) \end{array}$	0.107	1.11(1.094 - 1.14)	0.137
Heart failure	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.653	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.430	0.98(0.86 - 1.11) - 1.05(0.96 - 1.14) 1.15(1.04 - 1.26)	0.056
Coronary artery disase	$\begin{array}{c} 0.86(\ 0.67\ -\ 1.11) \\ 0.86(\ 0.74\ -\ 1.01) \\ 0.85(\ 0.66\ -\ 1.08) \end{array}$	0.817	0.79(0.65 - 0.96)	0.230	1.15(1.04 - 1.26) 1.15(1.06 - 1.25) 1.01(0.92 - 1.12)	0.383
Peripheral arterial disase	0.83(0.00 - 1.03)	0.117	0.71(0.64 - 0.80) 1.00(0.70 - 1.42)	0.176	1.01(0.92 - 1.12) 1.11(1.03 - 1.18) 1.00(0.83 - 1.21)	0.091
Prior ischaemic stroke	0.76(0.64 - 0.90) 0.90(0.73 - 1.12)	- 0.085	$\begin{array}{c} 0.71(\ 0.63 - \ 0.80) \\ 0.81(\ 0.64 - \ 1.03) \end{array}$	0.313	1.04(0.97 - 1.12) 1.11(0.98 - 1.26)	0.437
Prior haemorrhagic stroke No Yes Prior stroke (any)	0.87(0.76 - 1.00) [40events/23df]	0.215	0.73(0.66 - 0.82) [30events/23df]	??	1.10(1.03 - 1.17) [100events/23df]	?? 0.611
Prior transient ishaemic attack	0.76(0.64 - 0.90)	- 0.418	0.71(0.63 - 0.80)	0.294	1.05(0.97 - 1.13)	0.882
No Yes Prior systemic embolism	0.83(0.73 - 0.96)		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.234	$\frac{1.08(1.01 - 1.16)}{1.08(0.84 - 1.39)} - $	0.650
No Yes Prior gastointestinal bleeding	0.86(0.75 - 0.99)	0.425	0.73(0.65 - 0.81) [20events/32df]	??	1.09(1.02 - 1.16) [90events/32df]	??
Yes Prior intracranial bleeding	0.86(0.75 - 0.98) [10events/25df] 0.87(0.76 - 1.00)	0.478	0.73(0.65 - 0.81) [40events/25df]	??	1.08(1.01 - 1.16) [60events/25df]	?? 0.220
Yes	0.87(0.76 - 1.00) [40events/24df] ?:	<u>}</u>	0.73(0.66 - 0.82) [40events/24df]	??	1.10(1.03 - 1.17) [100events/24df]	??
	0.5 1	2	0.5	1 2	0.5	1 2
* Subgroup estimates conventionally adju	Favors apixaban	Favors Warfarin	Favors apixa		Favors apixaban	Favors Warfarin

Figure 15.27 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of apixaban vs. warfarin overall and in the subgroups – Sweden

		Any stroke or	SE	Any bleeding at acute	e hospitalization	Secondary composit	te outcome
² / ₃ ² / ₃ ² / ₃ ² / ₄ <th></th> <th>HR (95% CI)</th> <th>P-int</th> <th>HR (95% CI)</th> <th>P-int</th> <th>HR (95% CI)</th> <th>P-int</th>		HR (95% CI)	P-int	HR (95% CI)	P-int	HR (95% CI)	P-int
$\begin{array}{c} \mathbf{ex} \mathbf{ex}$	All Age		- 0.106		- 0.004		0.884
Ver Finale 0.352	<pre><05 years 65 - <75 years 75 - <85 years >= 85 years</pre>	0.78(0.45 - 1.38) 1.06(0.74 - 1.51) 0.67(0.48 - 0.93)		0.40(0.22 - 0.73) 0.65(0.48 - 0.87) $0.98(0.75 - 1.28)^{ }$	22		
BAADBSVASE 0.651 0.652 0.651 0.651 0.651 0.651 0.651 0.651 0.652 0.651 0.651 0.651 0.651 0.651 0.652 0.651 0.652 0.651 0.652 0.651 0.652 0.651 0.652	Sex Female		0.382		0.629		0.748
2HA0S2 102*ents/6d1 ?? 0.107 1AS 31LD 0.344 (0.76 + 1.16) 0.877 0.877 0.878 0.877 0.871 0.394 (0.76 + 1.16) 0.395 2hrong kidney disease 0.878 (0.62 + 1.23) 0.107 0.879 0.879 0.872 0.832 0.837 0.832 0.837 0.832 0.395 2hrong kidney disease 0.878 (0.62 + 1.23) 0.109 0.829 (0.62 + 0.422 0.832 0.629 0.832 0.837 0.832 0.745 1abeles 9.878 (0.62 + 1.28) 0.039 0.837 (0.85 + 1.23) 0.745 0.762 0.832 0.837 0.437 0.838 0.838 0.838 0.838 0.838 0.838 0.838 0.838 0.838 0.837 0.937 0.933 0.838 0.837 0.937 0.938 0.938 0.938 0.938 0.938 0.938 0.938 0.938	CHA2DS2VASc 0-1	0.61(0.20 - 1.25)	0.651	0.61(0.31 - 1.20)	0.008	1.06(0.65 - 1.74)	0.844
Q Idevents 6df 3? Q Idevents 6df 3? Q Idevents 6df 3? Q <thq< th=""> <thq< th=""> Q</thq<></thq<>	$2-3 \rightarrow = 4$	0.85(0.60 - 1.20)	0 107	0.61(0.46 - 0.79)		0.93(0.76 - 1.15)	0.776
IAS - BLD $837(8.70 - 1.1.33)$ 0.877 0.877 $0.73(8.77 - 1.83)$ 0.009 Dronic kidney disease $0.87(8.72 - 1.63)$ 0.009 $0.73(8.77 - 1.83)$ 0.009 Jabetes $0.87(8.72 - 1.63)$ 0.009 0.090 $0.837(8.72 - 1.63)$ 0.745 Jabetes $0.87(8.72 - 1.63)$ 0.090 0.78 $0.837(8.72 - 1.63)$ 0.745 Jabetes $0.837(8.72 - 1.63)$ 0.629 $0.897(8.63 - 1.43)$ 0.742 $0.89(8.63 - 1.43)$ 0.742 Jordia constraint strate $0.838(8.63 - 1.92)$ 0.738 $0.897(8.63 - 1.43)$ 0.743 $0.92(0.88 - 1.09)$ 0.742 $0.838(8.63 - 1.92)$ 0.738 $0.892(0.73 - 1.00)$ 0.779 0.742 $0.93(0.83 - 1.63)$ 0.779 0.993 $0.990000000000000000000000000000000000$		$\begin{bmatrix} 10 \text{ events} / 6 \text{ df} \end{bmatrix}$ 0.47 (-0.25 - 0.91) 0.94(-0.76 - 1.16)	-	$\begin{bmatrix} 10 \text{ events} / 6 \text{ df} \end{bmatrix}$ 0.61(0.36 - $\frac{1.06}{1.06}$??	[10events/ 6df] 0.83(0.54 - 1.30) 0.93(0.82 - 1.04)	??
Chronic kidney disease $9,87(0,71,-1,10)$ 27 0.109 $920(0.69,-0.97)$ 0.221 0.832 $996(0.84,-100)$ 0.745 Diabetes $0.51(16,03,-1,02)$ 0.629 0.628 0.629 <	≤ 3	· · · · · · · · · · · · · · · · · · ·	0.877	· · · · · · · · · · · · · · · · · · ·	- 0.050	· · · · · · · · · · · · · · · · · · ·	0.395
Jabeles $9,81(0.73, 1.42)$ 0.629 $89(0.83, 1.43)$ 0.422 $0.526(0.83, 1.40)$ 0.762 $0.88(0.83, 1.40)$ 0.762 $0.88(0.83, 1.40)$ 0.762 $0.88(0.83, 1.40)$ 0.762 $0.89(0.73, 1.40)$ 0.762 0.993 0.776 $0.88(0.83, 1.40)$ 0.776 $0.88(0.73, 0.43)$ 0.687 $0.982(0.83, 1.40)$ 0.776 $0.892(0.73, 0.47)$ 0.779 0.228 $0.95(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.779 $0.88(0.83, 1.40)$ 0.687 <th>INO</th> <th></th> <th>0.109</th> <th>· · · · · · · · · · · · · · · · · · ·</th> <th>0.832</th> <th></th> <th>0.745</th>	INO		0.109	· · · · · · · · · · · · · · · · · · ·	0.832		0.745
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diabetes		0.629		0.422		0.138
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heart failure	· · · · · ·	0.390		0.504	· · · · · · · · · · · · · · · · · · ·	0.762
$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	Coronary artery disase		0.738		0.437		0.002
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes Peripheral arterial disase		0.853		0.228		0.993
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes Prior ischaemic stroke		0.689	-	?? 0.416		??
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes Prior haemorrhagic stroke		0.897		0.738		0.550
$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	No -	0.89(0.73 - 1.09) [10events/34df] ?	0.842	0.82(0.70 - 0.97) [10events/34df]	??	0.95(0.85 - 1.07)	22
$ \begin{array}{c} \bigvee_{Ves}^{O} \\ Yes \\ Yes \\ Yes \\ Yes \\ Yes \\ \end{array} \begin{array}{c} 0.87(0.71, 1.07) \\ (.20vents/14df] \\ 0.87(0.73, 1.09) \\ (.20vents/14df] \\ 0.89(0.73, 1.09) \\ (.20vents/14df] \\ 0.82(0.69, 0.97) \\ (.20vents/39df] \\ (.20vents/14df] \\ 0.82(0.69, 0.97) \\ (.20vents/39df] \\ (.20vents/14df] \\ 0.82(0.69, 0.97) \\ (.20vents/39df] \\ (.20vents/39df] \\ (.20vents/14df] \\ (.20vents/39df] \\ (.20vents/14df] \\ (.20vents/39df] \\ (.20vents/14df] \\ (.20vents/39df] \\ (.20vents/14df] \\ (.20vents/14df) \\ (.20vents/14df] \\ (.20vents/14df) \\ (.20vents/14d$	NO Yes	0.86(0.67 - 1.10) = 0.85(0.61 - 1.18)	_ !	$\begin{array}{c} 0.79(\ 0.65 \ - \ 0.95) \\ 0.91(\ 0.64 \ - \ 1.30) \end{array}$	- ' '	$\begin{array}{c} 0.95(0.83 - 1.09) \\ 0.80(0.64 - 1.00) \end{array}$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No	0.87(0.71 - 1.07) [20events/14df]	- I	0.80(0.68 - 0.95) [30events/14df]		0.93(0.83 - 1.05) [80events/14df]	<mark>7</mark> 7
$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	No Yes	0.89(0.73 - 1.09))	0.82(0.69 - 0.97)	22	0.96(0.85 - 1.07)	22
$\frac{\begin{array}{c} 0.188 \\ 100 \text{ vents/39df} \end{array}}{0.5 1 2} \\ 0.5 1 2 \\ 0.5 1 \\ $	Prior gastointestinal bleeding		>		22		7 9
	Prior intracranial bleeding	1	0.188		0.552		0.232
	1 85	i			* * 		•
							1 2
¹ Subgroup estimates conventionally adjusted in case of fiewer than 10 events pr degree of freedom - no Cox regression run	* Subgroup estimates conventionally of	, v		· · · · · ·	an ravors wartarin	Favors dabigatran	ravors wartann

Figure 15.28 Pairwise propensity -score matched adjusted hazard ratios of the primary endpoints and the composite secondary endpoint
among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin overall and in the subgroups – Sweden

	Any stroke or	SE	Any bleeding at a	cute hospitalization	1	Secondary composit	te outcome
	HR (95% CI)	P-int	HR (95% CI)	I	P-int	HR (95% CI)	P-int
All Age	0.99(0.84 - 1.16)	0.260	1.19(1.05 - 1.35)		<.001	1.15(1.06 - 1.25)	0.015
<65 years 65 - <75 years 75 - <85 years	[40events/6df] ? 0.86(0.60 - 1.23) ? 0.94(0.73 - 1.20) . 1.23(0.91 - 1.66) .	_	[50events/ 6df] 0.90(0.69 - 1.16) 1.57(1.29 - 1.92) 1.14(0.90 - 1.44)		1	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Sex Female	0.98(0.78 - 1.23)	0.961	1.14(0.90 - 1.44) 1.18(0.96 - 1.44) 1.20(1.02 - 1.42)		0.766	1.26(1.10 - 1.44) 1.24(1.10 - 1.39) 1.08(0.96 - 1.20)	0.096
CHA2DS2VASc 0-1		0.498		??	0.136	· · · · · · · · · · · · · · · · · · ·	22 0.673
2-3 >=4 CHADS2	$\begin{bmatrix} 30 \text{ events}/10 \text{ df} \\ 1.02(0.72 - 1.44) \\ 1.01(0.83 - 1.22) \end{bmatrix} = \begin{bmatrix} 2 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 $	0.395	[40events/10df] 1.01(0.81 - 1.25) 1.31(1.11 - 1.54)		0.118	[70events/10df] 1.14(0.96 - 1.36) 1.16(1.05 - 1.27)	0.235
0	0.67(0.36 - 1.27) 1.01(0.86 - 1.20)	_	$\begin{bmatrix} 10 \text{events}/11 \text{df} \end{bmatrix}$ 0.66(0.38 - $\frac{1.16}{1.16}$	<u>??</u>		[10events/11df] 0.85(0.57 - 1.28) 1.16(1.07 - 1.26)	??
HAS-BLED	0.94(0.76 - 1.17)	0.623	1.12(0.96 - 1.31) 1.36(1.09 - 1.71)		0.313	1.17(1.06 - 1.30) 1.07(0.93 - 1.23)	0.342
Chronic kidney disease	0.99(0.84 - 1.16)	0.897	1.19(1.04 - 1.35) [40events/20df]		0.831	1.18(1.08 - 1.28) [140events/20df]	0.008
Yes Diabetes No	0.96(0.80 - 1.16) 1.10(0.77 - 1.58)	0.532	1.14(0.99 - 1.32) 1.40(1.05 - 1.87)	·	0.244	1.15(1.05 - 1.27) 1.18(1.01 - 1.38)	0.841
Yes Heart failure No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.467	1.40(1.03 - 1.87) 1.13(0.97 - 1.32) 1.34(1.05 - 1.71)		0.334	1.18(1.01 - 1.38) 1.15(1.04 - 1.28) 1.11(0.97 - 1.26)	0.630
Yes Coronary artery disase No	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.599	1.34(1.05 - 1.71) 1.18(1.02 - 1.38) 1.22(0.95 - 1.57)		0.962	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.002
Peripheral arterial disase	1.11(0.80 - 1.54) 1.01(0.85 - 1.19) [50events/10df]	0.687	1.22(0.95 - 1.57) 1.19(1.04 - 1.36) [70events/10df]		0.992	1.09(0.86 - 1.13)	0.479
Yes Prior ischaemic stroke No	0.97(0.80 - 1.19) 0.98(0.73 - 1.30)	0.829	[70events/10df] 1.20(1.05 - 1.39) 1.13(0.84 - 1.54)	?? 	0.469	1.02(0.79 - 1.31)	0.772
Yes Prior haemorrhagic stroke		0.041			0.438		0.168
Yës Prior stroke (any)	1.01(0.86 - 1.19) [10events/25df] ?	0.594	1.19(1.05 - 1.36) [20events/25df]	??	0.652	1.16(1.07 - 1.26) [40events/25df]	??
Yes Prior transient ishaemic attac	$\mathbf{k} \begin{bmatrix} 0.99(0.81 - 1.21) \\ 0.97(0.73 - 1.29) \end{bmatrix}$	0.140	1.19(1.04 - 1.38) 1.19(0.88 - 1.60)		0.802	1.14(1.04 - 1.25) 1.16(0.98 - 1.36) 1.15(1.06 - 1.25)	0.839
Yes Prior systemic embolism	0.95(0.80 - 1.13) [40events/9df] ?	0.689	1.20(1.05 - 1.36) [60events/9df]	??	0.901	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.038
Yes Prior gastointestinal bleeding	1.00(0.85 - 1.18) [30events/33df] ?	0.775	1.19(1.05 - 1.35) [20events/33df]	??	0.292	1.17(1.08 - 1.27) [60events/33df]	22
Yes Prior intracranial bleeding	0.99(0.84 - 1.16) [10events/38df] ?	0.289	1.20(1.05 - 1.36) [10events/38df]	??	0.817	1.15(1.06 - 1.25) [30events/38df]	?? 0.837
No Yes	1.00(0.85 - 1,18) [10events/33df] ?		1.19(1.05 - 1.35) [20events/33df]	??	-	1.15(1.06 - 1.25) [50events/33df]	??
	0.5 1	2	0.5	1 2	2	0.5	1 2
	Favors rivaroxaban	Favors Warfarin	Favors riv			Favors rivaroxaban	Favors Warfarin
* Subgroup estimates conventionally a	djusted in case of imbalance. [In case of few	er than 10 events pr degr	ee of freedom - no Cox regression r	un]			

Figure 15.29 Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin overall and in the subgroups – *Sweden*

Figure 15.30 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country

Country	Ischaemie	c stroke	Haemorrhagic stroke		
country	HR (95% CI)	1 1 1	HR (95% CI)	1 1 1	
All countries	1.00(0.90 - 1.12)		0.81(0.64 - 1.01)		
Denmark	1.16(0.94 - 1.43)		1.05(0.68 - 1.63)		
Norway	1.04(0.79 - 1.38)		0.72(0.42 - 1.22)		
Sweden	0.91(0.78 - 1.06)		0.72(0.53 - 0.98)		
	0.25	0.5 1 2 sapixaban Favors warfarin	0.25	0.5 1 2 ors apixaban Favors warfarin	

CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation

Figure 15.31 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country


Country	Intracran	ial bleeding	Gastointestinal bleeding	
country	HR (95% CI)	1 1	HR (95% CI)	
All countries	0.61(0.52 - 0.72)		0.79(0.70 - 0.90)	
Denmark	0.77(0.55 - 1.06)		0.74(0.59 - 0.92)	
Norway	0.66(0.43 - 1.00)		0.69(0.53 - 0.92)	
Sweden	0.54(0.43 - 0.66)		0.87(0.73 - 1.04)	
	0.25	0.5 1 vors apixaban Favors warfarin	2 0.25 0.5 1 Favors apixaban Favor	1 2 s warfarin

Figure 15.32 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country

Country	Bleeding with ON stay	Bleeding without ON stay	Bleeding as primary diag	
country	HR (95% CI)	HR (95% CI)	HR (95% CI)	
All countri				
	0.74(0.69 - 0.79)	0.74(0.67 - 0.81) -	0.67(0.61 - 0.74)	
Denmark	0.76(0.66 - 0.87)	0.82(0.64 - 1.05)	0.70(0.59 - 0.81)	
Norway	0.69(0.59 - 0.80)	0.59(0.41 - 0.83)	0.67(0.53 - 0.84)	
Sweden	0.75(0.67 - 0.83)	0.74(0.66 - 0.82)	0.66(0.58 - 0.75)	
	0.25 0.5 1	2 0.25 0.5 1 2	0.25 0.5 1 2	
	Favors apixaban	Favors apixaban	Favors apixaban	


CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; ON overnight

Figure 15.33 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; ON overnight

Figure 15.34 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country, overall and by country




CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation

Figure 15.35 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country

Country	Intracranial bleeding	Gastointestinal bleeding		
country	HR (95% CI)	HR (95% CI)		
All countries	0.48(0.39 - 0.59)	1.40(1.23 - 1.60)		
Denmark	0.51(0.36 - 0.71)	1.38(1.14 - 1.68)		
Norway	0.45(0.30 - 0.67)	1.60(1.23 - 2.07)		
Sweden	0.48(0.34 - 0.68)	1.28(1.00 - 1.64)		
	0.25 0.5 1 Favors dabigatran Favors warfarin	2 0.25 0.5 1 2 Favors dabigatran Favors warfarin		

Figure 15.36 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; ON overnight

Figure 15.37 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country





Figure 15.38 Pairwise propensity -score matched adjusted hazard ratios for the secondary stroke endpoints among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country




CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation

Figure 15.39 Pairwise propensity -score matched adjusted hazard ratios for the secondary site -specific bleeding endpoints among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country

Country	Intracranial bleeding		Gastointestinal bleeding	
country	HR (95% CI)		HR (95% CI)	
All countries	0.83(0.71 - 0.98)		1.38(1.22 - 1.56)	-
Denmark	0.80(0.59 - 1.08)	· · · · ·	1.14(0.93 - 1.39)	· · · · ·
Norway	0.89(0.65 - 1.22)		1.66(1.32 - 2.09)	
Sweden	0.82(0.64 - 1.05)		1.45(1.17 - 1.79)	
	0.25	0.5 1 2	0.25	0.5 1 2
	Favor	rs rivaroxaban Favors warfarin	Favors riva	aroxaban Favors warfarin

Figure 15.40 Pairwise propensity -score matched adjusted hazard ratios for the secondary and sensitivity analysis of any bleeding endpoints among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country




CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; ON overnight

Figure 15.41 Pairwise propensity -score matched adjusted hazard ratios for the secondary endpoints systemic embolism, acute myocardial infarction and death of any cause among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country

Country	Acute myocardial infarction	Systemic embolism	Death of any cause	
country	HR (95% CI)	HR (95% CI)	HR (95% CI)	
All countries				
	0.92(0.81 - 1.05)		1.31(1.23 - 1.39)	
Denmark	0.90(0.67 - 1.20)	0.17(-0.04 - 0.75)	1.49(1.35 - 1.64)	
Norway	0.98(0.78 - 1.21)	1.34(0.54 - 3.34)		
Sweden	0.89(0.73 - 1.09)	0.60(0.29 - 1.23)	1.27(1.15 - 1.39)	
Sweden				
	Favors rivaroxaban	Favors rivaroxaban	Favors rivaroxaban	


Figure 15.42 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite</u> <u>secondary endpoint</u> among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country



CI confidence interval; ITT intention to treat like analysis; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of apixaban vs. warfarin see Figure 15.18 (all countries); Figure 15.21 (Denmark); Figure 15.24 (Norway); Figure 15.27 (Sweden).


Figure 15.43 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite</u> <u>secondary endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country



CI confidence interval; ITT intention to treat like analysis; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of dabigatran vs. warfarin see Figure 15.19 (all countries); Figure 15.22 (Denmark); Figure 15.25 (Norway); Figure 15.28 (Sweden).


Figure 15.44 Sensitivity analysis (intention to treat): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite</u> <u>secondary endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country



CI confidence interval; ITT intention to treat like analysis; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of rivaroxaban vs. warfarin see Figure 15.20 (all countries); Figure 15.23 (Denmark); Figure 15.26 (Norway); Figure 15.29 (Sweden).


Figure 15.45 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism; WDT -80 80th percentile of the waiting time distribution

For main analyses of apixaban vs. warfarin see Figure 15.18 (all countries); Figure 15.21 (Denmark); Figure 15.24 (Norway); Figure 15.27 (Sweden).

Figure 15.46 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism; WDT -80 80th percentile of the waiting time distribution

For main analyses of dabigatran vs. warfarin see Figure 15.19 (all countries); Figure 15.22 (Denmark); Figure 15.25 (Norway); Figure 15.28 (Sweden).


Figure 15.47 Sensitivity analysis (alternative definition of on -treatment time for warfarin): Pairwise propensity -score matched adjusted hazard ratios of the <u>primary endpoints and the composite secondary endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country

Country	WTD-80 - Any stroke or SE	WTD-80 - Any bleeding a	tacute hWk friiDa Bio Rati Seacondary composite o		
	HR (95% CI)	HR (95% CI)	HR (95% CI)		
All countri	es 1.04(0.93 - 1.16) 1.03(0.92 - 1.14)	1.17(1.07 - 1.27) 1.15(1.07 - 1.25)	1.23(1.1) - 1.33)		
Denmark	0.98(0.81 - 1.18) 0.97(0.81 - 1.17)	1.11(0.96 - 1.28) 1.09(0.95 - 1.25)	1.38(1.26 - 1.51)		
Norway	1.17(0.93 - 1.47) 1.16(0.94 - 1.42)	1.12(0.97 - 1.30) 1.18(1.03 - 1.35)	1.14(1.01 - 1.27)		
Sweden	1.02(0.86 - 1.22) 0.99(0.84 - 1.16)	1.27(1.10 - 1.46) 1.19(1.05 - 1.35)	■ 1.21(1.11 - 1.33) □ 1.15(1.06 - 1.25)		
	0.5 1	2 0.5 1			
	Favors Rivaroxaban	7a Favors Rivaroxa	ban Fa Favors Rivaroxaban Fa		
Reference (main analysis) in grey					

CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism; WDT -80 80th percentile of the waiting time distribution

For main analyses of rivaroxaban vs. warfarin see Figure 15.20 (all countries); Figure 15.23 (Denmark); Figure 15.26 (Norway); Figure 15.29 (Sweden).


Figure 15.48 Sensitivity analysis (conventional adjustment): Pairwise conventionally adjusted hazard ratios of the <u>primary endpoints and the composite secondary</u> <u>endpoint</u> among patients with NVAF comparing initiators of <u>apixaban</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of apixaban vs. warfarin see Figure 15.18 (all countries); Figure 15.21 (Denmark); Figure 15.24 (Norway); Figure 15.27 (Sweden).


Figure 15.49 Sensitivity analysis (conventional adjustment): Pairwise conventionally adjusted hazard ratios of the <u>primary endpoints and the composite secondary</u> <u>endpoint</u> among patients with NVAF comparing initiators of <u>dabigatran</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of dabigatran vs. warfarin see Figure 15.19 (all countries); Figure 15.22 (Denmark); Figure 15.25 (Norway); Figure 15.28 (Sweden).

Figure 15.50 Sensitivity analysis (conventional adjustment): Pairwise conventionally adjusted hazard ratios of the <u>primary endpoints and the composite secondary</u> <u>endpoint</u> among patients with NVAF comparing initiators of <u>rivaroxaban</u> vs. warfarin, overall and by country



CI confidence interval; HR hazard ratio; NVAF non-valvular atrial fibrillation; SE systemic embolism

For main analyses of rivaroxaban vs. warfarin see Figure 15.20 (all countries); Figure 15.23 (Denmark); Figure 15.26 (Norway); Figure 15.29 (Sweden).